

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 May 2001 (03.05.2001)

PCT

(10) International Publication Number
WO 01/30848 A2

(51) International Patent Classification⁷: **C07K 14/705**

(21) International Application Number: PCT/EP00/10886

(22) International Filing Date: 26 October 2000 (26.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99402668.0 26 October 1999 (26.10.1999) EP
60/186,260 1 March 2000 (01.03.2000) US

(71) Applicant (for all designated States except US): **AVENTIS PHARMA S.A.** [FR/FR]; 20, avenue Raymond Aron, F-92160 Antony (FR).

[US/US]; 16 Valley Drive, Birdsboro, PA 19508 (US). **RE-MALEY, Alan** [US/US]; 4510 Traymore Street, Bethesda, MD 20892 (US). **BREWER, H., Bryan** [US/US]; 10805 Pebble Brook Lane, Potomac, MD 20854 (US). **DEAN, Michael** [US/US]; 1362 Hitchingpost Lane, Frederick, MD 21703 (US).

(74) Agent: **LECCA, Patricia**; Aventis Pharma S.A., Direction Brevets, 20, avenue Raymond Aron, F-92165 Antony Cedex (FR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DENEFLE, Patrice** [FR/FR]; 45, avenue des Fusillés de Chateaubriand, F-94100 Saint Maur (FR). **ROSIER-MONTUS, Marie-Françoise** [FR/FR]; 21, rue des Baconnets, F-92160 Antony (FR). **ARNOULD-REGUIGNE, Isabelle** [FR/FR]; 112, rue de Brie, F-94430 Chennevières (FR). **PRADES, Catherine** [FR/FR]; 30, avenue du Général de Gaulle, F-94320 Thiais (FR). **NAUDIN, Laurent** [FR/FR]; 11, bis rue de la Roche Plate, F-91150 Etampes (FR). **LEMOINE, Cendrine** [FR/FR]; 16, rue des Pichots, F-91310 Montlhéry (FR). **DUVERGER, Nicolas** [FR/FR]; 4, rue Rollin, F-75005 Paris (FR). **JAYE, Michael** [US/US]; 142 North Lynnwood Avenue, Glenside, PA 19038 (US). **SEARFOSS, George, H., III**

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NUCLEIC ACIDS OF THE HUMAN ABC1 GENE AND THEIR THERAPEUTIC AND DIAGNOSTIC APPLICATION

(57) Abstract: The present invention relates to nucleic acids corresponding to the various exons and introns of the ABC1 gene, which is a causal gene for pathologies linked to a cholesterol metabolism dysfunction inducing diseases such as atherosclerosis, more particularly disruption in the reverse transport of cholesterol, and more particularly familial HDL deficiencies (FHD), such as Tangier disease. The present invention also relates to ABC1 cDNAs encoding the novel full length ABC1 protein. The invention also relates to means for the detection of polymorphisms in general, and of mutations in particular, in the ABC1 gene or in the corresponding protein produced by the allelic form of the ABC1 gene.

WO 01/30848 A2

NUCLEIC ACIDS OF THE HUMAN ABC1 GENE AND THEIR THERAPEUTIC AND DIAGNOSTIC APPLICATION

FIELD OF THE INVENTION

5

The present invention relates to nucleic acids corresponding to the various exons and introns of the ABC1 gene, which is a causal gene for pathologies linked to a cholesterol metabolism dysfunction inducing diseases such as arteriosclerosis, more particularly disruption in the reverse transport of cholesterol, and more particularly familial HDL deficiencies (FHD), such as Tangier disease. The present invention also relates to ABC1 cDNAs encoding the novel full length ABC1 protein. The invention also relates to means for the detection of polymorphisms in general, and of mutations in particular, in the ABC1 gene or in the corresponding protein produced by the allelic form of the ABC1 gene.

15 BACKGROUND OF THE INVENTION

Lipids are water-insoluble organic biomolecules, which are essential components of diverse biological functions, including the storage, transport, and metabolism of energy, and membrane structure and fluidity. Lipids are derived from two sources in humans and other animals: some lipids are ingested as dietary fats and oils and other lipids are biosynthesized by the human or animal. In mammals at least 10% of the body weight is lipid, the bulk of which is in the form of triacylglycerols.

Triacylglycerols, also known as triglycerides and triacylglycerides, are made up of three fatty acids esterified to glycerol. Dietary triacylglycerols are stored in adipose tissues as a source of energy, or hydrolyzed in the digestive tract by triacylglycerol lipases, the most important of which is pancreatic lipase. Triacylglycerols are transported between tissues in the form of lipoproteins.

Lipoproteins are micelle-like assemblies found in plasma and contain varying proportions of different types of lipids and proteins (called apoproteins). There are five main classes of plasma lipoproteins, the major function of which is lipid transport. These classes are, in order of increasing density, chylomicrons, very low density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low density lipoproteins (LDL), and high density lipoproteins (HDL). Although many types of lipid are found associated with each lipoprotein class, each class transports predominantly one type of lipid: triacylglycerols are transported in chylomicrons, VLDL, and IDL; while phospholipids and cholesterol esters are transported in HDL and LDL respectively.

Phospholipids are di-fatty acid esters of glycerol phosphate, also containing a polar group coupled to the phosphate. Phospholipids are important structural components of cellular membranes. Phospholipids are hydrolyzed by enzymes called phospholipases. Phosphatidylcholine, an exemplary phospholipid, is a major component of most eukaryotic cell
5 membranes.

Cholesterol is the metabolic precursor of steroid hormones and bile acids as well as an essential constituent of cell membranes. In humans and other animals, cholesterol is ingested in the diet and also synthesized by the liver and other tissues. Cholesterol is transported between tissues in the form of cholesteryl esters in LDLs and other lipoproteins.

10 Membranes surround every living cell, and serve as a barrier between the intracellular and extracellular compartments. Membranes also enclose the eukaryotic nucleus, make up the endoplasmic reticulum, and serve specialized functions such as in the myelin sheath that surrounds axons. A typical membrane contains about 40% lipid and 60% protein, but there is considerable variation. The major lipid components are phospholipids, specifically
15 phosphatidylcholine and phosphatidylethanolamine, and cholesterol. The physicochemical properties of membranes, such as fluidity, can be changed by modification of either the fatty acid profiles of the phospholipids or the cholesterol content. Modulating the composition and organization of membrane lipids also modulates membrane-dependent cellular functions, such as receptor activity, endocytosis, and cholesterol flux.

20 High-density lipoproteins (HDL) are one of the four major classes of lipoproteins circulating in blood plasma. These lipoproteins are involved in various metabolic pathways such as lipid transport, the formation of bile acids, steroidogenesis, cell proliferation and, in addition, interfere with the plasma proteinase systems.

HDLs are perfect free cholesterol acceptors and, in combination with the cholesterol
25 ester transfer proteins (CETP), lipoprotein lipase (LPL), hepatic lipase (HL) and lecithin:cholesterol acyltransferase (LCAT), play a major role in the reverse transport of cholesterol, that is to say the transport of excess cholesterol in the peripheral cells to the liver for its elimination from the body in the form of bile acid. It has been demonstrated that the HDLs play a central role in the transport of cholesterol from the peripheral tissues to the liver.

30 Various diseases linked to an HDL deficiency have been described, including Tangier and/or FHD disease, HDL deficiency, and LCAT deficiency. In addition, HDL-cholesterol deficiencies have been observed in patients suffering from malaria and diabetes (Kittl et al., 1992; Nilsson et al., 1990; Djoumessi, 1989; Mohanty et al., 1992; Maurois et al., 1985; Grellier et al., 1997; Agbedana et al., 1990; Erel et al., 1998; Cuisinier et al., 1990; Chander et
35 al., 1998; Efthimiou et al., 1992; Baptista et al., 1996; Davis et al., 1993; Davis et al., 1995; Pirich et al., 1993; Tomlinson and Raper, 1996; Hager and Hajduk, 1997; Kwiterovich, 1995,

Syvanne et al., 1995a, Syvanne et al., 1995b, and French et al., 1993). The deficiency involved in Tangier and/or FHD disease is linked to a cellular defect in the translocation of cellular cholesterol which causes a degradation of the HDLs and leads to a disruption in the lipoprotein metabolism. Nevertheless, for Tangier and/or FHD disease, the exact nature of the defect has
5 not yet been precisely defined.

Tangier disease is an autosomal co-dominant condition characterized in the homozygous state by the absence of HDL-cholesterol (HDL-C) from plasma, hepatosplenomegaly, peripheral neuropathy, and frequently premature coronary artery disease (CAD). In heterozygotes, HDL-C levels are about one-half those of normal individuals.
10 Impaired cholesterol efflux from macrophages leads to the presence of foam cells throughout the body, which may explain the increased risk of CAD in some Tangier disease families.

In Tangier disease patients, the HDL particles do not incorporate cholesterol from the peripheral cells, are not metabolized correctly, and are rapidly eliminated from the body. The plasma HDL concentration in these patients is therefore, extremely reduced and the HDLs no
15 longer ensure the return of cholesterol to the liver. Cholesterol accumulates in these peripheral cells and causes characteristic clinical manifestations such as the formation of orange-colored tonsils. Furthermore, other lipoprotein disruptions, such as overproduction of triglycerides as well as increased synthesis and intracellular catabolism of phospholipids are also observed in Tangier disease patients.

20 Tangier disease, whose symptoms have been described above, is classified among the familial conditions linked to the metabolism of HDLs, which are the ones most commonly detected in patients affected by coronary diseases. Numerous studies have shown that a reduced level of HDL cholesterol is an excellent indicator of an individual's risk of developing or already having a cardiovascular condition. In this context, syndromes linked to HDL
25 deficiencies have been of increasing interest for the past decade because they make it possible to increase understanding of the role of HDLs in atherogenesis.

Atherosclerosis is defined in histological terms by deposits (lipid or fibrolipid plaques) of lipids and of other blood derivatives in blood vessel walls, especially the large arteries (aorta, coronary arteries, carotid). These plaques, which are more or less calcified according to the
30 degree of progression of the atherosclerotic process, may be coupled with lesions and are associated with the accumulation in the vessels of fatty deposits consisting essentially of cholesterol esters. These plaques are accompanied by a thickening of the vessel wall, hypertrophy of the smooth muscle, appearance of foam cells (lipid-laden cells resulting from uncontrolled uptake of cholesterol by recruited macrophages) and accumulation of fibrous
35 tissue. The atheromatous plaque protrudes markedly from the wall, endowing it with a stenosing character responsible for vascular occlusions by atheroma, thrombosis or embolism,

which occur in those patients who are most affected. These lesions can lead to serious cardiovascular pathologies such as infarction, sudden death, cardiac insufficiency, and stroke.

Mutations within genes that play a role in lipoprotein metabolism have been identified. Specifically, several mutations in the apolipoprotein apo A-I gene have been characterized. 5 These mutations are rare and may lead to a lack of production of apo A-I. Mutations in the genes encoding LPL or its activator apo C-II are associated with severe hypertriglyceridemias and substantially reduced HDL-C levels. Mutations in the gene encoding the enzyme LCAT are also associated with a severe HDL deficiency.

In addition, dysfunctions in the reverse transport of cholesterol may be induced by 10 physiological deficiencies affecting one or more of the steps in the transport of stored cholesterol, from the intracellular vesicles to the membrane surface where it is accepted by the HDLs.

Therefore, an increasing need exists in the state of the art to identify genes involved in any of the steps in the metabolism of cholesterol and/or lipoproteins, and in particular, genes 15 associated with dysfunctions in the reverse transport of cholesterol from the peripheral cells to the liver.

Recently, a study was conducted on the segregation of different allelic forms of 343 microsatellite markers distributed over the entire genome and distant from each other by 10.3 cM on average (Rust et al., 1998). This linkage study was carried out on a family 20 comprising five consanguineous lines and which has been well characterized over eleven generations, in which many members are affected by Tangier disease. This study identified a region located in the 9q31 locus of human chromosome 9 that is statistically associated with Tangier disease.

However, the study by Rust et al. (1998) only defined a wide region of the genome 25 whose impairments are likely to be associated with Tangier disease and that the relevant 9q31-34 region contains ESTs but no known gene. It has since been shown that a region of about 1cM situated in the 9q31 locus in humans was generally associated with familial HDL deficiencies (Rust et al., 1999 and Brooks-Wilson et al., 1999). More precisely, it has been shown that a gene encoding a protein of the family of ABC transporters, which is located 30 precisely in the region of 1 cM of the 9q31 locus, was involved in pathologies linked to a deficiency in the reverse transport of cholesterol. More particularly, mutations have been described within the gene encoding the ABC-1 transporter in patients impaired in the reverse transport of cholesterol, and most particularly in patients suffering from Tangier and FHD diseases (Rust et al., 1999, Brooks-Wilson et al., 1999, Bodzioch et al., 1999, Marcil et al., 35 1999b, and Lawn et al., 1999).

The ABC (ATP-binding cassette) transport proteins constitute a family of proteins that are extremely well conserved during evolution, from bacteria to humans. The ABC transport proteins are involved in membrane transport of various substrates, for example ions, amino acids, peptides, sugars, vitamins or steroid hormones.

5 The characterization of the complete amino acid sequence of some ABC transporters has made it possible to determine that these proteins had a common general structure, in particular two nucleotide binding folds (NBF) with Walker A and B type units as well as two transmembrane domains, each of the transmembrane domains consisting of six helices. The specificity of the ABC transporters for the various transported molecules appears to be
10 determined by the structure of the transmembrane domains, whereas the energy necessary for the transport activity is provided by the degradation of ATP at the level of the NBF fold.

Several ABC transport proteins that have been identified in humans are associated with various diseases. For example, cystic fibrosis is caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene. Moreover, some multiple drug resistance
15 phenotypes in tumor cells have been associated with mutations in the gene encoding the MDR (multi-drug resistance) protein, which also has an ABC transporter structure. Other ABC transporters have been associated with neuronal and tumor conditions (US Patent No. 5,858,719) or potentially involved in diseases caused by impairment of the homeostasis of metals, such as the ABC-3 protein. Likewise, another transport ABC, designated PFIC2,
20 appears to be involved in a progressive familial intrahepatic cholestasia form, this protein being potentially responsible, in humans, for the export of bile salts.

In 1994, a cDNA encoding a new mouse ABC transporter was identified and designated ABC1 (Luciani et al., 1994). This protein is characteristic of the ABC transporters in that it has a symmetrical structure comprising two transmembrane domains linked to a highly hydrophobic
25 segment and two NBF units.

In humans, a partial cDNA comprising a 6603 base pair (bp) open reading frame (ORF) of the human ABC1 transporter has been identified (Langmann et al., 1999). Based upon this partial cDNA, the human ABC1 protein is predicted to comprise 2201 amino acids (aa), which results in a protein of approximately 220 kDa in size (*Ibid.*). This study also showed that the
30 gene encoding this human ABC1 protein isoform is expressed in various tissues, and more particularly at high levels in the placenta, the liver, the lungs, the adrenal glands, as well as several fetal tissues. These authors demonstrated that the expression of the gene encoding the human ABC1 protein was induced during the differentiation of monocytes into macrophages *in vitro*. Furthermore, this study reported that the expression of the gene encoding the ABC1
35 protein is increased when human macrophages are incubated in the presence of acetylated low-density lipoproteins (AcLDLs). However, while it has been shown that patients suffering from

Tangier and FHD diseases have a mutated ABC1 gene (Rust et al., 1999, Brooks-Wilson et al., 1999, Bodzioch et al., 1999, Marcil et al., 1999b, and Lawn et al., 1999), the exact role of the human ABC1 protein in the lipid transport system is unknown. It is simply assumed that the ABC1 protein has a translocase activity for membrane lipid transport.

5 Recently, partial exonic and intronic ABC1 genomic DNA and an additional portion of the 3' untranslated region (UTR) of the human ABC1 cDNA have been isolated and identified (Rust et al., 1999).

 Because patients suffering from Tangier and FHD diseases have been shown to carry a mutated ABC1 gene (Rust et al., 1999, Brooks-Wilson et al., 1999, Bodzioch et al., 1999, 10 Marcil et al., 1999b, and Lawn et al., 1999), the translocase activity of the human ABC1 protein for membrane lipid transport has been investigated.

 The Applicant has discovered and isolated a human ABC1 full length cDNA containing additional sequences in the 5' and 3' UTR (untranslated regions) and encoding a ABC1 protein, which presents a longer amino acid sequence as to that of Langmann et al. (1999). Full length 15 human ABC1 cDNA was used to investigate the mechanisms of cholesterol and phospholipid efflux, demonstrating specific activity and interactions of the full length ABC1 protein with various lipid acceptors to promote cellular lipid efflux.

SUMMARY OF THE INVENTION

20

 The present invention relates to nucleic acids corresponding to the various exons and introns of the human ABC1 gene, which is a causal gene for pathologies linked to a cholesterol metabolism dysfunction inducing diseases such as arteriosclerosis, more particularly disruption in the reverse transport of cholesterol, and familial HDL deficiencies, such as Tangier and/or 25 FHD disease.

 Thus, a first subject of the invention is a nucleic acid comprising a polynucleotide sequence of any one of SEQ ID NOs: 1, 4-65, 68, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

 The invention also relates to a nucleic acid comprising at least 8 consecutive 30 nucleotides of a polynucleotide sequence of a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) 35 nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f)

nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence.

The invention also relates to a nucleic acid having at least 80% nucleotide identity with a nucleic acid comprising a polynucleotide sequence of a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence.

The invention also relates to a nucleic acid having at least 85%, preferably 90%, more preferably 95% and still more preferably 98% nucleotide identity with a nucleic acid comprising a polynucleotide sequence of a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence.

The invention also relates to a nucleic acid hybridizing, under high stringency conditions, with a polynucleotide of a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence.

The invention also relates to nucleic acids, particularly cDNA molecules, which encode the full length human ABC1 protein. Thus, the invention relates to a nucleic acid comprising a polynucleotide sequence of either SEQ ID NO: 69 or SEQ ID NO: 70, or of a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising a polynucleotide sequence as depicted in either SEQ ID NO: 69 or SEQ ID NO: 70, or a complementary polynucleotide sequence.

5 The invention also relates to a nucleic acid comprising nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising at least eight consecutive nucleotides of nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

10 The subject of the invention is also a nucleic acid having at least 80% nucleotide identity with a nucleic acid comprising nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid having at least 85%, preferably 90%, more preferably 95% and still more preferably 98% nucleotide identity with a nucleic acid
15 comprising nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

Another subject of the invention is a nucleic acid hybridizing, under high stringency conditions, with a nucleic acid comprising nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

20 According to the invention, a nucleic acid comprising a polynucleotide sequence of either SEQ ID NO: 69 or SEQ ID NO: 70 encodes a full length ABC1 polypeptide of 2261 amino acids comprising the amino acid sequence of SEQ ID NO: 71.

Thus, the invention also relates to a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71.

25 In a specific embodiment, the invention also relates to a nucleic acid encoding a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

Thus, the invention also relates to a polypeptide comprising an amino acid sequence of SEQ ID NO: 71.

30 The invention also relates to a polypeptide comprising an amino acid sequence as depicted in SEQ ID NO: 71.

The invention also relates to a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

35 The invention also relates to a polypeptide comprising an amino acid sequence having at least 80% amino acid identity with a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

The invention also relates to a polypeptide having at least 85%, preferably 90%, more preferably 95% and still more preferably 98% amino acid identity with a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

5 Preferably, a polypeptide according to the invention will have a length of 15, 18 or 20 to 25, 35, 40, 50, 70, 80, 100 or 200 consecutive amino acids of a polypeptide according to the invention, in particular a polypeptide comprising an amino acid sequence comprising amino acids 1-60 of SEQ ID NO: 71.

10 Alternatively, a polypeptide according to the invention will comprise a fragment having a length of 15, 18, 20, 25, 35, 40, 50, 100 or 200 consecutive amino acids of a polypeptide according to the invention, more particularly of a polypeptide comprising an amino acid sequence comprising amino acids 1-60 of SEQ ID NO: 71.

The invention also relates to a means for detecting polymorphisms in general, and mutations in particular, in the ABC1 gene or in the corresponding protein produced by the allelic form of the ABC1 gene. It has been recently shown that patients suffering from Tangier
15 and FHD diseases have a mutated ABC1 gene (Rust et al., 1999, Brooks-Wilson et al., 1999, Bodzioch et al., 1999, and Marcil et al., 1999b). According to the present invention, several additional mutations distributed in different exons of the ABC1 gene have been identified in the genome of various patients, in particular patients suffering from a severe form of the disease associated with cardiovascular disorders. Moreover, various polymorphisms have been found in
20 the introns of the ABC1 gene in patients suffering from the mildest forms of the disease, indicating that these patients carry particular alleles of the gene, distinct from the "wild-type" allele(s). Such alleles, partly characterized by these polymorphisms, are likely to contain substitutions, additions or deletions of nucleotides in the noncoding regions located respectively on the 5' side of the first exon or alternatively on the 3' side of the last exon of the
25 gene, in particular in the regulatory regions, for example, in the promoter sequences or alternatively in the enhancer sequences, of the type which induces defects. These defects may result in either an increase or a decrease in the synthesis of the ABC1 polypeptide.

Thus, the invention also relates to a polypeptide encoded by a mutated ABC1 gene, and more particularly a mutated ABC1 gene in patients suffering from a deficiency in the reverse
30 transport of cholesterol, most particularly in patients suffering from Tangier disease.

The invention therefore relates to a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 89-102.

The invention also relates to a polypeptide comprising an amino acid sequence as depicted in any one of SEQ ID NOs: 89-102.

Thus, another subject of the invention is a nucleic acid encoding a mutated ABC1 polypeptide, wherein the nucleic acid comprises a polynucleotide sequence of any one of SEQ ID NOs: 72-88, or of a complementary polynucleotide sequence.

The invention also relates to a nucleic acid encoding a mutated ABC1 polypeptide, wherein the nucleic acid comprises a polynucleotide sequence as depicted in any one of SEQ ID NOs: 72-88, or of a complementary polynucleotide sequence.

The invention also relates to a nucleic acid encoding a polypeptide comprising any one of SEQ ID NOs: 89-102.

According to another aspect, the invention also relates to the nucleotide sequences of the ABC1 gene comprising at least one biallelic polymorphism. Thus, another subject of the invention is a nucleic acid comprising a polynucleotide sequence of any one of SEQ ID NOs: 103 and 109-118, or of a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising a polynucleotide sequence comprising any one of SEQ ID NOs: 103 and 109-118, or of a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising a polynucleotide sequence as depicted in any one of SEQ ID NOs: 103 and 109-118, or of a complementary polynucleotide sequence.

Nucleotide probes and primers hybridizing with a nucleic acid sequence located in the region of an ABC1 nucleic acid (genomic DNA, messenger RNA, cDNA), in particular, a nucleic acid sequence comprising any one of the mutations or polymorphisms described above, also form part of the invention.

According to the invention, nucleic acid fragments derived from a nucleic acid comprising a polynucleotide sequence of a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence, are useful for the detection of the presence of at least one copy of a nucleotide sequence of the ABC1 gene or of a fragment or of a variant (containing a mutation or a polymorphism) thereof in a sample.

The nucleotide probes or primers according to the invention comprise at least 8 consecutive nucleotides of a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) 5 nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) 10 nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

Preferably, nucleotide probes or primers according to the invention will have a length of 10, 12, 15, 18 or 20 to 25, 35, 40, 50, 70, 80, 100, 200, 500, 1000, 1500 consecutive nucleotides of a nucleic acid according to the invention, in particular of a nucleic acid 15 comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a 20 complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

Alternatively, a nucleotide probe or primer according to the invention will consist of 25 and/or comprise the fragments having a length of 12, 15, 18, 20, 25, 35, 40, 50, 100, 200, 500, 1000, 1500 consecutive nucleotides of a nucleic acid according to the invention, more particularly of a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1- 30 242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) nucleotides 1-244 of SEQ ID 35 NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

The definition of a nucleotide probe or primer according to the invention therefore covers oligonucleotides which hybridize, under the high stringency hybridization conditions defined above, with a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) 5 nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) 10 nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

The preferred probes and primers according to the invention comprise all or part of a polynucleotide sequence comprising any one of SEQ ID NOs: 119-136, 138, and 141-152, or of 15 a complementary polynucleotide sequence.

The nucleotide primers according to the invention may be used to amplify any one of the nucleic acids according to the invention, and more particularly a nucleic acid comprising a polynucleotide sequence of any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence. Alternatively, the nucleotide primers 20 according to the invention may be used to amplify a nucleic acid fragment or variant of any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

In a particular embodiment, the nucleotide primers according to the invention may be used to amplify a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28- 25 35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ 30 ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence, or i) as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

35 Another subject of the invention relates to a method of amplifying a nucleic acid according to the invention, and more particularly a nucleic acid comprising a polynucleotide

sequence of any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence, or a nucleic acid fragment or variant thereof contained in a sample, said method comprising the steps of:

- a) bringing the sample in which the presence of the target nucleic acid is suspected into contact with a pair of nucleotide primers whose hybridization position is located respectively on the 5' side and on the 3' side of the region of the target nucleic acid whose amplification is sought, in the presence of the reagents necessary for the amplification reaction; and
- b) detecting the amplified nucleic acids.

Another subject of the invention relates to a method of amplifying a nucleic acid according to the invention, and more particularly a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence, or i) as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence, contained in a sample, said method comprising the steps of:

- a) bringing the sample in which the presence of the target nucleic acid is suspected into contact with a pair of nucleotide primers whose hybridization position is located respectively on the 5' side and on the 3' side of the region of the target nucleic acid whose amplification is sought, in the presence of the reagents necessary for the amplification reaction; and
- b) detecting the amplified nucleic acids.

The present invention also relates to a method of detecting the presence of a nucleic acid comprising a polynucleotide sequence of any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence, or a nucleic acid fragment or variant of any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence in a sample, said method comprising the steps of:

- 1) bringing one or more nucleotide probes according to the invention into contact with the sample to be tested;
- 2) detecting the complex which may have formed between the probe(s) and the nucleic acid present in the sample.

According to a specific embodiment of the method of detection according to the invention, the oligonucleotide probes are immobilized on a support.

According to another aspect, the oligonucleotide probes comprise a detectable marker.

Another subject of the invention is a box or kit for amplifying a nucleic acid comprising

- 5 a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68-70, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence, said box or kit comprising:

- 15 1) a pair of nucleotide primers in accordance with the invention, whose hybridization position is located respectively on the 5' side and 3' side of the target nucleic acid whose amplification is sought; and optionally,

2) reagents necessary for an amplification reaction.

- Such an amplification box or kit will preferably comprise at least one pair of nucleotide primers as described above.

- The subject of the invention is, in addition, a box or kit for amplifying all or part of a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence, said box or kit comprising:

- 30 1) a pair of nucleotide primers in accordance with the invention, whose hybridization position is located respectively on the 5' side and 3' side of the target nucleic acid whose amplification is sought; and optionally,

- 35 2) reagents necessary for an amplification reaction.

Such an amplification box or kit will preferably comprise at least one pair of nucleotide primers as described above.

The invention also relates to a box or kit for detecting the presence of a nucleic acid according to the invention in a sample, said box or kit comprising:

- 5 a) one or more nucleotide probes according to the invention;
- b) where appropriate, reagents necessary for a hybridization reaction.

According to a first aspect, the detection box or kit is characterized in that the nucleotide probe(s) and primer(s) are immobilized on a support.

According to a second aspect, the detection box or kit is characterized in that the
10 nucleotide probe(s) and primer(s) comprise a detectable marker.

According to a specific embodiment of the detection kit described above, such a kit will comprise a plurality of oligonucleotide probes and/or primers in accordance with the invention which may be used to detect target nucleic acids of interest or alternatively to detect mutations in the coding regions or the non-coding regions of the nucleic acids according to the invention.

15 According to preferred embodiment of the invention, the target nucleic acid comprises a polynucleotide sequence of any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary nucleic acid sequence. Alternatively, the target nucleic acid is a nucleic acid fragment or variant of a nucleic acid comprising any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

20 According to a preferred embodiment, two primers according to the invention comprise all or part of SEQ ID NOs: 125 and 126, making it possible to amplify the region of exon 5 of the ABC1 gene carrying the mutation as depicted in SEQ ID NO: 72 described above, or nucleic acids having a complementary polynucleotide sequence.

According to a second preferred embodiment, two primers according to the invention
25 comprise all or part of SEQ ID NOs: 127 and 128, making it possible to amplify the region of exon 6 of the ABC1 gene carrying the mutations as depicted in SEQ ID NOs: 73 or 74 described above, or nucleic acids having a complementary polynucleotide sequence.

According to a third preferred embodiment, two primers according to the invention
30 comprise all or part of SEQ ID NOs: 131 and 132, making it possible to amplify the region of exon 8 of the ABC1 gene carrying the mutations as depicted in SEQ ID NOs: 75-77 described above, or nucleic acids having a complementary polynucleotide sequence.

According to a fourth preferred embodiment, two primers according to the invention
35 comprise all or part of SEQ ID NOs: 155 and 156, making it possible to amplify the region of exon 27 of the ABC1 gene carrying the mutation as depicted in SEQ ID NO: 84 described above, or nucleic acids having a complementary polynucleotide sequence.

According to a fifth preferred embodiment, two primers according to the invention comprise all or part of SEQ ID NOs: 159 and 160, making it possible to amplify the region of exon 32 of the ABC1 gene carrying the mutation as depicted in SEQ ID NO: 85 described above, or nucleic acids having a complementary polynucleotide sequence.

- 5 According to a sixth preferred embodiment, two primers according to the invention comprise all or part of SEQ ID NOs: 175 and 176, making it possible to amplify the region of exon 47 of the ABC1 gene carrying the mutations as depicted in SEQ ID NOs: 87 or 88 described above, or nucleic acids having a complementary polynucleotide sequence.

10 According to another preferred embodiment, a primer according to the invention comprises, generally, all or part of any one of SEQ ID NOs: 119-136, 138, and 141-152, or a complementary sequence.

The invention also relates to a recombinant vector comprising a nucleic acid according to the invention. Preferably, such a recombinant vector will comprise a nucleic acid selected from the group consisting of

- 15 a) a nucleic acid comprising a polynucleotide sequence of any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence,
- b) a nucleic acid comprising a polynucleotide sequence as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence,
- 20 c) a nucleic acid comprising nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or of a complementary polynucleotide sequence,
- d) a nucleic acid having at least eight consecutive nucleotides of a nucleic acid comprising a polynucleotide sequence of 1) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; 2) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; 3) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; 4) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; 5) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; 6) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; 7) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or 8) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence;
- 25 e) a nucleic acid having at least 80% nucleotide identity with a nucleic acid comprising a polynucleotide sequence of 1) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; 2) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; 3) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; 4) nucleotides 1-1851 of SEQ ID
- 30
- 35

NO: 17; or of a complementary polynucleotide sequence; 5) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; 6) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; 7) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or 8) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence;

f) a nucleic acid having 85%, 90%, 95%, or 98% nucleotide identity with a nucleic acid comprising a polynucleotide sequence of 1) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; 2) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; 3) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; 4) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; 5) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; 6) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; 7) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or 8) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence;

g) a nucleic acid hybridizing, under high stringency hybridization conditions, with a nucleic acid comprising a polynucleotide sequence of 1) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; 2) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; 3) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; 4) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; 5) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; 6) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; 7) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or 8) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence;

h) a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71; and

i) a nucleic acid encoding a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

According to a first embodiment, a recombinant vector according to the invention is used to amplify a nucleic acid inserted therein, following transformation or transfection of a desired cellular host.

According to a second embodiment, a recombinant vector according to the invention corresponds to an expression vector comprising, in addition to a nucleic acid in accordance

with the invention, a regulatory signal or nucleotide sequence that directs or controls transcription and/or translation of the nucleic acid and its encoded mRNA.

According to an preferred embodiment, a recombinant vector according to the invention will comprise in particular the following components:

- 5 (1) an element or signal for regulating the expression of the nucleic acid to be inserted, such as a promoter and/or enhancer sequence;
- (2) a nucleotide coding region comprised within the nucleic acid in accordance with the invention to be inserted into such a vector, said coding region being placed in phase with the regulatory element or signal described in (1); and
- 10 (3) an appropriate nucleic acid for initiation and termination of transcription of the nucleotide coding region of the nucleic acid described in (2).

The present invention also relates to a defective recombinant virus comprising a cDNA nucleic acid encoding an ABC1 polypeptide involved in the transport and metabolism of cholesterol. In another preferred embodiment of the invention, the defective recombinant virus
15 comprises a gDNA nucleic acid encoding an ABC1 polypeptide involved in the transport and metabolism of cholesterol. Preferably, the ABC1 polypeptide comprises an amino acid sequence of SEQ ID NO: 71. More preferably, the ABC1 polypeptide comprises amino acids 1-60 of SEQ ID NO: 71.

In another preferred embodiment, the invention relates to a defective recombinant
20 virus comprising a nucleic acid encoding an ABC1 protein involved in the transport and metabolism of cholesterol under the control of a promoter chosen from RSV-LTR or the CMV early promoter.

According to a specific embodiment, a method of introducing a nucleic acid according to the invention into a host cell, in particular a host cell obtained from a mammal, *in vivo*,
25 comprises a step during which a preparation comprising a pharmaceutically compatible vector and a "naked" nucleic acid according to the invention, placed under the control of appropriate regulatory sequences, is introduced by local injection at the level of the chosen tissue, for example a smooth muscle tissue, the "naked" nucleic acid being absorbed by the cells of this tissue.

30 According to a specific embodiment of the invention, a composition is provided for the *in vivo* production of the ABC1 protein. This composition comprises a nucleic acid encoding the ABC1 polypeptide placed under the control of appropriate regulatory sequences, in solution in a physiologically acceptable vehicle and/or excipient.

Therefore, the present invention also relates to a composition comprising a nucleic acid
35 encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71, wherein the nucleic acid is placed under the control of appropriate regulatory elements.

The present invention also relates to a composition comprising a nucleic acid encoding a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, wherein the nucleic acid is placed under the control of appropriate regulatory elements.

Consequently, the invention also relates to a pharmaceutical composition intended for the prevention of or treatment of a patient or subject affected by a dysfunction in the reverse transport of cholesterol comprising a nucleic acid encoding the ABC1 protein, in combination with one or more physiologically compatible excipients.

Preferably, such a composition will comprise a nucleic acid comprising a polynucleotide sequence of either SEQ ID NO: 69 or SEQ ID NO: 70, wherein the nucleic acid is placed under the control of an appropriate regulatory element or signal.

The subject of the invention is, in addition, a pharmaceutical composition intended for the prevention of or treatment of a patient or a subject affected by a dysfunction in the reverse transport of cholesterol comprising a recombinant vector according to the invention, in combination with one or more physiologically compatible excipients.

The invention also relates to the use of a nucleic acid according to the invention encoding an ABC1 protein for the manufacture of a medicament intended for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

The invention also relates to the use of a recombinant vector according to the invention comprising a nucleic acid encoding an ABC1 protein for the manufacture of a medicament intended for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

The subject of the invention is therefore also a recombinant vector comprising a nucleic acid according to the invention that encodes an ABC1 protein or polypeptide involved in the metabolism of cholesterol.

The invention also relates to the use of such a recombinant vector for the preparation of a pharmaceutical composition intended for the treatment and/or for the prevention of cardiovascular diseases or conditions associated with HDL deficiency, such as the HDL deficiency associated with Tangier and/or FHD disease, HDL deficiency, LCAT deficiency, malaria, and diabetes.

The present invention also relates to the use of cells genetically modified *ex vivo* with such a recombinant vector according to the invention, or of cells producing a recombinant vector, wherein the cells are implanted in the body, to allow a prolonged and effective expression *in vivo* of a biologically active ABC1 polypeptide.

The invention also relates to the use of a nucleic acid according to the invention encoding an ABC1 protein for the manufacture of a medicament intended for the prevention or

treatment of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

The invention also relates to the use of a recombinant vector according to the invention comprising a nucleic acid encoding an ABC1 polypeptide according to the invention for the
5 manufacture of a medicament intended for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

The invention also relates to the use of a recombinant host cell according to the invention, comprising a nucleic acid encoding an ABC1 polypeptide according to the invention
10 for the manufacture of a medicament intended for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

The present invention also relates to the use of a recombinant vector according to the invention, preferably a defective recombinant virus, for the preparation of a pharmaceutical
15 composition for the treatment and/or prevention of pathologies linked to the transport of cholesterol.

The invention relates to the use of such a recombinant vector or defective recombinant virus for the preparation of a pharmaceutical composition intended for the treatment and/or for the prevention of cardiovascular disease linked to a deficiency in the
20 reverse transport of cholesterol. Thus, the present invention also relates to a pharmaceutical composition comprising one or more recombinant vectors or defective recombinant viruses according to the invention.

The present invention also relates to the use of cells genetically modified *ex vivo* with a virus according to the invention, or of cells producing such viruses, implanted in the body,
25 allowing a prolonged and effective expression *in vivo* of a biologically active ABC1 protein.

The present invention shows that it is possible to incorporate a nucleic acid encoding an ABC1 polypeptide according to the invention into a viral vector, and that these vectors make it possible to effectively express a biologically active, mature polypeptide. More particularly, the invention shows that the *in vivo* expression of ABC1 may be obtained by direct
30 administration of an adenovirus or by implantation of a producing cell or of a cell genetically modified by an adenovirus or by a retrovirus incorporating such a nucleic acid.

In this regard, another subject of the invention relates to any mammalian cell infected with one or more defective recombinant viruses according to the invention. More particularly, the invention relates to any population of human cells infected with these viruses. These may be
35 in particular cells of blood origin (totipotent stem cells or precursors), fibroblasts, myoblasts, hepatocytes, keratinocytes, smooth muscle and endothelial cells, glial cells and the like.

Another subject of the invention relates to an implant comprising mammalian cells infected with one or more defective recombinant viruses according to the invention or cells producing recombinant viruses, and an extracellular matrix. Preferably, the implants according to the invention comprise 10^5 to 10^{10} cells. More preferably, they comprise 10^6 to 10^8 cells.

5 More particularly, in the implants of the invention, the extracellular matrix comprises a gelling compound and optionally, a support allowing the anchorage of the cells.

The invention also relates to a recombinant host cell comprising a nucleic acid of the invention, and more particularly, a nucleic acid comprising either SEQ ID NO: 69 or SEQ ID NO: 70, or of a complementary polynucleotide sequence.

10 The invention also relates to a recombinant host cell comprising a nucleic acid of the invention, and more particularly a nucleic acid comprising a nucleotide sequence as depicted in SEQ ID NO: 69 or SEQ ID NO: 70, or of a complementary polynucleotide sequence.

Specifically, the invention relates to a recombinant host cell comprising nucleic acid comprising any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a
15 complementary polynucleotide sequence.

The invention also relates to a recombinant host cell comprising a nucleic acid comprising a polynucleotide sequence as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

The invention also relates to a recombinant host cell comprising a nucleic acid
20 comprising nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

The invention also relates to a recombinant host cell comprising a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71.

The invention also relates to a recombinant host cell comprising a nucleic acid encoding a
25 polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

According to another aspect, the invention also relates to a recombinant host cell comprising a recombinant vector according to the invention. Therefore, the invention also relates to a recombinant host cell comprising a recombinant vector comprising any of the nucleic acids of the invention, and more particularly a nucleic acid comprising a nucleotide
30 sequence of either SEQ ID NO: 69 or SEQ ID NO: 70, or of a complementary polynucleotide sequence.

Specifically, the invention relates to a recombinant host cell comprising a recombinant vector comprising a nucleic acid comprising any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

The invention also relates to a recombinant host cell comprising a recombinant vector comprising a nucleic acid comprising a polynucleotide sequence as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

- 5 The invention also relates to a recombinant host cell comprising a recombinant vector comprising a nucleic acid comprising nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or of a complementary polynucleotide sequence.

10 The invention also relates to a recombinant host cell comprising a recombinant vector comprising a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71.

The invention also relates to a recombinant host cell comprising a recombinant vector comprising a nucleic acid encoding a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

- 15 The invention also relates to a method for the production of a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, or of a peptide fragment or a variant thereof, wherein the peptide fragment or variant comprises amino acids 1-60 of SEQ ID NO: 71, said method comprising the steps of:

- a) inserting a nucleic acid encoding said polypeptide into an appropriate vector;
- b) culturing, in an appropriate culture medium, a previously transformed host cell or
- 20 transfecting a host cell with the recombinant vector of step a);
- c) recovering the conditioned culture medium or lysing the host cell, for example by sonication or by osmotic shock;
- d) separating and purifying said polypeptide from said culture medium or alternatively from the cell lysates obtained in step c); and
- 25 e) where appropriate, characterizing the recombinant polypeptide produced.

A specific embodiment of the invention relates to a method for producing a polypeptide comprising an amino acid sequence of amino acids 1-60 of SEQ ID NO: 71.

- 30 A polypeptide termed "homologous" to a polypeptide having an amino acid sequence comprising amino acids 1-60 of SEQ ID NO: 71 also forms part of the invention. Such a homologous polypeptide comprises an amino acid sequence possessing one or more substitutions of an amino acid by an equivalent amino acid, relative to amino acids 1-60 of SEQ ID NO: 71.

- 35 The ABC1 polypeptides according to the invention, in particular 1) a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, 2) a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, 3) a polypeptide fragment or variant of a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and

89-102, wherein the polypeptide fragment or variant comprises amino acids 1-60 of SEQ ID NO: 71, or 4) a polypeptide termed "homologous" to a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

In a specific embodiment, an antibody according to the invention is directed against 1) a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, 2) a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, 3) a polypeptide fragment or variant of a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, wherein the polypeptide fragment or variant comprises amino acids 1-60 of SEQ ID NO: 71, or 4) a polypeptide termed "homologous" to a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

The present invention relates to an antibody directed against 1) a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, 2) a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, 3) a polypeptide fragment or variant of a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, wherein the polypeptide fragment or variant comprises amino acids 1-60 of SEQ ID NO: 71, or 4) a polypeptide termed "homologous" to a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71 also forms part of the invention, as produced in the trioma technique or the hybridoma technique described by Kozbor et al. (1983b).

Thus, the subject of the invention is, in addition, a method of detecting the presence of a polypeptide according to the invention in a sample, said method comprising the steps of:

a) bringing the sample to be tested into contact with an antibody directed against 1) a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, 2) a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, 3) a polypeptide fragment or variant of a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, wherein the polypeptide fragment or variant comprises amino acids 1-60 of SEQ ID NO: 71, or 4) a polypeptide termed "homologous" to a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, and

b) detecting the antigen/antibody complex formed.

The invention also relates to a box or kit for diagnosis or for detecting the presence of a polypeptide in accordance with the invention in a sample, said box comprising:

a) an antibody directed against 1) a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, 2) a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, 3) a polypeptide fragment or variant of a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, wherein the polypeptide fragment or variant comprises amino acids 1-60 of SEQ ID NO: 71, or 4) a polypeptide "homologous" to a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, and

b) a reagent allowing the detection of the antigen/antibody complexes formed.

The invention also relates to a pharmaceutical composition comprising a nucleic acid according to the invention.

5 The invention also provides pharmaceutical compositions comprising a nucleic acid encoding an ABC1 polypeptide according to the invention and pharmaceutical compositions comprising an ABC1 polypeptide according to the invention intended for the treatment of diseases linked to a deficiency in the reverse transport of cholesterol, such as Tangier and/or FHD disease.

10 The present invention also relates to a new therapeutic approach for the treatment of pathologies linked to the transport of cholesterol, comprising transferring and expressing *in vivo* nucleic acids encoding an ABC1 protein according to the invention. Specifically, the present invention provides a new therapeutic approach for the treatment and/or prevention of HDL deficiency, such as the HDL deficiency associated with Tangier and/or FHD disease, HDL deficiency, LCAT deficiency, malaria, and diabetes.

15 Thus, the present invention offers a new approach for the treatment and prevention of cardiovascular and neurological pathologies linked to the abnormalities of the transport and metabolism of cholesterol. Specifically, the present invention provides methods to restore or promote improved reverse transport of cholesterol within a patient or subject.

20 Consequently, the invention also relates to a pharmaceutical composition intended for the prevention of or treatment of subjects affected by, a dysfunction in the reverse transport of cholesterol, comprising a nucleic acid encoding the ABC1 protein, in combination with one or more physiologically compatible vehicle and/or excipient.

25 According to a specific embodiment of the invention, a composition is provided for the *in vivo* production of the ABC1 protein. This composition comprises a nucleic acid encoding the ABC1 polypeptide placed under the control of appropriate regulatory sequences, in solution in a physiologically compatible vehicle and/or excipient.

Therefore, the present invention also relates to a composition comprising a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71, wherein the nucleic acid is placed under the control of appropriate regulatory elements.

30 The present invention also relates to a composition comprising a nucleic acid encoding a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, wherein the nucleic acid is placed under the control of appropriate regulatory elements.

35 Preferably, such a composition will comprise a nucleic acid comprising a polynucleotide sequence of SEQ ID NO: 69 or SEQ ID NO: 70, placed under the control of appropriate regulatory elements.

The invention also relates to a pharmaceutical composition intended for the prevention of or treatment of subjects affected by, a dysfunction in the reverse transport of cholesterol, comprising a recombinant vector according to the invention, in combination with one or more physiologically compatible vehicle and/or excipient.

5 According to another aspect, the subject of the invention is also a preventive or curative therapeutic method of treating diseases caused by a deficiency in the metabolism of cholesterol, more particularly in the transport of cholesterol and still more particularly in the reverse transport of cholesterol, such a method comprising a step in which there is administered to a patient a nucleic acid encoding an ABC1 polypeptide according to the invention in said patient,
10 said nucleic acid being, where appropriate, combined with one or more physiologically compatible vehicles and/or excipients.

 The invention relates to a pharmaceutical composition for the prevention or treatment of a patient or subject affected by a dysfunction in the reverse transport of cholesterol, comprising a therapeutically effective quantity of a polypeptide having an amino acid sequence
15 of SEQ ID NO: 71 or a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, combined with one or more physiologically compatible vehicles and/or excipients.

 According to a specific embodiment, a method of introducing a nucleic acid according to the invention into a host cell, in particular a host cell obtained from a mammal, *in vivo*, comprises a step during which a preparation comprising a pharmaceutically compatible vector
20 and a "naked" nucleic acid according to the invention, placed under the control of appropriate regulatory sequences, is introduced by local injection at the level of the chosen tissue, for example a smooth muscle tissue, the "naked" nucleic acid being absorbed by the cells of this tissue.

 According to yet another aspect, the subject of the invention is also a preventive or
25 curative therapeutic method of treating diseases caused by a deficiency in the metabolism of cholesterol, more particularly in the transport of cholesterol and still more particularly in the reverse transport of cholesterol, such a method comprising a step in which there is administered to a patient a therapeutically effective quantity of an ABC1 polypeptide according to the invention in said patient, said polypeptide being, where appropriate, combined with one or
30 more physiologically compatible vehicles and/or excipients.

 Preferably, a pharmaceutical composition comprising an ABC1 polypeptide according to the invention will be administered to the patient. Thus, the invention also relates to pharmaceutical compositions intended for the prevention or treatment of a deficiency in the metabolism of cholesterol such as atherosclerosis, particularly in the transport of cholesterol,
35 and still more particularly in the reverse transport of cholesterol, characterized in that they comprise a therapeutically effective quantity of a nucleic acid encoding a normal ABC1

polypeptide, in particular an ABC1 polypeptide having an amino acid sequence of SEQ ID NO: 71. In a specific embodiment, the ABC1 polypeptide comprises amino acids 1-60 of SEQ ID NO: 71.

5 The subject of the invention is, in addition, pharmaceutical compositions intended for the prevention or treatment of a deficiency in the metabolism of cholesterol such as atherosclerosis, particularly in the transport of cholesterol, and still more particularly in the reverse transport of cholesterol, characterized in that they comprise a therapeutically effective quantity of a normal ABC1 polypeptide, in particular of a polypeptide comprising an amino acid sequence of SEQ ID NO: 71. In a specific embodiment, the ABC1 polypeptide comprises
10 amino acids 1-60 of SEQ ID NO: 71.

The invention also provides methods for screening small molecules and compounds that act on the ABC1 protein to identify agonists and antagonists of ABC1 polypeptide that can restore or promote improved reverse transport of cholesterol to effectively combat arteriosclerosis from a therapeutic point of view. These methods are useful to identify small
15 molecules and compounds for therapeutic use in the treatment of diseases due to a deficiency in the metabolism of cholesterol, particularly in the transport of cholesterol, still more particularly in the reverse transport of cholesterol, such as Tangier disease, or more generally, FHD-type conditions.

Therefore, the invention also relates to the use of an ABC1 polypeptide or a cell
20 expressing an ABC1 polypeptide according to the invention, for screening active ingredients for the prevention or treatment of diseases resulting from a dysfunction in the reverse transport of cholesterol.

The invention also relates to a method of screening a compound or small molecule active on the metabolism of cholesterol, an agonist or antagonist of an ABC1 polypeptide, said
25 method comprising the following steps:

- a) preparing a membrane vesicle comprising an ABC1 polypeptide and a lipid substrate comprising a detectable marker;
- b) incubating the vesicle obtained in step a) with an agonist or antagonist candidate compound;
- 30 c) qualitatively and/or quantitatively measuring release of the lipid substrate comprising a detectable marker; and
- d) comparing the release measurement obtained in step b) with a measurement of release of a labeled lipid substrate by a vesicle that has not been previously incubated with the agonist or antagonist candidate compound.

35 In a first specific embodiment, the ABC1 polypeptide comprises SEQ ID NO: 71.

In a second specific embodiment, the ABC1 polypeptide comprises amino acids 1-60 of SEQ ID NO: 71.

The invention also relates to a method of screening a compound or small molecule active on the metabolism of cholesterol, an agonist or antagonist of an ABC1 polypeptide, said method comprising the following steps:

- a) obtaining a cell, for example a cell line, that, either naturally or after transfecting the cell with an ABC1 encoding nucleic acid, expresses an ABC1 polypeptide;
- b) incubating the cell of step a) in the presence of an anion labeled with a detectable marker;
- c) washing the cell of step b) in order to remove the excess of the labeled anion which has not penetrated into these cells;
- d) incubating the cell obtained in step c) with an agonist or antagonist candidate compound for the ABC1 polypeptide;
- e) measuring efflux of the labeled anion; and
- f) comparing the value of efflux of the labeled anion determined in step e) with a value of efflux of a labeled anion measured with cell which have not been previously incubated in the presence of the agonist or antagonist candidate compound for the ABC1 polypeptide.

In a first specific embodiment, the ABC1 polypeptide comprises SEQ ID NO: 71.

In a second specific embodiment, the ABC1 polypeptide comprises amino acids 1-60 of SEQ ID NO: 71.

The subject of the invention is also a method of screening a compound or small molecule active on the metabolism of cholesterol, an agonist or antagonist of an ABC1 polypeptide, said method comprising the following steps:

- a) culturing cells of a human monocytic line in an appropriate culture medium, in the presence of purified human albumin;
- b) incubating the cells of step a) simultaneously in the presence of a compound stimulating the production of IL-1 beta and of the agonist or antagonist candidate compound;
- c) incubating the cells obtained in step b) in the presence of an appropriate concentration of ATP;
- d) measuring IL-1 beta released into the cell culture supernatant; and
- e) comparing the value of the release of the IL-1 beta obtained in step d) with the value of the IL-1 beta released into the culture supernatant of cells which have not been previously incubated in the presence of the agonist or antagonist candidate compound.

BRIEF DESCRIPTION OF THE DRAWINGS

- Figure 1: ABC1 5'cDNA Extension Strategy;
- Figure 2: Agarose Gel Analysis of Primary and Secondary Human ABC1 5' cDNA Extension PCR Reactions;
- Figure 3: Agarose Gel Analysis of Nested Secondary Human ABC1 5' cDNA Extension Nested PCR Reactions;
- Figure 4: Measure of cholesterol efflux in HeLa cell lines expressing human full length ABC1 protein in the absence ■ or presence □ of apolipoproteins;
- Figure 5: Measure of phospholipid efflux in HeLa cell lines expressing human full length ABC1 protein in the absence ■ or presence □ of apolipoproteins;
- Figure 6A: Measure of cholesterol efflux in the absence ■ or presence □ of apolipoprotein A-I (AI);
- Figure 6B: Measure of phospholipid efflux in the absence ■ or presence □ of apolipoproteins A-I (AI);
- Figure 6C: Measure of cholesterol efflux in the absence ■ or presence □ of HDL;
- Figure 6D: Measure of cholesterol efflux in the absence ■ or presence □ of phosphatidylcholine(PC);
- Figure 7: [¹²⁵I] apoA-I incubated ABC1 cells were placed in the absence of apolipoprotein□, in the presence of apolipoprotein A-I (apoA-I) ■, or in the presence of apolipoprotein A-II (apoA-II) ▣ ;

DETAILED DESCRIPTION OF THE INVENTION

GENERAL DEFINITIONS

The present invention contemplates isolation of a gene encoding an ABC1 polypeptide of the invention, including a full length, or naturally occurring form of ABC1, and any antigenic fragments thereof from any animal, particularly mammalian or avian, and more particularly human, source.

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, *e.g.*, Sambrook et al., 1989; Glover, 1985; Gait, 1984; Hames and Higgins, 1985; Hames and Higgins, 1984; Freshney, 1986; Perbal, 1984; and F. Ausubel et al., 1994.

Therefore, if appearing herein, the following terms shall have the definitions set out below.

As used herein, the term "gene" refers to an assembly of nucleotides that encode a polypeptide, and includes cDNA and genomic DNA nucleic acids.

The term "isolated" for the purposes of the present invention designates a biological material (nucleic acid or protein) which has been removed from its original environment (the
5 environment in which it is naturally present).

For example, a polynucleotide present in the natural state in a plant or an animal is not isolated. The same polynucleotide separated from the adjacent nucleic acids in which it is naturally inserted in the genome of the plant or animal is considered as being "isolated".

Such a polynucleotide may be included in a vector and/or such a polynucleotide may be
10 included in a composition and remains nevertheless in the isolated state because of the fact that the vector or the composition does not constitute its natural environment.

The term "purified" does not require the material to be present in a form exhibiting absolute purity, exclusive of the presence of other compounds. It is rather a relative definition.

A polynucleotide is in the "purified" state after purification of the starting material or
15 of the natural material by at least one order of magnitude, preferably 2 or 3 and preferably 4 or 5 orders of magnitude.

For the purposes of the present description, the expression "nucleotide sequence" may be used to designate either a polynucleotide or a nucleic acid. The expression "nucleotide sequence" covers the genetic material itself and is therefore not restricted to the information
20 relating to its sequence.

The terms "nucleic acid", "polynucleotide", "oligonucleotide" or "nucleotide sequence" cover RNA, DNA, gDNA or cDNA sequences or alternatively RNA/DNA hybrid sequences of more than one nucleotide, either in the single-stranded form or in the duplex, double-stranded form.

25 A "nucleic acid" is a polymeric compound comprised of covalently linked subunits called nucleotides. Nucleic acid includes polyribonucleic acid (RNA) and polydeoxyribonucleic acid (DNA), both of which may be single-stranded or double-stranded. DNA includes cDNA, genomic DNA, synthetic DNA, and semi-synthetic DNA. The sequence of nucleotides that encodes a protein is called the sense sequence or coding sequence.

30 The term "nucleotide" designates both the natural nucleotides (A, T, G, C) as well as the modified nucleotides that comprise at least one modification such as (1) an analog of a purine, (2) an analog of a pyrimidine, or (3) an analogous sugar, examples of such modified nucleotides being described, for example, in the PCT application No. WO 95/04 064.

For the purposes of the present invention, a first polynucleotide is considered as being
35 "complementary" to a second polynucleotide when each base of the first nucleotide is paired

with the complementary base of the second polynucleotide whose orientation is reversed. The complementary bases are A and T (or A and U), or C and G.

"Heterologous" DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. Preferably, the heterologous DNA includes a gene foreign to the cell.

As used herein, the term "homologous" in all its grammatical forms and spelling variations refers to the relationship between proteins that possess a "common evolutionary origin," including proteins from superfamilies (*e.g.*, the immunoglobulin superfamily) and homologous proteins from different species (*e.g.*, myosin light chain, etc.) (Reeck et al., 1987). Such proteins (and their encoding genes) have sequence homology, as reflected by their high degree of sequence similarity.

Accordingly, the term "sequence similarity" in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that may or may not share a common evolutionary origin (*see* Reeck et al., *supra*). However, in common usage and in the instant application, the term "homologous," when modified with an adverb such as "highly," may refer to sequence similarity and not a common evolutionary origin.

In a specific embodiment, two DNA sequences are "substantially homologous" or "substantially similar" when at least about 50% (preferably at least about 75%, and more preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, *e.g.*, Maniatis et al., *supra*; Glover et al., 1985; Hames and Higgins, 1985.

Similarly, in a particular embodiment, two amino acid sequences are "substantially homologous" or "substantially similar" when greater than 30% of the amino acids are identical, or greater than about 60% are similar (functionally identical). Preferably, the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, *Version 7*, Madison, Wisconsin) pileup program.

The "percentage identity" between two nucleotide or amino acid sequences, for the purposes of the present invention, may be determined by comparing two sequences aligned optimally, through a window for comparison.

The portion of the nucleotide or polypeptide sequence in the window for comparison may thus comprise additions or deletions (for example "gaps") relative to the reference

sequence (which does not comprise these additions or these deletions) so as to obtain an optimum alignment of the two sequences.

The percentage is calculated by determining the number of positions at which an identical nucleic base or an identical amino acid residue is observed for the two sequences (nucleic or peptide) compared, and then by dividing the number of positions at which there is identity between the two bases or amino acid residues by the total number of positions in the window for comparison, and then multiplying the result by 100 in order to obtain the percentage sequence identity.

The optimum sequence alignment for the comparison may be achieved using a computer with the aid of known algorithms contained in the package from the company WISCONSIN GENETICS SOFTWARE PACKAGE, GENETICS COMPUTER GROUP (GCG), 575 Science Doctor, Madison, WISCONSIN.

By way of illustration, it will be possible to produce the percentage sequence identity with the aid of the BLAST software (versions BLAST 1.4.9 of March 1996, BLAST 2.0.4 of February 1998 and BLAST 2.0.6 of September 1998), using exclusively the default parameters (Altschul et al, 1990; Altschul et al, 1997). Blast searches for sequences similar/homologous to a reference "request" sequence, with the aid of the Altschul et al. algorithm. The request sequence and the databases used may be of the peptide or nucleic types, any combination being possible.

The term "corresponding to" is used herein to refer to similar or homologous sequences, whether the exact position is identical or different from the molecule to which the similarity or homology is measured. A nucleic acid or amino acid sequence alignment may include spaces. Thus, the term "corresponding to" refers to the sequence similarity, and not the numbering of the amino acid residues or nucleotide bases.

A gene encoding an ABC1 polypeptide of the invention, whether genomic DNA or cDNA, can be isolated from any source, particularly from a human cDNA or genomic library. Methods for obtaining genes are well known in the art, as described above (*see, e.g.*, Sambrook et al., 1989).

Accordingly, any animal cell potentially can serve as the nucleic acid source for the molecular cloning of an ABC1 gene. The DNA may be obtained by standard procedures known in the art from cloned DNA (*e.g.*, a DNA "library"), and preferably is obtained from a cDNA library prepared from tissues with high level expression of the protein, by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (See, for example, Sambrook et al., 1989; Glover, 1985). Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions;

clones derived from cDNA will not contain intron sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from genomic DNA, DNA fragments are generated, some of which will encode the desired gene. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNase in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired ABC1 gene may be accomplished in a number of ways. For example, if an amount of a portion of a ABC1 gene or its specific RNA, or a fragment thereof, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton and Davis, 1977; Grunstein and Hogness, 1975). For example, a set of oligonucleotides corresponding to the partial amino acid sequence information obtained for the ABC1 protein can be prepared and used as probes for DNA encoding ABC1, as was done in a specific example, *infra*, or as primers for cDNA or mRNA (e.g., in combination with a poly-T primer for RT-PCR). Preferably, a fragment is selected that is highly unique to an ABC1 nucleic acid or polypeptide of the invention. Those DNA fragments with substantial homology to the probe will hybridize. As noted above, the greater the degree of homology, the more stringent hybridization conditions can be used. In a specific embodiment, stringency hybridization conditions are used to identify a homologous ABC1 gene.

Further selection can be carried out on the basis of the properties of the gene, e.g., if the gene encodes a protein product having the isoelectric, electrophoretic, amino acid composition, or partial amino acid sequence of a ABC1 protein as disclosed herein. Thus, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, e.g., has similar or identical electrophoretic migration, isoelectric focusing or non-equilibrium pH gel electrophoresis behavior, proteolytic digestion maps, or antigenic properties as known for ABC1.

An ABC1 gene of the invention can also be identified by mRNA selection, i.e., by nucleic acid hybridization followed by *in vitro* translation. In this procedure, nucleotide fragments are used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified ABC1 DNA, or may be synthetic oligonucleotides designed

from the partial amino acid sequence information. Immunoprecipitation analysis or functional assays (*e.g.*, tyrosine phosphatase activity) of the *in vitro* translation products of the products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments, that contain the desired sequences. In addition, specific mRNAs may be selected by adsorption
5 of polysomes isolated from cells to immobilized antibodies specifically directed against an ABC1 polypeptide of the invention.

A radiolabeled ABC1 cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabeled mRNA or cDNA may then be used as a probe to identify homologous ABC1 DNA fragments from among other genomic DNA
10 fragments.

"Variant" of a nucleic acid according to the invention will be understood to mean a nucleic acid which differs by one or more bases relative to the reference polynucleotide. A variant nucleic acid may be of natural origin, such as an allelic variant which exists naturally, or it may also be a nonnatural variant obtained, for example, by mutagenic techniques.

15 In general, the differences between the reference (generally, wild-type) nucleic acid and the variant nucleic acid are small such that the nucleotide sequences of the reference nucleic acid and of the variant nucleic acid are very similar and, in many regions, identical. The nucleotide modifications present in a variant nucleic acid may be silent, which means that they do not alter the amino acid sequences encoded by said variant nucleic acid.

20 However, the changes in nucleotides in a variant nucleic acid may also result in substitutions, additions or deletions in the polypeptide encoded by the variant nucleic acid in relation to the polypeptides encoded by the reference nucleic acid. In addition, nucleotide modifications in the coding regions may produce conservative or non-conservative substitutions in the amino acid sequence of the polypeptide.

25 Preferably, the variant nucleic acids according to the invention encode polypeptides which substantially conserve the same function or biological activity as the polypeptide of the reference nucleic acid or alternatively the capacity to be recognized by antibodies directed against the polypeptides encoded by the initial reference nucleic acid.

Some variant nucleic acids will thus encode mutated forms of the polypeptides whose
30 systematic study will make it possible to deduce structure-activity relationships of the proteins in question. Knowledge of these variants in relation to the disease studied is essential since it makes it possible to understand the molecular cause of the pathology.

"Fragment" will be understood to mean a nucleotide sequence of reduced length relative to the reference nucleic acid and comprising, over the common portion, a nucleotide
35 sequence identical to the reference nucleic acid. Such a nucleic acid "fragment" according to the invention may be, where appropriate, included in a larger polynucleotide of which it is a

constituent. Such fragments comprise, or alternatively consist of, oligonucleotides ranging in length from 8, 10, 12, 15, 18, 20 to 25, 30, 40, 50, 70, 80, 100, 200, 500, 1000 or 1500 consecutive nucleotides of a nucleic acid according to the invention.

A "nucleic acid molecule" refers to the phosphate ester polymeric form of
5 ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or
deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine;
"DNA molecules"), or any phosphoester analogs thereof, such as phosphorothioates and
thioesters, in either single stranded form, or a double-stranded helix. Double stranded DNA-
DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in
10 particular DNA or RNA molecule, refers only to the primary and secondary structure of the
molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-
stranded DNA found, *inter alia*, in linear or circular DNA molecules (e.g., restriction
fragments), plasmids, and chromosomes. In discussing the structure of particular double-
stranded DNA molecules, sequences may be described herein according to the normal
15 convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand
of DNA (*i.e.*, the strand having a sequence homologous to the mRNA). A "recombinant DNA
molecule" is a DNA molecule that has undergone a molecular biological manipulation.

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a
cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can
20 anneal to the other nucleic acid molecule under the appropriate conditions of temperature and
solution ionic strength (*see* Sambrook et al., *supra*). The conditions of temperature and ionic
strength determine the "stringency" of the hybridization. For preliminary screening for
homologous nucleic acids, low stringency hybridization conditions, corresponding to a T_m of
55°, can be used, e.g., 5x SSC, 0.1% SDS, 0.25% milk, and no formamide; or 30% formamide,
25 5x SSC, 0.5% SDS). Moderate stringency hybridization conditions correspond to a higher T_m ,
e.g., 40% formamide, with 5x or 6x SCC. High stringency hybridization conditions correspond
to the highest T_m , e.g., 50% formamide, 5x or 6x SCC. Hybridization requires that the two
nucleic acids contain complementary sequences, although depending on the stringency of the
hybridization, mismatches between bases are possible. The appropriate stringency for
30 hybridizing nucleic acids depends on the length of the nucleic acids and the degree of
complementation, variables well known in the art. The greater the degree of similarity or
homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic
acids having those sequences. The relative stability (corresponding to higher T_m) of nucleic
acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For
35 hybrids of greater than 100 nucleotides in length, equations for calculating T_m have been
derived (*see* Sambrook et al., *supra*, 9.50-0.51). For hybridization with shorter nucleic acids,

i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., *supra*, 11.7-11.8). Preferably a minimum length for a hybridizable nucleic acid is at least about 10 nucleotides; preferably at least about 15 nucleotides; and more preferably the length is at least about 20 nucleotides.

- 5 In a specific embodiment, the term "standard hybridization conditions" refers to a T_m of 55°C, and utilizes conditions as set forth above. In a preferred embodiment, the T_m is 60°C; in a more preferred embodiment, the T_m is 65°C.

"High stringency hybridization conditions" for the purposes of the present invention will be understood to mean the following conditions:

10 1- Membrane competition and PREHYBRIDIZATION:

- Mix: 40 µl salmon sperm DNA (10 mg/ml)
 + 40 µl human placental DNA (10 mg/ml)
- Denature for 5 minutes at 96°C, then immerse the mixture in ice.
- Remove the 2X SSC and pour 4 ml of formamide mix in the hybridization tube containing the
- 15 membranes.
- Add the mixture of the two denatured DNAs.
- Incubation at 42°C for 5 to 6 hours, with rotation.

2- Labeled probe competition:

- 20 - Add to the labeled and purified probe 10 to 50 µl Cot I DNA, depending on the quantity of repeats.
- Denature for 7 to 10 minutes at 95°C.
 - Incubate at 65°C for 2 to 5 hours.

25 3- HYBRIDIZATION:

- Remove the prehybridization mix.
- Mix 40 µl salmon sperm DNA + 40 µl human placental DNA; denature for 5 min at 96°C, then immerse in ice.
- Add to the hybridization tube 4 ml of formamide mix, the mixture of the two DNAs and the
- 30 denatured labeled probe/Cot I DNA .
- Incubate 15 to 20 hours at 42°C, with rotation.

4- Washes and Exposure:

- One wash at room temperature in 2X SSC, to rinse.
- 35 - Twice 5 minutes at room temperature 2X SSC and 0.1% SDS at 65°C.
- Twice 15 minutes at 65°C 1X SSC and 0.1% SDS at 65°C.

- Envelope the membranes in clear plastic wrap and expose.

The hybridization conditions described above are adapted to hybridization, under high stringency conditions, of a molecule of nucleic acid of varying length from 20 nucleotides to several hundreds of nucleotides. It goes without saying that the hybridization conditions described above may be adjusted as a function of the length of the nucleic acid whose hybridization is sought or of the type of labeling chosen, according to techniques known to one skilled in the art. Suitable hybridization conditions may, for example, be adjusted according to the teaching contained in the manual by Hames and Higgins (1985) or in the manual by F. Ausubel et al. (1999).

As used herein, the term "oligonucleotide" refers to a nucleic acid, generally of at least 15 nucleotides, that is hybridizable to a nucleic acid according to the invention. Oligonucleotides can be labeled, *e.g.*, with ^{32}P -nucleotides or nucleotides to which a label, such as biotin, has been covalently conjugated. In one embodiment, a labeled oligonucleotide can be used as a probe to detect the presence of a nucleic acid encoding an ABC1 polypeptide of the invention. In another embodiment, oligonucleotides (one or both of which may be labeled) can be used as PCR primers, either for cloning full length or a fragment of an ABC1 nucleic acid, or to detect the presence of nucleic acids encoding ABC1. In a further embodiment, an oligonucleotide of the invention can form a triple helix with an ABC1 DNA molecule. Generally, oligonucleotides are prepared synthetically, preferably on a nucleic acid synthesizer. Accordingly, oligonucleotides can be prepared with non-naturally occurring phosphoester analog bonds, such as thioester bonds, etc.

"Homologous recombination" refers to the insertion of a foreign DNA sequence of a vector in a chromosome. Preferably, the vector targets a specific chromosomal site for homologous recombination. For specific homologous recombination, the vector will contain sufficiently long regions of homology to sequences of the chromosome to allow complementary binding and incorporation of the vector into the chromosome. Longer regions of homology, and greater degrees of sequence similarity, may increase the efficiency of homologous recombination.

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (*e.g.*, mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a

eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences.

"Regulatory region" means a nucleic acid sequence which regulates the expression of a nucleic acid. A regulatory region may include sequences which are naturally responsible for expressing a particular nucleic acid (a homologous region) or may include sequences of a different origin (responsible for expressing different proteins or even synthetic proteins). In particular, the sequences can be sequences of eukaryotic or viral genes or derived sequences which stimulate or repress transcription of a gene in a specific or non-specific manner and in an inducible or non-inducible manner. Regulatory regions include origins of replication, RNA splice sites, enhancers, transcriptional termination sequences, signal sequences which direct the polypeptide into the secretory pathways of the target cell, and promoters.

A regulatory region from a "heterologous source" is a regulatory region which is not naturally associated with the expressed nucleic acid. Included among the heterologous regulatory regions are regulatory regions from a different species, regulatory regions from a different gene, hybrid regulatory sequences, and regulatory sequences which do not occur in nature, but which are designed by one having ordinary skill in the art.

A "cassette" refers to a segment of DNA that can be inserted into a vector at specific restriction sites. The segment of DNA encodes a polypeptide of interest, and the cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation.


A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.

A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced and translated into the protein encoded by the coding sequence.

A "signal sequence" is included at the beginning of the coding sequence of a protein to be expressed on the surface of a cell. This sequence encodes a signal peptide, N-terminal to the mature polypeptide, that directs the host cell to translocate the polypeptide. The term "translocation signal sequence" is used herein to refer to this sort of signal sequence.

- 5 Translocation signal sequences can be found associated with a variety of proteins native to eukaryotes and prokaryotes, and are often functional in both types of organisms.

A "polypeptide" is a polymeric compound comprised of covalently linked amino acid residues. Amino acids have the following general structure:



15

Amino acids are classified into seven groups on the basis of the side chain R: (1) aliphatic side chains, (2) side chains containing a hydroxylic (OH) group, (3) side chains containing sulfur atoms, (4) side chains containing an acidic or amide group, (5) side chains containing a basic group, (6) side chains containing an aromatic ring, and (7) proline, an imino acid in which the side chain is fused to the amino group.

20

A "protein" is a polypeptide which plays a structural or functional role in a living cell.

The polypeptides and proteins of the invention may be glycosylated or unglycosylated.

"Homology" means similarity of sequence reflecting a common evolutionary origin.

- 25 Polypeptides or proteins are said to have homology, or similarity, if a substantial number of their amino acids are either (1) identical, or (2) have a chemically similar R side chain. Nucleic acids are said to have homology if a substantial number of their nucleotides are identical.

- 30 "Isolated polypeptide" or "isolated protein" is a polypeptide or protein which is substantially free of those compounds that are normally associated therewith in its natural state (e.g., other proteins or polypeptides, nucleic acids, carbohydrates, lipids). "Isolated" is not meant to exclude artificial or synthetic mixtures with other compounds, or the presence of impurities which do not interfere with biological activity, and which may be present, for example, due to incomplete purification, addition of stabilizers, or compounding into a pharmaceutically acceptable preparation.

- 35 "Fragment" of a polypeptide according to the invention will be understood to mean a polypeptide whose amino acid sequence is shorter than that of the reference polypeptide and

which comprises, over the entire portion with these reference polypeptides, an identical amino acid sequence. Such fragments may, where appropriate, be included in a larger polypeptide of which they are a part. Such fragments of a polypeptide according to the invention may have a length of 10, 15, 20, 30 to 40, 50, 100, 200 or 300 amino acids.

5 "Variant" of a polypeptide according to the invention will be understood to mean mainly a polypeptide whose amino acid sequence contains one or more substitutions, additions or deletions of at least one amino acid residue, relative to the amino acid sequence of the reference polypeptide, it being understood that the amino acid substitutions may be either conservative or nonconservative.

10 A "variant" of a polypeptide or protein is any analogue, fragment, derivative, or mutant which is derived from a polypeptide or protein and which retains at least one biological property of the polypeptide or protein. Different variants of the polypeptide or protein may exist in nature. These variants may be allelic variations characterized by differences in the nucleotide sequences of the structural gene coding for the protein, or may involve differential
15 splicing or post-translational modification. Variants also include a related protein having substantially the same biological activity, but obtained from a different species.

The skilled artisan can produce variants having single or multiple amino acid substitutions, deletions, additions, or replacements. These variants may include, *inter alia*: (a) variants in which one or more amino acid residues are substituted with conservative or non-
20 conservative amino acids, (b) variants in which one or more amino acids are added to the polypeptide or protein, (c) variants in which one or more of the amino acids includes a substituent group, and (d) variants in which the polypeptide or protein is fused with another polypeptide such as serum albumin. The techniques for obtaining these variants, including genetic (suppressions, deletions, mutations, etc.), chemical, and enzymatic techniques, are
25 known to persons having ordinary skill in the art.

If such allelic variations, analogues, fragments, derivatives, mutants, and modifications, including alternative mRNA splicing forms and alternative post-translational modification forms result in derivatives of the polypeptide which retain any of the biological properties of the polypeptide, they are intended to be included within the scope of this invention.

30 A "vector" is a replicon, such as plasmid, virus, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment. A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*, i.e., capable of replication under its own control.

The present invention also relates to cloning vectors containing genes encoding analogs
35 and derivatives of a ABC1 polypeptide of the invention, that have the same or homologous functional activity as that ABC1 polypeptide, and homologs thereof from other species. The

production and use of derivatives and analogs related to ABC1 are within the scope of the present invention. In a specific embodiment, the derivative or analog is functionally active, *i.e.*, capable of exhibiting one or more functional activities associated with a full-length, wild-type an ABC1 polypeptide of the invention.

5 ABC1 derivatives can be made by altering encoding nucleic acid sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Preferably, derivatives are made that have enhanced or increased functional activity relative to native ABC1. Alternatively, such derivatives may encode soluble fragments of the ABC1 extracellular domain that have the same or greater affinity for the natural ligand of an ABC1
10 polypeptide of the invention. Such soluble derivatives may be potent inhibitors of ligand binding to ABC1.

Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as an ABC1 gene may be used in the practice of the present invention. These include but are not limited to allelic genes,
15 homologous genes from other species, and nucleotide sequences comprising all or portions of ABC1 genes which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Likewise, the ABC1 derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of an ABC1 protein including altered
20 sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a conservative amino acid substitution. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the
25 class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Amino acids containing aromatic ring structures are phenylalanine, tryptophan, and tyrosine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and
30 histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such alterations will not be expected to affect apparent molecular weight as determined by polyacrylamide gel electrophoresis, or isoelectric point.

Particularly preferred substitutions are:

- Lys for Arg and vice versa such that a positive charge may be maintained;
- 35 - Glu for Asp and vice versa such that a negative charge may be maintained;
- Ser for Thr such that a free -OH can be maintained; and

- Gln for Asn such that a free CONH₂ can be maintained.

Amino acid substitutions may also be introduced to substitute an amino acid with a particularly preferable property. For example, a Cys may be introduced a potential site for disulfide bridges with another Cys. A His may be introduced as a particularly "catalytic" site (i.e., His can act as an acid or base and is the most common amino acid in biochemical catalysis). Pro may be introduced because of its particularly planar structure, which induces b-

turns in the protein's structure.

The genes encoding ABC1 derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned ABC1 gene sequence can be modified by any of numerous strategies known in the art (Sambrook et al., 1989, *supra*). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. In the production of the gene encoding a derivative or analog of ABC1, care should be taken to ensure that the modified gene remains within the same translational reading frame as the ABC1 gene, uninterrupted by translational stop signals, in the gene region where the desired activity is encoded.

Additionally, the ABC1-encoding nucleic acids can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Preferably, such mutations enhance the functional activity of the mutated ABC1 gene product. Any technique for mutagenesis known in the art can be used, including but not limited to, *in vitro* site-directed mutagenesis (Hutchinson, C., et al., 1978; Zoller and Smith, 1984; Oliphant et al., 1986; Hutchinson et al., 1986; Huygen et al., 1996) use of TAB® linkers (Pharmacia), etc. PCR techniques are preferred for site directed mutagenesis (see Higuchi, 1989, "Using PCR to Engineer DNA", in *PCR Technology: Principles and Applications for DNA Amplification*, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70).

The identified and isolated gene can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Examples of vectors include, but are not limited to, *Escherichia coli*, bacteriophages such as lambda derivatives, or plasmids such as pBR322 derivatives or pUC plasmid derivatives, e.g., pGEX vectors, pmal-c, pFLAG, etc. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules

may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated. Preferably, the cloned gene is contained on a shuttle vector plasmid, which provides for expansion in a cloning cell, *e.g.*, *Escherichia coli*, and facile purification for subsequent insertion into an appropriate expression cell line, if such is desired. For example, a shuttle vector, which is a vector that can replicate in more than one type of organism, can be prepared for replication in both *Escherichia coli* and *Saccharomyces cerevisiae* by linking sequences from an *Escherichia coli* plasmid with sequences from the yeast 2 μ plasmid.

In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.

The nucleotide sequence coding for an ABC1 polypeptide or antigenic fragment, derivative or analog thereof, or a functionally active derivative, including a chimeric protein, thereof, can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. Such elements are termed herein a "promoter." Thus, the nucleic acid encoding an ABC1 polypeptide of the invention is operationally associated with a promoter in an expression vector of the invention. Both cDNA and genomic sequences can be cloned and expressed under control of such regulatory sequences. An expression vector also preferably includes a replication origin.

The necessary transcriptional and translational signals can be provided on a recombinant expression vector, or they may be supplied by a native gene encoding ABC1 and/or its flanking regions.

Potential host-vector systems include but are not limited to mammalian cell systems infected with virus (*e.g.*, vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (*e.g.*, baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

A recombinant ABC1 protein of the invention, or functional fragment, derivative, chimeric construct, or analog thereof, may be expressed chromosomally, after integration of the coding sequence by recombination. In this regard, any of a number of amplification systems

may be used to achieve high levels of stable gene expression (*See* Sambrook et al., 1989, *supra*).

The cell into which the recombinant vector comprising the nucleic acid encoding an ABC1 polypeptide according to the invention is cultured in an appropriate cell culture medium
5 under conditions that provide for expression of the ABC1 polypeptide by the cell.

Any of the methods previously described for the insertion of DNA fragments into a cloning vector may be used to construct expression vectors containing a gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo*
10 recombination (genetic recombination).

Expression of an ABC1 polypeptide may be controlled by any promoter/enhancer element known in the art, but these regulatory elements must be functional in the host selected for expression. Promoters which may be used to control ABC1 gene expression include, but are not limited to, the SV40 early promoter region (Benoist and Chambon, 1981), the promoter
15 contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980), the herpes thymidine kinase promoter (Wagner et al., 1981), the regulatory sequences of the metallothionein gene (Brinster et al., 1982); prokaryotic expression vectors such as the b-lactamase promoter (Villa-Kamaroff, et al., 1978), or the *tac* promoter (DeBoer, et al., 1983); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94;
20 promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter; and the animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984; Ornitz et al., 1986; MacDonald, 1987); insulin gene
25 control region which is active in pancreatic beta cells (Hanahan, 1985), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984; Adames et al., 1985; Alexander et al., 1987), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986), albumin gene control region which is active in liver (Pinkert et al., 1987), alpha-fetoprotein gene control region which is
30 active in liver (Krumlauf et al., 1985; Hammer et al., 1987), alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987) beta-globin gene control region which is active in myeloid cells (Mogam et al., 1985; Kollias et al., 1986), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985), and
35 gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986).

Expression vectors containing a nucleic acid encoding an ABC1 polypeptide of the invention can be identified by four general approaches: (a) polymerase chain reaction (PCR) amplification of the desired plasmid DNA or specific mRNA, (b) nucleic acid hybridization, (c) presence or absence of selection marker gene functions, (d) analyses with appropriate restriction endonucleases, and (e) expression of inserted sequences. In the first approach, the nucleic acids can be amplified by PCR to provide for detection of the amplified product. In the second approach, the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted marker gene. In the third approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "selection marker" gene functions (e.g., b-galactosidase activity, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. In another example, if the nucleic acid encoding an ABC1 polypeptide is inserted within the "selection marker" gene sequence of the vector, recombinants containing the ABC1 nucleic acid insert can be identified by the absence of the ABC1 gene function. In the fourth approach, recombinant expression vectors are identified by digestion with appropriate restriction enzymes. In the fifth approach, recombinant expression vectors can be identified by assaying for the activity, biochemical, or immunological characteristics of the gene product expressed by the recombinant, provided that the expressed protein assumes a functionally active conformation.

A wide variety of host/expression vector combinations may be employed in expressing the nucleic acids of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., *Escherichia coli* plasmids col El, pCR1, pBR322, pMal-C2, pET, pGEX (Smith *et al.*, 1988), pMB9 and their derivatives, plasmids such as RP4; phage DNAs, e.g., the numerous derivatives of phage λ , e.g., NM989, and other phage DNA, e.g., M13 and filamentous single stranded phage DNA; yeast plasmids such as the 2 μ plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like.

For example, in a baculovirus expression systems, both non-fusion transfer vectors, such as but not limited to pVL941 (*Bam*H1 cloning site; Summers), pVL1393 (*Bam*H1, *Sma*I, *Xba*I, *Eco*R1, *Not*I, *Xma*III, *Bgl*II, and *Pst*I cloning site; Invitrogen), pVL1392 (*Bgl*II, *Pst*I, *Not*I, *Xma*III, *Eco*R1, *Xba*I, *Sma*I, and *Bam*H1 cloning site; Summers and Invitrogen), and pBlueBacIII (*Bam*H1, *Bgl*II, *Pst*I, *Nco*I, and *Hind*III cloning site, with blue/white recombinant

screening possible; Invitrogen), and fusion transfer vectors, such as but not limited to pAc700 (*Bam*HI and *Kpn*I cloning site, in which the *Bam*HI recognition site begins with the initiation codon; Summers), pAc701 and pAc702 (same as pAc700, with different reading frames), pAc360 (*Bam*HI cloning site 36 base pairs downstream of a polyhedrin initiation codon; Invitrogen(195)), and pBlueBacHisA, B, C (three different reading frames, with *Bam*HI, *Bgl*II, *Pst*I, *Nco*I, and *Hind*III cloning site, an N-terminal peptide for ProBond purification, and blue/white recombinant screening of plaques; Invitrogen (220) can be used.

Mammalian expression vectors contemplated for use in the invention include vectors with inducible promoters, such as the dihydrofolate reductase (DHFR) promoter, *e.g.*, any expression vector with a *DHFR* expression vector, or a *DHFR*/methotrexate co-amplification vector, such as pED (*Pst*I, *Sal*I, *Sba*I, *Sma*I, and *Eco*RI cloning site, with the vector expressing both the cloned gene and *DHFR*; *see* Kaufman, *Current Protocols in Molecular Biology*, 16.12 (1991). Alternatively, a glutamine synthetase/methionine sulfoximine co-amplification vector, such as pEE14 (*Hind*III, *Xba*I, *Sma*I, *Sba*I, *Eco*RI, and *Bcl*II cloning site, in which the vector expresses glutamine synthase and the cloned gene; Celltech). In another embodiment, a vector that directs episomal expression under control of Epstein Barr Virus (EBV) can be used, such as pREP4 (*Bam*HI, *Sfi*I, *Xho*I, *Not*I, *Nhe*I, *Hind*III, *Nhe*I, *Pvu*II, and *Kpn*I cloning site, constitutive RSV-LTR promoter, hygromycin selectable marker; Invitrogen), pCEP4 (*Bam*HI, *Sfi*I, *Xho*I, *Not*I, *Nhe*I, *Hind*III, *Nhe*I, *Pvu*II, and *Kpn*I cloning site, constitutive hCMV immediate early gene, hygromycin selectable marker; Invitrogen), pMEP4 (*Kpn*I, *Pvu*I, *Nhe*I, *Hind*III, *Not*I, *Xho*I, *Sfi*I, *Bam*HI cloning site, inducible methallothionein IIa gene promoter, hygromycin selectable marker; Invitrogen), pREP8 (*Bam*HI, *Xho*I, *Not*I, *Hind*III, *Nhe*I, and *Kpn*I cloning site, RSV-LTR promoter, histidinol selectable marker; Invitrogen), pREP9 (*Kpn*I, *Nhe*I, *Hind*III, *Not*I, *Xho*I, *Sfi*I, and *Bam*HI cloning site, RSV-LTR promoter, G418 selectable marker; Invitrogen), and pEBVHis (RSV-LTR promoter, hygromycin selectable marker, N-terminal peptide purifiable via ProBond resin and cleaved by enterokinase; Invitrogen). Selectable mammalian expression vectors for use in the invention include pRc/CMV (*Hind*III, *Bst*XI, *Not*I, *Sba*I, and *Apa*I cloning site, G418 selection; Invitrogen), pRc/RSV (*Hind*III, *Spe*I, *Bst*XI, *Not*I, *Xba*I cloning site, G418 selection; Invitrogen), and others. Vaccinia virus mammalian expression vectors (*see*, Kaufman, 1991, *supra*) for use according to the invention include but are not limited to pSC11 (*Sma*I cloning site, TK- and b-gal selection), pMJ601 (*Sal*I, *Sma*I, *Afl*I, *Nar*I, *Bsp*MI, *Bam*HI, *Apa*I, *Nhe*I, *Sac*II, *Kpn*I, and *Hind*III cloning site; TK- and b-gal selection), and pTKgptF1S (*Eco*RI, *Pst*I, *Sal*I, *Acc*I, *Hind*II, *Sba*I, *Bam*HI, and *Hpa*I cloning site, TK or XPRT selection).

Yeast expression systems can also be used according to the invention to express an ABC1 polypeptide. For example, the non-fusion pYES2 vector (*Xba*I, *Sph*I, *Sho*I, *Not*I, *Gst*XI,

EcoRI, *BstXI*, *BamHI*, *SacI*, *KpnI*, and *HindIII* cloning sit; Invitrogen) or the fusion pYESHisA, B, C (*XbaI*, *SphI*, *ShoI*, *NotI*, *BstXI*, *EcoRI*, *BamHI*, *SacI*, *KpnI*, and *HindIII* cloning site, N-terminal peptide purified with ProBond resin and cleaved with enterokinase; Invitrogen), to mention just two, can be employed according to the invention.

- 5 Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as
10 vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (*e.g.*, lambda), and plasmid and cosmid DNA vectors, to name but a few.

- In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Different host cells have characteristic and specific mechanisms for the translational and post-
15 translational processing and modification (*e.g.*, glycosylation, cleavage [*e.g.*, of signal sequence]) of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an nonglycosylated core protein product. However, the transmembrane ABC1 protein expressed in bacteria may not be properly folded.
20 Expression in yeast can produce a glycosylated product. Expression in eukaryotic cells can increase the likelihood of "native" glycosylation and folding of a heterologous protein. Moreover, expression in mammalian cells can provide a tool for reconstituting, or constituting, ABC1 activity. Furthermore, different vector/host expression systems may affect processing reactions, such as proteolytic cleavages, to a different extent.

- 25 Vectors are introduced into the desired host cells by methods known in the art, *e.g.*, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter (see, *e.g.*, Wu et al., 1992; Wu and Wu, 1988; Hartmut et al., Canadian Patent Application No. 2,012,311, filed March 15, 1990).

- 30 A cell has been "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. A cell has been "transformed" by exogenous or heterologous DNA when the transfected DNA effects a phenotypic change. Preferably, the transforming DNA should be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.

- 35 A recombinant marker protein expressed as an integral membrane protein can be isolated and purified by standard methods. Generally, the integral membrane protein can be

obtained by lysing the membrane with detergents, such as but not limited to, sodium dodecyl sulfate (SDS), Triton X-100 polyoxyethylene ester, Ipagel/nonidet P-40 (NP-40) (octylphenoxy)-polyethoxyethanol, digoxin, sodium deoxycholate, and the like, including mixtures thereof. Solubilization can be enhanced by sonication of the suspension. Soluble forms of the protein can be obtained by collecting culture fluid, or solubilizing inclusion bodies, e.g., by treatment with detergent, and if desired sonication or other mechanical processes, as described above. The solubilized or soluble protein can be isolated using various techniques, such as polyacrylamide gel electrophoresis (PAGE), isoelectric focusing, 2-dimensional gel electrophoresis, chromatography (e.g., ion exchange, affinity, immunoaffinity, and sizing column chromatography), centrifugation, differential solubility, immunoprecipitation, or by any other standard technique for the purification of proteins.

Alternatively, a nucleic acid or vector according to the invention can be introduced *in vivo* by lipofection. For the past decade, there has been increasing use of liposomes for encapsulation and transfection of nucleic acids *in vitro*. Synthetic cationic lipids designed to limit the difficulties and dangers encountered with liposome mediated transfection can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker (Felgner, et. al. 1987; Mackey, et al., 1988; Ulmer et al., 1993). The use of cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively charged cell membranes (Felgner and Ringold, 1989). Particularly useful lipid compounds and compositions for transfer of nucleic acids are described in International Patent Publications WO95/18863 and WO96/17823, and in U.S. Patent No. 5,459,127. The use of lipofection to introduce exogenous genes into the specific organs *in vivo* has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. It is clear that directing transfection to particular cell types would be particularly preferred in a tissue with cellular heterogeneity, such as pancreas, liver, kidney, and the brain. Lipids may be chemically coupled to other molecules for the purpose of targeting [see Mackey, et. al., *supra*]. Targeted peptides, e.g., hormones or neurotransmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to liposomes chemically.

Other molecules are also useful for facilitating transfection of a nucleic acid *in vivo*, such as a cationic oligopeptide (e.g., International Patent Publication WO95/21931), peptides derived from DNA binding proteins (e.g., International Patent Publication WO96/25508), or a cationic polymer (e.g., International Patent Publication WO95/21931).

It is also possible to introduce the vector *in vivo* as a naked DNA plasmid (see U.S. Patents 5,693,622, 5,589,466 and 5,580,859). Naked DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter (see, Wu et al., 1992; Wu and Wu, 1988; Hartmut et

al., Canadian Patent Application No. 2,012,311, filed March 15, 1990; Williams et al., 1991). Receptor-mediated DNA delivery approaches can also be used (Curiel et al., 1992; Wu and Wu, 1987).

5 "Pharmaceutically acceptable vehicle or excipient" includes diluents and fillers which are pharmaceutically acceptable for method of administration, are sterile, and may be aqueous or oleaginous suspensions formulated using suitable dispersing or wetting agents and suspending agents. The particular pharmaceutically acceptable carrier and the ratio of active compound to carrier are determined by the solubility and chemical properties of the composition, the particular mode of administration, and standard pharmaceutical practice.

10 Any nucleic acid, polypeptide, vector, or host cell of the invention will preferably be introduced *in vivo* in a pharmaceutically acceptable vehicle or excipient. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term
15 "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "excipient" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or
20 synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as excipients, particularly for injectable solutions. Suitable pharmaceutical excipients are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

Naturally, the invention contemplates delivery of a vector that will express a therapeutically
25 effective amount of an ABC1 polypeptide for gene therapy applications. The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and still more preferably prevent, a clinically significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a
30 clinically significant condition in the host.

"Lipid profile" means the set of concentrations of cholesterol, triglyceride, lipoprotein cholesterol and other lipids in the body of a human or other animal.

An "undesirable lipid profile" is the condition in which the concentrations of cholesterol, triglyceride, or lipoprotein cholesterol are outside of the age- and gender-adjusted
35 reference ranges. Generally, a concentration of total cholesterol > 200 mg/dl, of plasma triglycerides > 200 mg/dl, of LDL cholesterol > 130 mg/dl, of HDL cholesterol < 39 mg/dl, or a

ratio of total cholesterol to HDL cholesterol > 4.0 is considered to be an undesirable lipid profile. An undesirable lipid profile is associated with a variety of pathological conditions, including hyperlipidaemias, diabetes hypercholesterolaemia, atherosclerosis, and other forms of coronary artery disease.

5

NUCLEIC ACIDS OF THE ABC1 GENE

GENOMIC SEQUENCES

The human ABC1 gene is thought to comprise 48 exons and 47 introns, if reference is made in particular to the structure of the orthologous ABC1 gene in mice. Recently, partial
 10 exonic and intronic ABC1 genomic DNA has been isolated and identified (Rust et al., 1999). According to the invention, it has now been shown that the human ABC1 gene comprises 49 exons and 48 introns.

Several partial genomic nucleotide sequences of the ABC1 gene have been isolated and characterized according to the invention, these genomic sequences comprise both new exonic
 15 sequences and intronic sequences which may be used in particular for the production of various means of detection of the ABC1 gene or of its nucleotide expression products in a sample. These partial genomic sequences are represented in Table I.

Table I

20 **Partial (p) genomic DNA of the human ABC1 gene**

SEQ ID NO:	ABC1 genomic DNA
1	Intron 1(p), exon 2, intron 2, exon 3, intron 3, exon 4, intron 4(p)
4	Intron 4(p), exon 5, intron 5(p)
5	Intron 5(p), exon 6, intron 6(p)
6	Intron 6(p), exon 7, intron 7(p)
7	Intron 7(p), exon 8, intron 8(p)
8	Intron 8(p), exon 9, intron 9, exon 10, intron 10(p)
9	Intron 10(p), exon 11, intron 11(p)
10	Intron 11(p), exon 12, intron 12, exon 13,

	intron 13, exon 14, intron 14, exon 15, intron 15, exon 16, intron 16, exon 17, intron 17(p)
11	Intron 17(p), exon 18, intron 18(p)
12	Intron 38(p), exon 39, intron 39(p)
13	Intron 42(p), exon 43, intron 43(p)
14	Intron 43(p), exon 44, intron 44(p)
15	Intron 44(p), exon 45, intron 45 (p)
16	Intron 45(p), exon 46, intron 46, exon 47, intron 47(p)
17	Intron 48(p), exon 49, 3'distal sequence

Thus, a first subject of the invention consists in a nucleic acid comprising a polynucleotide sequence of any one of SEQ ID NOs: 1 and 4-17, or of a complementary polynucleotide sequence.

5 The invention also relates to a nucleic acid comprising at least 8 consecutive nucleotides of a polynucleotide sequence comprising a) any one of SEQ ID NOs: 1 and 4-8, and 11-16, or a complementary polynucleotide sequence, b) nucleotides 3154-3200 of SEQ ID NO: 9, or a complementary polynucleotide sequence, c) nucleotides 1-242 of SEQ ID NO: 10, or a complementary polynucleotide sequence, or d) nucleotides 1-1851 of SEQ ID NO: 17, or a
10 complementary polynucleotide sequence.

 The subject of the invention is, in addition, a nucleic acid having at least 80% nucleotide identity with a nucleic acid comprising a) any one of SEQ ID NOs: 1 and 4-8, and 11-16, or a complementary polynucleotide sequence, b) nucleotides 3154-3200 of SEQ ID NO: 9, or a complementary polynucleotide sequence, c) nucleotides 1-242 of SEQ ID NO: 10, or a
15 complementary polynucleotide sequence, or d) nucleotides 1-1851 of SEQ ID NO: 17, or a complementary polynucleotide sequence.

 The invention also relates to a nucleic acid having at least 85%, preferably 90%, more preferably 95% and still more preferably 98% nucleotide identity with a nucleic acid comprising a) any one of SEQ ID NOs: 1 and 4-8, and 11-16, or a complementary
20 polynucleotide sequence, b) nucleotides 3154-3200 of SEQ ID NO: 9, or a complementary polynucleotide sequence, c) nucleotides 1-242 of SEQ ID NO: 10, or a complementary

polynucleotide sequence, or d) nucleotides 1-1851 of SEQ ID NO: 17, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid hybridizing, under high stringency conditions, with a nucleic acid comprising a) any one of SEQ ID NOs: 1 and 4-8, and 11-16, or
 5 a complementary polynucleotide sequence, b) nucleotides 3154-3200 of SEQ ID NO: 9, or a complementary polynucleotide sequence, c) nucleotides 1-242 of SEQ ID NO: 10, or a complementary polynucleotide sequence, or d) nucleotides 1-1851 of SEQ ID NO: 17, or a complementary polynucleotide sequence.

Several exons of the ABC1 gene have been characterized, at least partially, by their
 10 nucleotide sequence and are indicated in Table II.

Table II

Human ABC1 Exon DNA

Exon No.	SEQ ID NO:	Located in SEQ ID NO:	Position of the 5' nucleotide	Position of the 3' nucleotide
2	18	1	4647	4740
3	19	1	9274	9415
4	20	1	10685	10803
5	21	4	254	375
6	22	5	161	337
7	23	6	107	199
8	24	7	604	844
9	25	8	615	754
10	26	8	1084	1200
11	27	9	3003	3200
17	28	10	7888	8001
18	29	11	388	559
39	30	12	4	127
43	31	13	266	372

44	32	14	16	157
45	33	15	177	311
46	34	16	377	480
47	35	16	963	1055
49	36	17	195	3088

Thus, the invention also relates to a nucleic acid comprising any one of SEQ ID NOs: 18-36, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising a polynucleotide sequence as depicted in any one of SEQ ID NOs: 18-36, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising at least 8 consecutive nucleotides of a) any one of SEQ ID NOs: 18-26 and 28-35, or a complementary polynucleotide sequence, b) nucleotides 152-198 of SEQ ID NO: 27, or a complementary polynucleotide sequence, or c) nucleotides 1-1657 of SEQ ID NO: 36, or a complementary polynucleotide sequence.

The subject of the invention is, in addition, a nucleic acid having at least 80% nucleotide identity with a nucleic acid comprising a) any one of SEQ ID NOs: 18-26 and 28-35, or a complementary polynucleotide sequence, b) nucleotides 152-198 of SEQ ID NO: 27, or a complementary polynucleotide sequence, or c) nucleotides 1-1657 of SEQ ID NO: 36, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid having at least 85%, preferably 90%, more preferably 95% and still more preferably 98% nucleotide identity with a nucleic acid comprising a) any one of SEQ ID NOs: 18-26 and 28-35, or a complementary polynucleotide sequence, b) nucleotides 152-198 of SEQ ID NO: 27, or a complementary polynucleotide sequence, or c) nucleotides 1-1657 of SEQ ID NO: 36, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid hybridizing, under high stringency conditions, with a nucleic acid comprising a) any one of SEQ ID NOs: 18-26 and 28-35, or a complementary polynucleotide sequence, b) nucleotides 152-198 of SEQ ID NO: 27, or a complementary polynucleotide sequence, or c) nucleotides 1-1657 of SEQ ID NO: 36, or a complementary polynucleotide sequence.

Moreover, several introns of the ABC1 gene have been isolated and characterized, at least partially. The intronic nucleic acids of the ABC1 gene, as well as their fragments and their variants may also be used as nucleotide probes or primers for detecting the presence of at least

one copy of the ABC1 gene in a sample, or alternatively for amplifying a given target sequence in the ABC1 gene.

The intronic nucleic acid sequences of the ABC1 gene are indicated in Table III.

5 Table III

Human ABC1 Intron DNA

Intron No.	SEQ ID NO:	Located in SEQ ID NO:	Position of the 5' nucleotide	Position of the 3' nucleotide
1 (3' end)	37	1	1	4646
2	38	1	4741	9273
3	39	1	9416	10684
4 (5' end)	40	1	10804	11754
4 (3' end)	41	4	1	253
5 (5' end)	42	4	376	571
5 (3' end)	43	5	1	160
6 (5' end)	44	5	338	428
6 (3' end)	45	6	1	106
7 (5' end)	46	6	200	213
7 (3' end)	47	7	1	603
8 (5' end)	48	7	845	1402
8 (3' end)	49	8	1	614
9	50	8	755	1083
10 (5' end)	51	8	1201	1808
11 (5' end)	52	9	3201	3215
11 (3' end)	53	10	1	639
17 (3' end)	54	11	1	387
18 (5' end)	55	11	560	578

38 (3' end)	56	12	1	3
39 (5' end)	57	12	128	384
42 (3' end)	58	13	1	265
43 (5' end)	59	13	373	386
43 (3' end)	60	14	1	15
44 (5' end)	61	14	158	345
44 (3' end)	62	15	1	176
45 (5' end)	63	15	312	618
45 (3' end)	64	16	1	376
46	65	16	481	962
47 (5' end)	137	16	1056	1329
48 (3' end)	68	17	1	194

Thus, the invention also relates to a nucleic acid comprising a polynucleotide sequence of any one of SEQ ID NOs: 37-65, 68, and 137, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising a polynucleotide sequence as depicted in any one of SEQ ID NOs: 37-65, 68, and 137, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising at least 8 consecutive nucleotides of a) any one of SEQ ID NOs: 37-52, 54-65, 68, and 137, or a complementary polynucleotide sequence, or b) nucleotides 1-242 of SEQ ID NO: 53, or a complementary polynucleotide sequence.

The subject of the invention is, in addition, a nucleic acid having at least 80% nucleotide identity with a nucleic acid comprising a) any one of SEQ ID NOs: 37-52, 54-65, 68, and 137, or a complementary polynucleotide sequence, or b) nucleotides 1-242 of SEQ ID NO: 53, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid having at least 85%, preferably 90%, more preferably 95% and still more preferably 98% nucleotide identity with a nucleic acid comprising a) any one of SEQ ID NOs: 37-52, 54-65, 68, and 137, or a complementary polynucleotide sequence, or b) nucleotides 1-242 of SEQ ID NO: 53, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid hybridizing, under high stringency conditions, with a nucleic acid comprising a) any one of SEQ ID NOs: 37-52, 54-65, 68, and 137, or a complementary polynucleotide sequence, or b) nucleotides 1-242 of SEQ ID NO: 53, or a complementary polynucleotide sequence.

5

cDNA MOLECULES ENCODING A FULL LENGTH ABC1 PROTEIN

As already indicated above, a partial cDNA sequence corresponding to the human ABC1 gene has been identified by Langmann et al. (1999). This partial cDNA sequence of ABC1 consists of 6880 nucleotides and contains a 6603 nucleotide open reading frame
10 corresponding to a partial 2201 amino acid (aa) ABC1 polypeptide produced in subjects not affected by disorders linked to the reverse transport of cholesterol. The cDNA sequence described by Langmann et al. (1999) contains, in addition, a portion of the 5'- untranslated region (UTR) (nucleotides 1 to 120) and a portion of the 3'-UTR (nucleotides 6727 to 6880).

Recently, an additional portion of the 3'-UTR of the human ABC1 cDNA has been
15 isolated and identified (Rust et al., 1999).

A cDNA that encodes the full length human ABC1 protein has now been identified according to the invention (see Example 2). This novel, human ABC1 cDNA (SEQ ID NO: 69) includes a newly identified 5'-region comprising 244 additional 5' nucleotides and the true initiation ATG codon. According to the invention, the new human ABC1 cDNA comprises a
20 larger open reading frame than that previously reported by Langmann et al. (1999) and Rust et al. (1999). In particular, this cDNA nucleic acid molecule of the invention encodes 60 additional amino acids at the N-terminus of the full length human ABC1 protein. In addition, this new cDNA molecule of the invention comprises a newly identified 5'UTR.

Specific activity of the full length ABC1 protein was tested *in vitro*, allowing to
25 demonstrate that full length ABC1 protein is capable of promoting cellular lipid efflux. In effect, the results presented herein below in Example 16 and Figures 4-7, show that apolipoproteins significantly increase cholesterol and phospholipid efflux in cells that are transfected with the full length ABC1 protein. Comparatively, HDL and phosphatidylcholine do not mediate or mediate only partially cholesterol efflux in full length ABC1 transfected cells.

30 These results seem to indicate that apolipoproteins are acceptors for ABC1 mediated cholesterol and phospholipid efflux. Moreover, Figure 7 unambiguously demonstrates a specific binding of apo A-I and A-II to full length ABC1 transfected cells, thereby suggesting that full length ABC1 protein act via direct interaction with apolipoproteins, and that these interactions are required for the lipid efflux facilitated by apolipoproteins and the full length
35 ABC1 protein. It is thus conceivable that in vivo apolipoproteins from the liver and intestine

circulate and interact with full length ABC1 protein on the cell surface to recruit lipid efflux from peripheral cells.

Specifically, a cDNA molecule of the human ABC1 gene having the polynucleotide sequence of SEQ ID NO: 69 comprises an open reading frame beginning from the nucleotide at position 185 (base A of the ATG codon for initiation of translation) to the nucleotide at position 6967. A polyadenylation signal (having the sequence ATTAAA) is present, starting from the nucleotide at position 9698 of the sequence SEQ ID NO: 69. According to the invention, the ABC1 cDNA comprising SEQ ID NO: 69 encodes a full length ABC1 polypeptide of 2261 amino acids comprising the amino acid sequence of SEQ ID NO: 71.

Consequently, the invention also relates to a nucleic acid comprising SEQ ID NO: 69, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising a polynucleotide sequence as depicted in SEQ ID NO: 69, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid molecule comprising nucleotides 1-244 of SEQ ID NO: 69, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising at least eight consecutive nucleotides of nucleotides 1-244 of SEQ ID NO: 69, or a complementary polynucleotide sequence.

The subject of the invention is also a nucleic acid having at least 80% nucleotide identity with a nucleic acid comprising nucleotides 1-244 of SEQ ID NO: 69, or a nucleic acid having a complementary polynucleotide sequence.

The invention also relates to a nucleic acid having at least 85%, preferably 90%, more preferably 95% and still more preferably 98% nucleotide identity with a nucleic acid comprising a nucleotides 1-244 of SEQ ID NOs: 69, or a nucleic acid having a complementary polynucleotide sequence.

Another subject of the invention is a nucleic acid hybridizing, under high stringency conditions, with a nucleic acid comprising nucleotides 1-244 of SEQ ID NO: 69, or a nucleic acid having a complementary polynucleotide sequence.

A search of the GenBank Database (www.ncbi.nlm.nih.gov) revealed an expressed sequence tag (EST), accession number Z44377, from normalized infant brain that overlapped with nucleotides 1-179 of SEQ ID NO: 69 at nucleotides 114-292 of the EST. Until the cDNA molecule according to the invention was identified, no connection between this EST and ABC1 was known. Therefore, this EST represents additional 5' UTR nucleotides of the human ABC1 cDNA.

Thus, the invention also relates to a cDNA molecule comprising nucleotides 1-113 of EST (GenBank Accession # Z44377) and nucleotides 1-9741 (SEQ ID NO: 69) of the ABC1

cDNA molecule. This second cDNA molecule comprises the nucleotide sequence of SEQ ID NO: 70. The ORF of this second cDNA molecule is located from nucleotide 298 to nucleotide 7080 of SEQ ID NO: 70 and the polyadenylation signal (having the sequence ATTAAG) is located beginning at nucleotide 9811 of SEQ ID NO: 70. The nucleic acid comprising SEQ ID NO: 70 also encodes the full length human ABC1 protein comprising an amino acid sequence of SEQ ID NO: 71.

Consequently, the invention also relates to a nucleic acid comprising SEQ ID NO: 70, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising a polynucleotide sequence as depicted in SEQ ID NO: 70, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising at least eight consecutive nucleotides of nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

The subject of the invention is also a nucleic acid having at least 80% nucleotide identity with a nucleic acid comprising nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid having at least 85%, preferably 90%, more preferably 95% and still more preferably 98% nucleotide identity with a nucleic acid comprising a nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

Another subject of the invention is a nucleic acid hybridizing, under high stringency conditions, with a nucleic acid comprising nucleotides 1-357 of SEQ ID NO: 70, or a nucleic acid having a complementary polynucleotide sequence.

According to the invention, a nucleic acid comprising a polynucleotide sequence of either SEQ ID NO: 69 or SEQ ID NO: 70 encodes a full length human ABC1 polypeptide of 2261 amino acids comprising the amino acid sequence of SEQ ID NO: 71.

Thus, the invention also relates to a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71.

The invention also relates to a nucleic acid encoding a polypeptide comprising an amino acid sequence as depicted in SEQ ID NO: 71.

In a specific embodiment, the invention also relates to a nucleic acid encoding a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

The invention also relates to a polypeptide comprising amino acid sequence of SEQ ID NO: 71.

The invention also relates to a polypeptide comprising amino acid sequence as depicted in SEQ ID NO: 71.

The invention relates to a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

The invention also relates to a polypeptide comprising an amino acid sequence having
5 at least 80% amino acid identity with a polypeptide comprising an amino acid sequence comprising amino acids 1-60 of SEQ ID NO: 71, or a peptide fragment thereof.

The invention also relates to a polypeptide having at least 85%, preferably 90%, more preferably 95% and still more preferably 98% amino acid identity with a polypeptide comprising an amino acid sequence comprising amino acids 1-60 of SEQ ID NO: 71.

10 Preferably, a polypeptide according to the invention will have a length of 15, 18 or 20 to 25, 35, 40, 50, 70, 80, 100 or 200 consecutive amino acids of a polypeptide according to the invention, in particular a polypeptide comprising an amino acid sequence comprising amino acids 1-60 of SEQ ID NO: 71.

15 Alternatively, a polypeptide according to the invention will comprise a fragment having a length of 15, 18, 20, 25, 35, 40, 50, 100 or 200 consecutive amino acids of a polypeptide according to the invention, more particularly of a polypeptide comprising an amino acid sequence comprising amino acids 1-60 of SEQ ID NO: 71.

POLYMORPHISMS WITHIN THE ABC1 GENE

20 *MUTATIONS*

The analysis of mutations in the ABC1 gene may be carried out on genomic DNA from several individuals belonging to a family of which several members suffer from Tangier and/or FHD disease with premature coronary disorders. According to the invention, several mutations have been identified in regions of the ABC1 gene, which encode the ABC1 polypeptide. These
25 mutations have been found particularly in patients suffering from severe forms of Tangier disease, associated with serious coronary disorders. Seventeen mutations are described in Table IV. The mutation of the wild-type (WT) sequence is indicated in Table IV for each mutant sequence.

30 **Table IV**

Mutations found in the ABC1 gene

ABC1 Gene Mutation Location	Nucleotide SEQ ID NO: of Mutant Exon:	Mutant ABC1 Polypeptide SEQ ID NO:	Mutation (WT → Mutant)	Effect of Mutation on ABC1 protein
-----------------------------------	---	--	---------------------------	--

Exon 5, nt 53	72	---	G → A	Silent at aa158
Exon 6, nt 113	73	89	G → A	R → K at aa219
Exon 6, nt 136	74	90	C → T	STOP at aa226
Exon 8, nt 31	75	91	C → T	STOP at aa281
Exon 8, nt 123	76	---	C → T	Silent at aa312
Exon 8, nt 135	77	---	G → A	Silent at aa316
Exon 13, nt 109	78	92	G → -	Frameshift at aa608 → STOP at aa634
Exon 15, nt 205	79	93	A → C	T → P at aa774
Exon 17, nt 9	80	94	G → A	G → R at aa851
Exon 17, nt 107	81	95	A → G	I → M at aa883
Exon 22, nt 101- 102	82	96	CT → -	Frameshift at aa1114 → STOP at aa1144
Exon 22, nt 102- 103	83	97	TC → -	Frameshift at aa1114 → STOP at aa1144
Exon 27, nt 123	84	98	C → T	R → W at aa1342
Exon 32, nt 19	85	99	G → A	W → STOP at aa1525
Exon 34, nt 62	86	100	G → A	R → K at aa1587
Exon 47, nt 2	87	101	A → G	M → V at aa2104
Exon 47, nt 27	88	102	C → -	Frameshift at aa2112 → STOP at aa2130

The structural characteristics which make it possible to differentiate the normal sequences from the mutated sequences of ABC1 (genomic sequences, messenger RNAs, cDNA) may be exploited in order to produce means of detection of the mutated sequences of

5 ABC1 in a sample, in particular, probes specifically hybridizing with the mutated sequences of

ABC1 or pairs of primers making it possible to selectively amplify the regions of the ABC1 gene carrying the mutations described above, it being possible to carry out the detection of the presence of these mutations in particular by distinguishing the length of the amplified nucleic acid fragments, by hybridization of the amplified fragments with the aid of the specific probes
5 described above, or by direct sequencing of these amplified fragments.

Thus, the invention relates to a nucleic acid comprising any one of SEQ ID NOs: 72-88, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising a polynucleotide sequence as depicted in any one of SEQ ID NOs: 72-88, or a complementary polynucleotide sequence.

10 A further subject of the invention is a nucleic acid encoding a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 89-102.

The invention also relates to a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 89-102.

15 ***OTHER POLYMORPHISMS***

Other polymorphisms have been found within the ABC1 gene, in particular nucleotide substitutions located in the noncoding regions (introns). Each of the eight polymorphisms identified in the ABC1 gene are represented in Table V. Table V depicts the wild type (WT) allele and the mutant allele, with the polymorphism itself being defined by the two nucleotide
20 sequences corresponding respectively to each of the alleles.

Table V
Polymorphisms found in the ABC1 gene

ABC1 Gene Intron Location	Wild Type Allele SEQ ID NO:	Mutant Allele SEQ ID NO:	Polymorphic base Allele1/Allele 2
Intron 7, nt 590	103	111	Insertion of an A
Intron 24, nt 23	104	112	G → A
Intron 31, nt 30	105	113	G → T
Intron 32, nt 982	106	114	G → A
Intron 32, nt 1099	107	115	G → C
Intron 40, nt 146	108	116	C → T
Intron 47, nt 13	109	117	A → G
Intron 47, nt 88	110	118	A → C

According to another aspect, the invention also relates to nucleic acids of the ABC1 gene comprising a nucleotide sequence comprising at least one biallelic polymorphism as described in Table V.

Thus, the invention relates to a nucleic acid comprising any one of SEQ ID NOs: 103 and 109-118, or a complementary polynucleotide sequence.

The invention also relates to a nucleic acid comprising a nucleotide sequence as depicted in SEQ ID NOs: 103 and 109-118, or a complementary polynucleotide sequence.

The detection of these ABC1 gene polymorphisms within a DNA sample obtained from a subject may, for example, be carried out by a specific amplification of the nucleotide region of ABC1 containing the polymorphic base, and then sequencing the amplified fragment in order to determine the nature of the allele or of the alleles carried by said subject.

The detection of these polymorphisms in a DNA sample obtained from a subject may also be carried out with the aid of nucleotide probes or primers specifically hybridizing with a given allele containing one of the polymorphic bases of a polymorphism of the ABC1 gene according to the invention.

By way of illustration, appropriate nucleotide primers are for example primers whose base at the 3' end hybridizes with the base located immediately on the 5' side of the polymorphic base of the fragment comprising said polymorphism. After the step of hybridization of the specific primer, a step of extension with a mixture of the two

dideoxynucleotides complementary to the polymorphic base of said polymorphism, for example differentially labeled by fluorescence, and then a step detection of the fluorescence signal obtained makes it possible to determine which of the two differentially labeled fluorescent dideoxynucleotides has been incorporated and to directly deduce the nature of the polymorphic base present at the level of this polymorphism.

Various approaches may be used for the labeling and detection of the dideoxynucleotides. A method in homogeneous phase based on FRET ("Fluorescence resonance energy transfer") has been described by Chen and Kwok (1997). According to this method, the amplified fragments of genomic DNA containing polymorphisms are incubated with a primer labeled with fluorescein at the 5' end in the presence of labeled dideoxynucleotide triphosphate and a modified Taq polymerase. The labeled primer is extended by one base by incorporation of the labeled dideoxynucleotide specific for the allele present on the complementary genomic DNA sequence. At the end of this genotyping reaction, the fluorescence intensities for the two labeling compounds for the labeled dideoxynucleotides are directly analyzed without separation or purification. All these steps may be carried out in the same tube and the modifications of the fluorescence signal monitored in real time. According to another embodiment, the extended primer may be analyzed by MALDI-TOF type mass spectrometry. The base located at the level of the polymorphic site is identified by measuring the mass added to the microsequencing primer (Haff and Smirnov, 1997).

Such nucleotide primers may, for example, be immobilized on a support. Furthermore, it is possible to immobilize on a support, for example in an orderly manner, multiple specific primers as described above, each of the primers being suited to the detection of one of the polymorphisms of the ABC1 gene according to the invention.

The polymorphisms of the ABC1 gene according to the invention are useful in particular as genetic markers in studies of association between the presence of a given allele in a subject and the predisposition of this subject to a given pathology, in particular to one of the pathologies already associated with the chromosomal region 9q31 preferably with a pathology linked to a dysfunction in the reverse transport of cholesterol.

The methods for the genetic analysis of complex characters (phenotypes) are of various types (Lander and Schork, 1994). In general, the biallelic polymorphisms according to the invention are useful in any of the methods described in the state of the art intended to demonstrate a statistically significant correlation between a genotype and a phenotype. The biallelic polymorphisms may be used in linkage analyses and in allele sharing methods. Preferably, the biallelic polymorphisms according to the invention are used to identify genes associated with detectable characters (phenotypes) in use for studies of association, an

approach which does not require the use of families affected by the character, and which allows, in addition, the identification of genes associated with complex and sporadic characters.

Other statistical methods using biallelic polymorphisms according to the invention are for example those described by Forsell et al. (1997), Xiong et al. (1999), Horvath et al. (1998),
 5 Sham et al. (1995) or Nickerson et al. (1992).

NUCLEOTIDE PROBES AND PRIMERS

Nucleotide probes and primers hybridizing with a nucleic acid (genomic DNA, messenger RNA, cDNA) according to the invention also form part of the invention.

10 According to the invention, nucleic acid fragments derived from a polynucleotide comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a
 15 complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence, are useful
 20 for the detection of the presence of at least one copy of a nucleotide sequence of the ABC1 gene or of a fragment or of a variant (containing a mutation or a polymorphism) thereof in a sample.

The nucleotide probes or primers according to the invention comprise a nucleotide sequence comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68,
 25 and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a
 30 complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

The nucleotide probes or primers according to the invention comprise at least 8 consecutive nucleotides of a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16,
 35 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c)

nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) 5 nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

Preferably, nucleotide probes or primers according to the invention will have a length of 10, 12, 15, 18 or 20 to 25, 35, 40, 50, 70, 80, 100, 200, 500, 1000, 1500 consecutive 10 nucleotides of a nucleic acid according to the invention, in particular of a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a 15 complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

Alternatively, a nucleotide probe or primer according to the invention will consist of and/or comprise the fragments having a length of 12, 15, 18, 20, 25, 35, 40, 50, 100, 200, 500, 1000, 1500 consecutive nucleotides of a nucleic acid according to the invention, more particularly of a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 25 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID 30 NO: 53, or of a complementary polynucleotide sequence, or h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

The definition of a nucleotide probe or primer according to the invention therefore covers oligonucleotides which hybridize, under the high stringency hybridization conditions defined above, with a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 35 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c)

- nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) 5 nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

According to a preferred embodiment, a nucleotide primer according to the invention comprises a nucleotide sequence of any one of SEQ ID NOs: 119-136, 138, and 141-152, or of 10 a complementary nucleic acid sequence.

Examples of primers and pairs of primers which make it possible to amplify various regions of the ABC1 gene are presented in Table VI below. The location of each primer of SEQ ID NOs: 119-136, 138, and 141-152 within SEQ ID NOs: 1, 4-9, 11, and 13-16, and its hybridizing region is indicated in Table VI. The abbreviation "Comp" refers to the 15 complementary nucleic acid sequence.

Table VI
Primers for the amplification of nucleic fragments of the ABC1 gene

Primer SEQ ID NO:	Located in SEQ ID NO:	Position in the sequence	Region for hybridization
119	1	4621-4642	Intron 1
120	1	Comp 4793-4814	Intron 2
121	1	9207-9226	Intron 2
122	1	Comp 9583-9603	Intron 3
123	1	10455-10475	Intron 3
124	1	Comp 10880-10897	Intron 4
125	4	101-121	Intron 4
126	4	Comp 473-492	Intron 5
127	5	83-102	Intron 5
128	5	Comp 378-395	Intron 6

129	6	4-25	Intron 6
130	6	Comp 193-212	Exon 7/Intron 7
131	7	449-470	Intron 7
132	7	Comp 881-899	Intron 8
133	8	451-472	Intron 8
134	8	Comp 916-934	Intron 9
135	8	870-891	Intron 9
136	8	Comp 1311-1330	Intron 10
138	9	Comp 3191-3212	Exon 11/Intron 11
141	11	251-269	Intron 17
142	11	Comp 551-570	Exon 18/Intron 18
143	13	189-209	Intron 42
144	13	Comp 364-385	Exon 43/Intron 43
145	14	12-32	Intron 43/Exon 44
146	14	Comp 184-202	Intron 44
147	15	23-40	Intron 44
148	15	Comp 437-455	Intron 45
149	16	158-178	Intron 45
150	16	Comp 528-549	Intron 46
151	16	817-836	Intron 46
152	16	Comp 1174-1195	Intron 47

According to a specific embodiment of preferred probes and primers according to the invention, they comprise all or part of a polynucleotide sequence comprising any one of

SEQ ID NOs: 119-136, 138, and 141-152, or a nucleic acid having a complementary nucleic acid sequence.

5 A nucleotide primer or probe according to the invention may be prepared by any suitable method well known to persons skilled in the art, including by cloning and action of restriction enzymes or by direct chemical synthesis according to techniques such as the phosphodiester method by Narang et al. (1979) or by Brown et al. (1979), the diethylphosphoramidite method by Beaucage et al. (1980) or the technique on a solid support described in EU patent No. EP 0,707,592.

10 Each of the nucleic acids according to the invention, including the oligonucleotide probes and primers described above, may be labeled, if desired, by incorporating a marker which can be detected by spectroscopic, photochemical, biochemical, immunochemical or chemical means. For example, such markers may consist of radioactive isotopes (^{32}P , ^{33}P , ^3H , ^{35}S), fluorescent molecules (5-bromodeoxyuridine, fluorescein, acetylaminofluorene, digoxigenin) or ligands such as biotin. The labeling of the probes is preferably carried out by
15 incorporating labeled molecules into the polynucleotides by primer extension, or alternatively by addition to the 5' or 3' ends. Examples of nonradioactive labeling of nucleic acid fragments are described in particular in French patent No. 78 109 75 or in the articles by Urdea et al. (1988) or Sanchez-pescador et al. (1988).

20 Preferably, the nucleotide probes and primers according to the invention may have structural characteristics of the type to allow amplification of the signal, such as the probes described by Urdea et al. (1991) or alternatively in European patent No. EP-0,225,807 (CHIRON).

25 The oligonucleotide probes according to the invention may be used in particular in Southern-type hybridizations with the genomic DNA or alternatively in hybridizations with the corresponding messenger RNA when the expression of the corresponding transcript is sought in a sample.

The probes and primers according to the invention may also be used for the detection of products of PCR amplification or alternatively for the detection of mismatches.

30 Nucleotide probes or primers according to the invention may be immobilized on a solid support. Such solid supports are well known to persons skilled in the art and comprise surfaces of wells of microtiter plates, polystyrene beds, magnetic beds, nitrocellulose bands or microparticles such as latex particles.

35 Consequently, the present invention also relates to a method of detecting the presence of a nucleic acid comprising a polynucleotide sequence of any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence, or a nucleic acid fragment or variant of any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and

137, or of a complementary polynucleotide sequence in a sample, said method comprising the steps of:

1) bringing one or more nucleotide probes or primers according to the invention into contact with the sample to be tested;

5 2) detecting the complex which may have formed between the probe(s) and the nucleic acid present in the sample.

According to a specific embodiment of the method of detection according to the invention, the oligonucleotide probes and primers are immobilized on a support.

According to another aspect, the oligonucleotide probes and primers comprise a
10 detectable marker.

The invention relates, in addition, to a box or kit for detecting the presence of a nucleic acid according to the invention in a sample, said box or kit comprising:

a) one or more nucleotide probe(s) or primer(s) as described above;

b) where appropriate, the reagents necessary for the hybridization reaction.

15 According to a first aspect, the detection box or kit is characterized in that the probe(s) or primer(s) are immobilized on a support.

According to a second aspect, the detection box or kit is characterized in that the oligonucleotide probes comprise a detectable marker.

According to a specific embodiment of the detection kit described above, such a kit will
20 comprise a plurality of oligonucleotide probes and/or primers in accordance with the invention which may be used to detect a target nucleic acid of interest or alternatively to detect mutations in the coding regions or the non-coding regions of the nucleic acids according to the invention, more particularly of nucleic acids comprising any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or a complementary polynucleotide sequence.

25 Thus, the probes according to the invention, immobilized on a support, may be ordered into matrices such as "DNA chips". Such ordered matrices have in particular been described in US patent No. 5,143,854, in published PCT applications WO 90/15070 and WO 92/10092.

Support matrices on which oligonucleotide probes have been immobilized at a high density are for example described in US patent No. 5,412,087 and in published PCT application
30 WO 95/11995.

The nucleotide primers according to the invention may be used to amplify any one of the nucleic acids according to the invention, and more particularly a nucleic acid comprising a polynucleotide sequence of any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence. Alternatively, the nucleotide primers
35 according to the invention may be used to amplify a nucleic acid fragment or variant of any one

of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

In a particular embodiment, the nucleotide primers according to the invention may be used to amplify a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence, or i) as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

Another subject of the invention relates to a method of amplifying a nucleic acid according to the invention, and more particularly a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence, or i) as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence, contained in a sample, said method comprising the steps of:

- a) bringing the sample in which the presence of the target nucleic acid is suspected into contact with a pair of nucleotide primers whose hybridization position is located respectively on the 5' side and on the 3' side of the region of the target nucleic acid whose amplification is sought, in the presence of the reagents necessary for the amplification reaction; and
- b) detecting the amplified nucleic acids.

To carry out the amplification method as defined above, use will be preferably made of any of the nucleotide primers described above.

The subject of the invention is, in addition, a box or kit for amplifying a nucleic acid according to the invention, and more particularly a nucleic acid comprising a) any one of SEQ

ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68-70, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence, or i) as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence, said box or kit comprising:

- a) a pair of nucleotide primers in accordance with the invention, whose hybridization position is located respectively on the 5' side and 3' side of the target nucleic acid whose amplification is sought; and optionally,
- b) reagents necessary for the amplification reaction.

Such an amplification box or kit will preferably comprise at least one pair of nucleotide primers as described above.

The subject of the invention is, in addition, a box or kit for amplifying all or part of a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or h) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence, said box or kit comprising:

- 1) a pair of nucleotide primers in accordance with the invention, whose hybridization position is located respectively on the 5' side and 3' side of the target nucleic acid whose amplification is sought; and optionally,

- 2) reagents necessary for an amplification reaction.

Such an amplification box or kit will preferably comprise at least one pair of nucleotide primers as described above.

The invention also relates to a box or kit for detecting the presence of a nucleic acid according to the invention in a sample, said box or kit comprising:

- a) one or more nucleotide probes according to the invention;
- b) where appropriate, reagents necessary for a hybridization reaction.

According to a first aspect, the detection box or kit is characterized in that the nucleotide probe(s) and primer(s) are immobilized on a support.

- 5 According to a second aspect, the detection box or kit is characterized in that the nucleotide probe(s) and primer(s) comprise a detectable marker.

- According to a specific embodiment of the detection kit described above, such a kit will comprise a plurality of oligonucleotide probes and/or primers in accordance with the invention which may be used to detect target nucleic acids of interest or alternatively to detect mutations in the coding regions or the non-coding regions of the nucleic acids according to the invention. According to preferred embodiment of the invention, the target nucleic acid comprises a polynucleotide sequence of any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary nucleic acid sequence. Alternatively, the target nucleic acid is a nucleic acid fragment or variant of a nucleic acid comprising any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.
- 10 According to a preferred embodiment, two primers according to the invention comprise all or part of SEQ ID NOs: 125 and 126, making it possible to amplify the region of exon 5 of the ABC1 gene carrying the mutation as depicted in SEQ ID NO: 72 described above, or nucleic acids having a complementary polynucleotide sequence.
- 15 According to a second preferred embodiment, two primers according to the invention comprise all or part of SEQ ID NOs: 127 and 128, making it possible to amplify the region of exon 6 of the ABC1 gene carrying the mutations as depicted in SEQ ID NOs: 73 or 74 described above, or nucleic acids having a complementary polynucleotide sequence.

- 20 According to a third preferred embodiment, two primers according to the invention comprise all or part of SEQ ID NOs: 131 and 132, making it possible to amplify the region of exon 8 of the ABC1 gene carrying the mutations as depicted in SEQ ID NOs: 75-77 described above, or nucleic acids having a complementary polynucleotide sequence.
- 25 According to a fourth preferred embodiment, two primers according to the invention comprise all or part of SEQ ID NOs: 155 and 156, making it possible to amplify the region of exon 27 of the ABC1 gene carrying the mutation as depicted in SEQ ID NO: 84 described above, or nucleic acids having a complementary polynucleotide sequence.

- 30 According to a fifth preferred embodiment, two primers according to the invention comprise all or part of SEQ ID NOs: 159 and 160, making it possible to amplify the region of exon 32 of the ABC1 gene carrying the mutation as depicted in SEQ ID NO: 85 described above, or nucleic acids having a complementary polynucleotide sequence.
- 35

According to a sixth preferred embodiment, two primers according to the invention comprise all or part of SEQ ID NOs: 175 and 176, making it possible to amplify the region of exon 47 of the ABC1 gene carrying the mutations as depicted in SEQ ID NOs: 87 or 88 described above, or nucleic acids having a complementary polynucleotide sequence.

- 5 According to another preferred embodiment, a primer according to the invention comprise, generally, all or part of any one of SEQ ID NOs: 119-136, 138, and 141-152, or a complementary sequence.

The nucleotide primers according to the invention are particularly useful in methods of genotyping subjects and/or of genotyping populations, in particular in the context of studies of association between particular allele forms or particular forms of groups of alleles (haplotypes) in subjects and the existence of a particular phenotype (character) in these subjects, for example the predisposition of these subjects to develop diseases linked to a deficiency in the reverse transport of cholesterol, or alternatively the predisposition of these subjects to develop a pathology whose candidate chromosomal region is situated on chromosome 9, more precisely on the 9q arm and still more precisely in the 9q31 locus.

RECOMBINANT VECTORS

The invention also relates to a recombinant vector comprising a nucleic acid according to the invention. "Vector" for the purposes of the present invention will be understood to mean a circular or linear DNA or RNA molecule which is either in single-stranded or double-stranded form.

Preferably, such a recombinant vector will comprise a nucleic acid chosen from the following nucleic acids:

- a) a nucleic acid comprising a polynucleotide sequence of any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence,
- b) a nucleic acid comprising a polynucleotide sequence as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence,
- c) a nucleic acid comprising nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or of a complementary polynucleotide sequence,
- d) a nucleic acid having at least eight consecutive nucleotides of a nucleic acid comprising a polynucleotide sequence of 1) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; 2) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; 3) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; 4) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; 5) nucleotides 152-198 of

SEQ ID NO: 27, or of a complementary polynucleotide sequence; 6) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; 7) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or 8) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence;

- 5 e) a nucleic acid having at least 80% nucleotide identity with a nucleic acid comprising a polynucleotide sequence of 1) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; 2) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; 3) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; 4) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; 5) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; 6) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; 7) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or 8) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence;
- 10 f) a nucleic acid having 85%, 90%, 95%, or 98% nucleotide identity with a nucleic acid comprising a polynucleotide sequence of 1) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; 2) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; 3) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; 4) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; 5) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; 6) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; 7) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or 8) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence;
- 15 g) a nucleic acid hybridizing, under high stringency hybridization conditions, with a nucleic acid comprising a polynucleotide sequence of 1) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; 2) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; 3) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; 4) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; 5) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; 6) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; 7) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence, or 8) nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence;
- 20 30 35

h) a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71; and

i) a nucleic acid encoding a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

5 According to a first embodiment, a recombinant vector according to the invention is used to amplify a nucleic acid inserted therein, following transformation or transfection of a desired cellular host.

According to a second embodiment, a recombinant vector according to the invention corresponds to an expression vector comprising, in addition to a nucleic acid in accordance
10 with the invention, a regulatory signal or nucleotide sequence that directs or controls transcription and/or translation of the nucleic acid and its encoded mRNA.

According to a preferred embodiment, a recombinant vector according to the invention will comprise in particular the following components:

(1) an element or signal for regulating the expression of the nucleic acid to be inserted,
15 such as a promoter and/or enhancer sequence;

(2) a nucleotide coding region comprised within the nucleic acid in accordance with the invention to be inserted into such a vector, said coding region being placed in phase with the regulatory element or signal described in (1); and

(3) an appropriate nucleic acid for initiation and termination of transcription of the
20 nucleotide coding region of the nucleic acid described in (2).

In addition, the recombinant vectors according to the invention may include one or more origins for replication in the cellular hosts in which their amplification or their expression is sought, markers or selectable markers.

By way of example, the bacterial promoters may be the LacI or LacZ promoters, the T3
25 or T7 bacteriophage RNA polymerase promoters, the lambda phage PR or PL promoters.

The promoters for eukaryotic cells will comprise the herpes simplex virus (HSV) virus thymidine kinase promoter or alternatively the mouse metallothionein-L promoter.

Generally, for the choice of a suitable promoter, persons skilled in the art can preferably refer to the book by Sambrook et al. (1989) cited above or to the techniques
30 described by Fuller et al. (1996).

When the expression of the genomic sequence of the ABC1 gene will be sought, use will preferably be made of the vectors capable of containing large insertion sequences. In a particular embodiment, bacteriophage vectors such as the P1 bacteriophage vectors such as the vector p158 or the vector p158/neo8 described by Sternberg (1992, 1994) will be preferably
35 used.

The preferred bacterial vectors according to the invention are for example the vectors pBR322(ATCC37017) or alternatively vectors such as pAA223-3 (Pharmacia, Uppsala, Sweden), and pGEM1 (Promega Biotech, Madison, WI, UNITED STATES).

5 There may also be cited other commercially available vectors such as the vectors pQE70, pQE60, pQE9 (Qiagen), psiX174, pBluescript SA, pNH8A, pNH16A, pNH18A, pNH46A, pWLNEO, pSV2CAT, pOG44, pXTI, pSG (Stratagene).

They may also be vectors of the baculovirus type such as the vector pVL1392/1393 (Pharmingen) used to transfect cells of the Sf9 line (ATCC No. CRL 1711) derived from *Spodoptera frugiperda*.

10 They may also be adenoviral vectors such as the human adenovirus of type 2 or 5.

A recombinant vector according to the invention may also be a retroviral vector or an adeno-associated vector (AAV). Such adeno-associated vectors are for example described by Flotte et al. (1992), Samulski et al. (1989), or McLaughlin BA et al. (1996).

15 To allow the expression of a polynucleotide according to the invention, the latter must be introduced into a host cell. The introduction of a polynucleotide according to the invention into a host cell may be carried out *in vitro*, according to the techniques well known to persons skilled in the art for transforming or transfecting cells, either in primer culture, or in the form of cell lines. It is also possible to carry out the introduction of a polynucleotide according to the invention *in vivo* or *ex vivo*, for the prevention or treatment of diseases linked to a deficiency in
20 the reverse transport of cholesterol.

To introduce a polynucleotide or vector of the invention into a host cell, a person skilled in the art can preferably refer to various techniques, such as the calcium phosphate precipitation technique (Graham et al., 1973 ; Chen et al., 1987), DEAE Dextran (Gopal, 1985), electroporation (Tur-Kaspa, 1896 ; Potter et al., 1984), direct microinjection (Harland et al.,
25 1985), liposomes charged with DNA (Nicolau et al., 1982, Fraley et al., 1979).

Once the polynucleotide has been introduced into the host cell, it may be stably integrated into the genome of the cell. The integration may be achieved at a precise site of the genome, by homologous recombination, or it may be randomly integrated. In some embodiments, the polynucleotide may be stably maintained in the host cell in the form of an
30 episome fragment, the episome comprising sequences allowing the retention and the replication of the latter, either independently, or in a synchronized manner with the cell cycle.

According to a specific embodiment, a method of introducing a polynucleotide according to the invention into a host cell, in particular a host cell obtained from a mammal, *in vivo*, comprises a step during which a preparation comprising a pharmaceutically compatible
35 vector and a "naked" polynucleotide according to the invention, placed under the control of appropriate regulatory sequences, is introduced by local injection at the level of the chosen

tissue, for example a smooth muscle tissue, the "naked" polynucleotide being absorbed by the cells of this tissue.

Compositions for use *in vitro* and *in vivo* comprising "naked" polynucleotides are for example described in PCT Application No. WO 95/11307 (Institut Pasteur, Inserm, University
5 of Ottawa) as well as in the articles by Tacson et al. (1996) and Huygen et al. (1996) .

According to a specific embodiment of the invention, a composition is provided for the *in vivo* production of the ABC1 protein. This composition comprises a polynucleotide encoding the ABC1 polypeptide placed under the control of appropriate regulatory sequences, in solution in a physiologically acceptable vector.

10 The quantity of vector which is injected into the host organism chosen varies according to the site of the injection. As a guide, there may be injected between about 0.1 and about 100 µg of polynucleotide encoding the ABC1 protein into the body of an animal, preferably into a patient likely to develop a disease linked to a deficiency in the reverse transport of cholesterol or who has already developed this disease, in particular a patient having a predisposition to
15 Tangier disease or a patient who has already developed the disease.

Consequently, the invention also relates to a pharmaceutical composition intended for the prevention of or treatment of a patient or subject affected by a dysfunction in the reverse transport of cholesterol comprising a nucleic acid encoding the ABC1 protein, in combination with one or more physiologically compatible excipients.

20 Preferably, such a composition will comprise a nucleic acid comprising a polynucleotide sequence of either SEQ ID NO: 69 or SEQ ID NO: 70, wherein the nucleic acid is placed under the control of an appropriate regulatory element or signal.

The subject of the invention is, in addition, a pharmaceutical composition intended for the prevention of or treatment of a patient or a subject affected by a dysfunction in the reverse
25 transport of cholesterol comprising a recombinant vector according to the invention, in combination with one or more physiologically compatible excipients.

The invention also relates to the use of a nucleic acid according to the invention, encoding the ABC1 protein, for the manufacture of a medicament intended for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by
30 a dysfunction in the reverse transport of cholesterol.

The invention also relates to the use of a recombinant vector according to the invention, comprising a nucleic acid encoding the ABC1 protein, for the manufacture of a medicament intended for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

The subject of the invention is therefore also a recombinant vector comprising a nucleic acid according to the invention that encodes an ABC1 protein or polypeptide involved in the metabolism of cholesterol.

5 The invention also relates to the use of such a recombinant vector for the preparation of a pharmaceutical composition intended for the treatment and/or for the prevention of cardiovascular diseases or conditions associated with HDL deficiency, such as the HDL deficiency associated with Tangier and/or FHD disease, HDL deficiency, LCAT deficiency, malaria, and diabetes.

10 The present invention also relates to the use of cells genetically modified *ex vivo* with such a recombinant vector according to the invention, or of cells producing a recombinant vector, wherein the cells are implanted in the body, to allow a prolonged and effective expression *in vivo* of a biologically active ABC1 polypeptide.

Vectors useful in methods of somatic gene therapy and compositions containing such vectors

15 The present invention also relates to a new therapeutic approach for the treatment of pathologies linked to the transport of cholesterol. It provides an advantageous solution to the disadvantages of the prior art, by demonstrating the possibility of treating the pathologies linked to the transport of cholesterol by gene therapy, by the transfer and expression *in vivo* of a gene encoding an ABC1 protein involved in the transport and the metabolism of cholesterol.
20 The invention thus offers a simple means allowing a specific and effective treatment of related pathologies such as, for example, atherosclerosis.

Gene therapy consists in correcting a deficiency or an abnormality (mutation, aberrant expression and the like) and in bringing about the expression of a protein of therapeutic interest by introducing genetic information into the affected cell or organ. This genetic information may
25 be introduced either *ex vivo* into a cell extracted from the organ, the modified cell then being reintroduced into the body, or directly *in vivo* into the appropriate tissue. In this second case, various techniques exist, among which various transfection techniques involving complexes of DNA and DEAE-dextran (Pagano et al., 1967), of DNA and nuclear proteins (Kaneda et al., 1989), of DNA and lipids (Felgner et al., 1987), the use of liposomes (Fraley et al., 1980), and
30 the like. More recently, the use of viruses as vectors for the transfer of genes has appeared as a promising alternative to these physical transfection techniques. In this regard, various viruses have been tested for their capacity to infect certain cell populations. In particular, the retroviruses (RSV, HMS, MMS, and the like), the HSV virus, the adeno-associated viruses and the adenoviruses.

The present invention therefore also relates to a new therapeutic approach for the treatment of pathologies linked to the transport of cholesterol, consisting in transferring and in expressing *in vivo* genes encoding ABC1. Specifically, the present invention provides a new therapeutic approach for the treatment and/or prevention of HDL deficiency, such as the HDL deficiency associated with Tangier and/or FHD disease, HDL deficiency, LCAT deficiency, malaria, and diabetes. In a particularly preferred manner, the applicant has now found that it is possible to construct recombinant vectors comprising a nucleic acid encoding an ABC1 protein involved in the metabolism of cholesterol, to administer these recombinant vectors *in vivo*, and that this administration allows a stable and effective expression of a biologically active ABC1 protein *in vivo*, with no cytopathological effect.

The present invention also results from the demonstration that adenoviruses constitute particularly efficient vectors for the transfer and the expression of the ABC1 gene. In particular, the present invention shows that the use of recombinant adenoviruses as vectors makes it possible to obtain sufficiently high levels of expression of this gene to produce the desired therapeutic effect. Other viral vectors such as retroviruses or adeno-associated viruses (AAV) allowing a stable expression of the gene are also claimed.

The present invention thus offers a new approach for the treatment and prevention of cardiovascular and neurological pathologies linked to the abnormalities of the transport of cholesterol.

The subject of the invention is therefore also a defective recombinant virus comprising a nucleic acid according to the invention that encodes an ABC1 protein or polypeptide involved in the metabolism of cholesterol.

The invention also relates to the use of such a defective recombinant virus for the preparation of a pharmaceutical composition intended for the treatment and/or for the prevention of cardiovascular diseases or conditions associated with HDL deficiency, such as the HDL deficiency associated with Tangier and/or FHD disease, HDL deficiency, LCAT deficiency, malaria, and diabetes.

The present invention also relates to the use of cells genetically modified *ex vivo* with such a defective recombinant virus according to the invention, or of cells producing a defective recombinant virus, wherein the cells are implanted in the body, to allow a prolonged and effective expression *in vivo* of a biologically active ABC1 polypeptide.

The present invention shows that it is possible to incorporate a DNA sequence encoding ABC1 into a viral vector, and that these vectors make it possible to effectively express a biologically active, mature form. More particularly, the invention shows that the *in vivo* expression of ABC1 may be obtained by direct administration of an adenovirus or by

implantation of a producing cell or of a cell genetically modified by an adenovirus or by a retrovirus incorporating such a DNA.

The present invention is particularly advantageous because it makes it possible to induce a controlled expression, and with no harmful effect, of ABC1 in organs which are not normally involved in the expression of this protein. In particular, a significant release of the ABC1 protein is obtained by implantation of cells producing vectors of the invention, or infected *ex vivo* with vectors of the invention.

The activity of transport of cholesterol produced in the context of the present invention may be of the human or animal ABC1 type. The nucleic sequence used in the context of the present invention may be a cDNA, a genomic DNA (gDNA), an RNA (in the case of retroviruses) or a hybrid construct consisting, for example, of a cDNA into which one or more introns (gDNA) would be inserted. It may also involve synthetic or semisynthetic sequences. In a particularly advantageous manner, a cDNA or a gDNA is used. In particular, the use of a gDNA allows a better expression in human cells. To allow their incorporation into a viral vector according to the invention, these sequences are preferably modified, for example by site-directed mutagenesis, in particular for the insertion of appropriate restriction sites. The sequences described in the prior art are indeed not constructed for use according to the invention, and prior adaptations may prove necessary, in order to obtain substantial expressions. In the context of the present invention, the use of a nucleic sequence encoding a human ABC1 protein is preferred. Moreover, it is also possible to use a construct encoding a derivative of these ABC1 proteins. A derivative of these ABC1 proteins comprises, for example, any sequence obtained by mutation, deletion and/or addition relative to the native sequence, and encoding a product retaining the cholesterol transport activity. These modifications may be made by techniques known to a person skilled in the art (see general molecular biological techniques below). The biological activity of the derivatives thus obtained can then be easily determined, as indicated in particular in the examples of the measurement of the efflux of cholesterol from cells. The derivatives for the purposes of the invention may also be obtained by hybridization from nucleic acid libraries, using as probe the native sequence or a fragment thereof.

These derivatives are in particular molecules having a higher affinity for their binding sites, molecules exhibiting greater resistance to proteases, molecules having a higher therapeutic efficacy or fewer side effects, or optionally new biological properties. The derivatives also include the modified DNA sequences allowing improved expression *in vivo*.

In a first embodiment, the present invention relates to a defective recombinant virus comprising a cDNA encoding an ABC1 polypeptide involved in the transport and metabolism of cholesterol. In another preferred embodiment of the invention, a defective recombinant virus

comprises a genomic DNA (gDNA) encoding an ABC1 polypeptide involved in the transport and metabolism of cholesterol. Preferably, the ABC1 polypeptide comprises an amino acid sequence of SEQ ID NO: 71. More preferably, the ABC1 polypeptide comprised amino acids 1-60 of SEQ ID NO:71.

5 The vectors of the invention may be prepared from various types of viruses. Preferably, vectors derived from adenoviruses, adeno-associated viruses (AAV), herpesviruses (HSV) or retroviruses are used. It is preferable to use an adenovirus, for direct administration or for the ex vivo modification of cells intended to be implanted, or a retrovirus, for the implantation of producing cells.

10 The viruses according to the invention are defective, that is to say that they are incapable of autonomously replicating in the target cell. Generally, the genome of the defective viruses used in the context of the present invention therefore lacks at least the sequences necessary for the replication of said virus in the infected cell. These regions may be either eliminated (completely or partially), or made nonfunctional, or substituted with other sequences
15 and in particular with the nucleic sequence encoding the ABC1 protein. Preferably, the defective virus retains, nevertheless, the sequences of its genome which are necessary for the encapsidation of the viral particles.

 As regards more particularly adenoviruses, various serotypes, whose structure and properties vary somewhat, have been characterized. Among these serotypes, human
20 adenoviruses of type 2 or 5 (Ad 2 or Ad 5) or adenoviruses of animal origin (see Application WO 94/26914) are preferably used in the context of the present invention. Among the adenoviruses of animal origin which can be used in the context of the present invention, there may be mentioned adenoviruses of canine, bovine, murine (example: Mav1, Beard et al., Virology 75 (1990) 81), ovine, porcine, avian or simian (example: SAV) origin. Preferably, the
25 adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus [Manhattan or A26/61 strain (ATCC VR-800) for example]. Preferably, adenoviruses of human or canine or mixed origin are used in the context of the invention. Preferably, the defective adenoviruses of the invention comprise the ITRs, a sequence allowing the encapsidation and the sequence encoding the ABC1 protein. Preferably, in the genome of the adenoviruses of the
30 invention, the E1 region at least is made nonfunctional. Still more preferably, in the genome of the adenoviruses of the invention, the E1 gene and at least one of the E2, E4 and L1-L5 genes are nonfunctional. The viral gene considered may be made nonfunctional by any technique known to a person skilled in the art, and in particular by total suppression, by substitution, by partial deletion or by addition of one or more bases in the gene(s) considered. Such
35 modifications may be obtained in vitro (on the isolated DNA) or in situ, for example, by means of genetic engineering techniques, or by treatment by means of mutagenic agents. Other regions

may also be modified, and in particular the E3 (WO95/02697), E2 (WO94/28938), E4 (WO94/28152, WO94/12649, WO95/02697) and L5 (WO95/02697) region. According to a preferred embodiment, the adenovirus according to the invention comprises a deletion in the E1 and E4 regions and the sequence encoding ABC1 is inserted at the level of the inactivated E1
5 region. According to another preferred embodiment, it comprises a deletion in the E1 region at the level of which the E4 region and the sequence encoding ABC1 (French Patent Application FR94 13355) are inserted.

The defective recombinant adenoviruses according to the invention may be prepared by any technique known to persons skilled in the art (Levrero et al., 1991, EP 185 573; and
10 Graham, 1984). In particular, they may be prepared by homologous recombination between an adenovirus and a plasmid carrying, *inter alia*, the nucleic acid encoding the ABC1 protein. The homologous recombination occurs after cotransfection of said adenoviruses and plasmid into an appropriate cell line. The cell line used must preferably (i) be transformable by said elements, and (ii), contain the sequences capable of complementing the part of the defective adenovirus
15 genome, preferably in integrated form in order to avoid the risks of recombination. By way of example of a line, there may be mentioned the human embryonic kidney line 293 (Graham et al., 1977), which contains in particular, integrated into its genome, the left part of the genome of an Ad5 adenovirus (12%) or lines capable of complementing the E1 and E4 functions as described in particular in Applications No. WO 94/26914 and WO95/02697.

20 Next, the adenoviruses which have multiplied are recovered and purified according to conventional molecular biological techniques, as illustrated in the examples.

As regards the adeno-associated viruses (AAV), they are DNA viruses of a relatively small size, which integrate into the genome of the cells which they infect, in a stable and site-specific manner. They are capable of infecting a broad spectrum of cells, without inducing any
25 effect on cellular growth, morphology or differentiation. Moreover, they do not appear to be involved in pathologies in humans. The genome of AAVs has been cloned, sequenced and characterized. It comprises about 4700 bases, and contains at each end an inverted repeat region (ITR) of about 145 bases, serving as replication origin for the virus. The remainder of the genome is divided into 2 essential regions carrying the encapsidation functions: the left hand
30 part of the genome, which contains the rep gene, involved in the viral replication and the expression of the viral genes; the right hand part of the genome, which contains the cap gene encoding the virus capsid proteins.

The use of vectors derived from AAVs for the transfer of genes *in vitro* and *in vivo* has been described in the literature (see in particular WO 91/18088; WO 93/09239; US
35 4,797,368, US5,139,941, EP 488 528). These applications describe various constructs derived from AAVs, in which the rep and/or cap genes are deleted and replaced by a gene of interest,

and their use for transferring *in vitro* (on cells in culture) or *in vivo* (directly into an organism) said gene of interest. However, none of these documents either describes or suggests the use of a recombinant AAV for the transfer and expression *in vivo* or *ex vivo* of an ABC1 protein, or the advantages of such a transfer. The defective recombinant AAVs according to the invention
5 may be prepared by cotransfection, into a cell line infected with a human helper virus (for example an adenovirus), of a plasmid containing the sequence encoding the ABC1 protein bordered by two AAV inverted repeat regions (ITR), and of a plasmid carrying the AAV encapsidation genes (rep and cap genes). The recombinant AAVs produced are then purified by conventional techniques.

10 As regards the herpesviruses and the retroviruses, the construction of recombinant vectors has been widely described in the literature: see in particular Breakfield et al., (1991); EP 453242, EP178220, Bernstein et al. (1985); McCormick, (1985), and the like.

In particular, the retroviruses are integrating viruses, infecting dividing cells. The genome of the retroviruses essentially comprises two long terminal repeats (LTRs), an
15 encapsidation sequence and three coding regions (gag, pol and env). In the recombinant vectors derived from retroviruses, the gag, pol and env genes are generally deleted, completely or partially, and replaced with a heterologous nucleic acid sequence of interest. These vectors may be produced from various types of retroviruses such as in particular MoMuLV ("murine moloney leukemia virus"; also called MoMLV), MSV ("murine moloney sarcoma virus"),
20 HaSV ("harvey sarcoma virus"); SNV ("spleen necrosis virus"); RSV ("rous sarcoma virus") or Friend's virus.

To construct recombinant retroviruses containing a sequence encoding the ABC1 protein according to the invention, a plasmid containing in particular the LTRs, the encapsidation sequence and said coding sequence is generally constructed, and then used to
25 transfect a so-called encapsidation cell line, capable of providing in trans the retroviral functions deficient in the plasmid. Generally, the encapsidation lines are therefore capable of expressing the gag, pol and env genes. Such encapsidation lines have been described in the prior art, and in particular the PA317 line (US 4,861,719), the PsiCRIP line (WO 90/02806) and the GP+envAm-12 line (WO 89/07150). Moreover, the recombinant retroviruses may
30 contain modifications at the level of the LTRs in order to suppress the transcriptional activity, as well as extended encapsidation sequences, containing a portion of the gag gene (Bender et al., 1987). The recombinant retroviruses produced are then purified by conventional techniques.

To carry out the present invention, it is preferable to use a defective recombinant
35 adenovirus. The particularly advantageous properties of adenoviruses are preferred for the *in vivo* expression of a protein having a cholesterol transport activity. The adenoviral vectors

according to the invention are particularly preferred for a direct administration *in vivo* of a purified suspension, or for the *ex vivo* transformation of cells, in particular autologous cells, in view of their implantation. Furthermore, the adenoviral vectors according to the invention exhibit, in addition, considerable advantages, such as in particular their very high infection efficiency, which makes it possible to carry out infections using small volumes of viral suspension.

According to another particularly preferred embodiment of the invention, a line producing retroviral vectors containing the sequence encoding the ABC1 protein is used for implantation *in vivo*. The lines which can be used to this end are in particular the PA317 (US 4,861,719), PsiCrip (WO 90/02806) and GP+envAm-12 (US 5,278,056) cells modified so as to allow the production of a retrovirus containing a nucleic sequence encoding an ABC1 protein according to the invention. For example, totipotent stem cells, precursors of blood cell lines, may be collected and isolated from a subject. These cells, when cultured, may then be transfected with the retroviral vector containing the sequence encoding the ABC1 protein under the control of viral, nonviral or nonviral promoters specific for macrophages or under the control of its own promoter. These cells are then reintroduced into the subject. The differentiation of these cells will be responsible for blood cells expressing the ABC1 protein, in particular for monocytes which, when transformed to macrophages, participate in the removal of cholesterol from the arterial wall. These macrophages expressing the ABC1 protein will have an increased capacity to metabolize cholesterol in excess and will make it available to the cell surface for its removal by the primary acceptors of membrane cholesterol.

Preferably, in the vectors of the invention, the sequence encoding the ABC1 protein is placed under the control of signals allowing its expression in the infected cells. These may be expression signals which are homologous or heterologous, that is to say signals different from those which are naturally responsible for the expression of the ABC1 protein. They may also be in particular sequences responsible for the expression of other proteins, or synthetic sequences. In particular, they may be sequences of eukaryotic or viral genes or derived sequences, stimulating or repressing the transcription of a gene in a specific manner or otherwise and in an inducible manner or otherwise. By way of example, they may be promoter sequences derived from the genome of the cell which it is desired to infect, or from the genome of a virus, and in particular the promoters of the E1A or major late promoter (MLP) genes of adenoviruses, the cytomegalovirus (CMV) promoter, the RSV-LTR and the like. Among the eukaryotic promoters, there may also be mentioned the ubiquitous promoters (HPRT, vimentin, α -actin, tubulin and the like), the promoters of the intermediate filaments (desmin, neurofilaments, keratin, GFAP, and the like), the promoters of therapeutic genes (of the MDR, CFTR or factor VIII type, and the like), tissue-specific promoters (pyruvate kinase, villin, promoter of the fatty

acid binding intestinal protein, promoter of the smooth muscle cell α -actin, promoters specific for the liver; Apo AI, Apo AII, human albumin and the like) or promoters corresponding to a stimulus (steroid hormone receptor, retinoic acid receptor and the like). In addition, these expression sequences may be modified by addition of enhancer or regulatory sequences and the like. Moreover, when the inserted gene does not contain expression sequences, it may be inserted into the genome of the defective virus downstream of such a sequence.

In a specific embodiment, the invention relates to a defective recombinant virus comprising a nucleic acid encoding an ABC1 protein involved in the metabolism of cholesterol under the control of a promoter chosen from RSV-LTR or the CMV early promoter.

As indicated above, the present invention also relates to any use of a virus as described above for the preparation of a pharmaceutical composition for the treatment and/or prevention of pathologies linked to the transport of cholesterol.

The present invention also relates to a pharmaceutical composition comprising one or more defective recombinant viruses as described above. These pharmaceutical compositions may be formulated for administration by the topical, oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous, intraocular or transdermal route and the like. Preferably, the pharmaceutical compositions of the invention comprises a pharmaceutically acceptable vehicle or physiologically compatible excipient for an injectable formulation, in particular for an intravenous injection, such as for example into the patient's portal vein. These may relate in particular to isotonic sterile solutions or dry, in particular, freeze-dried, compositions which, upon addition depending on the case of sterilized water or physiological saline, allow the preparation of injectable solutions. Direct injection into the patient's portal vein is preferred because it makes it possible to target the infection at the level of the liver and thus to concentrate the therapeutic effect at the level of this organ.

The doses of defective recombinant virus used for the injection may be adjusted as a function of various parameters, and in particular as a function of the viral vector, of the mode of administration used, of the relevant pathology or of the desired duration of treatment. In general, the recombinant adenoviruses according to the invention are formulated and administered in the form of doses of between 10^4 and 10^{14} pfu/ml, and preferably 10^6 to 10^{10} pfu/ml. The term "pfu" (plaque forming unit) corresponds to the infectivity of a virus solution, and is determined by infecting an appropriate cell culture and measuring, generally after 48 hours, the number of plaques that result from infected cell lysis. The techniques for determining the pfu titer of a viral solution are well documented in the literature.

As regards retroviruses, the compositions according to the invention may directly contain the producing cells, with a view to their implantation.

In this regard, another subject of the invention relates to any mammalian cell infected with one or more defective recombinant viruses according to the invention. More particularly, the invention relates to any population of human cells infected with such viruses. These may be in particular cells of blood origin (totipotent stem cells or precursors), fibroblasts, myoblasts, hepatocytes, keratinocytes, smooth muscle and endothelial cells, glial cells and the like.

The cells according to the invention may be derived from primary cultures. These may be collected by any technique known to persons skilled in the art and then cultured under conditions allowing their proliferation. As regards more particularly fibroblasts, these may be easily obtained from biopsies, for example according to the technique described by Ham (1980). These cells may be used directly for infection with the viruses, or stored, for example by freezing, for the establishment of autologous libraries, in view of a subsequent use. The cells according to the invention may be secondary cultures, obtained for example from pre-established libraries (see for example EP 228458, EP 289034, EP 400047, EP 456640).

The cells in culture are then infected with a recombinant virus according to the invention, in order to confer on them the capacity to produce a biologically active ABC1 protein. The infection is carried out in vitro according to techniques known to persons skilled in the art. In particular, depending on the type of cells used and the desired number of copies of virus per cell, persons skilled in the art can adjust the multiplicity of infection and optionally the number of infectious cycles produced. It is clearly understood that these steps must be carried out under appropriate conditions of sterility when the cells are intended for administration in vivo. The doses of recombinant virus used for the infection of the cells may be adjusted by persons skilled in the art according to the desired aim. The conditions described above for the administration in vivo may be applied to the infection in vitro. For the infection with a retrovirus, it is also possible to co-culture a cell to be infected with a cell producing the recombinant retrovirus according to the invention. This makes it possible to eliminate purification of the retrovirus.

Another subject of the invention relates to an implant comprising mammalian cells infected with one or more defective recombinant viruses according to the invention or cells producing recombinant viruses, and an extracellular matrix. Preferably, the implants according to the invention comprise 10^5 to 10^{10} cells. More preferably, they comprise 10^6 to 10^8 cells.

More particularly, in the implants of the invention, the extracellular matrix comprises a gelling compound and optionally a support allowing the anchorage of the cells.

For the preparation of the implants according to the invention, various types of gelling agents may be used. The gelling agents are used for the inclusion of the cells in a matrix having the constitution of a gel, and for promoting the anchorage of the cells on the support, where

appropriate. Various cell adhesion agents can therefore be used as gelling agents, such as in particular collagen, gelatin, glycosaminoglycans, fibronectin, lectins and the like. Preferably, collagen is used in the context of the present invention. This may be collagen of human, bovine or murine origin. More preferably, type I collagen is used.

5 As indicated above, the compositions according to the invention preferably comprise a support allowing the anchorage of the cells. The term anchorage designates any form of biological and/or chemical and/or physical interaction causing the adhesion and/or the attachment of the cells to the support. Moreover, the cells may either cover the support used, or penetrate inside this support, or both. It is preferable to use in the context of the invention a
10 solid, nontoxic and/or biocompatible support. In particular, it is possible to use polytetrafluoroethylene (PTFE) fibers or a support of biological origin.

 The present invention thus offers a very effective means for the treatment or prevention of pathologies linked to the transport of cholesterol, in particular obesity, HDL deficiency, hypertriglyceridemia, atherosclerosis, or, in the field of cardiovascular conditions,
15 myocardial infarction, angina, sudden death, cardiac decompensation and cerebrovascular accidents.

 In addition, this treatment may be applied to both humans and any animals such as ovines, bovines, domestic animals (dogs, cats and the like), horses, fish and the like.

20 **RECOMBINANT HOST CELLS**

 The invention relates to a recombinant host cell comprising a nucleic acid of the invention, and more particularly, a nucleic acid comprising a polynucleotide sequence of either SEQ ID NO: 69 or SEQ ID NO: 70, or of a complementary polynucleotide sequence.

 The invention also relates to a recombinant host cell comprising a nucleic acid of the
25 invention, and more particularly a nucleic acid comprising a nucleotide sequence as depicted in SEQ ID NO: 69 or SEQ ID NO: 70, or of a complementary polynucleotide sequence.

 Specifically, the invention relates to a recombinant host cell comprising nucleic acid comprising any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

30 The invention also relates to a recombinant host cell comprising a nucleic acid comprising a polynucleotide sequence as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

 The invention also relates to a recombinant host cell comprising a nucleic acid comprising nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a
35 complementary polynucleotide sequence.

The invention also relates to a recombinant host cell comprising a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71.

The invention also relates to a recombinant host cell comprising a nucleic acid encoding a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

5 According to another aspect, the invention also relates to a recombinant host cell comprising a recombinant vector according to the invention. Therefore, the invention also relates to a recombinant host cell comprising a recombinant vector comprising any of the nucleic acids of the invention, and more particularly a nucleic acid comprising a nucleotide sequence of either SEQ ID NO: 69 or SEQ ID NO: 70, or of a complementary polynucleotide sequence.

10 Specifically, the invention relates to a recombinant host cell comprising a recombinant vector comprising a nucleic acid comprising any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

15 The invention also relates to a recombinant host cell comprising a recombinant vector comprising a nucleic acid comprising a polynucleotide sequence as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

20 The invention also relates to a recombinant host cell comprising a recombinant vector comprising a nucleic acid comprising nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or of a complementary polynucleotide sequence.

 The invention also relates to a recombinant host cell comprising a recombinant vector comprising a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71.

25 The invention also relates to a recombinant host cell comprising a recombinant vector comprising a nucleic acid encoding a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

 The preferred host cells according to the invention are for example the following:

30 a) prokaryotic host cells: strains of *Escherichia coli* (strain DH5- α), of *Bacillus subtilis*, of *Salmonella typhimurium*, or strains of genera such as *Pseudomonas*, *Streptomyces* and *Staphylococcus* ;

 b) eukaryotic host cells: HeLa cells (ATCC No. CCL2), Cv 1 cells (ATCC No. CCL70), COS cells (ATCC No. CRL 1650), Sf-9 cells (ATCC No. CRL 1711), CHO cells (ATCC No. CCL-61) or 3T3 cells (ATCC No. CRL-6361).

MUTATED ABC1 POLYPEPTIDES

According to another aspect, the invention relates to a polypeptide encoded by a mutated ABC1 gene, and more particularly a mutated ABC1 gene in patients suffering from a deficiency in the reverse transport of cholesterol, more particularly in patients suffering from
5 Tangier disease.

As indicated above, seventeen mutations have been identified in the ABC1 gene according to the invention (see Table IV).

The polypeptides as depicted in SEQ ID NOs: 89-102 correspond to the non-silent ABC1 gene mutations, and are useful in particular for the preparation of antibodies specifically
10 recognizing them. Such antibodies constitute a means for detecting the production of mutated ABC1 polypeptides in a sample obtained from a subject to be tested, preferably a patient having symptoms characteristic of a deficiency in the reverse transport of cholesterol, and more preferably in a patient having the symptoms characteristic of Tangier and/or FHD disease.

According to another aspect, the invention also relates to a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 89-102.
15

According to another aspect, the invention also relates to a polypeptide comprising an amino acid sequence as depicted in any one of SEQ ID NOs: 89-102.

Generally, the polypeptides according to the invention are provided in an isolated or purified form.
20

METHODS FOR PRODUCING ABC1 POLYPEPTIDES

The invention also relates to a method for the production of a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, said method comprising the steps of:

- 25 a) inserting a nucleic acid encoding said polypeptide into an appropriate vector;
b) culturing, in an appropriate culture medium, a previously transformed host cell or transfecting a host cell with the recombinant vector of step a);
c) recovering the conditioned culture medium or lysing the host cell, for example by sonication or by osmotic shock;
30 d) separating and purifying said polypeptide from said culture medium or alternatively from the cell lysates obtained in step c); and
e) where appropriate, characterizing the recombinant polypeptide produced.

A specific embodiment of the invention relates to a method for producing a polypeptide comprising an amino acid sequence of amino acids 1-60 of SEQ ID NO: 71.

The polypeptides according to the invention may be characterized by binding to an immunoaffinity chromatography column on which the antibodies directed against this polypeptide or against a fragment or a variant thereof have been previously immobilized.

According to another aspect, a recombinant polypeptide according to the invention may
5 be purified by passing it over an appropriate series of chromatography columns, according to methods known to persons skilled in the art and described for example in F. Ausubel et al (1989).

A polypeptide according to the invention may also be prepared by conventional chemical synthesis techniques either in homogeneous solution or in solid phase. By way of
10 illustration, a polypeptide according to the invention may be prepared by the technique either in homogeneous solution described by Houben Weyl (1974) or the solid phase synthesis technique described by Merrifield (1965a; 1965b).

A polypeptide termed "homologous" to a polypeptide having an amino acid sequence comprising amino acids 1-60 of SEQ ID NO: 71 also forms part of the invention. Such a
15 homologous polypeptide comprises an amino acid sequence possessing one or more substitutions of an amino acid by an equivalent amino acid, relative to amino acids 1-60 of SEQ ID NO: 71.

An "equivalent amino acid" according to the present invention will be understood to mean for example replacement of a residue in the L form by a residue in the D form or the
20 replacement of a glutamic acid (E) by a pyro-glutamic acid according to techniques well known to persons skilled in the art. By way of illustration, the synthesis of peptide containing at least one residue in the D form is described by Koch (1977). According to another aspect, two amino acids belonging to the same class, that is to say two uncharged polar, nonpolar, basic or acidic amino acids, are also considered as equivalent amino acids.

25 Polypeptides comprising at least one nonpeptide bond such as a retro-inverse bond (NHCO), a carba bond (CH₂CH₂) or a ketomethylene bond (CO-CH₂) also form part of the invention.

Preferably, the polypeptides according to the invention comprising one or more additions, deletions, substitutions of at least one amino acid will retain their capacity to be
30 recognized by antibodies directed against the nonmodified polypeptides.

ANTIBODIES

The ABC1 polypeptides according to the invention, in particular 1) a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, 2) a
35 polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, 3) a polypeptide fragment or variant of a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and

89-102, wherein the polypeptide fragment or variant comprises amino acids 1-60 of SEQ ID NO: 71, or 4) a polypeptide termed "homologous" to a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, may be used for the preparation of an antibody, in particular for detecting the production of a normal or altered form of an ABC1 polypeptide in a patient.

5 An antibody directed against a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, also forms part of the present invention.

An antibody directed against a polypeptide termed "homologous" to a polypeptide having an amino acid sequence comprising amino acids 1-60 of SEQ ID NO: 71 also forms part of the invention. Such an antibody is directed against a homologous polypeptide comprising an amino acid sequence possessing one or more substitutions of an amino acid by an equivalent amino acid, relative to amino acids 1-60 of SEQ ID NO: 71.

10 "Antibody" for the purposes of the present invention will be understood to mean in particular polyclonal or monoclonal antibodies or fragments (for example the F(ab)'₂ and Fab fragments) or any polypeptide comprising a domain of the initial antibody recognizing the target polypeptide or polypeptide fragment according to the invention.

15 Monoclonal antibodies may be prepared from hybridomas according to the technique described by Kohler and Milstein (1975).

According to the invention, a polypeptide produced recombinantly or by chemical synthesis, and fragments or other derivatives or analogs thereof, including fusion proteins, may be used as an immunogen to generate antibodies that recognize a polypeptide according to the invention. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. The anti-ABC1 antibodies of the invention may be cross reactive, *e.g.*, they may recognize an ABC1 polypeptide from different species. Polyclonal antibodies have greater likelihood of cross reactivity. Alternatively, an antibody of the invention may be specific for a single form of ABC1. Preferably, such an antibody is specific for human ABC1.

20 Various procedures known in the art may be used for the production of polyclonal antibodies to an ABC1 polypeptide or derivative or analog thereof. For the production of antibody, various host animals can be immunized by injection with an ABC1 polypeptide, or a derivative (*e.g.*, fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the ABC1 polypeptide or fragment thereof can be conjugated to an immunogenic carrier, *e.g.*, bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins,

dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies directed toward the ABC1 polypeptide, or fragment, analog, or derivative thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein (1975), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983a); Cote et al. (1983), and the EBV-hybridoma technique to produce human monoclonal antibodies [Cole et al., 1985]. In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals [International Patent Publication No. WO 89/12690, published 28 December 1989]. In fact, according to the invention, techniques developed for the production of "chimeric antibodies" [Morrison et al., (1984); Neuberger et al., (1984); Takeda et al., (1985)] by splicing the genes from a mouse antibody molecule specific for an ABC1 polypeptide together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such human or humanized chimeric antibodies are preferred for use in therapy of human diseases or disorders (described *infra*), since the human or humanized antibodies are much less likely than xenogenic antibodies to induce an immune response, in particular an allergic response, themselves.

According to the invention, techniques described for the production of single chain antibodies [U.S. Patent Nos. 5,476,786 and 5,132,405 to Huston; U.S. Patent 4,946,778] can be adapted to produce ABC1 polypeptide-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for an ABC1 polypeptide, or its derivatives, or analogs.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement

fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope of an ABC1 polypeptide, one may assay generated hybridomas for a product which binds to an ABC1 polypeptide fragment containing such epitope. For selection of an antibody specific to an ABC1 polypeptide from a particular species of animal, one can select on the basis of positive binding with an ABC1 polypeptide expressed by or isolated from cells of that species of animal.

The foregoing antibodies can be used in methods known in the art relating to the localization and activity of an ABC1 polypeptide, *e.g.*, for Western blotting, ABC1 polypeptide *in situ*, measuring levels thereof in appropriate physiological samples, etc. using any of the detection techniques mentioned above or known in the art.

In a specific embodiment, antibodies that agonize or antagonize the activity of an ABC1 polypeptide can be generated. Such antibodies can be tested using the assays described *infra* for identifying ligands.

The present invention relates to an antibody directed against 1) a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, 2) a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, 3) a polypeptide fragment or variant of a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, wherein the polypeptide fragment or variant comprises amino acids 1-60 of SEQ ID NO: 71, or 4) a polypeptide termed "homologous" to a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, also forms part of the invention, as produced in the trioma technique or the hybridoma technique described by Kozbor et al. (1983b).

The invention also relates to single-chain Fv antibody fragments (ScFv) as described in US patent No. 4,946,778 or by Martineau et al. (1998).

The antibodies according to the invention also comprise antibody fragments obtained with the aid of phage libraries as described by Ridder et al., (1995) or humanized antibodies as described by Reinmann et al. (1997) and Leger et al., (1997).

The antibody preparations according to the invention are useful in immunological detection tests intended for the identification of the presence and/or of the quantity of antigens present in a sample.

An antibody according to the invention may comprise, in addition, a detectable marker which is isotopic or nonisotopic, for example fluorescent, or may be coupled to a molecule such as biotin, according to techniques well known to persons skilled in the art.

Thus, the subject of the invention is, in addition, a method of detecting the presence of
5 a polypeptide according to the invention in a sample, said method comprising the steps of:

- a) bringing the sample to be tested into contact with an antibody directed against 1) a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, 2) a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, 3) a polypeptide fragment or variant of a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and
10 89-102, wherein the polypeptide fragment or variant comprises amino acids 1-60 of SEQ ID NO: 71, or 4) a polypeptide termed "homologous" to a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, and
- b) detecting the antigen/antibody complex formed.

The invention also relates to a box or kit for diagnosis or for detecting the presence of a
15 polypeptide in accordance with the invention in a sample, said box comprising:

- a) an antibody directed against 1) a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, 2) a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, 3) a polypeptide fragment or variant of a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, wherein the polypeptide fragment or
20 variant comprises amino acids 1-60 of SEQ ID NO: 71, or 4) a polypeptide termed "homologous" to a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, and
- b) a reagent allowing the detection of the antigen/antibody complexes formed.

25 PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF TREATMENT

The invention also relates to pharmaceutical compositions intended for the prevention or treatment of a deficiency in the metabolism of cholesterol such as atherosclerosis, particularly in the transport of cholesterol, and still more particularly in the reverse transport of cholesterol, characterized in that they comprise a therapeutically effective quantity of a
30 polynucleotide capable of giving rise to the production of an effective quantity of the normal ABC1 polypeptide, in particular a polypeptide comprising an amino acid sequence of SEQ ID NO: 71. In a preferred embodiment, the ABC1 polypeptide comprises amino acids 1-60 of SEQ ID NO: 71.

The subject of the invention is, in addition, pharmaceutical compositions intended for
35 the prevention or treatment of a deficiency in the metabolism of cholesterol such as atherosclerosis, particularly in the transport of cholesterol, and still more particularly in the

reverse transport of cholesterol, characterized in that they comprise a therapeutically effective quantity of the normal ABC1 polypeptide, in particular a polypeptide comprising an amino acid sequence of SEQ ID NO: 71. In a preferred embodiment, the ABC1 polypeptide comprises amino acids 1-60 of SEQ ID NO: 71.

- 5 The invention also relates to the use of the ABC1 polypeptide having an amino acid sequence of SEQ ID NO: 71 or amino acids 1-60 of SEQ ID NO: 71 for the manufacture of a medicament intended for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

- 10 The invention relates to a pharmaceutical composition for the prevention or treatment of subjects affected by a dysfunction in the reverse transport of cholesterol, comprising a therapeutically effective quantity of the polypeptide having an amino acid sequence of SEQ ID NO: 71 or amino acids 1-60 of SEQ ID NO: 71.

- 15 According to yet another aspect, the subject of the invention is also a preventive or curative therapeutic method of treating diseases caused by a deficiency in the metabolism of cholesterol, more particularly in the transport of cholesterol and still more particularly in the reverse transport of cholesterol, such a method comprising a step in which there is administered to a patient a therapeutically effective quantity of the ABC1 polypeptide in said patient, said polypeptide being, where appropriate, combined with one or more physiologically compatible vehicles and/or excipients.

- 20 Preferably, a pharmaceutical composition comprising a polypeptide according to the invention will be administered to the patient. Thus, the invention also relates to pharmaceutical compositions intended for the prevention or treatment of a deficiency in the metabolism of cholesterol such as atherosclerosis, particularly in the transport of cholesterol, and still more particularly in the reverse transport of cholesterol, characterized in that they comprise a therapeutically effective quantity of a polynucleotide capable of giving rise to the production of an effective quantity of a normal ABC1 polypeptide, in particular of a polypeptide having an amino acid sequence of SEQ ID NO: 71 or amino acids 1-60 of SEQ ID NO: 71.

- 30 The subject of the invention is, in addition, pharmaceutical compositions intended for the prevention or treatment of a deficiency in the metabolism of cholesterol such as atherosclerosis, particularly in the transport of cholesterol, and still more particularly in the reverse transport of cholesterol, characterized in that they comprise a therapeutically effective quantity of a normal ABC1 polypeptide, in particular of a polypeptide having an amino acid sequence of SEQ ID NO: 71 or amino acids 1-60 of SEQ ID NO: 71.

- 35 Such pharmaceutical compositions will be preferably suitable for the administration, for example by the parenteral route, of a quantity of the ABC1 polypeptide ranging from

1 µg/kg/day to 10 mg/kg/day, preferably at least 0.01 mg/kg/day and more preferably between 0.01 and 1 mg/kg/day.

The invention also provides pharmaceutical compositions comprising a nucleic acid encoding an ABC1 polypeptide according to the invention and pharmaceutical compositions comprising an ABC1 polypeptide according to the invention intended for the treatment of diseases linked to a deficiency in the reverse transport of cholesterol, such as Tangier and/or FHD disease.

The present invention also relates to a new therapeutic approach for the treatment of pathologies linked to the transport of cholesterol, comprising transferring and expressing *in vivo* nucleic acids encoding an ABC1 protein according to the invention. Specifically, the present invention provides a new therapeutic approach for the treatment and/or prevention of HDL deficiency, such as the HDL deficiency associated with Tangier and/or FHD disease, HDL deficiency, LCAT deficiency, malaria, and diabetes.

Thus, the present invention offers a new approach for the treatment and prevention of cardiovascular and neurological pathologies linked to the abnormalities of the transport and metabolism of cholesterol. Specifically, the present invention provides methods to restore or promote improved reverse transport of cholesterol within a patient or subject.

Consequently, the invention also relates to a pharmaceutical composition intended for the prevention of or treatment of subjects affected by, a dysfunction in the reverse transport of cholesterol, comprising a nucleic acid encoding the ABC1 protein, in combination with one or more physiologically compatible vehicle and/or excipient.

According to a specific embodiment of the invention, a composition is provided for the *in vivo* production of the ABC1 protein. This composition comprises a nucleic acid encoding the ABC1 polypeptide placed under the control of appropriate regulatory sequences, in solution in a physiologically acceptable vehicle and/or excipient.

Therefore, the present invention also relates to a composition comprising a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71, wherein the nucleic acid is placed under the control of appropriate regulatory elements.

The present invention also relates to a composition comprising a nucleic acid encoding a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, wherein the nucleic acid is placed under the control of appropriate regulatory elements.

Preferably, such a composition will comprise a nucleic acid comprising a polynucleotide sequence of either SEQ ID NO: 69 or SEQ ID NO: 70, placed under the control of appropriate regulatory elements.

According to another aspect, the subject of the invention is also a preventive or curative therapeutic method of treating diseases caused by a deficiency in the metabolism of cholesterol,

more particularly in the transport of cholesterol and still more particularly in the reverse transport of cholesterol, such a method comprising a step in which there is administered to a patient a nucleic acid encoding an ABC1 polypeptide according to the invention in said patient, said nucleic acid being, where appropriate, combined with one or more physiologically compatible vehicles and/or excipients.

The invention also relates to a pharmaceutical composition intended for the prevention of or treatment of subjects affected by, a dysfunction in the reverse transport of cholesterol, comprising a recombinant vector according to the invention, in combination with one or more physiologically compatible excipients.

According to a specific embodiment, a method of introducing a nucleic acid according to the invention into a host cell, in particular a host cell obtained from a mammal, *in vivo*, comprises a step during which a preparation comprising a pharmaceutically compatible vector and a "naked" nucleic acid according to the invention, placed under the control of appropriate regulatory sequences, is introduced by local injection at the level of the chosen tissue, for example a smooth muscle tissue, the "naked" nucleic acid being absorbed by the cells of this tissue.

The invention also relates to the use of a nucleic acid according to the invention, encoding the ABC1 protein, for the manufacture of a medicament intended for the prevention or treatment of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

The invention also relates to the use of a recombinant vector according to the invention, comprising a nucleic acid encoding the ABC1 protein, for the manufacture of a medicament intended for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

As indicated above, the present invention also relates to the use of a defective recombinant virus according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of pathologies linked to the transport of cholesterol.

The invention relates to the use of such a defective recombinant virus for the preparation of a pharmaceutical composition intended for the treatment and/or for the prevention of cardiovascular disease linked to a deficiency in the reverse transport of cholesterol. Thus, the present invention also relates to a pharmaceutical composition comprising one or more defective recombinant viruses according to the invention.

The present invention also relates to the use of cells genetically modified *ex vivo* with a virus according to the invention, or of producing cells such as viruses, implanted in the body, allowing a prolonged and effective expression *in vivo* of a biologically active ABC1 protein.

The present invention shows that it is possible to incorporate a nucleic acid encoding an ABC1 polypeptide into a viral vector, and that these vectors make it possible to effectively express a biologically active, mature form. More particularly, the invention shows that the *in vivo* expression of ABC1 may be obtained by direct administration of an adenovirus or by
5 implantation of a producing cell or of a cell genetically modified by an adenovirus or by a retrovirus incorporating such a DNA.

Preferably, the pharmaceutical compositions of the invention comprise a pharmaceutically acceptable vehicle or physiologically compatible excipient for an injectable formulation, in particular for an intravenous injection, such as for example into the patient's
10 portal vein. These may relate in particular to isotonic sterile solutions or dry, in particular, freeze-dried, compositions which, upon addition depending on the case of sterilized water or physiological saline, allow the preparation of injectable solutions. Direct injection into the patient's portal vein is preferred because it makes it possible to target the infection at the level of the liver and thus to concentrate the therapeutic effect at the level of this organ.

15 A "pharmaceutically acceptable vehicle or excipient" includes diluents and fillers which are pharmaceutically acceptable for method of administration, are sterile, and may be aqueous or oleaginous suspensions formulated using suitable dispersing or wetting agents and suspending agents. The particular pharmaceutically acceptable carrier and the ratio of active compound to carrier are determined by the solubility and chemical properties of the
20 composition, the particular mode of administration, and standard pharmaceutical practice.

Any nucleic acid, polypeptide, vector, or host cell of the invention will preferably be introduced *in vivo* in a pharmaceutically acceptable vehicle or excipient. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset,
25 dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "excipient" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can
30 be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as excipients, particularly for injectable solutions. Suitable pharmaceutical excipients are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

35 The pharmaceutical compositions according to the invention may be equally well administered by the oral, rectal, parenteral, intravenous, subcutaneous or intradermal route.

The invention also relates to the use of the ABC1 polypeptide having an amino acid sequence of SEQ ID NO: 71 or amino acids 1-60 of SEQ ID NO: 71 for the manufacture of a medicament intended for the prevention of atherosclerosis in various forms or more particularly for the treatment of a patient or subject affected by a dysfunction in the reverse transport of cholesterol.

The invention finally relates to a pharmaceutical composition for the prevention or treatment of a patient or subject affected by a dysfunction in the reverse transport of cholesterol, comprising a therapeutically effective quantity of a polypeptide having an amino acid sequence of SEQ ID NO: 71 or a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71, combined with one or more physiologically compatible vehicles and/or excipients.

According to another aspect, the subject of the invention is also a preventive or curative therapeutic method of treating diseases caused by a deficiency in the metabolism of cholesterol, more particularly in the transport of cholesterol and still more particularly in the reverse transport of cholesterol, such a method comprising a step in which there is administered to a patient or subject a nucleic acid encoding an ABC1 polypeptide in said patient, said nucleic acid being, where appropriate, combined with one or more physiologically compatible vehicles and/or excipients.

According to yet another aspect, the subject of the invention is also a preventive or curative therapeutic method of treating diseases caused by a deficiency in the metabolism of cholesterol, more particularly in the transport of cholesterol and still more particularly in the reverse transport of cholesterol, such a method comprising a step in which there is administered to a patient or subject a therapeutically effective quantity of an ABC1 polypeptide according to the invention in said patient or subject, said polypeptide being, where appropriate, combined with one or more physiologically compatible vehicles and/or excipients.

In another embodiment, the nucleic acids, polypeptides, recombinant vectors, and compositions according to the invention can be delivered in a vesicle, in particular a liposome (see Langer, 1990; Treat et al., 1989; and Lopez-Berestein, 1989).

In yet another embodiment, the nucleic acids, polypeptides, recombinant vectors, recombinant cells, and compositions according to the invention can be delivered in a controlled release system. For example, the polypeptide may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration. In one embodiment, a pump may be used (see Langer, 1990; Sefton, 1987; Buchwald et al., 1980; Saudek et al., 1989). In another embodiment, polymeric materials can be used (Langer and Wise, 1974; Smolen and Ball, 1984; Ranger and Peppas, 1983; Levy et al., 1985; During et al., 1989; and Howard et al., 1989). In yet another embodiment, a controlled release system can be placed in proximity of the target tissue or organ, *i.e.*, the cardiovascular

system, thus requiring only a fraction of the systemic dose (see Goodson, 1984). Other controlled release systems are discussed in the review by Langer (1990).

In a further aspect, recombinant cells that have been transformed with a nucleic acid according to the invention and that express high levels of an ABC1 polypeptide according to the invention can be transplanted in a subject in need of ABC1 polypeptide. Preferably autologous cells transformed with an ABC1 encoding nucleic acid according to the invention are transplanted to avoid rejection; alternatively, technology is available to shield non-autologous cells that produce soluble factors within a polymer matrix that prevents immune recognition and rejection.

Thus, the ABC1 polypeptide can be delivered by intravenous, intraarterial, intraperitoneal, intramuscular, or subcutaneous routes of administration. Alternatively, the ABC1 polypeptide, properly formulated, can be administered by nasal or oral administration. A constant supply of ABC1 can be ensured by providing a therapeutically effective dose (*i.e.*, a dose effective to induce metabolic changes in a subject) at the necessary intervals, *e.g.*, daily, every 12 hours, etc. These parameters will depend on the severity of the disease condition being treated, other actions, such as diet modification, that are implemented, the weight, age, and sex of the subject, and other criteria, which can be readily determined according to standard good medical practice by those of skill in the art.

A subject in whom administration of the nucleic acids, polypeptides, recombinant vectors, recombinant host cells, and compositions according to the invention is performed is preferably a human, but can be any animal. Thus, as can be readily appreciated by one of ordinary skill in the art, the methods and pharmaceutical compositions of the present invention are particularly suited to administration to any animal, particularly a mammal, and including, but by no means limited to, domestic animals, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, and porcine subjects, wild animals (whether in the wild or in a zoological garden), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, etc., avian species, such as chickens, turkeys, songbirds, etc., *i.e.*, for veterinary medical use.

Preferably, a pharmaceutical composition comprising a nucleic acid, a recombinant vector, a polypeptide, or a recombinant host cell, as defined above, will be administered to the patient or subject.

METHODS OF SCREENING AN AGONIST OR ANTAGONIST COMPOUND FOR THE ABC1 POLYPEPTIDE

According to another aspect, the invention also relates to various methods of screening compounds or small molecules for therapeutic use which are useful in the treatment of diseases

due to a deficiency in the metabolism of cholesterol, particularly in the transport of cholesterol, still more particularly in the reverse transport of cholesterol, such as Tangier disease, or more generally FHD-type conditions.

5 The invention therefore also relates to the use of an ABC1 polypeptide, or of cells expressing an ABC1 polypeptide, for screening active ingredients for the prevention or treatment of diseases resulting from a dysfunction in the reverse transport of cholesterol.

The catalytic sites and oligopeptide or immunogenic fragments of an ABC1 polypeptide can serve for screening product libraries by a whole range of existing techniques. The polypeptide fragment used in this type of screening may be free in solution, bound to a solid support, at the
10 cell surface or in the cell. The formation of the binding complexes between the ABC1 polypeptide fragments and the tested agent can then be measured.

Another product screening technique which may be used in high-flux screenings giving access to products having affinity for the protein of interest is described in application WO84/03564. In this method, applied to an ABC1 protein, various products are
15 synthesized on a solid surface. These products react with the ABC1 protein or fragments thereof and the complex is washed. The products binding the ABC1 protein are then detected by methods known to persons skilled in the art. Non-neutralizing antibodies can also be used to capture a peptide and immobilize it on a support.

Another possibility is to perform a product screening method using an ABC1
20 neutralizing antibody competition, an ABC1 protein and a product potentially binding the ABC1 protein. In this manner, the antibodies may be used to detect the presence of a peptide having a common antigenic unit with an ABC1 polypeptide or protein.

Of the products to be evaluated for their ability to increase ABC1 activity, there may be mentioned in particular kinase-specific ATP homologs involved in the activation of the
25 molecules, as well as phosphatases, which may be able to avoid the dephosphorylation resulting from said kinases. There may be mentioned in particular inhibitors of the phosphodiesterase (PDE) theophylline and 3-isobutyl-1-methylxanthine type or the adenylylase forskolin activators.

Accordingly, this invention relates to the use of any method of screening products, *i.e.*,
30 compounds, small molecules, and the like, based on the method of translocation of cholesterol (see Example 13) between the membranes or vesicles, this being in all synthetic or cellular types, that is to say of mammals, insects, bacteria, or yeasts expressing constitutively or having incorporated a human ABC1 encoding nucleic acid. To this effect, labeled lipid analogs may be used.

35 Likewise, it has been described that the ABC1 protein allowed anion transport (Becq et al., 1997 and Yamon et al., 1997) and this transport was activated by phosphatase

inhibitors such as okadaic acid and orthovanadate as well as part of the elevation of cAMP by agents such as forskolin. The present invention also relates to the use of such a system for screening molecules modulating the activity of the ABC1 protein (see Example 14).

5 Yamon et al (1997) have demonstrated that the mouse ABC1 protein was involved in the secretion of a proinflammatory cytokine IL-1beta in mouse peritoneal macrophages. It is therefore also possible to provide a method of screening products modulating the activity of the ABC1 protein by determining the release of IL-1beta from any cell type expressing two proteins (see Example 15).

10 Furthermore, knowing that the disruption of numerous transporters have been described (van den Hazel et al., 1999), it is possible to think of using cellular mutants having a characteristic phenotype and to complement the function thereof with ABC1 and to use the whole for screening purposes.

The invention also relates to a method of screening a compound or small molecule active on the metabolism of cholesterol, an agonist or antagonist of an ABC1 polypeptide, said
15 method comprising the following steps:

a) preparing a membrane vesicle comprising an ABC1 polypeptide and a lipid substrate comprising a detectable marker;

b) incubating the vesicle obtained in step a) with an agonist or antagonist candidate compound;

20 c) qualitatively and/or quantitatively measuring release of the lipid substrate comprising a detectable marker; and

d) comparing the release measurement obtained in step b) with a measurement of release of labeled lipid substrate by a vesicle that has not been previously incubated with the agonist or antagonist candidate compound.

25 In a first specific embodiment, the ABC1 polypeptide comprises an amino acid sequence of SEQ ID NO: 71.

In a second specific embodiment, the ABC1 polypeptide comprises amino acids 1-60 of SEQ ID NO: 71.

30 According to a first aspect of the above screening method, the membrane vesicle is a synthetic lipid vesicle, which may be prepared according to techniques well known to a person skilled in the art. According to this particular aspect, the ABC1 protein may be a recombinant ABC1 protein.

35 According to a second aspect, the membrane vesicle is a vesicle of a plasma membrane derived from cells expressing an ABC1 polypeptide. These may be cells naturally expressing an ABC1 polypeptide or cells transfected with a nucleic acid encoding an ABC1 polypeptide or recombinant vector comprising a nucleic acid encoding an ABC1 polypeptide.

According to a third aspect of the above screening method, the lipid substrate is chosen from cholesterol or phosphatidylcholine.

According to a fourth aspect, the lipid substrate is radioactively labeled, for example with an isotope chosen from ^3H or ^{125}I .

5 According to a fifth aspect, the lipid substrate is labeled with a fluorescent compound, such as NBD or pyrene.

According to a sixth aspect, the membrane vesicle comprising the labeled lipid substrate and the ABC1 polypeptide is immobilized at the surface of a solid support prior to step b).

10 According to a seventh aspect, the measurement of the fluorescence or of the radioactivity released by the vesicle is the direct reflection of the activity of lipid substrate transport by the ABC1 polypeptide.

The invention also relates to a method of screening a compound or small molecule active on the metabolism of cholesterol, an agonist or antagonist of an ABC1 polypeptide, said
15 method comprising the following steps:

a) obtaining cells, for example a cell line, that, either naturally or after transfecting the cell with an ABC1 encoding nucleic acid, expresses an ABC1 polypeptide;

b) incubating the cells of step a) in the presence of an anion labeled with a detectable marker;

20 c) washing the cells of step b) in order to remove the excess of the labeled anion which has not penetrated into these cells;

d) incubating the cells obtained in step c) with an agonist or antagonist candidate compound for the ABC1 polypeptide;

e) measuring efflux of the labeled anion; and

25 f) comparing the value of efflux of the labeled anion determined in step e) with a value of the efflux of a labeled anion measured with cells that have not been previously incubated in the presence of the agonist or antagonist candidate compound for the ABC1 polypeptide.

In a first specific embodiment, the ABC1 polypeptide comprises an amino acid sequence of SEQ ID NO: 71.

30 In a second specific embodiment, the ABC1 polypeptide comprises amino acids 1-60 of SEQ ID NO: 71.

According to a first aspect of the above screening method, the cells used are cells naturally expressing an ABC1 polypeptide. They may be human monocytes in primary culture, purified from a population of human blood mononuclear cells. They may also be human
35 monocytic cell lines, such as the monocytic leukemia line THP1.

According to a second aspect, the cells used in the screening method described above may be cells not naturally expressing, or alternatively expressing at a low level, an ABC1 polypeptide, said cells being transfected with a recombinant vector according to the invention capable of directing the expression of a nucleic acid encoding an ABC1 polypeptide.

- 5 According to a third aspect, the cells may be cells having a natural deficiency in anion transport, or cells pretreated with one or more anion channel inhibitors such as Verapamil™ or tetraethylammonium.

According to a fourth aspect of said screening method, the anion is a radioactively labeled iodide, such as the salts $K^{125}I$ or $Na^{125}I$.

- 10 According to a fifth aspect, the measurement of efflux of the labeled anion is determined periodically over time during the experiment, thus making it possible to also establish a kinetic measurement of this efflux.

According to a sixth aspect, the value of efflux of the labeled anion is determined by measuring the quantity of labeled anion present at a given time in the cell culture supernatant.

- 15 According to a seventh aspect, the value of efflux of the labeled anion is determined as the proportion of radioactivity found in the cell culture supernatant relative to the total radioactivity corresponding to the sum of the radioactivity found in the cell lysate and the radioactivity found in the cell culture supernatant.

- 20 The subject of the invention is also a method of screening a compound or small molecule active on the metabolism of cholesterol, an agonist or antagonist of an ABC1 polypeptide, said method comprising the following steps:

a) culturing cells of a human monocytic line in an appropriate culture medium, in the presence of purified human albumin;

- 25 b) incubating the cells of step a) simultaneously in the presence of a compound stimulating the production of IL-1 beta and of an agonist or antagonist candidate compound;

c) incubating the cells obtained in step b) in the presence of an appropriate concentration of ATP;

d) measuring IL-1 beta released into the cell culture supernatant; and

- 30 e) comparing the value of the release of the IL-1 beta obtained in step d) with the value of the IL-1 beta released into the culture supernatant of cells which have not been previously incubated in the presence of the agonist or antagonist candidate compound.

According to a first aspect of the screening method described above, the cells used belong to the human leukemic monocytic line THP1.

- 35 According to a second aspect of the screening method, the compound stimulating the production of IL-1 beta is a lipopolysaccharide.

According to a third aspect of said method, the production of IL-1 alpha, IL-6 and TNF alpha by these cells is also qualitatively and/or quantitatively determined.

According to a fourth aspect, the level of expression of the messenger RNA encoding IL-1 beta is also determined.

5

The following examples are intended to further illustrate the present invention but do not limit the invention.

EXAMPLES

10

EXAMPLE 1: Tissue distribution of the transcripts of the ABC1 gene according to the invention.

The profile of expression of the polynucleotides according to the present invention is determined according to the protocols for PCR-coupled reverse transcription and Northern blot analysis described in particular by Sambrook et al. (1989).

For example, in the case of an analysis by reverse transcription, a pair of primers as described above may be synthesized from a cDNA of the human ABC1 gene comprising a polynucleotide sequence as depicted in SEQ ID NOs: 69 and 70. This primer pair may be used to detect the corresponding ABC1 cDNA. Specifically, two oligonucleotide primers specific for ABC1 and comprising either 1) a sequence contained within nucleotide region 1-184 of SEQ ID NO: 69 and a complementary sequence contained within nucleotide region 6968-9741 of SEQ ID NO: 69, or 2) a sequence contained within nucleotide region 1-297 of SEQ ID NO: 70 and a complementary sequence contained within nucleotide region 7081-9854 of SEQ ID NO: 70, may be used to isolate the ABC1 cDNA.

The polymerase chain reaction (PCR) is carried out on cDNA templates corresponding to retrotranscribed polyA⁺ mRNAs (Clontech). The reverse transcription to cDNA is carried out with the enzyme SUPERScript II (GibcoBRL, Life Technologies) according to the conditions described by the manufacturer. The polymerase chain reaction is carried out according to standard conditions, in 20 µl of reaction mixture with 25 ng of cDNA preparation. The reaction mixture is composed of 400 µM of each of the dNTPs, 2 units of *Thermus aquaticus* (Taq) DNA polymerase (Ampli Taq Gold; Perkin Elmer), 0.5 µM of each primer, 2.5 mM MgCl₂, and PCR buffer. Thirty four PCR cycles [denaturing 30 seconds at 94°C, annealing of 30 seconds divided up as follows during the 34 cycles: 64°C (2 cycles), 61°C (2 cycles), 58°C (2 cycles), and 55°C (28 cycles), and an extension of one minute per kilobase at 72°C] are carried out after a first step of denaturing at 94°C for 10 minutes using a Perkin Elmer 9700

thermocycler. The PCR reactions are visualized on agarose gel by electrophoresis. The cDNA fragments obtained may be used as probes for a Northern blot analysis and may also be used for the exact determination of the polynucleotide sequence.

5 In the case of a Northern Blot analysis, a cDNA probe produced as described above is labeled with ^{32}P by means of the DNA labeling system High Prime (Boehringer) according to the instructions indicated by the manufacturer. After labeling, the probe is purified on a Sephadex G50 microcolumn (Pharmacia) according to the instructions indicated by the manufacturer. The labeled and purified probe is then used for the detection of the expression of the mRNAs in various tissues.

10 The Northern blot containing samples of RNA of different human tissues (Multiple Tissue Northern, MTN, Clontech) Blot 2, reference 77759-1) is hybridized with the labeled probe. The protocol followed for the hybridizations and washes may be either directly as that described by the manufacturer (Instruction manual PT1200-1) or an adaptation of this protocol using methods known to persons skilled in the art and described for example in F. Ausubel et al
15 (1999). It is thus possible to vary, for example, the prehybridization and hybridization temperatures in the presence of formamide.

For example, it may be possible to use the following protocol:

1- Membrane competition and PREHYBRIDIZATION:

- Mix: 40 μl salmon sperm DNA (10 mg/ml)
- 20 + 40 μl human placental DNA (10 mg/ml)
- Denature for 5 minutes at 96°C, then immerse the mixture in ice.
- Remove the 2X SSC and pour 4 ml of formamide mix in the hybridization tube containing the membranes.
- Add the mixture of the two denatured DNAs.
- 25 - Incubation at 42°C for 5 to 6 hours, with rotation.

2- Labeled probe competition:

- Add to the labeled and purified probe 10 to 50 μl Cot I DNA, depending on the quantity of repeat sequences.
- 30 - Denature for 7 to 10 minutes at 95°C.
- Incubate at 65°C for 2 to 5 hours.

3- HYBRIDIZATION:

- Remove the prehybridization mix.
- 35 - Mix 40 μl salmon sperm DNA + 40 μl human placental DNA; denature for 5 min at 96°C, then immerse in ice.

- Add to the hybridization tube 4 ml of formamide mix, the mixture of the two DNAs and the denatured labeled probe/Cot I DNA.
- Incubate 15 to 20 hours at 42°C, with rotation.

5 4- Washes:

- One wash at room temperature in 2X SSC, to rinse.
- Twice 5 minutes at room temperature 2X SSC and 0.1% SDS at 65°C.
- Twice 15 minutes at 65°C 1X SSC and 0.1% SDS at 65°C.

10 After hybridization and washing, the blot is analyzed after overnight exposure in contact with a phosphorus screen revealed with the aid of Storm (Molecular Dynamics, Sunnyvale, CA).

EXAMPLE 2 : 5' Extension of the human ABC1 cDNA.

15

 This Example describes the isolation and identification of cDNA molecules encoding the full length human ABC1 protein. 5' extension of the partial ABC1 cDNA sequence (GenBank Accession # AJ012376, Langmann et al., 1999) was performed using a modified 5' RACE approach.

20

Experimental design:

 A human monocytic THP1 cDNA library (in the Lambda phage vector lZip-lox, Life Tech®) which had previously been made from THP1 cells that were differentiated with phorbol ester and then loaded with acetylated LDL to convert them to the foam cell phenotype was used in this Example. It has been shown that THP1 cells, when loaded with cholesterol, strongly up-regulate the expression of the human ABC1 gene (Langmann et al., 1999). This THP1 cDNA library was used to 5' extend the human ABC1 cDNA, since it should be enriched for ABC1 cDNA.

30

 A set of nested PCR primers (SEQ ID NOs: 155 and 156) which hybridize to nucleotides of the 5' published sequence region of human ABC1 cDNA (Langmann et al., 1999) was used to elongate the ABC1 cDNA in the 5' direction (see Table VII). Two sets of nested vector arm specific primers (SEQ ID NOs: 2, 140, 153, and 154) were designed for the reverse synthesis in the direction towards the human ABC1 cDNA specific primer (see Table VII and Figure 1). Within Table VII, the term "Comp" refers to the complementary nucleotide sequence of the nucleotide positions indicated. In this manner, a PCR product corresponding to

35

the true 5' end of the human ABC1 cDNA can be obtained, regardless of its orientation within the vector.

5 TABLE VII

5' ABC1 cDNA EXTENSION PRIMERS

PCR Primer	PCR Primer SEQ ID NO:	Primary, Secondary, or Sequencing Reaction Use	Position in SEQ ID NO: 69	Orientation Relative to Human ABC1 cDNA
ABC1-3'	155	Primary PCR	Comp nt 803- 824	antisense
ABC1-9	156	Secondary PCR	Comp nt 703- 727	antisense
ABC1-7	139	Sequencing	Comp nt 448- 468	antisense
λ Zip-forward	140	Primary PCR	---	sense
λ Zip-reverse	153	Primary PCR	---	sense
λ Zip-seq-1	154	Secondary PCR	---	sense
λ Zip-seq-2	2	Secondary PCR	---	sense

Materials and Methods:

10

Primary PCR. An aliquot of the THP1 cDNA library (cleared bacterial lysate, containing approximately 5×10^9 pfu/ml of λ Zip-lox-THP1-FC library phage, 2.5×10^6 recombinants, with an average insert size of 1.5kb) was heated to 95°C for 10 minutes to lyse the phage and release its DNA. Four μ l of the lysed phage was then used in a 50 μ l PCR reaction containing 20mM Tris pH8.4, 50mM KCl, 1.5mM MgCl₂, 0.2mM dNTPs, 2.5units of Platinum® Taq polymerase-HF (BRL), and 0.2 μ M of each primer [ABC1-3' (SEQ ID NO: 155), and either λ Zip-forward (SEQ ID NO: 140) or λ Zip-reverse (SEQ ID NO: 153)]. Amplification was performed for 35 cycles of 94°C for 10 seconds, 58°C for 20 seconds, and 72°C for 2.5 minutes. Five μ l of the PCR reaction were electrophoresed on a 0.8% agarose /TBE gel containing .02 μ g/ml of ethidium bromide. The gel was photographed and examined for evidence of product.

15

20

Secondary PCR. From selected primary PCR reactions, 1ul of the reaction was removed and diluted into 50ul of 10mM Tris pH 8.5. One ul of the diluted primary PCR reaction was used in a secondary PCR reaction using a nested ABC1 primer (ABC1-9, SEQ ID NO: 156) and the appropriate nested arm primer λ Zip-seq-1 (SEQ ID NO: 154) or λ Zip-seq-2 (SEQ ID NO: 2).

- 5 The PCR reaction was amplified as above except the cycling parameters were adjusted as follows: 25 cycles at 94°C for 20 seconds, 56°C for 20 seconds, and 72°C for 1.5 minutes. Five ul of the secondary PCR reaction were analyzed on an agarose gel as described above.

- Gel Purification of PCR product. The secondary PCR reactions which appeared to have a product of the appropriate size were then analyzed on an agarose gel and the bands corresponding to the ABC1 cDNA 5' extension product were excised and purified using the Qiagen Qiaquick™ gel extraction purification system. The purified DNA fragments were eluted in a volume of 30ul of 10mM Tris pH 8.5. Five ul of the eluted PCR products were analyzed on an agarose gel to determine the approximate yields.

- 15 Sequencing. Five ul of each of the purified PCR products along with 20ng of ABC1-7 sequencing primer (SEQ ID NO: 139) using BigDye™ terminator cycle sequencing on an ABI 377 sequencing apparatus. The purified 5' extended human ABC1 cDNA PCR products' sequence results were analyzed using the Lasergene DNA Star software package and the
- 20 BLAST program at the NCBI web site (<http://www.ncbi.nlm.nih.gov>).

Results and Discussion:

- The primary PCR reactions yielded only faint bands, other than the primers staining (see Figure 2-a). Therefore, a secondary nested PCR reaction was performed. The secondary
- 25 PCR reactions (Figure 2-b) produced an intensely stained, single band of approximately 800bp using primers ABC1-9 (SEQ ID NO: 156) and λ Zip-seq-2 (SEQ ID NO: 2) in two of the reactions (see lanes 3 and 6, Figure 2-b), while there was a fainter band of approximately 750bp in lane 7 using primers ABC1-9 (SEQ ID NO: 156) and λ Zip-seq-1 (SEQ ID NO: 154).

- To verify that the PCR products were authentic and specific for human ABC1 cDNA,
- 30 an additional nested PCR reaction was performed using the diluted primary PCR reactions that had yielded the bands obtained in the secondary PCR reactions (lanes 3, 6, and 7 of Figure 2-b) using primers ABC1-7 (SEQ ID NO: 139) and λ Zip-seq-2 (SEQ ID NO: 154) or λ Zip-seq-1 (SEQ ID NO: 2), respectively. This additional nested PCR reaction should yield a product that is 254bp smaller than the one obtained in the secondary PCR reactions. This was indeed the
- 35 case for the samples corresponding to lanes 3 and 6. However, the sample of lane 7 yielded no

such product and therefore, was not likely to be ABC1 cDNA specific and was not analyzed further.

An additional 100ul PCR reaction was performed to generate more of the product obtained in the secondary PCR reaction corresponding to the sample in lane 3. The secondary PCR reactions consisting of the first sample 3, the 100ul scale-up of sample 3, and sample 6 were gel purified in preparation for cloning and sequencing (see Figure 3). Following purification, 5ul of the three gel purified samples were sequenced using the ABC1-7 oligonucleotide (SEQ ID NO: 139) as a primer. In addition, the purified products were each cloned into the plasmid, PCR2.1 (Invitrogen).

The sequencing results revealed that a nucleic acid comprising an additional 244 nucleotides (SEQ ID NO: 3) 5' of the published partial human ABC1 cDNA had been obtained. An open reading frame search was performed on this nucleic acid and a new ORF was identified that was contiguous with the previously published open reading frame. This new open reading frame extended the human ABC1 protein by an additional 60 amino acid residues (amino acids 1-60 of SEQ ID NO: 71) as compared to the sequence of Langmann et al. (1999). The newly identified initiator ATG codon (nucleotides 185-187 of SEQ ID NO: 3) conformed well with the Kozak consensus sequence for eukaryotic translation initiation and significantly, there was an in-frame TGA terminator nine bases upstream (nucleotides 176-178 of SEQ ID NO: 3) of the new ATG initiation codon. Thus, the invention provides nucleic acids encoding the full length human ABC1 protein (SEQ ID NO: 71). In particular, the present invention provides nucleic acids encoding a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.

In addition, two, third position nucleotide differences were also identified compared to the published sequence at new positions 260 and 262 of SEQ ID NO: 3 [corresponding to nucleotide positions 16 and 18 of Langmann et al. (1999)]. These nucleotide differences are conservative changes: 260:T→C and 262:A→G; and do not lead to any codon changes. SEQ ID NOs: 69 and 70 comprise the new 5' extended ABC1 cDNA region (SEQ ID NO: 3) obtained within this Example. Specifically, nucleotides 1-244 of SEQ ID NO: 3 correspond to nucleotides 1-244 of SEQ ID NO: 69 and nucleotides 114-357 of SEQ ID NO: 70, respectively.

Various other approaches may be used to isolate the cDNA corresponding to the complete cDNA of ABC1. For example, a complete clone may be directly isolated by hybridization by screening a cDNA library by means of a polynucleotide probe specific for the sequence of the gene of interest. In particular, a specific probe of 30-40 nucleotides is synthesized using a synthesizer of the Applied Biosystem/Perkin Elmer trademark depending on the chosen sequence. The oligonucleotide obtained is radiolabeled, for example with

[γ -³²P]ATP using T4 polynucleotide kinase and is purified according to the customary methods (e.g. Maniatis et al., 1982 or F. Ausubel et al., 1989).

5 The clone library containing the cDNA that is desired to screen is established on a culture medium in a Petri dish (1.5% agar) containing the appropriate antibiotics according to the customary methods cited above (F. Ausubel et al.). The colonies thus produced after incubation are transferred on nitrocellulose filters and screened by means of the radiolabeled nucleotide probe, according to the customary methods and the colonies hybridizing with the probe are isolated and subcloned.

10 The DNA of the clones thus identified is prepared and analyzed by sequencing. The clones containing the fragments corresponding to the complete cDNA are purified and recloned into the vector pcDNA3 according to the protocols known to persons skilled in the art and presented for example in F. Ausubel et al (1989).

15 Various methods are known for identifying the 5' and 3' ends of the cDNA corresponding to the genes described in the present application. These methods include but are not limited to hybridization cloning, to cloning using protocols similar or identical to 3' or 5' RACE-PCR (Rapid Amplification of cDNA End-PCR) which are well known to persons skilled in the art.

For example, it will be possible to use the kit marketed by the company Clontech (Marathon Ready™ cDNA kit, protocol identified by the reference PT1156-1) or alternatively a method similar to 5'RACE is available for characterizing any absent 5' end of a cDNA (Fromont-Racine et al., 1993). Briefly, an RNA oligonucleotide is ligated to the 5' end of an mRNA population. After retrotranscription to cDNA, a set of primers specific respectively for the adaptor ligated in 5' and for a sequence situated in 3' of the gene of interest is used in PCR to amplify the 5' portion of the desired cDNA. The amplified fragment is then used to reconstruct the complete cDNA.

EXAMPLE 3 : Analysis of the gene expression profile for Tangier disease

30 The verification of the impairment of the level of expression of the ABC1 gene causing the Tangier cellular phenotype may be determined by hybridizing these sequences with probes corresponding to the mRNAs obtained from fibroblasts of subjects suffering or otherwise from the disease, according to the methods described below:

1. Preparation of the total RNAs, of the poly(A)⁺ mRNAs and of cDNA probes

The total RNAs are obtained from cell cultures of the fibroblasts of normal subjects or subjects suffering from Tangier disease by the guanidine isothiocyanate method (Chomczynski & Sacchi, 1987). The poly(A)⁺ mRNAs are obtained by affinity chromatography on oligo(dT)-cellulose columns (Sambrook et al., 1989) and the cDNAs used as probes are obtained by
5 RT-PCR (DeRisi et al., 1997) with oligonucleotides labeled with a fluorescent product (Amersham Pharmacia Biotech ; CyDyeTM).

2. Hybridization and detection of the expression levels

The glass membranes containing the sequences presented in this patent application,
10 corresponding to the Tangier gene are hybridized with the cDNA probes obtained from fibroblasts (Iyer et al., 1999). The use of the Amersham/molecular Dynamics system (Avalanche MicroscannerTM) allows the quantification of the expressions of the products of sequences on healthy or affected cell types.

15 **EXAMPLE 4 : Construction of the expression vector containing the complete cDNA of ABC1 in mammalian cells**

The ABC1 gene may be expressed in mammalian cells. A typical eukaryotic expression vector contains a promoter which allows the initiation of the transcription of the mRNA, a
20 sequence encoding the protein, and the signals required for the termination of the transcription and for the polyadenylation of the transcript. It also contains additional signals such as enhancers, the Kozak sequence and sequences necessary for the splicing of the mRNA. An effective transcription is obtained with the early and late elements of the SV40 virus promoters, the retroviral LTRs or the CMV virus early promoter. However, cellular elements such as the
25 actin promoter may also be used. Many expression vectors may be used to carry out the present invention, an example of such a vector is pcDNA3 (Invitrogen).

EXAMPLE 5 : Production of normal and mutated ABC1 polypeptides.

30 The normal ABC1 polypeptide encoded by the complete cDNA of ABC1 whose isolation is described in Example 2 (cloning of the complete cDNA), or the mutated ABC1 polypeptides whose complete cDNA may also be obtained according to the techniques described in Example 2, may be easily produced in a bacterial or insect cell expression system using the baculovirus vectors or in mammalian cells with or without the vaccinia virus vectors.
35 All the methods are now widely described and are known to persons skilled in the art. A detailed description thereof will be found for example in F. Ausubel et al. (1989).

EXAMPLE 6 : Production of an antibody directed against one of the mutated ABC1 polypeptides.

5

The antibodies in the present invention may be prepared by various methods (Current Protocols In Molecular Biology Volume 1 edited by Frederick M. Ausubel, Roger Brent, Robert E. Kingston, David D. Moore, J.G. Seidman, John A. Smith, Kevin Struhl - Massachusetts General Hospital Harvard Medical School, chapter 11, 1989). For example, the
10 cells expressing a polypeptide of the present invention are injected into an animal in order to induce the production of serum containing the antibodies. In one of the methods described, the proteins are prepared and purified so as to avoid contaminations. Such a preparation is then introduced into the animal with the aim of producing polyclonal antisera having a higher activity.

15

In the preferred method, the antibodies of the present invention are monoclonal antibodies. Such monoclonal antibodies may be prepared using the hybridoma technique (Köhler et al, 1975 ; Köhler et al, 1976 ; Köhler et al, 1976 ; Hammeling et al., 1981). In general, such methods involve immunizing the animal (preferably a mouse) with a polypeptide or better still with a cell expressing the polypeptide. These cells may be cultured in a suitable
20 tissue culture medium. However, it is preferable to culture the cells in an Eagle medium (modified Earle) supplemented with 10% fetal bovine serum (inactivated at 56°C) and supplemented with about 10 g /l of nonessential amino acids, 1000 U/ml of penicillin and about 100 µg/ml of streptomycin.

25

The splenocytes of these mice are extracted and fused with a suitable myeloma cell line. However, it is preferable to use the parental myeloma cell line (SP2O) available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium and then cloned by limiting dilution as described by Wands et al. (1981). The hybridoma cells obtained after such a selection are tested in order to identify the clones secreting antibodies capable of binding to the polypeptide.

30

Moreover, other antibodies capable of binding to the polypeptide may be produced according to a 2-stage procedure using anti-idiotypic antibodies such a method is based on the fact that the antibodies are themselves antigens and consequently it is possible to obtain an antibody recognizing another antibody. According to this method, the antibodies specific for the protein are used to immunize an animal, preferably a mouse. The splenocytes of this animal
35 are then used to produce hybridoma cells, and the latter are screened in order to identify the clones which produce an antibody whose capacity to bind to the specific antibody-protein

complex may be blocked by the polypeptide. These antibodies may be used to immunize an animal in order to induce the formation of antibodies specific for the protein in a large quantity.

It is preferable to use Fab and F(ab')₂ and the other fragments of the antibodies of the present invention according to the methods described here. Such fragments are typically produced by proteolytic cleavage with the aid of enzymes such as Papain (in order to produce the Fab fragments) or Pepsin (in order to produce the F(ab')₂ fragments). Otherwise, the secreted fragments recognizing the protein may be produced by applying the recombinant DNA or synthetic chemistry technology.

For the in vivo use of antibodies in humans, it would be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies may be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. The methods for producing the chimeric antibodies are known to persons skilled in the art (for a review, see : Morrison, (1985) ; Oi et al., (1986) ; Cabilly et al., US patent No. 4,816,567 ; Taniguchi et al., EP 171496 ; Morrison et al., EP 173494 ; Neuberger et al., WO 8601533 ; Robinson et al., WO 8702671 ; Boulianne et al ; (1984) ; and Neuberger et al., (1985).

EXAMPLE 7 : Correction of the cellular phenotype of the Tangier disease

The Tangier disease is characterized by an accelerated catabolism of the high-density lipoprotein (HDL) particles and an accumulation of cholesterol in the tissues. In particular, the fibroblasts of the skin of patients suffering from Tangier disease have a reduced capacity to eliminate their cholesterol content by the process of efflux of cholesterol carried out by apolipoprotein A-I (apoA-I), the major protein of the HDLs (Francis et al., 1995). This characteristic corresponding to a loss of function is also found in other fibroblast cells of patients suffering from familial HDL deficiency (Marcil et al., 1999a).

The correction of the phenotype of the Tangier fibroblasts can be carried out by the transfection of the complete cDNA of ABC1 according to the invention, into said cells. The cDNA is inserted into an expression vector which is then transfected according to the methods described below :

1. Preparation of the fibroblast cultures of normal subjects and of subjects suffering from Tangier disease

The primary fibroblasts of human skin are obtained by culturing a skin biopsy obtained from the forearm. These biopsies are performed on patients suffering from Tangier disease having the clinical and biochemical features of the "homozygotes", that is to say orange-colored tonsils, plasma concentrations of apoA-I and of cholesterol-HDL less than the 5th percentile.

The normal fibroblast lines are obtained from the American Type Culture Collection (Rockville, MD). The fibroblasts are cultured in an EMMEM (Eagle-modified minimum essential medium ; GIBCO) medium supplemented with 10% fetal calf serum, 2 mM glutamine, 100 IU/ml of penicillin and 100 µg/ml of streptomycin (medium designated EMMEM10). In order to carry out the study of the efflux of cholesterol, these cells are preloaded with cholesterol by incubating for 24 hours with 50 µg/ml of cholesterol in the medium described above without calf serum but containing 2 mg/ml of bovine albumin (BSA, fraction V).

2. Study of the efflux of cholesterol

The fibroblasts preloaded with cholesterol at confluence on 24-well plates are incubated in the EMMEM10 medium and 1 µCi/ml of 1,2-³H-cholesterol (50 Ci/mmol ; Dupont ; Wilmington, DE) for 48 hours. About 100,000 counts per minute are obtained per well or 1000 counts per minute and per µg of cellular protein. The cells are washed three times with EMMEM/BSA medium, and incubated with this medium for 24 hours before transfecting the gene of interest and starting the efflux by adding 10 µg/ml of proteoliposome containing apoA-I in EMMEM/BSA medium. These proteoliposomes are prepared by sonication of phosphatidylcholine and purified human apoA-I (Jonas, 1986). The cell transfection is carried out by the calcium phosphate precipitation technique (Sambrook et al., 1989). After the period of efflux, in general 20 hours, the medium is collected, centrifuged (1000 g, 5 min), and the radioactivity determined by liquid scintillation counting. The residual radioactivity in the cells is also determined overnight after extraction of the lipids in isopropanol. The percentage efflux is calculated by dividing the radioactivity measured in the supernatant by the sum of the radioactivities measured, in the supernatant and the cellular extract. An internal standard is prepared by transfection of a marker gene and incubation for 24 hours with an EMMEM/BSA medium without proteoliposome containing apoA-I. The efflux of cellular cholesterol from normal fibroblasts transfected with a control gene correspond to 6±2% whereas that obtained from fibroblasts suffering from Tangier disease and transfected with this control gene is less than 1%. On the other hand, the transfection of the fibroblasts suffering from Tangier disease with a plasmid containing the complete cDNA or the genomic DNA for ABC1 according to the invention could make it possible to restore the capacity of these cells to eliminate their excess of cholesterol at a level corresponding to that of normal fibroblasts.

EXAMPLE 8 : Isolation and characterization of genomic fragments of the human ABC1 gene.

5 A fragment of about 3 kb of the human ABC1 cDNA was obtained from the cDNA clone designated "pf10" containing the first ATP-binding domain of ABC1, this cDNA clone being described in the article by Luciani et al. (1994).

 This cDNA fragment obtained by digestion of the clone pf10 with the aid of the restriction endonuclease EcoRI, was isolated on an agarose gel after electrophoresis, then
10 labeled with digoxigenin according to the manufacturer's instructions (kit marketed by Boehringer Mannheim, reference 1 585 614)

 The labeled cDNA fragment was used to screen the LLNL (Lawrence Livermore National Labs) cosmid library of chromosome 9, immobilized on a NylonTM filter.

 Six positive clones were identified. For these six cosmids, the probe hybridized with
15 single colonies.

 A representative clone was isolated from each of these colonies.

 The clones LLNLC 131J087 Q2 (designated here cos3a) and LLNLc 131O1165 Q2 (designated here cos6f) were analyzed in greater detail.

 The clone cos3a was subcloned in the form of an EcoRI fragment into the vector
20 Gen3zf(-) and sequenced at both ends using the Big Dye Terminator technology on an ABI377 type sequencer (Applied Biosystems, Perkin Elmer).

 The clones containing distinct inserts (determined after sequencing of the ends of the various inserts or by determining the size thereof) which were too long to be completely sequenced with the aid of the primers hybridizing with the sequences of the vector, were
25 analyzed more before by the technique of transposon insertion and then of sequencing with the aid of primers specific to the transposon ("GPS" system marketed by the company New England Biolabs).

 In this manner, genomic sequences corresponding to the human ABC1 gene were isolated and characterized. These sequences were compared with human and mouse sequences
30 identified by references in the databases making it possible to determine the intron-exon junctions.

 Primers for the amplification of the DNA of the patients were designed from nonrepetitive sequences of the intron DNA of the ABC1 gene, in such a way that an amplification of the intron-exon junctions as well as the bases essential for the formation of the
35 secondary structure during the splicing step are included in the amplified fragments.

The genomic DNA of the patients was amplified with the aid of the primers described above using Qiagen's Star Taq kit or the Supertaq kit, using the hybridization conditions and the amplification cycle conditions recommended by the manufacturer.

The amplified PCR products were then purified using a kit marketed by the company
5 Qiagen, and then sequenced by the Big Dye Terminator method on an ABI377 sequencer.

EXAMPLE 9 : Determination of polymorphisms/mutations in the ABC1 gene.

The detection of polymorphisms or of mutations in the sequences of the transcripts or
10 in the genomic sequence of the ABC1 gene may be carried out according to various protocols. The preferred method is direct sequencing.

For patients from whom it is possible to obtain an mRNA preparation, the preferred method consists in preparing the cDNAs and sequencing them directly. For patients for whom only DNA is available, and in the case of a transcript where the structure of the corresponding
15 gene is unknown or partially known, it is necessary to precisely determine its intron-exon structure as well as the genomic sequence of the corresponding gene. This therefore involves, in a first instance, isolating the genomic DNA BAC or cosmid clone(s) corresponding to the transcript studied according to the method described in Example 8, sequencing the insert of the corresponding clone(s) and determining the intron-exon structure by comparing the cDNA
20 sequence to that of the genomic DNA obtained.

The technique of detection of mutations by direct sequencing consists in comparing the genomic sequences of the ABC1 gene obtained from homozygotes for the disease or from at least 8 individuals (4 individuals affected by the pathology studied and 4 individuals not affected). The sequence divergences constitute polymorphisms. All those modifying the amino
25 acid sequence of the wild-type protein may be mutations capable of affecting the function of said protein which it is preferred to consider more particularly for the study of cosegregation of the mutation and of the disease (denoted genotype-phenotype correlation) in the pedigree or in the studies of case/control association for the analysis of the sporadic cases.

30 **EXAMPLE 10 : Identification of a causal gene for a disease linked to a deficiency in the reverse transport of cholesterol by causal mutation or a transcriptional difference**

Among the mutations identified according to the method described in Example 9, all those associated with the disease phenotype are capable of being causal. Validation of these
35 results is made by sequencing the gene in all the affected individuals and their relations (whose DNA is available).

Moreover, Northern blot or RT-PCR analysis, according to the methods described in Example 1, using RNA specific to affected or nonaffected individuals makes it possible to detect notable variations in the level of expression of the gene studied, in particular in the absence of transcription of the gene.

5

EXAMPLE 11 : Identification of biallelic polymorphisms in the ABC1 gene

Primers for the amplification of the DNA of the patients were designed from nonrepetitive sequences of the intron DNA of the ABC1 gene, in such a way that an amplification of the intron-exon junctions as well as the bases essential for the formation of the secondary structure during the RNA splicing step are included in the amplified fragments.

10

The various pairs of primers specifically developed are presented in Table VI.

The results found on the DNA from 7 families containing cases of Tangier or FHD disease are shown in Table V.

15

The genomic DNA of the patients was amplified with the aid of the primers described above using Qiagen's Star Taq kit or the Supertaq kit, using the hybridization conditions and the amplification cycle conditions recommended by the manufacturer.

The amplified PCR products were then purified using a kit marketed by the company Qiagen, and then sequenced by the Big Dye Terminator method on an ABI377 sequencer (Applied Biosystems, Perkin Elmer).

20

EXAMPLE 12 : Construction of recombinant vectors comprising a nucleic acid encoding a ABC1 protein

I. Synthesis of a nucleic acid encoding a human ABC1 protein:

25

Total RNA (500 ng) isolated from a human cell (i.e., placental tissue, Clontech, Palo Alto, CA, USA, or THP1 cells) may be used as source for the synthesis of the cDNA of the human ABC1 gene. Methods to reverse transcribe mRNA to cDNA are well known in the art. For example, one may use the system "Superscript one step RT-PCR (Life Technologies, Gaithersburg, MD, USA).

30

Oligonucleotide primers specific for ABC1 cDNA may be used for this purpose. Specifically, two oligonucleotide primers specific for ABC1 (0.25 μ M) comprising either 1) a sequence contained within nucleotide region 1-184 of SEQ ID NO: 69 and a complementary sequence contained within nucleotide region 6968-9741 of SEQ ID NO: 69, or 2) a sequence contained within nucleotide region 1-297 of SEQ ID NO: 70 and a complementary sequence

35

contained within nucleotide region 7081-9854 of SEQ ID NO: 70, may be used to isolate a nucleic acid encoding an ABC1 protein.

These oligonucleotide primers may be synthesized by the phosphoramidite method on a DNA synthesizer of the ABI 394 type (Applied Biosystems, Foster City, CA, USA).

5 Sites recognized by the restriction enzyme NotI may be incorporated into the amplified ABC1 cDNA to flank the ABC1 cDNA region desired for insertion into the recombinant vector by a second amplification step using 50 ng of human ABC1 cDNA as template, and 0.25 μ M of the ABC1 specific oligonucleotide primers used above containing, at their 5' end, the site recognized by the restriction enzyme NotI (5'-GCGGCCGC-3'), in the presence of 200 μ M of
10 each of said dideoxynucleotides dATP, dCTP, dTTP and dGTP as well as the *Pyrococcus furiosus* DNA polymerase (Stratagene, Inc. La Jolla, CA, USA).

The PCR reaction may be carried out over 30 cycles each comprising a step of denaturation at 95°C for one minute, a step of renaturation at 50°C for one minute and a step of extension at 72°C for two minutes, in a thermocycler apparatus for PCR (Cetus Perkin Elmer
15 Norwalk, CT, USA).

II. Cloning of the cDNA of the human ABC1 gene into an expression vector:

The human ABC1 cDNA insert may then be cloned into the NotI restriction site of an expression vector, for example, the pCMV vector containing a cytomegalovirus (CMV) early
20 promoter and an enhancer sequence as well as the SV40 polyadenylation signal (Beg et al., 1990; Applebaum-Boden, 1996), in order to produce an expression vector designated pABC1.

The sequence of the cloned cDNA can be confirmed by sequencing on the two strands using the reaction set "ABI Prism Big Dye Terminator Cycle Sequencing ready" (marketed by Applied Biosystems, Foster City, CA, USA) in a capillary sequencer of the ABI 310 type
25 (Applied Biosystems, Foster City, CA, USA).

III. Construction of a recombinant adenoviral vector containing the cDNA of the human ABC1 gene:

30 A- Modification of the expression vector pCMV- β :

The β -galactosidase cDNA of the expression vector pCMV- β (Clontech, Palo Alto, CA, USA, Gene Bank Accession No. U02451) may be deleted by digestion with the restriction endonuclease NotI and replaced with a multiple cloning site containing, from the 5' end to the 3' end, the following sites: NotI, AscI, RsrII, AvrII, SwaI, and NotI, cloned at the region of the
35 NotI restriction site. The sequence of this multiple cloning site is:

5'-CGGCCGCGGCGCGCCCGGACCGCCTAGGATTTAAATCGCGGCCCGCG-3' (SEQ ID NO: 66).

- 5 The DNA fragment between the EcoRI and SmaI sites of the modified expression vector pCMV may be isolated and cloned into the modified XbaI site of the shuttle vector pXCXII (McKinnon et al., 1982; McGrory et al., 1988).

B-modification of the shuttle vector pXCXII:

- 10 A multiple cloning site comprising, from the 5' end to the 3' end the XbaI, EcoRI, SfiI, PmeI, NheI, SrfI, PacI, SalI and XbaI restriction sites having the sequence:

5'-GCTCTAGAATTCGGCCTCCGTGGCCGTTTAAACGCTAGCGCCCGGGCTTAATTAA
GTCGACTCTAGAGC-3' (SEQ ID NO: 67).

- 15 may be inserted at the level of the XbaI site (nucleotide at position 3329) of the vector pXCXII (McKinnon et al., 1982; McGrory et al., 1988).

- 20 The EcoRI-SalI DNA fragment isolated from the modified vector pCMV-β containing the CMV promoter/enhancer, the donor and acceptor splicing sites of FV40 and the polyadenylation signal of FV40 may then be cloned into the EcoRI-SalI site of the modified shuttle vector pXCX, designated pCMV-11.

C- Preparation of the shuttle vector pAD12-ABC1:

- 25 The human ABC1 cDNA is obtained by an RT-PCR reaction, as described above, and cloned at the level of the NotI site into the vector pCMV-12, resulting in the obtaining of the vector pCMV-ABC1.

D. Construction of the ABC1 recombinant adenovirus:

- 30 The ABC1-rdV recombinant adenovirus containing the human ABC1 cDNA may be constructed according to the technique described by McGrory et al. (1988).

Briefly, the vector pAD12-ABC1 is cotransfected with the vector tGM17 according to the technique of Chen and Okayama (1987).

Likewise, the vector pAD12-Luciferase was constructed and cotransfected with the vector pJM17.

The recombinant adenoviruses are identified by PCR amplification and subjected to two purification cycles before a large-scale amplification in the human embryonic kidney cell line HEK 293 (American Type Culture Collection, Rockville, MD, USA).

5 The infected cells are collected 48 to 72 hours after their infection with the adenoviral vectors and subjected to five freeze-thaw lysing cycles.

The crude lysates are extracted with the aid of Freon (Halocarbhone 113, Matheson Product, Scaucus, N.J. USA), sedimented twice in cesium chloride supplemented with 0.2% murine albumine (Sigma Chemical Co., St Louis, MO, USA) and dialysed extensively against buffer composed of 150 mM NaCl, 10 mM Hepes (pH 7.4), 5 mM KCl, 1 mM MgCl₂, and 1
10 mM CaCl₂.

The recombinant adenoviruses are stored at -70°C and titrated before their administration to animals or their incubation with cells in culture.

The absence of wild-type contaminating adenovirus is confirmed by screening with the aid of PCR amplification using oligonucleotide primers located in the structural portion of the
15 deleted region.

IV Validation of the expression of the human ABC1 cDNA:

Polyclonal antibodies specific for a human ABC1 polypeptide may be prepared as described above in rabbits and chicks by injecting a synthetic polypeptide fragment derived
20 from an ABC1 protein, comprising all or part of an amino acid sequence as described in SEQ ID NO: 71. These polyclonal antibodies are used to detect and/or quantify the expression of the human ABC1 gene in cells and animal models by immunoblotting and/or immunodetection.

The biological activity of ABC1 may be monitored by quantifying the cholesterol fluxes induced by apoA-I using cells transfected with the vector pCMV-ABC1 which have been
25 loaded with cholesterol (Remaley et al., 1997).

V. Expression in vitro of the human ABC1 cDNA in cells:

Cells of the HEK293 line and of the COS-7 line (American Tissue Culture Collection, Bethesda, MD, USA), as well as fibroblasts in primary culture derived from Tangier patients or
30 from patients suffering from hypo-alpha-lipoproteinemia are transfected with the expression vector pCMV-ABC1 (5-25 µg) using Lipofectamine (BRL, Gaithersburg, MD, USA) or by coprecipitation with the aid of calcium chloride (Chen et al., 1987).

These cells may also be infected with the vector pABC1-AdV (Index of infection, MOI=10).

The expression of human ABC1 may be monitored by immunoblotting as well as by quantification of the efflux of cholesterol induced by apoA-I using transfected and/or infected cells.

5 The complementation of the genetic defect from which the Tangier patients and the hypo-alpha-lipoproteinemic patients are suffering using fibroblasts of these patients, may be confirmed by the detection of the expression of the normal ABC1 gene, which makes it possible to establish the functional importance of this receptor.

VI. Expression in vivo of the ABC1 gene in various animal models:

10 An appropriate volume (100 to 300 µl) of a medium containing the purified recombinant adenovirus (pABC1-AdV or pLucif-AdV) containing from 10^8 to 10^9 lysis plaque-forming units (pfu) are infused into the Saphenous vein of mice (C57BL/6, both control mice and models of transgenic or knock-out mice) on day 0 of the experiment.

15 The evaluation of the physiological role of the ABC1 protein in the metabolism of lipoproteins is carried out by determining the total quantity of cholesterol, of triglycerides, of phospholipids and of free cholesterol (Sigma and Wako Chemicals, Richmond, VA, USA), of cholesterol-HDL (CIBA-Corning, Oberlin, OH, USA) and apolipoproteins A-I, A-II, E and B from mice (Foger et al., 1997), before (day zero) and after (days 2, 4, 7, 10, 14) the administration of the adenovirus.

20 Kinetic studies with the aid of radioactively labelled produces such as apoA-I-HDL, CE-HDL as well as apoB-LDL and CE-LDL are carried out on day 5 after the administration of the vectors rLucif-AdV and rABC1-AdV in order to evaluate the effect of the expression of ABC1 on the metabolism of the HDLs and of the LDLs as well as on the release of cholesterol toward the liver.

25 The effect of the expression of ABC1 on the development of atherosclerosis may be evaluated by quantifying the mean surface area of aortic lesion in apoE mice after administration of the vector rABC1-Adv.

30 Furthermore, transgenic mice and rabbits overexpressing the ABC1 gene may be produced, in accordance with the teaching of Vaisman (1995) and Hoeg (1996) using constructs containing the human ABC1 cDNA under the control of endogenous promoters such as ABC1, CMV or apoE.

The evaluation of the long-term effect of the expression of ABC1 on the kinetics of the plasma lipids, lipoproteins and apolipoproteins and on atherosclerosis may be carried out as described above.

EXAMPLE 13 : Use of vesicles for screening for agonist and antagonist molecules of an ABC1 protein.

5 The basis of this screening test is the reconstitution of membranes which have incorporated the ABC1 protein and containing substrates such as cholesterol or phospholipids. The ABC1 protein may then be activated or its function repressed by the addition of molecules of interest. The outflow of the substrates through the channel formed by the ABC1 protein is then detected.

10 **a) Reconstitution of a membrane comprising an ABC1 protein and a labeled lipid substrate.**

Various strategies may be used to manufacture these membranes, methods using organic solvents, mechanical means such as sonication, the "French press", or by freeze-thaw cycles or using detergents (cholates, Chaps, Chapso) (see Rigaud et al., 1995).

15 More particularly, a lipid substrate such as phospholipids, cholesterol or cholesterol ester, a radioactive substrate of the ^3H -cholesterol, ^{125}I -cholesterol or ^3H -phosphatidylcholine type or a fluorescent substrate with NBD or pyrene (Molecular Probes ; <http://www.probes.com>) and phosphatidylcholine from eggs (1 mM) are dried on the pellet of a glass flask. Sodium cholate and the ABC1 protein are mixed in this flask in a mol to mol ratio
20 of 0.3. The whole is vortex-mixed for 5 minutes and then incubated at 25°C for 30 minutes and then dialysed against a saline buffer. The proteoliposome produced according to this protocol is monitored by turbidimetry in order to verify that its manufacture is good.

b) Capture of the proteoliposome on a solid surface.

25 This step may be carried out by incorporating binding proteins of the integrin type. In this protocol, a capture by the antibodies directed against the ABC1 protein and previous adsorbed on a 96- or 384-well plate is used.

A solution containing these antibodies at the concentration of 100 µg/l are absorbed on these multi-well plates by incubating overnight at 4°C. After washing, the plate is then
30 saturated with bovine albumin at 1 mg/ml incubated for 2 hours at 37°C. The whole is then washed and incubated with the proteoliposomes containing ABC1 for 2 hours at 37°C.

c) Binding to the molecules of interest.

This step is carried out by incubation of products for 1 hour at 37°C.

35

d) Determination of the activation or inhibition of the ABC1 protein.

If the substrate is fluorescent, the fluorescence of the supernatant shows us the activity of a product in inducing a transport of lipid to the outside of the proteoliposome. Alternatively, the use of a Confocal system gives us information on the quantities of substrate inside and outside the proteoliposome. If the substrate is radioactive, the use of CytoStar-type plates having a bottom with scintillation liquid makes it possible to reveal the substrate still sequestered in the proteoliposome.

EXAMPLE 14 : Use of anion transport for screening of agonist and antagonist molecules of an ABC1 protein.

The principle of this test lies in the property that the ABC1 protein has for transporting the anions during its activation.

a) The macrophage cells of the THP-1 lines, monocytic leukemia human cells, are a model of differentiated macrophages. The cells are cultured in an RPMI 1640 medium supplemented with 10% fetal calf serum in 48-multiwell plates at the density of 2×10^5 cells per well. The fibroblast cells of patients suffering from Tangier disease may be used as a negative control because their ABC1 protein is not functional. Another negative control may be obtained by the addition of anti-ABC1 antibodies.

b) The use of anion transport defective cells or cells treated with anion channel inhibitors (Verapamil type, an inhibitor of P-glycoprotein or tetraethylammonium, a potassium channel inhibitor) may also be used.

c) For the actual test itself, the cells are then washed with an Earle's modified salt solution (ESS) medium preloaded with 1 ml of KI at $1 \mu\text{mol/L}$ ($0.1 \mu\text{Ci/ml}$ of NaI^{125}) in this ESS medium for 30 minutes at 37°C . The products are then added to the extracellular medium. The cells are then washed with the ESS medium.

d) The quantity of iodide in the medium is detected every minute for 11 minutes. The first two points correspond to the basal efflux. At the end of the incubation, the medium is taken up and the quantity of iodine remaining in the cells is counted following lysis of the cells in 1 molar NaOH.

e) The total quantity of radioactivity at time zero is equal to the sum of the radioactivity found in the supernatant and the residual radioactivity in the cells. The efflux curves are

constructed by plotting the percentage of radioactivity released into the medium as a function of time.

EXAMPLE 15 : Use of THP-1 macrophages expressing IL-1beta to screen for agonist and antagonist molecules of an ABC1 protein.

The principle of this test is that any substance that modulates the activity of an ABC1 protein will have an effect on the synthesis of IL-1beta.

10 a) The macrophage cells of the THP-1 lines, monocytic leukemia human cells, are a model of differentiated macrophages. The cells are cultured in an RPMI 1640 medium supplemented with 10% fetal calf serum in multiwell plates at the density of 2×10^5 cells per well.

15 b) For the actual test itself, the cells are then washed and placed in an RPMI 1640 medium containing 1 mg/ml of purified human albumin fraction IV.

20 c) The products are added to the extracellular medium. Simultaneously, the cells are then activated by addition of lipopolysaccharide (LPS) over 3 hours at 1 μ g/ml followed by an incubation of 30 minutes in the presence of ATP at 5 mmol/L.

25 d) The concentrations of IL-1beta and of control IL-1alpha, tumor necrosis factor alpha (TNFalpha) and IL-6 are determined by ELISA kits according to the manufacturers' instructions (R&D System ; human IL-1beta Chemiluminescent ELISA reference QLB00). The variations of mRNA for IL-1beta which is not supposed to be affected are evaluated by the Northern blotting technique with the corresponding probe.

EXAMPLE 16 : ABC1 mediated phospholipid and cholesterol efflux

30 **I - Culture Cell**

Human Hela Tet-Off[®] cells (Clontech, Palo Alto, CA) were grown in Dulbecco-modified Minimum Essential Medium (DMEM) (GIBCO BRL, Rockville, MD) supplemented with 10% fetal calf serum, 2 mM glutamine, 100 IU/ml of penicillin, 100 μ g/ml of streptomycin (EMEM10), and 250 μ g/mL of G418. Cell lines stably expressing human ABC1-GFP fusion
35 protein were obtained by co-transfection with the pTR2 plasmid (Clontech, Palo Alto, CA),

containing the cDNA of the fusion protein, and pHygro, which encodes a resistance marker for hygromycin. Approximately 2 weeks after selection with 1mg/mL of hygromycin, cells positive for GFP, as assessed by fluorescence microscopy, were cloned and expanded.

5 II- Cholesterol Efflux Assay

The cholesterol efflux assay was essentially performed as described by Oram et al. (1986) and Rothblat et al. (1986).

Confluent cholesterol-loaded fibroblasts grown on 24-well plates were incubated with
10 EMEM10 containing 1 μ Ci/ml of 1,2- ³H-cholesterol (50 Ci/mmol)(Dupont, Wilmington, DE) for 48 h. Typically, this labeling protocol resulted in approximately 100,000 CPM/well or 1000 CPM/ μ g protein. Cells were washed three times with EMEM/BSA and EMEM/BSA media in presence or absence of 10 μ g/ml cholesterol acceptors, *i.e.*, apoA-I, apoA-II, apoA-IV, apoC-I, apoC-II, apoC-III, apoE₃ were added and incubated for 24 h at 37°C, prior to efflux with
15 cholesterol. After the efflux period (18 h), media was collected and centrifuged (10,000 X g for 5 min), and an aliquot of the media was counted for radioactivity by liquid scintillation counting. The residual radioactive count in the cell fraction was determined after an over night extraction with isopropanol. The percent efflux was calculated by dividing the radioactive counts in the efflux media by the sum of the radioactive counts in the media plus the cell
20 fraction. Unless indicated, EMEM/BSA media was used as a blank and the results from the blank were subtracted from the radioactive counts obtained in the presence of a cholesterol acceptor.

The results as presented in Figure 4, clearly demonstrate that addition of various apolipoproteins A-I, A-II, A-IV, C-I, C-II, C-III, and E₃ markedly increases cholesterol efflux in
25 ABC1 transfected cells, thereby indicating that full length ABC1 protein according to the present invention is capable of promoting cholesterol efflux mediated by various apolipoproteins A-I, A-II, A-IV, C-I, C-II, C-III, and E₃.

30 III- Phospholipid Efflux Assay

The phospholipid efflux assay was essentially performed as described by Mendez et al. (1994).

Choline-containing phospholipids were labeled by incubating confluent cholesterol-loaded fibroblasts grown on 24 well plates with EMEM10 medium containing 5 μ Ci/ml of
35 methyl-³Hcholine chloride (84Ci/mmol (Amersham; Arlington Heights, Ill) for 24 h. Cells were washed three times with EMEM/BSA, followed by a 1h pre-incubation in EMEM/BSA, prior to

incubation with EMEM/BSA media in presence or absence of 10 µg/ml phospholipid acceptors, i.e., apoA-I, apoA-II, apoA-IV, apoC-I, apoC-II, apoC-III, apoE₃. Typically, this labeling protocol resulted in approximately 500,000 CPM/well or 5000 CPM/ug protein. After the efflux period (18 h), media was collected and centrifuged (10,000 X g; 5 min). An aliquot of the supernatant was extracted with chloroform:methanol (2:1), and radioactivity was determined by liquid scintillation counting of the organic phase. The remaining counts in the cell fraction was determined after an overnight extraction with isopropanol, followed by a 1 h extraction with hexane:isopropanol (3:2).

The percent efflux is calculated by dividing the radioactive counts in the efflux media by the sum of the radioactive counts in the efflux media plus the cell fraction. Unless indicated, EMEM/BSA media was used as a blank and the results from the blank were subtracted from the radioactive counts obtained in the presence of a phospholipid acceptor.

The results as presented in Figure 5, clearly demonstrate that addition of various apolipoproteins A-I, A-II, A-IV, C-I, C-II, C-III, and E₃ markedly increases phospholipid efflux in ABC1 transfected cells, thereby indicating that full length ABC1 protein according to the present invention is also involved in apolipoproteins A-I, A-II, A-IV, C-I, C-II, C-III, and E₃ mediated cellular phospholipid efflux.

IV- Lipoprotein, Apolipoprotein Vesicles Preparation

HDL (d = 1.063- 1.021 g/ml) was isolated from human plasma by density gradient ultracentrifugation, as described by Shumaker et al.

Apolipoproteins were purified from human plasma by column chromatography as described by Brewer et al. (1986) and were determined to be over 99 % pure, as assessed by SDS-polyacrylamide gel electrophoresis and aminoterminal sequence analysis. Phosphatidylcholine vesicles and reconstitution of apoA-I with egg yolk phosphatidylcholine at a ratio of 1:2.5 (w/w) was performed by sonication, as previously described by Jonas et al. (1986).

Results in Figure 5, show that apoA-I and HDL respectively fully and partially mediate cholesterol efflux in ABC1 transfected cells. In addition, apoA-I mediates phospholipid efflux in ABC1transfected cells. However, phosphatidylcholine (PC) does not mediate cholesterol efflux in ABC1transfected cells.

V- ApoA-I and ApoA-II binding to ABC1

ApoA-I was iodinated with isotopic ¹²⁵ Iodide by the iodide monochloride method to a specific activity of 2 X 10⁶ cpm/μg. Confluent fibroblasts grown on 24-well plates were
5 incubated with iodinated apoA-I for 3 h at 37°C in the presence and absence of a 50-fold excess of the apolipoprotein A-I and A-II fractions isolated from HDL. Cells were rapidly washed three times with EMEM/BSA at 4°C. Bound iodinated ligands were determined by gamma counting, after dissolving the cell fraction with 0.1 M NaOH and 0.1 %SDS.

10 REFERENCES CITED

- Adames et al., 1985, Nature 318:533-538.
- Agbedana et al., 1990. Ann Trop Med Parasitol., 84:529-30.
- Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444.
- Altschul et al., 1990. J. Mol. Biol., 215:403-410.
- 15 Altschul et al., 1997. Nucleic Acids Res., 25:3389-3402.
- Applebaum-Boden, 1996. JCI 97.
- Ausubel et al., 1989. Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.
- Baptista et al., 1996. Parasite, 3:335-40.
- 20 Beard et al., 1990. Virology, 75:81.
- Beaucage et al., 1981. Tetrahedron Lett, 22: 1859-1862.
- Becq et al., 1997. Journal of Biological Chemistry, 272:2695-2699.
- Beg et al., 1990. PNAS, 87:3473.
- Bender et al., 1987. J. Virol., 61:1639.
- 25 Benoist and Chambon, 1981, Nature 290:304-310.
- Benton and Davis, 1977, Science 196:180.
- Bernstein et al., 1985. Genet. Eng., 7:235.
- Bodzioch et al., 1999. Nature Genetics, 22:347-351.
- Boulianne et al., 1984. Nature, 312:643.

- Breakfield et al., 1991. *New Biologist*, 3:203.
- Brewer et al., 1986. *Methods of Enzymology*. J.P. Segrest, J.J. Albers, editors. Academic Press. Inc., London 128: 223-246
- Brinster et al., 1982, *Nature* 296:39-42.
- 5 Brooks et al., 1999. *Nature Genetics*, 22:336-345.
- Brown EL, Belagaje R, Ryan MJ, Khorana HG, 1979. *Methods Enzymol*, 68:109-151.
- Buchwald et al., 1980. *Surgery* 88:507.
- Cabilly et al., US patent No. 4,816,567.
- Chander et al., 1998. *Indian J Exp Biol.*, 36:371-4.
- 10 Chen and Kwok, 1997. *Nucleic Acids Research* 25:347-353.
- Chen and Okayama, 1987. *Mol Cell Biol.*, 7:2745-2752.
- Chen et al., 1997. *Proc. Natl. Acad. Sci. USA*, 94/20:10756-10761.
- Chen et al., 1987. *Mol. Cell. Biol.*, 7 : 2745-2752.
- Chomczynski, P. and Sacchi, 1987. *Anal. Biochem.*, 162:156-159.
- 15 Cole et al., 1985. In: *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96.
- Cote et al., 1983. *Proc. Natl. Acad. Sci. U.S.A.* 80:2026-2030.
- Cuisinier et al., 1990. *Med Trop (Mars)*. 50:91-5.
- Curiel et al., 1992. *Hum. Gene Ther.* 3:147-154.
- 20 Davis et al., 1993. *J. Infect.* 26:279-85.
- Davis et al., 1995. *J. Infect.* 31:181-8.
- DeBoer, et al., 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:21-25.
- DeRisi J. et al., 1997. *Science*, 278:680-686.
- Dib C. et al., 1996. *Nature*, 380:152-154.
- 25 Djoumessi, 1989. *Pathol Biol.*, 37:909-11.
- During et al., 1989. *Ann. Neurol.* 25:351.
- Efthimiou et al., 1992. *Wein Klin Wochenschr.*, 104:705-6.
- Erel et al., 1998. *Haematologia (Budap)*, 29:207-12.

- Felgner et al., 1987. PNAS 84:7413.
- Felgner and Ringold, 1989. Science 337:387-388.
- Flotte et al., 1992. Am. J. Respir. Cell Mol. Biol., 7:349-356.
- Foger et al., 1997. J. Biol. Chem., 272:27393-400.
- 5 Forsell Y. et al., 1997. Biol. Psychiatry, 42:898-903.
- Fraley et al., 1979. Proc. Natl. Acad. Sci. USA, 76:3348-3352.
- Fraley et al., 1980. J.Biol.Chem., 255:10431.
- Francis et al., 1995. J. Clin. Invest., 96:78-87.
- French et al., 1993. Am J Cardiol. 71:505-510.
- 10 Freshney (ed.), 1986. *Immobilized Cells And Enzymes*, IRL Press.
- Fromont-Racine et al, 1993. Nucleic Acid Res.21(7):1683-1684.
- Fuller S.A. et al., 1996. *Immunology, In: Current Protocols in Molecular Biology*, Ausubel et al.(eds.).
- Gait (ed.), 1984. *Nucleic Acid Hybridization*.
- 15 Glover (ed.), 1985. *DNA Cloning: A Practical Approach, Volumes I and II Oligonucleotide Synthesis*, MRL Press, Ltd., Oxford, U.K.
- Goodson, 1984. In: *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley: New York , vol. 2, pp. 115-138.
- Gopal, 1985. Mol. Cell. Biol., 5:1188-1190.
- 20 Graham et al., 1973. Virology, 52:456-457.
- Graham et al., 1977. J. Gen. Virol., 36:59.
- Graham, 1984. EMBO J., 3:2917.
- Grellier et al., 1997. Vox Sang., 72:211-20.
- Grosschedl et al., 1984, Cell 38:647-658.
- 25 Grunstein and Hogness, 1975, Proc.Natl. Acad. Sci. U.S.A. 72:3961.
- Haff L.A. and Smirnov I.P., 1997. Genome Research, 7:378-388.
- Hager and Hajduk, 1997. Nature 385:823-6.
- Ham, 1980. Methods Cell. Biol., 21a:255.

Hames and Higgins (eds.), 1984. *Animal Cell Culture*.

Hames and Higgins (eds.), 1985. *Transcription And Translation*.

Hames BD and Higgins SJ, 1985. *Nucleic acid hybridization : a practical approach*, Hames and Higgins Ed., IRL Press, Oxford.

- Hammeling et al., 1981. In : Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681.
- Hammer et al., 1987, Science 235:53-58.
- Hanahan, 1985, Nature 315:115-122.
- 5 Harland et al., 1985. J. Cell. Biol., 101:1094-1095.
- Hartmut et al., Canadian Patent Application No. 2,012,311, filed March 15, 1990.
- Higuchi, 1989, "Using PCR to Engineer DNA", in *PCR Technology: Principles and Applications for DNA Amplification*, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70.
- Hoeg, 1996. PNAS, 93:11448.
- 10 Horvath S. et al., 1998. Am. J. Hum. Genet., 63:1886-1897.
- Houben Weyl, 1974. In: Meuthode der Organischen Chemie, E. Wunsch Ed., 15-I:15-II.
- Howard et al., 1989. J. Neurosurg. 71:105.
- Huse et al., 1989. Science 246:1275-1281.
- Hutchinson, C., et al., 1978, J. Biol. Chem. 253:6551.
- 15 Hutchinson et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:710.
- Huygen et al., 1996. Nature Medicine, 2(8):893-898.
- Jonas et al., 1986. Methods Enzymol., 128:553-82.
- Kaneda et al., 1989. Science 243:375.
- Kaufman, 1991. *Current Protocols in Molecular Biology*, 16.12.
- 20 Kelsey et al., 1987, Genes and Devel. 1:161-171.
- Kim et al., 1996. Genomics, 34:213-218.
- Kittl, et al., 1992. Wein Klin Wochenschr 104:21-4.
- Koch Y., 1977. Biochem. Biophys. Res. Commun., 74:488-491.
- Köhler et al, 1976. Eur. J. Immunol., 6:511.
- 25 Köhler et al., 1976. Eur. J. Immunol. 6:292.
- Köhler et al., 1975. Nature, 256:495.
- Kohler G. and Milstein C., 1975. Nature, 256:495-497.
- Kollias et al., 1986, Cell 46:89-94.

- Kozbor et al., 1983a. *Immunology Today*, 4:72.
- Kozbor et al., 1983b. *Hybridoma*, 2(1):7-16.
- Krumlauf et al., 1985, *Mol. Cell. Biol.* 5:1639-1648.
- Kwiterovich, 1995. *Ann NY Acad Sci.*, 748:313-30; discussion 331-2.
- 5 Lander and Schork, 1994. *Science*, 265:2037-2048.
- Langer, 1990. *Science*, 249:1527-1533.
- Langer and Wise (eds.), 1974. In: *Medical Applications of Controlled Release*, CRC Press: Boca Raton, Florida.
- Langmann T. et al., 1999. *Biochem. Biophys. Res. Comm.*, 257:29-33.
- 10 Lawn et al., 1999. *J. Clin. Invest.*, 104:R25-R31.
- Leder et al., 1986, *Cell* 45:485-495.
- Leger OJ, et al., 1997. *Hum Antibodies*, 8(1):3-16.
- Levrero et al., 1991. *Gene* 101.
- Levy et al., 1985. *Science* 228:190.
- 15 Lopez-Berestein, 1989. In: *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss: New York, pp. 317-327.
- Luciani M.F. et al., 1994. *Genomics*, 21:150-159.
- Lyer V. et al., 1999. *Science*, 283:83-87.
- MacDonald, 1987, *Hepatology* 7:425-515.
- 20 Mackey, et al., 1988. *Proc. Natl. Acad. Sci. U.S.A.* 85:8027-8031.
- MacKinnon et al., 1982. *Gene* 19:33.
- Maniatis et al., 1982. *Molecular cloning : A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY.
- Marcil M. et al., 1999a. *Arteriosclerosis Throbosis and Vascular Biology*, 17:1813-1821.
- 25 Marcil et al., 1999b. *Lancet*, 354:1341-46.
- Martineau P, Jones P, Winter G, 1998. *J Mol Biol*, 280(1):117-127.
- Mason et al., 1986, *Science* 234:1372-1378.
- Maurois et al., 1985. *Biochimie.*, 67:227-39.

- McCormick, 1985. *BioTechnology*, 3:689.
- McGrory et al, 1988. *Virology*, 163:614.
- McLaughlin BA et al., 1996. *Am. J. Hum. Genet.*, 59:561-569.
- Mendez AJ et al., 1994. *J. Clin. Invest.* 94, 1698-1705
- 5 Merrifield RB, 1965a. *Nature*, 207(996):522-523.
- Merrifield RB., 1965b. *Science*, 150(693):178-185.
- Mogram et al., 1985, *Nature* 315:338-340.
- Mohanty, et al., 1992. *Ann Trop Med Parasitol.*, 86:601-6.
- Morrison et al., EP 173494.
- 10 Morrison et al., 1984. *J. Bacteriol.* 159:870.
- Morrison, 1985. *Science* 229:1202.
- Narang SA, Hsiung HM, Brousseau R, 1979. *Methods Enzymol*, 68:90-98.
- Neuberger et al., 1984. *Nature*, 312:604-608.
- Neuberger et al., 1985. *Nature*, 314:268.
- 15 Neuberger et al., WO 8601533.
- Nickerson D.A. et al., 1992. *Genomics*, 12:377-387.
- Nicolau C. et al., 1987. *Methods Enzymol.*, 149:157-76.
- Nilsson et al., 1990. *J Intern Med.*, 227:151-5.
- Oi et al., 1986. *Biotechnology*, 4:214.
- 20 Okayama, 1987. *Mol Cell. Biol.*, 7:2745.
- Oliphant et al., 1986, *Gene* 44:177.
- Oram et al., 1986, Oram, J.F. (1986). *Methods Enzymology*. J.P. Segrest, J.J. Albers, Editors. Academic Press Inc., London. 129:645-659
- 25 Ornitz et al., 1986, *Cold Spring Harbor Symp. Quant. Biol.* 50:399-409.
- Pagano et al., 1967. *J.Virol.*, 1:891.
- Perbal, 1984. *A Practical Guide To Molecular Cloning*.
- Pinkert et al., 1987, *Genes and Devel.* 1:268-276.

- Pirich et al., 1993. *Semin Thromb Hemost.*, 19:138-43.
- Potter et al., 1984. *Proc Natl Acad Sci U S A.*, 81(22):7161-5.
- Ranger and Peppas, 1983. *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61.
- Readhead et al., 1987, *Cell* 48:703-712.
- 5 Reeck et al., 1987, *Cell* 50:667.
- Reimann KA, et al., 1997. *AIDS Res Hum Retroviruses*, 13(11):933-943.
- Remaley et al., 1997. *ATVB*, 17:1813.
- Ridder R, Schmitz R, Legay F, Gram H, 1995. *Biotechnology (NY)*, 13(3):255-260.
- Rigaud et al., 1995. *Biochimica et Biophysica Acta*, 1231:223-246.
- 10 Robinson et al., WO 8702671.
- Rothblat et al., 1986. *Methods of Enzymology*. J.P. Segrest, J.J. Albers, editors. Academic Press Inc., London 129:628-644.
- Rust S. et al., 1998. *Nature Genetics*, 20:96-98.
- 15 Rust et al., 1999. *Nature Genetics*, 22:352-355.
- Sambrook, J. Fritsch, E. F., and T. Maniatis, 1989. *Molecular cloning: a laboratory manual*. 2ed. Cold Spring Harbor Laboratory, Cold spring Harbor, New York.
- Samulski et al., 1989. *J. Virol.*, 63:3822-3828.
- Sanchez-Pescador R., 1988. *J. Clin. Microbiol.*, 26(10):1934-1938.
- 20 Sani, 1985, *Nature* 314:283-286.
- Saudek et al., 1989 *N. Engl. J. Med.* 321:574.
- Sefton, 1987. *CRC Crit. Ref. Biomed. Eng.* 14:201.
- Schumaker et al., 1986. *Methods of Enzymology*. J.P. Segrest, J.J. Albers, editors. Academic Press Inc., London 128: 155-169
- 25 Sham P.C. et al., 1995. *Ann. Hum. Genet.*, 59:323-336.
- Smith *et al.*, 1988, *Gene* 67:31-40.
- Smolen and Ball (eds.), 1984. *Controlled Drug Bioavailability, Drug Product Design and Performance*, Wiley: New York.
- Sternberg N.L., 1992. *Trends Genet.*, 8:1-16.

Sternberg N.L., 1994. Mamm. Genome, 5:397-404.

Strautnieks S.S. et al., 1998. Nature Genetics, 20:233-235.

Swift et al., 1984, Cell 38:639-646.

Syvanne et al., 1995a. Circulation, 92:364-70.

- Syvanne et al., 1995b. *J. Lipid Res.*, 36:573-82.
- Tacson et al., 1996. *Nature Medicine*, 2(8):888-892.
- Takeda et al., 1985. *Nature* 314:452-454.
- Taniguchi et al., EP 171496.
- 5 Tomlinson and Raper, 1996. *Nat. Biotechnol.*, 14:717-21.
- Treat et al., 1989. In: *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss: New York, pp. 353-365.
- Tur-Kaspa et al, 1986. *Mol. Cell. Biol.*, 6:716-718.
- Ulmer et al., 1993. *Science* 259:1745-1748.
- 10 Urdea M.S., 1988. *Nucleic Acids Research*, 11:4937-4957.
- Urdea MS et al., 1991. *Nucleic Acids Symp Ser.*, 24:197-200.
- Vaisman, 1995. *J.Biol. Chem.*, 270:12269.
- Van, den Hazel. H., H. Pichler, V. M. M. do, E. Leitner, A. Goffeau, and G. Daum, 1999. *J Biol Chem.*, 274:1934-41.
- 15 Villa-Kamaroff, et al., 1978, *Proc. Natl. Acad. Sci. U.S.A.* 75:3727-3731.
- Wagner et al., 1981, *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445.
- Wands et al., 1981. *Gastroenterology*, 80:225-232.
- Williams et al., 1991. *Proc. Natl. Acad. Sci. USA* 88:2726-2730.
- Wu et al., 1992, *J. Biol. Chem.* 267:963-967.
- 20 Wu and Wu, 1987. *J. Biol. Chem.* 262:4429-4432.
- Wu and Wu, 1988, *J. Biol. Chem.* 263:14621-14624.
- Xiong M. et al., 1999. *Am. J. Hum. Genet.*, 64:629-640.
- Yamamoto, et al., 1980, *Cell* 22:787-797.
- Yamon et al., 1997. *Blood*, 90:2911-2915.
- 25 Zoller and Smith, 1984, *DNA* 3:479-488.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the

accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

CLAIMS

1. An isolated nucleic acid comprising any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.
- 5 2. An isolated nucleic acid comprising at least eight consecutive nucleotides of a polynucleotide sequence of a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence.
- 10
3. An isolated nucleic acid comprising at least 80% nucleotide identity with a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence.
- 15
4. The isolated nucleic acid according to claim 3, wherein the nucleic acid comprises an 85%, 90%, 95%, or 98% nucleotide identity with the nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence.
- 20
5. An isolated nucleic acid that hybridizes under high stringency conditions with a nucleic acid comprising a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO:
- 25
- 30
- 35

10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence.

6. An isolated nucleic acid comprising a polynucleotide sequence as depicted in any one of SEQ ID NOs: 1, 4-65, 68-70, 72-88, 103, 109-118, and 137, or of a complementary polynucleotide sequence.

7. An isolated nucleic acid comprising nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

8. An isolated nucleic acid comprising at least eight consecutive nucleotides of nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

9. An isolated nucleic acid comprising at least 80% nucleotide identity with nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

10. The isolated nucleic acid according to claim 9 comprising an 85%, 90%, 95%, or 98% nucleotide identity with nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

11. An isolated nucleic acid that hybridizes under high stringency conditions with nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

12. A nucleotide probe or primer specific for an ABC1 gene, wherein the nucleotide probe or primer comprises at least 15 consecutive nucleotides of a polynucleotide sequence of a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence.

13. A nucleotide probe or primer specific for an ABC1 gene, wherein the nucleotide probe or primer comprises at least 15 consecutive nucleotides of nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence.

14. A nucleotide probe or primer specific for an ABC1 gene, wherein the nucleotide probe or primer comprises any one of SEQ ID NOs: 119-136, 138, and 141-152, or of a complementary polynucleotide sequence.

15. A method of amplifying a region of the nucleic acid according to claim 1,
5 wherein the method comprises:

a) contacting the nucleic acid with two nucleotide primers, wherein the first nucleotide primer hybridizes at a position 5' of the region of the nucleic acid, and the second nucleotide primer hybridizes at a position 3' of the region of the nucleic acid, in the presence of reagents necessary for an amplification reaction; and

10 b) detecting the amplified nucleic acid region.

16. A method of amplifying a region of the nucleic acid according to claim 15, wherein the two nucleotide primers are selected from the group consisting of

A) a nucleotide primer comprising at least 15 consecutive nucleotides of a polynucleotide sequence of a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-
15 65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of
20 a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence,

B) a nucleotide primer comprising at least 15 consecutive nucleotides of nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a nucleic acid having a complementary sequence, and

25 C) a nucleotide primer comprising a polynucleotide sequence of any one of SEQ ID NOs: 119-136, 138, and 141-152, or a nucleic acid having a complementary sequence.

17. A kit for amplifying the nucleic acid according to claim 1, wherein the kit comprises:

a) two nucleotide primers whose hybridization position is located respectively 5' and
30 3' of the region of the nucleic acid; and optionally,

b) reagents necessary for an amplification reaction.

18. The kit according to claim 17, wherein the two nucleotide primers are selected from the group consisting of

A) a nucleotide primer comprising at least 15 consecutive nucleotides of a
35 polynucleotide sequence of a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of

SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of
 5 a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a complementary polynucleotide sequence,

B) a nucleotide primer comprising at least 15 consecutive nucleotides of nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence, and

10 C) a nucleotide primer comprising a polynucleotide sequence of any one of SEQ ID NOs: 119-136, 138, and 141-152, or of a complementary polynucleotide sequence.

19. The nucleotide probe or primer according to claim 12, wherein the nucleotide probe or primer comprises a marker compound.

20. The nucleotide probe or primer according to claim 13, wherein the nucleotide
 15 probe or primer comprises a marker compound.

21. The nucleotide probe or primer according to claim 14, wherein the nucleotide probe or primer comprises a marker compound.

22. A method of detecting a nucleic acid according to claim 1, wherein the method comprises:

20 A) contacting the nucleic acid with a nucleotide probe selected from the group consisting of

1) a nucleotide probe comprising at least 15 consecutive nucleotides of a polynucleotide sequence of a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of
 25 SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a
 30 complementary polynucleotide sequence,

2) a nucleotide primer comprising at least 15 consecutive nucleotides of nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence, and

3) a nucleotide probe comprising a polynucleotide sequence of any one of SEQ
 35 ID NOs: 119-136, 138, and 141-152, or of a complementary polynucleotide sequence,
 and

B) detecting a complex formed between the nucleic acid and the probe.

23. The method of detection according to claim 22, wherein the probe is immobilized on a support.

24. A kit for detecting the nucleic acid according to claim 1, wherein the kit
5 comprises

A) a nucleotide probe selected from the group consisting of

1) a nucleotide probe comprising at least 15 consecutive nucleotides of a polynucleotide sequence of a) any one of SEQ ID NOs: 1, 4-8, 11-16, 18-26, 28-35, 37-52, 54-65, 68, and 137, or of a complementary polynucleotide sequence; b) nucleotides 3154-3200 of
10 SEQ ID NO: 9 or of a complementary polynucleotide sequence; c) nucleotides 1-242 of SEQ ID NO: 10 or of a complementary polynucleotide sequence; d) nucleotides 1-1851 of SEQ ID NO: 17; or of a complementary polynucleotide sequence; e) nucleotides 152-198 of SEQ ID NO: 27, or of a complementary polynucleotide sequence; f) nucleotides 1-1657 of SEQ ID NO: 36, or of a complementary polynucleotide sequence; or g) nucleotides 1-242 of SEQ ID NO: 53, or of a
15 complementary polynucleotide sequence,

2) a nucleotide primer comprising at least 15 consecutive nucleotides of nucleotides 1-244 of SEQ ID NO: 69 or nucleotides 1-357 of SEQ ID NO: 70, or a complementary polynucleotide sequence, and

3) a nucleotide probe comprising any one of SEQ ID NOs: 119-136, 138, and
20 141-152, or of a complementary polynucleotide sequence, and optionally,

B) reagents necessary for a hybridization reaction.

25. The kit according to claim 24, wherein the probe is immobilized on a support.

26. A recombinant vector comprising the nucleic acid according claim 1.

25 27. The vector according to claim 26, wherein the vector is an adenovirus.

28. A recombinant vector comprising the nucleic acid according claim 6.

29. The vector according to claim 28, wherein the vector is an adenovirus.

30. A recombinant vector comprising the nucleic acid according claim 7.

31. The vector according to claim 30, wherein the vector is an adenovirus.

30 32. A recombinant host cell comprising the nucleic acid according claim 1.

33. A recombinant host cell comprising the recombinant vector according to claim

26.

34. A recombinant host cell comprising the nucleic acid according claim 6.

35. A recombinant host cell comprising the recombinant vector according to claim

35 28.

36. A recombinant host cell comprising the nucleic acid according claim 7.

37. A recombinant host cell comprising the recombinant vector according to claim 30.
38. An isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71.
- 5 39. An isolated nucleic acid encoding a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.
40. A recombinant vector comprising the nucleic acid according to claim 38.
41. A recombinant vector comprising the nucleic acid according to claim 39.
42. A recombinant host cell comprising the nucleic acid according to claim 38.
- 10 43. A recombinant host cell comprising the nucleic acid according to claim 39.
44. A recombinant host cell comprising the recombinant vector according to claim 40.
45. A recombinant host cell comprising the recombinant vector according to claim 41.
- 15 46. An isolated polypeptide selected from the group consisting of
- a) a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102,
- b) a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71,
- c) a polypeptide fragment or variant of a polypeptide comprising an amino acid
- 20 sequence of any one of SEQ ID NOs: 71 and 89-102, wherein the polypeptide fragment or variant comprises amino acids 1-60 of SEQ ID NO: 71, and
- d) a polypeptide homologous to a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71.
47. An antibody directed against the isolated polypeptide according to claim 46.
- 25 48. The antibody according to claim 47, wherein the antibody comprises a detectable compound.
49. A method of detecting a polypeptide, wherein the method comprises
- a) contacting the polypeptide with an antibody according to claim 47; and
- b) detecting an antigen/antibody complex formed between the polypeptide and the
- 30 antibody.
50. A diagnostic kit for detecting a polypeptide, wherein the kit comprises
- a) the antibody according to claim 47; and
- b) a reagent allowing detection of an antigen/antibody complex formed between the polypeptide and the antibody.
- 35 51. A pharmaceutical composition comprising the nucleic acid according to claim 1 and a physiologically compatible excipient.

52. A pharmaceutical composition comprising the nucleic acid according to claim 6 and a physiologically compatible excipient.
53. A pharmaceutical composition comprising the nucleic acid according to claim 7 and a physiologically compatible excipient.
- 5 54. A pharmaceutical composition comprising the nucleic acid according to claim 38 and a physiologically compatible excipient.
55. A pharmaceutical composition comprising the nucleic acid according to claim 39 and a physiologically compatible excipient.
56. A pharmaceutical composition comprising the recombinant vector according to
10 claim 26 and a physiologically compatible excipient.
57. A pharmaceutical composition comprising the recombinant vector according to claim 28 and a physiologically compatible excipient.
58. A pharmaceutical composition comprising the recombinant vector according to claim 30 and a physiologically compatible excipient.
- 15 59. A pharmaceutical composition comprising the recombinant vector according to claim 40 and a physiologically compatible excipient.
60. A pharmaceutical composition comprising the recombinant vector according to claim 41 and a physiologically compatible excipient.
- 20 61. Use of the nucleic acid according to claim 1 for the manufacture of a medicament intended for the prevention of atherosclerosis in various forms or more particularly for the treatment of a subject affected by a dysfunction in the reverse transport of cholesterol.
62. Use of the nucleic acid according to claim 6 for the manufacture of a medicament for the prevention of atherosclerosis in various forms or more particularly for the treatment of a subject affected by a dysfunction in the reverse transport of cholesterol.
- 25 63. Use of the nucleic acid according to claim 7 for the manufacture of a medicament for the prevention of atherosclerosis in various forms or more particularly for the treatment of a subject affected by a dysfunction in the reverse transport of cholesterol.
64. Use of the nucleic acid according to claim 38 for the manufacture of a medicament for the prevention of atherosclerosis in various forms or more particularly for the
30 treatment of a subject affected by a dysfunction in the reverse transport of cholesterol.
65. Use of the nucleic acid according to claim 39 for the manufacture of a medicament for the prevention of atherosclerosis in various forms or more particularly for the treatment of a subject affected by a dysfunction in the reverse transport of cholesterol.
- 35 66. Use of a recombinant vector according to claim 26 for the manufacture of a medicament for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

67. Use of a recombinant vector according to claim 28 for the manufacture of a medicament intended for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

5 68. Use of a recombinant vector according to claim 30 for the manufacture of a medicament for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

69. Use of a recombinant vector according to claim 40 for the manufacture of a medicament for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

10 70. Use of a recombinant vector according to claim 41 for the manufacture of a medicament for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

71. Use of an isolated ABC1 polypeptide comprising an amino acid sequence of SEQ ID NO: 71 or amino acids 1-60 of SEQ ID NO: 71 for the manufacture of a medicament
15 intended for the prevention of atherosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

72. A pharmaceutical composition comprising a polypeptide comprising an amino acid sequence of SEQ ID NO: 71 and a physiologically compatible excipient.

20 73. A pharmaceutical composition comprising a polypeptide comprising amino acids 1-60 of SEQ ID NO: 71 and a physiologically compatible excipient.

74. A pharmaceutical composition comprising a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102, and a physiologically compatible excipient.

25 75. Use of an isolated ABC1 polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 71 and 89-102 for screening an active ingredient for the prevention or treatment of a disease resulting from a dysfunction in the reverse transport of cholesterol.

76. Use of a recombinant host cell expressing an ABC1 polypeptide comprising an amino acid sequence of SEQ ID NOs: 71 and 89-102 for screening an active ingredient for the prevention or treatment of a disease resulting from a dysfunction in the reverse transport of
30 cholesterol.

77. A method of screening a compound active on cholesterol metabolism, an agonist, or an antagonist of an ABC1 polypeptide, wherein the method comprises

a) preparing a membrane vesicle comprising an ABC1 polypeptide and a lipid substrate comprising a detectable marker;

35 b) incubating the vesicle obtained in step a) with an agonist or antagonist candidate compound;

c) qualitatively and/or quantitatively measuring a release of the lipid substrate comprising the detectable marker; and

d) comparing the release of the lipid substrate measured in step b) with a measurement of a release of a labeled lipid substrate by a membrane vesicle that has not been previously incubated with the agonist or antagonist candidate compound.

78. A method of screening a compound active on cholesterol metabolism, an agonist, or an antagonist of a ABC1 polypeptide, wherein the method comprises

a) incubating a cell that expresses an ABC1 polypeptide with an anion labeled with a detectable marker;

b) washing the cell of step a) whereby excess labeled anion that has not penetrated into the cell is removed;

c) incubating the cell obtained in step b) with an agonist or antagonist candidate compound for the ABC1 polypeptide;

d) measuring efflux of the labeled anion from the cell; and

e) comparing the efflux of the labeled anion determined in step d) with efflux of a labeled anion measured with a cell that has not been previously incubated with the agonist or antagonist candidate compound.

79. A method of screening a compound active on cholesterol metabolism, an agonist, or an antagonist of an ABC1 polypeptide, wherein the method comprises

a) culturing a cell of a human monocytic line in an appropriate culture medium with a purified human albumin;

b) incubating the cell of step a) simultaneously with a compound that stimulates the production of IL-1 beta and an agonist or antagonist candidate compound;

c) incubating the cell obtained in step b) with an appropriate concentration of ATP;

d) measuring IL-1 beta released by the cell obtained in step c) into the cell culture supernatant, and

e) comparing the released IL-1 beta obtained in step d) with IL-1 beta released into a culture supernatant of a cell that has not been previously incubated with the agonist or antagonist candidate compound.

80. An implant comprising the recombinant host cell according to claim 32.

81. An implant comprising the recombinant host cell according to claim 34.

82. An implant comprising the recombinant host cell according to claim 36.

83. An isolated nucleic acid comprising any one of a) SEQ ID NOs: 1, 17, 36, 37, 38, 40, 69, and 70, or a complementary nucleotide sequence thereof, b) nucleotides 1-387 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, c) nucleotides 11498-11754 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, d) nucleotides 1-110 of

SEQ ID NO: 69, or a complementary nucleotide sequence thereof, e) nucleotides 7971-9741 of
SEQ ID NO: 69, f) nucleotides 1-223 of SEQ ID NO: 70, or a complementary nucleotide
sequence thereof, g) nucleotides 8084-9854 of SEQ ID NO: 70, or a complementary nucleotide
sequence thereof, h) nucleotides 696-951 of SEQ ID NO: 40, or a complementary nucleotide
5 sequence thereof, i) nucleotides 296-2894 of SEQ ID NO: 36, or a complementary nucleotide
sequence thereof, and j) nucleotides 490-5352 of SEQ ID NO: 17, or a complementary
nucleotide sequence thereof.

84. An isolated nucleic acid comprising at least eight consecutive nucleotides of a
nucleotide sequence of a) any one of SEQ ID NOs: 1, 17, 36, 37, 38, 40, 69, and 70, or a
10 complementary nucleotide sequence thereof, b) nucleotides 1-387 of SEQ ID NO: 1, or a
complementary nucleotide sequence thereof, c) nucleotides 11498-11754 of SEQ ID NO: 1, or
a complementary nucleotide sequence thereof, d) nucleotides 1-110 of SEQ ID NO: 69, or a
complementary nucleotide sequence thereof, e) nucleotides 7971-9741 of SEQ ID NO: 69, f)
nucleotides 1-223 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, g)
15 nucleotides 8084-9854 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, h)
nucleotides 696-951 of SEQ ID NO: 40, or a complementary nucleotide sequence thereof, i)
nucleotides 296-2894 of SEQ ID NO: 36, or a complementary nucleotide sequence thereof, and
j) nucleotides 490-5352 of SEQ ID NO: 17, or a complementary nucleotide sequence thereof.

85. An isolated nucleic acid comprising at least 80% nucleotide identity with a
20 nucleic acid comprising a) any one of SEQ ID NOs: 1, 17, 36, 37, 38, 40, 69, and 70, or a
complementary nucleotide sequence thereof, b) nucleotides 1-387 of SEQ ID NO: 1, or a
complementary nucleotide sequence thereof, c) nucleotides 11498-11754 of SEQ ID NO: 1, or
a complementary nucleotide sequence thereof, d) nucleotides 1-110 of SEQ ID NO: 69, or a
complementary nucleotide sequence thereof, e) nucleotides 7971-9741 of SEQ ID NO: 69, f)
25 nucleotides 1-223 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, g)
nucleotides 8084-9854 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, h)
nucleotides 696-951 of SEQ ID NO: 40, or a complementary nucleotide sequence thereof, i)
nucleotides 296-2894 of SEQ ID NO: 36, or a complementary nucleotide sequence thereof, and
j) nucleotides 490-5352 of SEQ ID NO: 17, or a complementary nucleotide sequence thereof.

86. The isolated nucleic acid according to claim 85, wherein the nucleic acid
30 comprises an 85%, 90%, 95%, or 98% nucleotide identity with the nucleic acid comprising a)
any one of SEQ ID NOs: 1, 17, 36, 37, 38, 40, 69, and 70, or a complementary nucleotide
sequence thereof, b) nucleotides 1-387 of SEQ ID NO: 1, or a complementary nucleotide
sequence thereof, c) nucleotides 11498-11754 of SEQ ID NO: 1, or a complementary
35 nucleotide sequence thereof, d) nucleotides 1-110 of SEQ ID NO: 69, or a complementary
nucleotide sequence thereof, e) nucleotides 7971-9741 of SEQ ID NO: 69, f) nucleotides 1-223

of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, g) nucleotides 8084-9854 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, h) nucleotides 696-951 of SEQ ID NO: 40, or a complementary nucleotide sequence thereof, i) nucleotides 296-2894 of SEQ ID NO: 36, or a complementary nucleotide sequence thereof, and j) nucleotides 490-5352 of SEQ ID NO: 17, or a complementary nucleotide sequence thereof.

87. An isolated nucleic acid that hybridizes under high stringency conditions with a nucleic acid comprising a) any one of SEQ ID NOs: 1, 17, 36, 37, 38, 40, 69, and 70, or a complementary nucleotide sequence thereof, b) nucleotides 1-387 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, c) nucleotides 11498-11754 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, d) nucleotides 1-110 of SEQ ID NO: 69, or a complementary nucleotide sequence thereof, e) nucleotides 7971-9741 of SEQ ID NO: 69, f) nucleotides 1-223 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, g) nucleotides 8084-9854 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, h) nucleotides 696-951 of SEQ ID NO: 40, or a complementary nucleotide sequence thereof, i) nucleotides 296-2894 of SEQ ID NO: 36, or a complementary nucleotide sequence thereof, and j) nucleotides 490-5352 of SEQ ID NO: 17, or a complementary nucleotide sequence thereof.

88. An isolated nucleic acid comprising a nucleotide sequence as depicted in a) any one of SEQ ID NOs: 1, 17, 36, 37, 38, 40, 69, and 70, or a complementary nucleotide sequence thereof, b) nucleotides 1-387 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, c) nucleotides 11498-11754 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, d) nucleotides 1-110 of SEQ ID NO: 69, or a complementary nucleotide sequence thereof, e) nucleotides 7971-9741 of SEQ ID NO: 69, f) nucleotides 1-223 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, g) nucleotides 8084-9854 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, h) nucleotides 696-951 of SEQ ID NO: 40, or a complementary nucleotide sequence thereof, i) nucleotides 296-2894 of SEQ ID NO: 36, or a complementary nucleotide sequence thereof, and j) nucleotides 490-5352 of SEQ ID NO: 17, or a complementary nucleotide sequence thereof..

89. A nucleotide probe or primer specific for an ABC1 gene, wherein the nucleotide probe or primer comprises at least 15 consecutive nucleotides of a nucleotide sequence of a) any one of SEQ ID NOs: 1, 17, 36, 37, 38, 40, 69, and 70, or a complementary nucleotide sequence thereof, b) nucleotides 1-387 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, c) nucleotides 11498-11754 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, d) nucleotides 1-110 of SEQ ID NO: 69, or a complementary nucleotide sequence thereof, e) nucleotides 7971-9741 of SEQ ID NO: 69, f) nucleotides 1-223 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, g) nucleotides 8084-9854 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, h)

nucleotides 696-951 of SEQ ID NO: 40, or a complementary nucleotide sequence thereof, i) nucleotides 296-2894 of SEQ ID NO: 36, or a complementary nucleotide sequence thereof, and j) nucleotides 490-5352 of SEQ ID NO: 17, or a complementary nucleotide sequence thereof.

90. The nucleotide probe or primer according to claim 89, wherein the nucleotide probe
5 or primer comprises a marker compound.

91. A method of amplifying a region of the nucleic acid according to claim 83, wherein the method comprises:

a) contacting the nucleic acid with two nucleotide primers, wherein the first nucleotide primer hybridizes at a position 5' of the region of the nucleic acid, and the second nucleotide
10 primer hybridizes at a position 3' of the region of the nucleic acid, in the presence of reagents necessary for an amplification reaction; and

b) detecting the amplified nucleic acid region.

92. A method of amplifying a region of the nucleic acid according to claim 91, wherein the two nucleotide primers are selected from the group consisting of a nucleotide
15 primer comprising at least 15 consecutive nucleotides of a nucleotide sequence of a) any one of SEQ ID NOs: 1, 17, 36, 37, 38, 40, 69, and 70, or a complementary nucleotide sequence thereof, b) nucleotides 1-387 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, c) nucleotides 11498-11754 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, d) nucleotides 1-110 of SEQ ID NO: 69, or a complementary nucleotide
20 sequence thereof, e) nucleotides 7971-9741 of SEQ ID NO: 69, f) nucleotides 1-223 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, g) nucleotides 8084-9854 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, h) nucleotides 696-951 of SEQ ID NO: 40, or a complementary nucleotide sequence thereof, i) nucleotides 296-2894 of SEQ ID NO: 36, or a complementary nucleotide sequence thereof, and j) nucleotides 490-5352 of SEQ
25 ID NO: 17, or a complementary nucleotide sequence thereof.

93. A kit for amplifying the nucleic acid according to claim 83, wherein the kit comprises:

a) two nucleotide primers whose hybridization position is located respectively 5' and 3' of the region of the nucleic acid; and optionally,

30 b) reagents necessary for an amplification reaction.

94. The kit according to claim 93, wherein the two nucleotide primers are selected from the group consisting of a nucleotide primer comprising at least 15 consecutive nucleotides of a nucleotide sequence of a) any one of SEQ ID NOs: 1, 17, 36, 37, 38, 40, 69, and 70, or a complementary nucleotide sequence thereof, b) nucleotides 1-387 of SEQ ID NO: 1, or a
35 complementary nucleotide sequence thereof, c) nucleotides 11498-11754 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, d) nucleotides 1-110 of SEQ ID NO: 69, or a

complementary nucleotide sequence thereof, e) nucleotides 7971-9741 of SEQ ID NO: 69, f) nucleotides 1-223 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, g) nucleotides 8084-9854 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, h) nucleotides 696-951 of SEQ ID NO: 40, or a complementary nucleotide sequence thereof, i) nucleotides 296-2894 of SEQ ID NO: 36, or a complementary nucleotide sequence thereof, and j) nucleotides 490-5352 of SEQ ID NO: 17, or a complementary nucleotide sequence thereof.

95. A method of detecting a nucleic acid according to claim 83, wherein the method comprises:

A) contacting the nucleic acid with a nucleotide probe selected from the group consisting of a nucleotide probe comprising at least 15 consecutive nucleotides of a nucleotide sequence of a) any one of SEQ ID NOs: 1, 17, 36, 37, 38, 40, 69, and 70, or a complementary nucleotide sequence thereof, b) nucleotides 1-387 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, c) nucleotides 11498-11754 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, d) nucleotides 1-110 of SEQ ID NO: 69, or a complementary nucleotide sequence thereof, e) nucleotides 7971-9741 of SEQ ID NO: 69, f) nucleotides 1-223 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, g) nucleotides 8084-9854 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, h) nucleotides 696-951 of SEQ ID NO: 40, or a complementary nucleotide sequence thereof, i) nucleotides 296-2894 of SEQ ID NO: 36, or a complementary nucleotide sequence thereof, and j) nucleotides 490-5352 of SEQ ID NO: 17, or a complementary nucleotide sequence thereof, and

B) detecting a complex formed between the nucleic acid and the probe.

96. The method of detection according to claim 95, wherein the probe is immobilized on a support.

97. A kit for detecting the nucleic acid according to claim 83, wherein the kit comprises

A) a nucleotide probe selected from the group consisting of a nucleotide probe comprising at least 15 consecutive nucleotides of a nucleotide sequence of a) any one of SEQ ID NOs: 1, 17, 36, 37, 38, 40, 69, and 70, or a complementary nucleotide sequence thereof, b) nucleotides 1-387 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, c) nucleotides 11498-11754 of SEQ ID NO: 1, or a complementary nucleotide sequence thereof, d) nucleotides 1-110 of SEQ ID NO: 69, or a complementary nucleotide sequence thereof, e) nucleotides 7971-9741 of SEQ ID NO: 69, f) nucleotides 1-223 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, g) nucleotides 8084-9854 of SEQ ID NO: 70, or a complementary nucleotide sequence thereof, h) nucleotides 696-951 of SEQ ID NO: 40, or a

complementary nucleotide sequence thereof, i) nucleotides 296-2894 of SEQ ID NO: 36, or a complementary nucleotide sequence thereof, and j) nucleotides 490-5352 of SEQ ID NO: 17, or a complementary nucleotide sequence thereof, and optionally,

B) reagents necessary for a hybridization reaction.

5

98. The kit according to claim 97, wherein the probe is immobilized on a support.

99. A recombinant vector comprising the nucleic acid according any one of claims 83 and 88.

100. The vector according to claim 99, wherein the vector is an adenovirus.

101. A recombinant host cell comprising the nucleic acid according to any one of
10 claims 83 and 88.

102. A recombinant host cell comprising the recombinant vector according to claim 99.

103. An isolated nucleic acid of sequence chosen from SEQ ID NO: 69 or 70 encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 71.

104. A recombinant vector comprising the nucleic acid according to claim 103.

15

105. A recombinant host cell comprising the nucleic acid according to claim 103.

106. A recombinant host cell comprising the recombinant vector according to claim
104.

107. A pharmaceutical composition comprising the nucleic acid according to any one of claims 83, 88, and 103 and a physiologically compatible excipient.

20

108. A pharmaceutical composition comprising the recombinant vector according to claim 104 and a physiologically compatible excipient.

109. Use of the nucleic acid according to any one of claims 83, 88, and 103 for the manufacture of a medicament intended for the prevention of arteriosclerosis in various forms or more particularly for the treatment of a subject affected by a dysfunction in the reverse
25 transport of cholesterol.

110. Use of a recombinant vector according to claim 104 for the manufacture of a medicament for the prevention of arteriosclerosis in various forms or more particularly for the treatment of subjects affected by a dysfunction in the reverse transport of cholesterol.

111. An implant comprising the recombinant host cell according to claim 106.

ABC1 5' Extension Strategy

THP1-FC λ Zip-lox ABC1 cDNA clone




Figure 1

Human ABC1 5' Extension PCRs




Figure 2

ABC1 Specific 2° PCR products after gel purification





Figure 3


ABC1 Cholesterol Efflux mediated by apolipoproteins

Fig. 4:




ABC1 Phospholipid Efflux mediated by apolipoproteins

Fig. 5




ABC1 Lipid Efflux mediated by apoA-I, HDL, or PC

Fig. 6:



ApoA-I and ApoA-II Binding to HeLa Cells Expressing ABC1 full length protein

Fig. 7



SEQUENCE LISTING

<110> DENEFFLE, Patrice
ROSIER-MONTUS, Marie-Francoise
5 ARNOULD-REGUIGNE, Isabelle
PRADES, Catherine
NAUDIN, Laurent
LEMOINE, Cendrine
DUVERGER, Nicolas
10 JAYE, Michael
SEARFOSS, III, George
REMALEY, Alan
BREWER, H. Bryan
DEAN, Michael
15
<120> NUCLEIC ACIDS OF THE HUMAN ABC1 GENE AND THEIR
THERAPEUTIC AND DIAGNOSTIC APPLICATION

<130> A3738-EP
20
<140>
<141>

<160> 156
25
<170> PatentIn Ver. 2.1

<210> 1
<211> 11754
30 <212> DNA
<213> Homo sapiens

<400> 1
ccattccacc tagtggggcc atttcctacc tgagtcaccc gtggtgtcaa atagaatgtc 60
35 atgtggcctc ctgagttggg tagaattggc tgctcatctc aaccccgcta ctgactatct 120
ctgtgattta cccttcctcc agccttagcc ttgctacata taaaatcaag acaataatgt 180
ttcctatctc acaggggtgt cctgaggatt aaattaagta attaataataa aatgtgcctt 240
gtacatattg ggcctaaat aaacagtagc tactatttat ccttaaagta caaatggtag 300

tttcagagct tcaaggctga tggctattta tcttactcat actctttgtt tagcttcatt 360
tttttcccct aatttcatta gtattttctt ttcttttttt tttttttttt tttttttttt 420
tttggaggtg aagtctcact ctgttgccca ggctggagtg caatggagcg atcttggctc 480
accccaacct ctgtctcctg ggttcaaaca gttctcctgc ctcagcctcc cgagtagctg 540
5 ggattacagg ctcccgccac catgcccagc tatttttttg tattttcagt agagatgggg 600
tttcaccctt ttgaccaggc tggctcttga ctcctgacct catgatcaac ccacctcagc 660
ctcccaaagt gctgggatta caggtgtgag ccaccacgcc cggcctcata agtattttct 720
aaatttat tt acagtcattgc catttaaaag gaaagttgta ttctgtctt tgttaatat 780
tataagtgat ttatttcagc tacaagcttg gaatggcata taattttgta ttctgctttt 840
10 ttactttaat attacatggc taatgatttc tgtgtttcat aaacattatt ctgatgatgg 900
catgatatat tgttgagtac atgtaccata attgaatcat ttccctattg ctatgcaatt 960
aagttgtttc caatatattt caattataat gtttcaatga atgaataact ttatgcata 1020
agctttttga tatcttaagt tcagtttctt aggatgaatt tccaggaata gtaattgggc 1080
aaatgggata aacatgactc ttgaatacgt attgttaaca ttgctttccc aaagggtc 1140
15 actgatttat atttccgtgt tcattatctt ttaaaccagc tcatttactc accaaacatt 1200
tttaaagcca ttatcatgtg gtaggcttag taagaagaaa gtgaccctaa gggagaagct 1260
tatatataaa tagggctcct ggtgtaccaa gtgtgatac agacacaaag tacctgggga 1320
aattgagatg agggagtcct ggctcagctg ggagaaaagt tcattttcat agagtcattg 1380
ttttgttctt tggcagaaag aaaattgctt tcttccccac cccaccccc agctttattg 1440
20 aggtataatt gacaaataaa aattgtatat cttaagata tgcaatgtga tatatatgta 1500
tatctcaact taaaaataa gctacagaat aaaaagggtg ttgctattaa aaaaaagaa 1560
aaggctgaat gtcattccca agcttgaaa tttgagtatg ttgcctctt gggattattt 1620
acagaaatat tagcaagacc agccccatct ttggtcttga gtactccact gtcagcatgc 1680
tttcttccag agagggatcc atttgccctt atttttcatt ctgttgtgcc gtctatgcaa 1740
25 actattcttg atagttttat ggtaacagt tttttttgtt ccatgagata atttatacat 1800
gtcattgtg gaaaatttag aaaagacagg aaagtattaa aaacatcact tttttttttt 1860
tttttttttt ttttttttta agagacagag tcttgcctct tgcgccaggc cggagtgcag 1920
tggcgtgac tcagctcaca gcaacctccg cttcccaggt ttaagtgatt ctctgcctc 1980
agcctcccaa gtagctggga gtacaggcat gcaccaccac gcccggttaa ttttgtattt 2040
30 ttagtagaga tgggggttca ccatgttggc caggctggtc tcaaactcct gacctcagg 2100
gatccgcctg ccttggcctc gcaaagtctt gggattatag gcaggagcca ctgcgccagc 2160
cacacctag ttcttatcat cctagtacat ccactgtcat tatcttgcct tatttcttct 2220
tgccagctc cactctgac atgcagtggc gtgatcatgc agtgatctcg gctcactgca 2280
acctaggcct tctgggttcg agtgattctc ctgccttagc ctctgggtt caagtgatct 2340
35 tcttgccttg gcctcccaag tagctgggat tacaggcata caccctcatg cccatcta 2400
ttttgtattt ttagtagaca cagcgttca ctaaaatttt gtatttttag tagagatggg 2460
gtttcaccat gttggccagg ctggtctcca actcctgacc tcaggtgatc cgctgcctt 2520
ggcctcaca agtgattaca ggcattgagc actgcattca tcgccaaaaa gattttttta 2580

aagagtttaa tgtagaacca tatcaaaggt ctttggaaat aaaaaacagt tttttaaaaa 2640
 tatcagaaat aaaacaacaa ataaataaat aaataaaaaa cccaaaacaa tctgaagcac 2700
 gagcacctag cagaaagggt caattatgat ctattcatag agtggaaatat caagtagaca 2760
 ttacaggaca tgttttaaga ttatatTTTA tgtcatggga aatgctctcc cagtatgatg 2820
 5 ttaaataaaa aaacagaata caaaagtata tatgctgcat agtctcaata ttgtagagaa 2880
 aaaatattat ttatgtatgc atgaaaaaag acaaaagatg ttaacagaga tccattgtta 2940
 cttcagttta ctagggttg tctctgggag gtaggattaa ggtgatttat atttaccttt 3000
 ttaaactttt ctgtattttt ttattttcaa attttccata aaaatataag gacttgaaga 3060
 tcaagaaaaa atttctgctt tggctcagtg cagtggctca cgcctgtaat cccagcagtt 3120
 10 tgggagccct aggggagagg atcacttgaa cccaagagtt tgacgttcca gtgagctatg 3180
 atctccggat cgtaccgctt ggacgatgga gcaagacctt gtctcaaaaa aaaaaatctt 3240
 tgcttttttt ttttgtttgt ttttgagacg gagtctctct ctgttgcccc agctggagta 3300
 cagtggcaca atctcagctc accgcaacct ctgcctcctg ggttcaagcg attctcttgc 3360
 ctcagcctcc caagtacctg ggattccatg caccacccac tatgcccagc tacttttttg 3420
 15 tattttcagt agagacaggg tttcaccatg ttggccaggc tggctctgaa ttcttgacct 3480
 cagctgatcc accggccttg gcctcccaa gtgctgggat tacaggcatg agccactgtg 3540
 cccagcccaa tcttttgctt tttttaaaaa aagaagacaa aaagggattt tataaccagta 3600
 ttatcttggc tgtgtgactc tgaagccaca gttgtaagtt ataattactc tgaaacacaa 3660
 ggccctgtga ctcttttggg ctctttgggt tttatcttga ttacaacgtt ggaatataga 3720
 20 aatgaaagga atgggagagg tgatagactt caggcagtg aactagtgtt ctgaacacta 3780
 ctggctcaat tatattgtgt ctagtattt ccactctgtc cgtctgctaa tttatcgctt 3840
 ggtaactcac tgaggcaggg ttttcctttg gagaaacctc attgttttaa ccagtgtatc 3900
 atgcttgttt agaagttcaa tgatcttttt aactcatcgg agaagatgat gaccagacct 3960
 ggacagatgg ggaaggactt tgcactctct ctttacagtc ctgagtgcac acagggtcaat 4020
 25 atggaactat gtgtgaattt tcattgtctt tgagagccct cttctctgcc ccatagggag 4080
 cagctttgtg tgcaattaga ggagcaaggg ttgtgtgtat ttagcacagc aggttggcct 4140
 ggtcctctcc tctcaacata gtcaccacat acctggcact atgctaaggc tgggaatgca 4200
 gacagatggg tgcttgcttt cagagtgtc aatgtgtga ggaagccagc aacagaaaca 4260
 gatgatttca ggagctccag gaaaatgcta caggaggagt gtgcctgggt tactggagta 4320
 30 gcacaggagg agggcttcta gctcaggctg agattttagt aaaggaaatt atgccacgat 4380
 gaatcctgaa gaatgaatag aagtgaacca gataaagcac gataggaagc atcttccctt 4440
 acctaaagga agacacagag gtatatggaa tggtatgtta aaaggttggg actccaaaca 4500
 gttctgttaa agcttagaga gtggtgggag agactggaga agttgattaa ttagtaaatg 4560
 aagttgtctg tggatttccc agatcccagt ggcattggat atccgtatca ttttaaatta 4620
 35 cagtgttcta tcttatttcc actcagtgtc agctgctgct ggaagtggcc tggcctctat 4680
 ttatcttctt gatcctgac tctgttcggc tgagctaccc acctatgaa caacatgaat 4740
 gtaagtaact gtggatgttg cctgagactc accaatggca gggaaaatcc aggcaattaa 4800
 cgtgggctaa attggacttt tccaaagatg ctgtcttttg gaaacatcac acatgctttg 4860

gatcagaaaa cctaggcttc taatttggtg ataaggcatg aactcaggag actgttttca 4920
gtcctagtga atggtgataa ttgtaattat aacagtagac aacatctctt ttacacattt 4980
taaatacatga aaatagaata accttactga taattttaga aagtgggtgat taaaagcaca 5040
tttaagataa tgccttaaca cctagtcttt tccatatgca tgatgtctta atcacacatt 5100
5 gcaaatacatg gaacacagaa ttttaagcag cattttgtgta gaacttctca gttttactaa 5160
tattattttta ttttattctc ataacaacct tgaatagaac tcagatcatc tgtcaatcat 5220
gtattttgat aacagccttt acagtgagca tagaaaatac agtagtggct aacaacacag 5280
gctccagatg tcagggttatc tgggtatgaa ttctgggtgc agcattcact aagcatatga 5340
ccttggacaa gtgatttaag tttcttttaa acagagaata gtaataccta cctcatatta 5400
10 ttattgtcag tgtatcatct tacaatcaca gtctttctct tagggctggg ctcagtgggt 5460
ggattgacac tgcagaaatg gccagatcta aaggatcaac atttacgtag ctgggaaatg 5520
tagctgggac ttcagtttca ctgcgctagt gatttttctt accactaagc agctcagtcc 5580
atacccttac gagaccacac agcttatgag atactgttct tccaggaaag cagtggggcc 5640
agggccacct ttaattgtg tttcttggcc tgggtccatc tttctcaca tatatagcaa 5700
15 cagttattta ctgtctgatt ttctaatac catcacacat agtcatatta aacacacaca 5760
cacacacaca cacacacaca caccctcaa gaaacatttt ctgagacgtg atttctgat 5820
ttcatcaaaa aagaaaagag cgggccaggc acagtgggaa gtcaaggtgg gtggatcact 5880
tgaggtcagg agtttgaaac cagcctggcc aacacggtgg aacctcgtct ctactaaaaa 5940
tacaaaaatt agccaggcgt ggtggcgac acctgtaatc ccagctactg gggaggctga 6000
20 ggcaggagaa ttgcttcaac ctgcgaggct gaggttgag tgagccgaga ttgcgccatt 6060
gcactccagc ctgggcaaca gagtgagact ctgtctcaa aaaaaaaaaa aaaaaaaag 6120
cataaactga aatttatatg caatttatat gcctgtgaga taattctgtt ttctctttt 6180
gaaccccaaa gagatttttt tgattgatga gcaatacat tttagatttt atttaagcat 6240
tatgccaagc accactgaag tataagtttc aagggcaaac tcagtttttt catctactag 6300
25 acgaatgatt ttctggaatg attacaagca ggcaagatgg tgtagtggaa atagcaaatg 6360
tcttcggcat cagacaagtt ggggtttgtt tgtatcctgc ctctgccctt caccgaggtt 6420
gtgatcttgg gcagattgtt gaggtttaac ctgattcct ctgactccag atcataaatt 6480
ttcagaaaag ttctgaaatt ctgtatatata ctgatggtaa atgagacttt tccttacatc 6540
tatgcacttc tttgtttgtt tgttttgaga tggctctgt ctgttgccca gactggagt 6600
30 cagtgtgca atctcgcctc actacaatgt ctgcctcca ggttccagt agcctcctgc 6660
ctcagcctcc caaatagctg agactacagg catgtgccac cagtcgggc taatttttgt 6720
atttttagta gagacaggtt tttgccatgt tgaccacact ggtctcgaac tcttggcctc 6780
aggtgattcg ccgcctcag cctcccaaag tgctgggat acaggcatga gccaccatgc 6840
ccggccatat ccatgcactt ctgcaacct taccttcttt tctcatcacc ctccaggag 6900
35 ctagtggaa gagcagagtt aaaagttaag gtgaaacttg gagaggtgtc ttgtccctag 6960
gaacaaagga ctggtttgaa attctctgta aatcttcccc agttcaaacc agagttatca 7020
aggtcttaaa aacttccctg ggtcctgaga gccattata ttatttactt gtcttccctg 7080
acaccactg cctagtctg atcctacttt tgtttgcaa taggatggg cacaacgtac 7140

aaggaagggc ctttggcacc cctgctaagg gataacctga aataccttca ccatcactgc 7200
 cctgtgctgc ttttcaccta tgccagtctg tctacagtgc cagtgtctcc tggcattgaa 7260
 aggggagaaat cttttggtcc tttgagtatt tgggtgggtt acataaatct ccctgaatga 7320
 agagcagctg acttaggcaa ggggccttgt ttggttttcc ttgaactatt aacaggaaga 7380
 5 tagggagatt aactgtgtaa atgttcaata ggccagagtc cctgcagagg gtggccacag 7440
 tgatcagatc ttatcacatc cttgcttttg gtgttcctc tctggttga gtatggatag 7500
 aaaagaaaga aagaccctat attgaaatgc aaagtgcagc aagtcctgac tttggattaa 7560
 cttctcagcc catttgcag aaaataaaaa gatgaataaa acaaggttcc cactttggag 7620
 ggaggtggtg gctgtgagat ggaaggagtg ttcctgctgg gcaacagcag agtaagtgt 7680
 10 ggggtagatt cactcccaca gtgcctggaa aatcctcata ggctcatttg ttgagtcttt 7740
 gtccacacc aggcactctg caaaaacgct ttgcctgcaa ggtctcatgc gatgctcacc 7800
 acagctctgt gaagttaatt gtacttttat caccatttta cagatgagaa aactgaggg 7860
 atggggtcaa tgacttggt aaagtcactg cttagcaagc tgcagggact ggatgtgaat 7920
 tccaattggt ttgactccaa agcctgtgaa gctacttgtt cttcaccacc tagagctgtg 7980
 15 gttcttgata actgtgaact cttttggggt cacaatatgc cctgagaata tgatagaagc 8040
 aggagctctg gcctttctgt ccatacctga acaggtcctt gggttaagag cccctcgtcc 8100
 agggcctatt aatcttgatc ctcataagca gcatccatgt ataaaggccg caaaccaaac 8160
 tgtgccagac cgaatcctag gaccaagccc aaatatgtcc catcctcctt ttggtaaaga 8220
 gctcattgta agaaagaaag aggagagcaa gaggatgacc tagtgcattg ggctcattg 8280
 20 ttttaattag tgacaaaaca acaataataa caacaaaacc cccgaagctt cacagatgac 8340
 atcagacccc aagcctgtgt gtttttcagg tgcccttgag gagctttgta gctggcagag 8400
 gaggtgaaac tgacaaatgt ttggcagatg gaggagagta ccagaggggt ttgagatgag 8460
 ctaaattcca atctaaccgc aggtgtgagg aagaggcttg gattgggacc atggagatgg 8520
 gggttctact cccagtcacg ccagctgact ttgcgagtgt tctttgtcag tcactttatc 8580
 25 ttattttatt tatttttatt tttttgaaat ggagtttcgc tcttgtcgcc caggctggag 8640
 tgaaatggcg cgatcttggc tcaactgcaac ctccccctcc tgagttcaag cgattctcct 8700
 gcctcagcct ccagagtacc tgggattaca ggcgcctgcc accaagccca tcgaattttt 8760
 gtatgcttag tagagacagg gtttcgccat gttggccagg gtggtcttga actcctgacc 8820
 tcagggtgatc cgccacactt ggctcccaa agtgctggga ttacaggcgc gagccactgt 8880
 30 gcccagccca cttcatctta ccgtagttag ctccttagag tatgaaaaaa taggcttagg 8940
 gcatcccaaa gtccctctta tgtctgagag ctgaggctgg ctgtcaaaga ggaactaagg 9000
 atgccaggga ctttctgctt aggacccctc tcatcacttc tccaacgctg gtatcatgaa 9060
 ccccatctta cagatgatgt ccactagatt aagaatggca tgtgaggca agtttccacc 9120
 tgagagtcag ttttattcag aagagacagg tctctgggat gtggggaatg ggacggacag 9180
 35 acttggcatg aagcattgta taaatggagc ctcaaaatcg cttcaggga ttaatgtttc 9240
 tcctgtgtt tttctactcc tcgatttgaa caggccattt tccaaataaa gccatgccct 9300
 ctgcaggaac acttccttgg gttcagggga ttatctgtaa tgccaacaac cctgttttcc 9360
 gttacccgac tcctggggag gctcccgag ttgttgaaa ctttaacaaa tccatgtaag 9420

tatcagatca ggttttcttt ccaaacttgt cagttaatcc ttttccttcc tttcttgtcc 9480
 tctggagaat tttgaatggc tggatttaag tgaagttgtt tttgtaaatg cttgtgtgat 9540
 agagtctgca gaatgagggg agggagaatt ttggagaatt tggggtattt ggggtatcca 9600
 tcacctcgag tatttatcat ttctgtatgt tgtgaacatt tcaagtcctg tctgctagct 9660
 5 attttggaa atactatatg ttgttaatga tatcatgcag cagacgtgca tctgaatggg 9720
 ctggctctag gagctagagg gtaggggctg gcacaaagat gcatgctgga agggtccttg 9780
 cccataagaa gctgacagcc aaggctaggg gagttctgtc ttctctgcat caggtcacct 9840
 ctctcacctc tgtcactgcc ccatcagact acaatgtctg caggctcttc tccctgagt 9900
 gtgagctccc tgagcaaagc aggatgctgc ccttccctt tgtattcctg gctcctggct 9960
 10 tcagtgcctg gacataagta tgggcataat aagtgtcccc caaatgagac attgaggatt
 10020
 cttcaaatgc acaggaccgt gatgtgagtt aggacggagt aaggacgatg ggatgtggct
 10080
 caggacaatc ctgaggaagc tgcagctgcg gcacgcaggg ccacactgtc atgttcatgg
 15 10140
 accctagact ggctttgtag cctccatggg ccccttccat acacaaatat taaaaattat
 10200
 atttcatgac tgcattggta taaagatgaa tataatccag accagattca tgattattca
 10260
 20 tacattttta gtgtattaac ttttaattct gcttttaaaa taaattaaaa cattctaata
 10320
 tgcccttaag agtatcccag gcccaggcca ctgagcctac tgtggttcat ggataagttg
 10380
 gccctggggg catgtgtgtg catgcatgtg tgtgcacatg catgatgagc cgggccttga
 25 10440
 aggggtggtaa gatttgggtg tgtagaccaa tggagaaagg catttggggc agtgatgatg
 10500
 ggtgggggag ggaacatggt gatgaatgga gctgggtgtg gggagccatg ggagtgggtt
 10560
 30 agggccagcc tgtggaggac ctgggagcca ggctgagttc tatgcacttg gcagtcactt
 10620
 ctgtaaagca gcagaggcag ttggcctagc taaagccttt cgccttttct tgcacccttt
 10680
 acagtgtggc tcgectgttc tcagatgctc ggaggcttct tttatacagc cagaaagaca
 35 10740
 ccagcatgaa ggacatgcgc aaagtcttga gaacattaca gcagatcaag aaatccagct
 10800

	caagtaagta	aaaaccttct	ctgcatccgt	ttataattgg	aaattgacct	gcaccagggga
	10860					
	aagagagtag	cccaggtgtc	tggggcttgt	tcccattaga	tcttcccaa	ggggtttttc
	10920					
5	tccttggtgg	ctggcctgtg	gggcccctct	ccaggaggca	ttggtgaaga	aactagggga
	10980					
	gctggttgcc	acagacagtg	atgtactaat	cttctctggg	aagacagaag	aaaagtcccc
	11040					
	agggagaagt	actacagact	tggccttagg	gacagctagg	ggtgcagatt	gctgccaact
10	11100					
	gcattttttc	tgaagttggc	catatggttg	cagtgaatgg	atztatagac	agagtatttc
	11160					
	tgtgcatata	agagcaatta	cagttgtaag	ttgatatgga	taagtgaag	ttaagcactt
	11220					
15	ctttctaaaa	agagaatgca	attcattttc	ccctaatacat	ttcaattagt	ctgatgggca
	11280					
	tttgaacttg	ttgtctttta	aaagtgaagt	ctttacctct	gatctggtaa	gtatccaggc
	11340					
	aattttcttg	gtgccaccca	ggaggtatct	ggggagtggg	cattttctga	ctgaggcatt
20	11400					
	ggctgccata	gcatcagagc	agccttccag	gcagtggcct	ggcaagggga	cagaggctgg
	11460					
	tgggagcagc	tggctgagtg	cagccagtaa	tggcatgtgc	atggctctga	gagaatgtag
	11520					
25	aagcaataat	gaagccgata	aaagctggtc	tgcattttat	tattatcatg	cgccggtggt
	11580					
	tctaaacaat	gtcagtgata	aattactcct	ccccatcatg	gaccaatggc	tgccactgct
	11640					
	ccagggaagt	gctttttatt	ccgtttggtg	tttagggagg	gatggagtgg	gctggccttt
30	11700					
	gctgaaaggc	ctaccagttt	gttttctatt	tggcaaaaga	agaaatgata	aagt
	11754					
35	<210> 2					
	<211> 21					
	<212> DNA					
	<213> Artificial Sequence					

<220>

<223> Description of Artificial Sequence:

Oligonucleotide Primer

5

<400> 2

atttaggtga cactatagaa g

21

10 <210> 3

<211> 446

<212> DNA

<213> Artificial Sequence

15 <220>

<223> Description of Artificial Sequence:

Oligonucleotide Primer

<400> 3

20 cttgtttttt ccccggttct gttttctccc cttctccgga aggcttgta aggggtagga 60
gaaagagacg caaacacaaa agtggaac agttaatgac cagccacggc gtccctgctg 120
tgagctctgg ccgctgcctt ccagggtcc cgagccacac gctgggggtg ctggctgagg 180
gaacatggct tggtggcctc agctgaggtt gctgctgtgg aagaacctca ctttcagaag 240
aagacaaaca tgtcagctgc tgctggaagt ggcctggcct ctatttatct tcctgaccc 300
25 gatctctgtt cggctgagct acccacccta tgaacaacat gaatgccatt ttccaaataa 360
agccatgcc tctgcaggaa cacttccttg ggttcagggg attatctgta atgccaacaa 420
ccctgtttc cgttaccgga ttctgg 446

30 <210> 4

<211> 571

<212> DNA

<213> Homo sapiens

35 <400> 4

ttcntggttc cgtttttttt ttcctttcag gtgtcgtgaa aagcttgaat tcggcgcgcc 60
agatatcaca cgtgccaagg ggctggctca ctgatatggc gatgctcccc tatctcatc 120
ctgtgtgtgt ttagccaggc aactgttgat catcaatatt atgataacgt ttctccactg 180

tcccattgtg cccacttttt tttttttttt gaggttactt actaaataaa aataaaacac 240
tatttctcaa tagacttgaa gcttcaagat ttcctggtgg acaatgaaac cttctctggg 300
ttcctgtatc acaacctctc tctcccaaag tctactgtgg acaagatgct gagggctgat 360
gtcattctcc acaaggtaag ctgatgcctc cagcttcctc agtagggctg atggcaatta 420
5 cgttgtgcag ctactggaaa gaaatgaata aacccttgct cttgtaatgg tgggaaggg 480
gagggaggta gtttgaatac aacttcactt aattttactt ccctattcag gcaggaattg 540
ccaaaccatc caggactcca atatgcaacc t 571

10 <210> 5
<211> 428
<212> DNA
<213> Homo sapiens

15 <400> 5
gtcagtaaag agacctgatg cattggactg ttgcaatgga acctgtttta agatcttcaa 60
agctgtattg atatgaagtt ctccaaaaga cttcaaggac ccagcttcca atcttcataa 120
tcctcttgtg cttgtctctc tttgcatgaa atgcttccag gtatttttgc aaggctacca 180
gttacatttg acaagtctgt gcaatggatc aaaatcagaa gagatgattc aacttggtga 240
20 ccaagaagtt tctgagcttt gtggcctacc aaggagagaa ctggctgcag cagagcgagt 300
acttcgttcc aacatggaca tcctgaagcc aatcctggtg agtagacttg ctactggag 360
aaacttcaag cactaatgct ttcggaatgt gaggcctttc cttggacagc atgactttgt 420
tttgtagc 428

25 <210> 6
<211> 213
<212> DNA
<213> Homo sapiens

30 <400> 6
tgttaaactc aagattgtga acgagtttta attcacttgt ttatttccaa tagagatttc 60
aggtttacat ttgaattcag aaacaaagtt ttctttctca ttacagagaa cactaaactc 120
tacatctccc ttcccagca aggagctggc cgaagccaca aaaacattgc tgcatagtct 180
35 tgggactctg gccagagg taagttgtgt ctt 213

<210> 7

<211> 1402

<212> DNA

<213> Homo sapiens

5 <400> 7

ttcattgcnt gacacttttac tgagaccaag atagggaact tcacatacca gaccttttct 60
cccaaggcgg aagagggctg ttcaatttct aactagagt tcggggagtt ttagaaatga 120
gccagttgtc gaggatgaga gcagttcctg ataggctcaa ccacaatgag atgtagctgt 180
tcagagaaag cattcttata tataaactgg aagataatcc cggtgaaaca aagcccagcc 240
10 ccaggggctt cactaactcc aggctgtgct tctcaaactt tagtgagcat aggaatcacc 300
tgggcatctt gtgaagctgt agatttgaat tctgcaggtc ggcagagggg tctcagaatc 360
cgcatttcca acaatgtctc cagtaatgct gatgctgctc gtccctggac cacagattgg 420
gtagccaggt tctggcaagc tcatcccaag gctttgagat gacatcagac aaaatatgtt 480
ctgggacatg gcttttgaga ggtcaagaaa ataagatgtt tctttctctt ctcatcccca 540
15 acccttgac tgcccttttc tccctcccc taccctcctt tctgtcccca tccctgacgc 600
cagctgttca gcatgagaag ctggagtgac atgagacagg aggtgatgtt tctgaccaat 660
gtgaacagct ccagctcctc cacccaaact taccaggctg tgtctcgtat tgtctgcggg 720
catcccgagg gaggggggct gaagatcaag tctctcaact ggtatgagga caacaactac 780
aaagccctct ttggaggcaa tggcactgag gaagatgctg aaaccttcta tgacaactct 840
20 acaagtgagt gtccatgcag accccagccc tgtccccaac cccatccctc ccttagttct 900
ggccttggcc tgtgtcatct cctccctctg tagcagcgtt agatgtctac atgcccattt 960
gcccaccaga ctgagctctt cctagaggag agaggcttct cttgaatagc tacctgtccc 1020
cagttctctg aatgcagcct ggcacatctc aggtgcacag tagtgtttat caatggaatg 1080
aatgattgac agccaacctt ctggttttct gggggatgtg gaagggtggc ttccaggggtg 1140
25 atcaagaatg agataatggc agaaggacaa atcctgcaag atctcactta tatatggaat 1200
atatgtaagg tagaaagtgt cagtttcaca tgatgaataa gttcctggga tcttgatgta 1260
catcgtgatg actatagtta gtaacactgt atagtatact tgaaatttgc taagagagta 1320
gatccgaagt gttcacacta cacaaaaaag gcaactatga ggtgatggat ttattaacaa 1380
gcttggattg nggtgatcct tt 1402

30

<210> 8

<211> 1808

<212> DNA

35 <213> Homo sapiens

<400> 8

cctanttttg tattttttag aaagacaggg tttttccatg ttggtcaggc tggctctgaa 60

ctccacccct cagggtgggtc gcccgcccttg gcctcccaaa gtgctgggat tgcaggcatg 120
agccactgcg cccagcccca aattttgggtt tttgcttgaa aactgaggtc tgaattcagc 180
cttctgggttg cccctcaaga gtcagtttaa atgttggtca tgtagttgt cagtgaanaac 240
aatggtgagg ctggcatgag agtgtgaacc tggatgggag ggcttggtct tcacgaaaac 300
5 atttttccag atcagctcag tcgtgagtta tccgtcattg acgttataat aagctctgat 360
tatttatcaa gcatcattct ttatagatat ctgagttta tctgagataa tcttctccac 420
atctctccac atagatgta tgaattttac ttttacagag gagccaactg aggctcagat 480
aagttactta ttatatgact agtagtgna gagctgggtt ttcaaactaa gaactntctg 540
gtcccaaagc ccttgtaagt ttctatcagt atatgaccat gcatatgagc atttgtctct 600
10 cctcttcttc atagctcctt actgcaatga ttgatgaag aatttgaggt ctgctcctct 660
ttcccgcat atctgaaaag ctctgaagcc gctgctcgtt gggaagatcc tgtatacacc 720
tgacactcca gccacaaggc aggtcatggc tgaggtaagc tgccccagc ccaagactcc 780
ctccccagaa tctccccaga actgggggca aaaaactcaa ggtagcttca gaggtgtgag 840
ctaagtatac tcacggctct tctggaattc ccagagtga aacctcaagt ctgatgcaga 900
15 ccagagctgg gccagctccc cagtcgtggg tatagaatca tagttacaag caggcatttc 960
ttggggatgg ggaggactgg cacagggtct ctgtgatggg gtatcttttc agggaggagc 1020
caaagcgctc attgtctgtg cttctccttt ttctgcggtc cctggctccc cacctgactc 1080
cagggtgaaca agaccttcca ggaactggct gtgttccatg atctggaagg catgtgggag 1140
gaactcagcc ccaagatctg gaccttcatg gagaacagcc aagaaatgga ccttgtcccg 1200
20 gtgagtgtcc ctcccattat taccatgtgc ctgcttgata ctggagaggt gaggttcttg 1260
tcactttccc aggtgtgagt gaggtgagaa ttctttcagt ttatctagct gggggaatt 1320
gtagttagca tagctaaaag tcacatggg caccaacctc tccatgaagt acaggccatg 1380
gtgcaagaga taacgcntgt gcatatnagc catcccatgc ccacntcanc ggtccaaata 1440
agcagttttc tgcaaaaactt agtgagggtt ggtgttttga agtgagggtt agtaattgca 1500
25 gtaccctatt ttcctttttg gctgcagcct ctgagccagc cacagcatct ccctgtgtct 1560
tggtaggttt tggaaaagag tgtgggagca aaagcatgat gttacatgta gactggcctg 1620
agatactcat tctcagggca ctgtgtgaat gatgagctgc tgttactgtg tggaggggaa 1680
atgcacttag tgcttcagag ccacttgaaa gggataagt ctctagagac aattggattc 1740
aaatgtggag caggctgagc aagaacagaa tgtctccttt gcctgagcct gagtgtggt 1800
30 aatcacat 1808

<210> 9

<211> 3215

35 <212> DNA

<213> Homo sapiens

<400> 9

acatggcaat ggcattcatt aggaatctag ctgggaaaat ccagtgtgta tgcttgaaa 60
tgagggatct ggggctggag agaaaggcat gggcatgcct tggagggact tgtgtgtcaa 120
gctgaggacc ttacttttaa gctctagggg accaggcaag gggagatgta gatacgttac 180
tctgatgggg tggatgaatt gaagaaggat gaggcaagaa tgaaggcaga gaccagggag 240
5 gaggctctcc aagtggccaa ggcataaagc aagaaatgag gcctggtgac tgcttagtg 300
cagagcagtg aaagagaggg aggcatacaa gtgagtctcg atttctagct ggggtgggtg 360
tagcgatgtc cagtaggcca gtggctactg aggtctgcag tggaggaggg tggttgggct 420
ggagacagat gatgaggag tcatcagcct gtgggtggaa gaaaaggga cctcttccaa 480
ctgttttctt tgcttcttcc ctctctttct cttttttttt ttttttgac agagtcttgc 540
10 tctgtcaccg aggtgaaat gcagtggcat gatcttggct caccacagcc tccgcctcct 600
gggttcaagc aattctcctg tctcagcctc cagagtagct gggattacag gcacatatca 660
ctgtgcccgg ctaatttttg tattttcagt ggagatggga ttccaccatg ttggtcgggc 720
tggaatgaac tcttgacctc aagtgatcca cctgcctcag cctcccaaag tgttgggatt 780
acaggcattg agccaccggg cccggccttt ctccctctc ttaaagagt tttatttaat 840
15 tccacaaaca tgagcttgtc acccctgtg gcctggcatc tctacacga ggtgatggct 900
gaggcttctg ctctgctgg ggtagctctg atcttctgc tttctctggc actgtctacc 960
catgttgctt caccceacag gtcccagggc acctctctcg ggcaagtctt ggaacctctt 1020
gacactgatt tgctctcttt tctgagctgc ttttagccac ccctcctcg gacctgtttt 1080
ctctctgcct ccacctctgc gggcagtctt aggtctcctg cccctcacga gcacccaga 1140
20 gaggccacgt gctcagtgt ctcagtgggc gcatctttct agtcttgcta ttcttttttg 1200
ccatgttggt cagaaacat actgggcagg gccgacttca ccctaaaggc tgcgtctctt 1260
cactctgctt ttgtttgttc caaataaagt ggcttcagaa ttgctaacc tagcctctgt 1320
gaacttgta ggtacaattt tgtgtctgtt atgttaacaa aaatacatat ataccttctt 1380
ggtgatgta taaattgcta ttctctattg gaaagcaatt tggaatgaaa atttaaagaa 1440
25 ccatttttaa atatgctatc ctgcgtacct ccattccacc cacccccagg gatgtagcct 1500
actgaaataa ttttaaagaa gtcaccatat gagagaaaat gttattgcta tattgttatt 1560
gtgagaaatt ggaaatagac taaatgttca gcactatagg aataattaat gaaattacat 1620
atactctata caatcattat gctgccattg aaataataaa tacaaggcg caagggggga 1680
aaagcttata atgttagtga aactaagact gatTTTTTTT taaagcagca gttttcagac 1740
30 ccttgagac tccaattcgg tagaaccaga gcttcactt ctctgtcgaa gctgtgacag 1800
gagttgcaaa tgctctcct ttttgctgag tttgcagctg ctgtttttcc ggcagcacat 1860
ctgtgcaggc ctctgcctcg gccctctcg atctgctgat tgagcagcg attgatctgt 1920
ccttctcttt cgtgttgacc catgtgagga accaactggc aagggaacaa gaaatggaaa 1980
taggcctcct ttgcatcatg acctgtacat cctgcaattg gaaaagattg tactttagtt 2040
35 ggtttaacca gcagcattat ttttctaaac taagcagtaa gaaggaaata ggttttatgt 2100
gggatcaaca gactgggtct caaaagagga aggtgataga acacagtggg gagggggagg 2160
tgactagaa acagagggcc tatgctttca ttctggcttt gctacttaat agctgtgtga 2220
cccaatctta gagacttaac ctctctgaac ttccattttc tcatgtataa aatgggaaat 2280

attaaaggat actcactggg ctggtggctt gtgcctgtaa tcccagcact tggggaggtt 2340
 gaggtgggag gatcacttga gccaggtgt tcaagaccag cccaggcaac atggcaagac 2400
 tctgtctcta tgaaaaaatt aaaaattagc caggtgtggt ggtgtgcacc tgtagtctta 2460
 gctacttggg aggtgagat gggaggatca cttgggcttg ggaggtcaag gctgcggtga 2520
 5 gctgtgattc catcactgca ctccagcccg ggcggcagag cgagacactg aatccaaacg 2580
 acaacaacaa caaaaggcaa aaaaataaaa gtgccctctt tatggagttg tgtaagggtga 2640
 agcatataca ctattcaaca tagtaactat ataaaggaa gattgttgtt gttactgtag 2700
 ttaataccat taagtgtgat gtttcgtata gtggaaagca catggactct gaattcagac 2760
 tgggtctgact ttgagtctca gctccacatc tagtaatact atgaccaagc cctgggttaa 2820
 10 atcatgtttt tttttcttca gccttagtct tctcacatat aaaataggga cactgtcatt 2880
 tacctcagtt ttctgtgagg ataaaacaac gacagtgtat atgcaagtat ttgttaaatt 2940
 ttgtagtgtc cctcaagatt tagttggtgt ttactacttg tactttctca ctggaatggc 3000
 agatgctgtt ggacagcagg gacaatgacc acttttggga acagcagttg gatggcttag 3060
 attggacagc ccaagacatc gtggcgtttt tggccaagca cccagaggat gtccagtcca 3120
 15 gtaatggttc tgtgtacacc tggagagaag ctttcaacga gactaaccag gcaatccgga 3180
 ccatatctcg cttcatggag gtaatctgtt gctgg 3215

<210> 10

20 <211> 9181

<212> DNA

<213> Homo sapiens

<400> 10

25 tttggctcctt ggcaaagttc acaaatactg gatttgataa caaaaggnac ttaataaatg 60
 ttagttgagt ggttgaatga gtaaataaac ctctagcttt agtaaattaa ctctagcctt 120
 attctatata ggctcaagag aatatttcta cccattttct tctaggtttt cctatctcag 180
 tgactaatgg tagcaaagca ttcccttaaa aaggcattat ttgtgaaact tatctaaaa 240
 cgaattcggg tccaattaaa tttttgaaat tttatattaa aaattatatt agtagggatg 300
 30 ggtaagaggt gttttggtct ggttggttg ttagttgcta tgactcagaa ttgctaagaa 360
 aacagaaaag taagataaga tcattgtttt aacctctttt cctccacaaa atcaataaat 420
 aacatatccc taaattactc ttagaatttc tcttaaattg cagtgaaaaa ccaaatcct 480
 tcattcttyg ttgaaggttg gaaaactacg ttagagagga ttagagagag aggatgagca 540
 atcgtgtagt cagcccttgc ctctagtgt aggatttgtc tcagccactg cttgttgtcc 600
 35 tggctgccaa cgttctcatg aaggctgttc ttctatcagt gtgtcaacct gaacaagcta 660
 gaacccatag caacagaagt ctggctcatc aacaagtcca tggagctgct ggatgagagg 720
 aagttctggg ctggtattgt gttcactgga attactccag gcagcattga gctgccccat 780
 catgtcaagt acaagatccg aatggacatt gacaatgtgg agaggacaaa taaatcaag 840

gatgggtaag tggaatccca tcacaccagc ctggctcttg ggaggtccag agcacctatt 900
 atattaggac aagaggtact ttattttaac taaaaatttg gttagaattt caacaacaac 960
 aaaaaaactc aacttggtgt catgattttg gtgaaatttg tacatgactt gctggaaggt 1020
 ttttcatagg tcataaaata acagtatctt ttgatttagc atttctactc aagggaaatta 1080
 5 attccaggaa ttttggtggc aggcacctgt aatcccagct actcgggagg ctgaggcagg 1140
 agaattgctt gaaccagga ggcagaggtt gcagtgcgt aagatcgcat cattgcactc 1200
 cgcctgggc aataagagt aaactccatc tcaaaaaaaa aaaaagatac aaaaatagaa 1260
 aaaggggctt ggtaagggta gtagggtttt gggcaatttt tttttttttt tttttttatt 1320
 gtatggttct aaaggaatgg ttgattacct gtggtttggt ttttaggtact gggaccttg 1380
 10 tctcagagct gacccctttg aggcacatgc gtacgtctgg gggggcttcg cctacttgca 1440
 ggatgtggtg gagcaggcaa tcatcaggtt gctgcagggc accgagaaga aaactggtgt 1500
 ctatatgcaa cagatgcctt atccctgtta cgttgatgac atgtaagtta cctgcaagcc 1560
 actgttttta accagtttat actgtgccag atgggggtgt atatatgtgt gtgcatgtgc 1620
 atgcatgtgt gaatgatctg gaaataagat gccagatgta agttgtcaac agttgcagcc 1680
 15 acatgacaga catagatata tgtgcacaca ctagttaaacc tctttccttc tcatccatgg 1740
 ttgccacttt tatcttttta tttttatttt tttttttgag atggagtctc gctctgacgc 1800
 ccaggctgga gtgcagtggc tcgatctcgg ctactgcaa cctttgcctc ccgggttcaa 1860
 gctattctcc tgccctagcc tccacagtag ctgggactac aggtcatgc tgccacgccc 1920
 ggctgacttt ttgtatttta gtagagacga ggtttcacca tgttaccag gctagacttc 1980
 20 aactcctgag ctccaggcaat ccaccctcct tggcctccca aagtgtctggg attacaggtg 2040
 tgagccactg caccagccc accactttaa ttttttacac tctacccttt tggtaaaaat 2100
 ttgctcaatc tgcaagctta aaatgtgtca tgacaaacac atgcaagcac atactcacac 2160
 atagatgcag aaacagcgtc taaacttata aaagcacagt ttatgtaaat gtgtgcactt 2220
 cttctcccta ggtggtaaac cacatttcaa aacaaccaa ataaaactga acaaagcttc 2280
 25 ttcctcttag actttttaga aaatctttca gtgctgagtc actaagctgc caagttctca 2340
 ttgtgggaac tatgcctttg gatgtaatga tttcttctaa gacaatgggc ggaggtgtag 2400
 ttattgcaga catctgaaat atgtaatgtt tcttcagat tctggaaatt ctcttattct 2460
 ctgtggttg tgggtggtgt gggatgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg 2520
 tgtaggatc aggatgcggg aggagctggg ttctgcttgt attggttctc tgttttgcat 2580
 30 tgaatagtgt gtttccttgt atggctatct atagcttttc aaggcacca gaaattatcc 2640
 tgtttttcac cttctaaaca attagctgga atttttcaaa ggaagacttt tacaagacc 2700
 cctaagctaa ggtttactct agaaaggatg tcttaagaca gggcacagga gttcagaggc 2760
 attaagagct ggtgcctgtt gtcattgtag gagtatgtgc ctacatggtt aagctttgac 2820
 gtgaacctca agttcagggt ccaaaatctg tgtgcctttt tactttgcac atctgcattt 2880
 35 tctattctag cttggaatct gaaacattga caagagctgc ctgaaatgta tgtctgtggt 2940
 gtgattagag ttacgataag caagtcaata gtgagatgac cttggagatg ttgaactttt 3000
 gtgagagaat gagttgtttt tttgttttg ttttagtac ttttaacataa tctaccttta 3060
 gtttaagtat cgctcacagt tacctagtta ctgaagcaag ccccaaaga aatttggttt 3120

ggcaacactt tgtagcctc gtttttctct ctacattgca ttgctcgtga agcattggat 3180
catacgtaca ttccagagtc tagagggcct gtccttctgt ggcccagatg tgggtgctccc 3240
tctagcatgc aggtcagag gccttgccc atcacctgg ctcacgtgtg tctttctttc 3300
tccccctgtc ctccctggg gcctccagct ttctgcgggt gatgagccg tcaatgcccc 3360
5 tcttcatgac gctggcctgg atttactcag tggctgtgat catcaagggc atcgtgtatg 3420
agaaggaggc acggctgaaa gagaccatgc ggatcatggg cctggacaac agcatcctct 3480
ggtttagctg gttcattagt agcctcattc ctcttcttgt gagcgtctgg ctgctagtgg 3540
tcctcctgaa ggtaaggcag cctcactcgc tcttccctgc caggaaactc cgaaatagct 3600
caacacgggc taagggagga gaagaagaaa aaaaatccaa gcctctggta gagaaggggt 3660
10 catacctgtc atttccctgca atttcatcca tttatagtgt gggaagtga ggcccagaga 3720
ggggcagtga cttgcccag gtcaaccag ccgggtagca gctaagtagg atgagagtgc 3780
agggttcatg ctttccagat aaccacatgc tcaactgtgc catgctgtct cattggtagt 3840
ggttcatggc agcatctgaa agctatttat tttcttagat atattgggtg gcgattcttc 3900
ctaagtttct aagaacaata atcagaagga tatatattgt tgcaggtag actgtctgga 3960
15 agcagaggct gaaatagagt ttgatgtatg ggtatttatg agggctcaat acctatgaag 4020
agatatggaa gatgcaggat tgggcagagg gaggagtga actgtgatat agggccaacc 4080
ccgtggggca ctctanagaa tatgcagctt gttggagtgt tnttcatcg agctgaaaca 4140
tccagccctt tgtgctcccc caaggcctcc ctctgacac cacctacctc agccctctca 4200
atcaatcact ggatgtgggc tgccctggga aggtcgtgcc ccagggccta catggctctc 4260
20 tgctgctgtg acaaaccag agttgctgat gcctgaggcc gtctactgac agctgggcaa 4320
caaggcttcc ctgaatggg actctgggca gtgcagttt gtgtctgaac catacattaa 4380
tatatttata tccgaatttt ctttctctgc aagcatttca tataaagaca catcaggtaa 4440
aaataaatgt ttttgaagca aaaggagtac aaagagataa gaactaacta atttaatact 4500
agttaccatc tgttacaaat agttcctact gattgccaag gactgtttta acacatcaca 4560
25 tgggcttctt cttctatcct cactaacctt ttaacagac aaggaaatga ggctcaggaa 4620
ggtaaggac ttatttgagg ttccacagta ggatacagtt cttgctaaaa gcaaccctc 4680
cctcatgctc tgttatctaa ctgcaaggg aaggtcagt gcagaggtag tggtoecatg 4740
gttggtgcat aagagctgct ctgagacaac tgcatgctgg tgggtcctgc agacatgtac 4800
ccatcagccg gagataggct caaatatcc acaagagttt ggatgattgt gggaatgcag 4860
30 aatccatggt gatcaagagg gaaagtcaag ttgcctggcc attttccttg gcttttagac 4920
agaaaagtta cgtgggatat tatctcccac agctcttctg tggtgccacc agtcatagtc 4980
cttatataag gagaaaccag ttgaaattac ctattgaaga aacaaagagc aaactcgccc 5040
actgaaatgc gtagaaagcc ctggactctg ttgtattcat aactctgcca ttatttttct 5100
gcgtagtttt gggtaagtca cttatcttct ttaggatggg aatgatcagt tgcctcatca 5160
35 gaaagatgaa cagcattacg cctctgcatt gtctctaaca tgagtaggaa taaacctgt 5220
ctttttctg tagatcatc aagtgagtgc ttgggattgt tgaggcagca catttgatgt 5280
gtctcttctt tccagttag gaaacctgct gccctacagt gatccagcg tgggtgttgt 5340
cttctgtcc gtgtttgctg tggtgacaat cctgcagtgc ttcctgatta gcacactctt 5400

ctccagagcc aacctggcag cagcctgtgg gggcatcacc tacttcacgc tgtacctgcc 5460
ctacgtcctg tgtgtggcat ggcaggacta cgtgggcttc acactcaaga tcttcgctgt 5520
gagtacctct ggcctttctt cagtggctgt aggcatttga ccttccttgg gagtcctga 5580
ataaaagcag caagttgaga acagaagatg attgtctttt ccaatgggac atgaacctta 5640
5 gctctagatt tctcagtgaa tcttggttga attgaattga atggaatttt aaattgttta 5700
cctttagtct tctcagtgaa tcttggttga attgaattga atggaatttt aaattgttta 5760
agactgcacc ttgaactggg ctggggataa atggcattga ggaatggctt caggcaacag 5820
atggccacaa atagaactga aaactcttga tgtcagagat gacctctctt gtcttccttg 5880
10 tgtccagtat ggtgttttgc ttgagtaatg ttttctgaac cctcgtacag agcaggggga 6000
gtgctcacc ccacaaatc ctgacttggg tgcaggttgg cctcagtcctt ggttcctag 6120
tatcttggag agtggttggg cctcagtcctt tctcagtcctt ggttcctag 6180
atcagggaag ctaagagtg ctaacagtg gctcagtcctt tctcagtcctt ggttcctag 6240
gcacagcag ccccaacag cgcagtcgtg tgggggaaca ggttccttga gcttcctag 6300
15 ctcagaagac tgtgggtatg taaaagtgt taaagtgtt tatgttctac tgtatagca 6420
atctttgtaa acataaagt tacaagtgtt atcattttat atgttacttg gtatccacc 6480
actcccttaa agggactct tggataattt acactagaag agatagaaa atgagactga 6540
tgcaaatca aatttctcca ggtatattt tctcagagc cctgctgtct cctgtggctt 6600
20 ccaggaaatg gataggtgac ttgcccctt ttgaggagca gggcatttga gtcagtggtt 6660
ttgggttttg ctgtgagtc ctgtgagtc ttgcccctt ttgaggagca gggcatttga 6720
acaacctgtt tgagagtcct gtcagagtc ttgcccctt ttgaggagca gggcatttga 6780
caggtacact gcttgggca tctgttggg aaatagact ttgagtcctt gtcagagtc 6840
25 tgtgctagaa tcttgcagc gcatgggctt cctggggaag agtacaattt ttatacat 6900
tagtaaacag atagtccaag aactgtgtgc gaagtagtga ctataataac cagcaatttt 7020
tacagcactt gtttcttga aactgtgtgc gaagtagtga ctataataac cagcaatttt 7140
tgcttcattt aattctcaca aggtactctt aagtaaccag ggtcaataag ccttgggca 7200
30 caaatgagag aactgtgact caaagagctt ggttacctt tactagctct aaggcctgcc 7260
aatgttggtg cgtggagtc ttctgtattt ctgtgtctt tactagctct aaggcctgcc 7320
tctcccaat gctcagtcac aggtgtttaa taattaaata tactagctct aaggcctgcc 7380
aggttctgtt tctcagtcac aggtgtttaa taattaaata tactagctct aaggcctgcc 7440
tgtgatttaa ttacattctt accaagtcac ccttcttggg ttcacctctt gacccctcc 7500
taataataa ctcttcttg caagatttaa ccttcttggg ttcacctctt gacccctcc 7560
35 gagatcaaat tcatgaaat atttattact cctgctgaa ccttcttctt gacccctcc 7620
taaggaggtg atcagattt tggatttaa ttctgagctt taacttactg gctgaggagc 7680
cttggatagg ctcttatcc ctgatttcc tcatctctaa aatgggagtg gcacctgcc 7680

cgtgggttgt tggaaggact tacagagggtg cagaatgtac gttgtacata gcaggtttca 7740
 gcaaagtta gctccctctt tccccacatc cattcaaate tgttccttct ccaaaggatg 7800
 tgtcaaggag gaaatggacc tggctgggaa accctcagaa tactgggatg atgctgagct 7860
 tggctcatat ctgtgctttg ctttcaggcc agtacggaat tcccaggccc tgggtattttc 7920
 5 cttgcaccaa gtcctactgg tttggcgagg aaagtgatga gaagagccac cctggttcca 7980
 accagaagag aatatcagaa agtaagtgtt gttgacctcc tgctctttct ttaacctagt 8040
 gctgctgcct ctgctaactg ttgggggcaa gcgatgtctc ctgcctttct aaaagactgt 8100
 gaaaccactc caggggcaga gaaatcacat gcagtgtccc ttccaaate ctccatgcc 8160
 atttatgtcc aatgctgttg acctattggg agttcacggt ctcgatccct gagggacatt 8220
 10 ttctttgttg tcttggcttc tagaagagta tcttttactt gccccctccc aaacacacat 8280
 ttcatggtct cctaacaagc tagaagaaag aggtaaagac aagcgtgatt gtggaaccat 8340
 agcctcgctg cctgcctgtg acatggtgac ctgtgtatca gcctgtgtgg gctgagacca 8400
 agtggctacc acagagctca gcctatgctt cataatgtaa tcattacca gatccctaatt 8460
 cctctcttgg ctcttaactg cagacagaga tgtccacagc tcatcaaagg ctctgccttc 8520
 15 tgggttcttt gtgcttagag tggcttcta aatatttaatt aggtcccttt tctgccagtc 8580
 tcttctgtgc ccatccctg attgcccttg gtaaaagtat gatgccctt agtgtagcac 8640
 gcttgcctgc tgttcctaatt catcttctcc tacctcctct ttacacctag ctctgtttc 8700
 agtcacctag aaatgtcac agtcgctgga atatgtcatg ttcttcaca cctccatgcc 8760
 tttgtaggta ctgtttgtc tcacaggaga actttctctc taacttgctt atcttctcaa 8820
 20 ctctccttt ctctccaaga tctagtccg gatccctcc cctgagcatc cctccttgg 8880
 tctcaggtag tcagtcactc tctgcctga acttccatgg cagtgaaag aaaatctttt 8940
 tattttaaaa caattacaga ctcaaga gtaatacaaa ttacatgagg gggttccctt 9000
 aaacctttca tccagtttcc ccaatggtag cagcatgtgt aactgtagaa tagtatcaaa 9060
 accatgaaat tgacataggt acaattcaca aaccttcttc agatttact agctttatgt 9120
 25 gcgctcattt gtgtgtgtgt gtgcgtattt agttctatgc aattttatca tgtgtgaatt 9180
 c 9181

<210> 11

30 <211> 578

<212> DNA

<213> Homo sapiens

<400> 11

35 ttagatctat ccaagttgtg tgtgtcaaca gttcattcct ctntcactgc tgagtgtgt 60
 tccctgggag ggggtgatca cagttccatg gcanttttta gatgtatttt ttaaagagct 120
 ttcagcatcc tctattttta ttgtntcatc aagtcctttt tcccaataga ctctgaatgc 180
 tcctttatca tcgtanttcc catcaccaac atcagtaccc aaataggccc taaataaaca 240

tttatangcc tctgcctgc ctgagaaacc agggtaggaca tggagagaag gcacttcntg 300
 aaagttcaag cgcagtgcc tgtgtcctta cactccactc ctcagtgcnt ttctgtgggt 360
 tcattttctgt cttctctcct gtcacagtct gcatggagga ggaaccacc cacttgaagc 420
 tgggcgtgtc cattcagaac ctggtaaaag tctaccgaga tgggatgaag gtggctgtcg 480
 5 atggcctggc actgaatatt tatgagggcc agatcacctc cttcctgggc cacaatggag 540
 cggggaagac gaccaccatg tcaatgaggg cgggtagc 578

<210> 12
 10 <211> 384
 <212> DNA
 <213> Homo sapiens

<400> 12
 15 tagaagctga ataatatcaa tgatatactg aagtcctgt tcttgatctt cccacatttt 60
 tgcctgggac gagggctcat cgacatggtg aaaaaccagg caatggctga tgcctggaa 120
 aggtttggtg agtgaagcag tggctgtagg atgctttaat ggagatggca ctctgcatag 180
 gccttggtac cctgaacttt gttttggaaa gaagcaggtg actaagcaca ggatgttccc 240
 ccacccccat gccagtaac agggctcatg ccaacacagc tggttgtggc atgggttttg 300
 20 tgacacaacc atttgtctgt gtctctgata gcattagaaa agtaaagggc agttttaagg 360
 taaggaaaaa ggttttgctg gaca 384

<210> 13
 25 <211> 386
 <212> DNA
 <213> Homo sapiens

<400> 13
 30 tggctagctg gctttcatta ctgtttttca cacattaact ttggcctcaa cttgacaact 60
 caaataatat ttataaatac agccacactt aaaatggtec cattatgaaa tacatattta 120
 aatatctata cgatgtgtta aaaccaagaa aatatttgat tcttctctga tatttaagaa 180
 ttgaagggtt gaggtagtta cgtgttaggg gcatttata tcatgttttt agagtntgt 240
 tancaactta atctttcctt ttcagtgtt tgggctcctg ggagttaatg gggctggaaa 300
 35 atcatcaact ttcaagatgt taacaggaga taccactgtt accagaggag atgctttcct 360
 taacagaaat aggtgagaaa agaagt 386

<210> 14
<211> 345
<212> DNA
<213> Homo sapiens

5

<400> 14
tcttgtcctt tgcagtatct tatcaaacaat ccatgaagta catcagaaca tgggctactg 60
ccctcagttt gatgccatca cagagctgtt gactgggaga gaacacgtgg agttctttgc 120
ccttttgaga ggagtcccag agaaagaagt tggcaaggta ctagtgnggc acctgaaagc 180
10 cagcctagtc tcctttggca tcctagacaa tatatacctt atgagctttc ccacacgcc 240
ttagacttca gagctagttt ttccttcattg atanncagca gcacaaaatg cctgagttct 300
ttgtatctgc tttcagangt nggaaaccnt ggtaacgagt gagtg 345

15 <210> 15
<211> 618
<212> DNA
<213> Homo sapiens

20 <400> 15
gtgcctgctc ccaccacacg agtcccttct cctgctttg gtcctcacc agttgtcagg 60
ttatgattat agaattctagt cctactcagt gaaagaactt tcatacatgt atgtgtagga 120
cagcatgata aaattcccaa gccagaccaa agtcaagggtg ctttttatca ctgtagggtg 180
gtgagtgggc gattcggaat ctgggcctcg tgaagtatgg agaaaaatat gctggtaact 240
25 atagtggagg caacaaacgc aagctctcta cagccatggc ttgatcggc gggcctcctg 300
tgggtgtttct ggtataactg tggatggaaa actgttggtc tggcctgagt ggaaaacatg 360
actgttcaaa agtcctatat gtccagggtt gttgtatgat tggcttgtct tccccagggt 420
acagcagagc aaccttgga aagcagaggg aagcttctcc cttggcacac actggggttg 480
ctgtaccatg cctgcagatg ctcccaaata gaggcactcc aagcacnttt gtttcttagc 540
30 gtgattgagg ctggatatgt gatttgatct ttctctggaa cattctttct aatcatcttt 600
gtgttcattc cctgaaaa 618

<210> 16
35 <211> 1329
<212> DNA
<213> Homo sapiens

<400> 16
aaaggaattt caccccaatc ttatactgac ttcaatagag ctttcagaca aaaagttggt 60
ttgtatatac tnatcagtca tgaaaagata attacaacta aatggccttt ttccttcctt 120
atattatttg agaaatttaa ttacataaga aagtactcag aatatgtgag tttcctgcat 180
5 caataagaca ttataataa tgaccntggt tacaatgaa ttgaaagtn actctaattc 240
tttgattcat caagaaataa ctagaatggc aagttaaaat ttaagctggt tcaaagatgc 300
ttcngcantt agaaactcnn ttatctttga tnttctgtcc cncnagcaaa taanacttan 360
tntatntna tancaggatg aaccaccac aggcattgat cccaaagccc ggcgggttctt 420
gtggaattgt gccctaagtg ttgtcaagga ggggagatca gtagtgctta catctcatag 480
10 gtccgtagta aagtcttggg ttcctcactg tgggatgttt taactttcca agtagaatat 540
gcatcattt tgtaaaaatt agaaaatata gaaaagcaaa gagtaaaaca attattacct 600
gaaattatat atgcatattc ttacaaaaat gcaagcccg tataaatact gctcttttct 660
acttaataa ttgtaaacat tattccaagt cagtgcattt aggtgtcatt tcttatagct 720
ggatagtatt ccattaggat atactcttat ttaactattc ccccttttgt agacatttgg 780
15 attatttcca acttgttcac aattgtanac nccaccacac tgaacagcat catccctata 840
tccacatgna cttgtaacag aatacaattc cctaggaagc tggaatgctg gaagtcattg 900
tgatgttctc atggtnacag agaactcttc taganctaan acctctctct gttttaccgc 960
agtatggaag aatgtgaagc tctttgcact aggatggcaa tcatgggtcaa tggaaggttc 1020
aggtgccttg gcagtgtcca gcacttaaaa aataggtaat aaagataatt tctttgggat 1080
20 angtgcctag tgagaaggct tgatatttat tctttgtng agtatataaa tgggtgcctct 1140
aaaataaagg gaaataaaac tgagcaaaac agtgtagtg aaagaatgag ggctttgaag 1200
tccgaactgc attcaaatc tgtctttacc atttactggt tctgtgactc ttgggcaagt 1260
tacttaacta ctgtaagagt tagtttccct ggaagatcta cctcctagct ttgtgtata 1320
gatgaaatg 1329

25

<210> 17

<211> 5352

<212> DNA

30 <213> Homo sapiens

<400> 17

aagtctattt ttaagttggt attgcttttt tcaagtattc ttccttcctt cacacacagt 60
tttctagtta atccatttat gtaattctgt atgctcctac ttgacctaat ttcaacatct 120
35 ggaaaaatag aactagaata aagaatgagc aagttgagtg gtatttataa aggtccatct 180
taatctttta acaggatttt gtgaactttg ccaaggacca aagtgatgat gaccacttaa 240
aagacctctc attacacaaa aaccagacag tagtggacgt tgcagttctc acatcttttc 300
tacaggatga gaaagtgaag gaaagctatg tatgaagaat cctgttcata cgggggtggct 360

gaaagtaaag aggnactaga ctttcctttg caccatgtga agtggttggtg agaaaagagc 420
cagaagttga tgtgggaaga agtaaaactgg atactgtact gatactattc aatgcaatgc 480
aattcaatgc aatgaaaaca aaattccatt acaggggagcag tgcctttgtg gcctatgtct 540
tgtatggctc tcaagtgaag gacttgaatt tagtttttta cctataccta tgtgaaactc 600
5 tattatggaa cccaatggac atatgggttt gaactcacac tttttttttt tttttgttcc 660
tgtgtattct cattggggtt gcaacaataa ttcatacaagt aatcatggcc agcgattatt 720
gatcaaaatc aaaaggtaat gcacatcctc attcactaag ccatgccatg cccaggagac 780
tgggtttccg gtgacacatc cattgctggc aatgagtgtg ccagagtat tagtgccaag 840
tttttcagaa agtttgaagc accatgggtg gtcatactca cttttgtgaa agctgctctg 900
10 ctgagagtct atcaacattg aatatcagtt gacagaatgg tgccatgcgt ggctaacatc 960
ctgctttgat tccctctgat aagctgttct ggtggcagta acatgcaaca aaaatgtggg 1020
tgtctctagg cacgggaaac ttggttccat tgttatattg tcctatgctt cgagccatgg 1080
gtctacaggg tcatccttat gagactctta aatatactta gatcctggta agaggcaaaag 1140
aatcaacagc caaactgctg gggctgcaag ctgctgaagc cagggcatgg gattaaagag 1200
15 attgtgcgtt caaacctagg gaagcctgtg cccatttgtc ctgactgtct gctaacatgg 1260
tacactgcat ctcaagatgt ttatctgaca caagtgtatt atttctggct ttttgaatta 1320
atctagaaaa tgaaaagatg gagttgtatt ttgacaaaaa tgtttgtact ttttaattgt 1380
atttggaaat ttaagttcta tcagtacttt ctgaatcctt agaatggcct cttttagtaa 1440
ccctgtggta tagaggagta tggccactgc cccactattt ttattttctt atgtaagttt 1500
20 gcatatcagt catgactagt gcctagaaag caatgtgatg gtcaggatct catgacatta 1560
tatttgagtt tctttcagat catttaggat actcttaatc tcacttcac ccaataatat 1620
tttttgagtg tatgctgtag ctgaaagagt atgtacgtac gtataagact agagagatat 1680
taagtctcag tacacttcct gtgccatgtt attcagctca ctgggtttaca aatataggtt 1740
gtcttgtggt tgtaggagcc cactgtaaca atactgggca gccttttttt ttttttttaa 1800
25 ttgcaacaat gcaaaagcca agaaagtata agggtcacaa gtctaaacaa tgaattcttc 1860
aacagggaaa acagctagct tgaaaacttg ctgaaaaaca caacttgtgt ttatggcatt 1920
tagtaccttc aaataattgg ctttgcagat attggatacc ccattaaatc tgacagtctc 1980
aaatttttca tctcttcaat cactagtcaa gaaaaatata aaaacaacaa atacttccat 2040
atggagcatt tttcagagtt ttctaacc ca gctttatttt tctagtcagt aaacatttgt 2100
30 aaaaatactg tttcactaat acttactgtt aactgtcttg agagaaaaga aaaatatgag 2160
agaactattg tttggggaag ttcaagtgat ctttcaatat cattactaac ttcttccact 2220
ttttccaaaa tttgaatatt aacgctaaag gtgtaagact tcagatttca aattaatctt 2280
tctatatttt ttaaatttac agaattatt ataacccact gctgaaaaag aaaaaatga 2340
ttgtttttaga agttaaagtc aatattgatt ttaaatataa gtaatgaagg catatttcca 2400
35 ataactagt atatggcatc gttgcatttt acagtatctt caaaaatata gaatttatag 2460
aataatttct cctcatttaa ttttttcaa aatcaaagtt atgggttctt cattttacta 2520
aaatcgatct ctaattcttc attatagtaa atctatgagc aactccttac ttcgggttct 2580
ctgatttcaa ggccatattt taaaaaatca aaaggcactg tgaactattt tgaagaaaac 2640

acaacatttt aatacagatt gaaaggacct ctctgaagc tagaacaat ctatagttat 2700
acatcttcat taatactgtg ttacctttta aaatagtaat tttttacatt ttctgtgtg 2760
aacctaattg tggtagaagt ttttaccac tctatactca atcaagcaaa atttctgtat 2820
attccctgtg gaatgtacct atgtgagttt cagaaattct caaaatacgt gttcaaaaa 2880
5 ttctgctttt gcatcttttg gacacctcag aaaacttatt acaactgtg aatatgagaa 2940
atacagaaga aaataataag cctctatatac ataatgtccc agcacaattc ttgttataaa 3000
aacaacaaa cctcacacta ctgtatttca ttatctgtac tgaagcaaa agcattgtg 3060
ctattaaatg ttgtgtgtt tctatttact gtatataat acattattt ttttcaaat ttgtgtgtg 3120
10 catgtaatac tgaaccactt tgatattgag acattattt ttttcaaat ttgtgtgtg 3180
ctagtaatac tgtaatactg tagaataatt gctctaattc ttttcaaat ttgtgtgtg 3240
cccttagaat gtttctattt ccataaggat ttatgtatgc ttttcaaat ttgtgtgtg 3300
taagatgaag ctgtttttgt gctcttctgt catcattgac cctcatttca agcattgtg 3360
gctgtctgta atgggattca tttttgacct ggaatatctg agaattgcaa aactagacaa 3420
15 aagtttcat gtcaataacc ttttatgaa gtattaaat gcatatttct atgtgtgtg 3480
atgtttgtat gtcaataacc ttttatgaa gtattaaat gcatatttct atgtgtgtg 3540
ataatgagtc acaaaataaa gctgtgacag ttctgtgtgt ctacagaat ttactttgt 3600
gcattttgtg caccacctac aaactttaga aaagattcaa atgttctctt aatcataaa 3660
20 gtattttgtg tcaaaaggaa aaactttaga aaagattcaa atgttctctt aatcataaa 3720
gagaactgag ctggtattta ggttttagag tttttagata aatatttctt taaatgtta 3780
tactgagtaa ctgagatttc tgaataagct ttcttagata aatatttctt taaatgtta 3840
tgaagctgca ctgagatttc tgaataagct ttcttagata aatatttctt taaatgtta 3900
cttgggtatg ggaagctac aaaggcagcc ttcttagata aatatttctt taaatgtta 3960
25 atataaggac acaatgtatg agttatactg ggaagctgct ggtttcttct taaatgtta 4020
gcaggaaggc gaagtagata tgcagacac aatgatacta atctggtgta ttcttctct 4080
ttttctctg ataagtagat atcagtttca gaaagagatg tctgcttatt ttgctactg 4140
aagaatccct gtcaaacagt ccttttgagc ggttttctc ttgtgtgtg atctgactc 4200
30 tctggtcaga aaaatcttg cttcaagtga gccaagatg cccctgagca tcaagacac 4260
aacttctctg tgaacaatg atcagtttca gaaagagatg tctgcttatt ttgctactg 4320
ggtattttag atgaaaatat gttaccatg aggtttgtt ttgtgtgtg atctgactc 4380
ttgagaaaca gaatctcgt cttcaagtga gccaagatg cccctgagca tcaagacac 4440
35 actgcaacct ccgctctctg ggttcaagc gaaagagatg tctgcttatt ttgctactg 4500
tacaggcatg gccaggctg tctcaaatg atttctctc gtttcccaag tagctgtgt 4560
ctatacgtt gccaggctg tctcaaatg atttctctc gtttcccaag tagctgtgt 4620
tcccaagtg ctgggattac aggcattgag cacttgctt ggcctaccc atgagcctg 4680
4740
4800
4860
4920

actaaaacat tcttctatct gtagaaaagc ccaaaagaac ttttccagat tcaaaaaact 4980
tggcactttg taatggtaat gtttacatta agtaaaaaaa aaaaaaaaaa acccacttag 5040
cttcagtttt caagtgttta ctgtgttgtc atgcacttca ttttaattctc aacacctgcc 5100
ctatgaggta aaaagtacca ttttacatat gagtaaatta cagctcagtg gataagaaac 5160
5 tctgccaaag gtacagggtc agtcaagtgg cagaggggtc tttttgttga agttaggtat 5220
cagttaaaat tgaccttgta aaatcacatc agcatcaata tacattaatt taacaaatat 5280
ttattgaact ttactgtatg ccagatactt ctctaggtac taggggggtac aatgtagaag 5340
aaaatagaat tc 5352

10

<210> 18
<211> 94
<212> DNA
<213> Homo sapiens

15

<400> 18
tgtcagctgc tgctggaagt ggcctggcct ctatttatct tcctgatcct gatctctgtt 60
cggctgagct acccacccta tgaacaacat gaat 94

20

<210> 19
<211> 142
<212> DNA
<213> Homo sapiens

25

<400> 19
gccattttcc aaataaagcc atgccctctg caggaacact tccttgggtt caggggatta 60
tctgtaatgc caacaacccc tgtttccgtt acccgactcc tggggaggct cccggagttg 120
ttggaaactt taacaaatcc at 142

30

<210> 20
<211> 119
<212> DNA

35 <213> Homo sapiens

<400> 20
tgtggctcgc ctgttctcag atgctcggag gcttctttta tacagccaga aagacaccag 60

catgaaggac atgcgcaaag ttctgagaac attacagcag atcaagaaat ccagctcaa 119

<210> 21

5 <211> 122

<212> DNA

<213> Homo sapiens

<400> 21

10 acttgaagct tcaagatttc ctggtggaca atgaaacctt ctctgggttc ctgtatcaca 60
acctctctct cccaaagtct actgtggaca agatgctgag ggctgatgtc attctccaca 120
ag 122

15 <210> 22

<211> 177

<212> DNA

<213> Homo sapiens

20 <400> 22

gtatttttgc aaggctacca gttacatttg acaagtctgt gcaatggatc aaaatcagaa 60
gagatgattc aacttggtga ccaagaagtt tctgagcttt gtggcctacc aaggagaaaa 120
ctggctgcag cagagcgagt acttcgttcc aacatggaca tctgaagcc aatcctg 177

25

<210> 23

<211> 93

<212> DNA

<213> Homo sapiens

30

<400> 23

agaacactaa actctacatc tcccttcccg agcaaggagc tggccgaagc cacaaaaaca 60
ttgctgcata gtcttgggac tctggcccag gag 93

35

<210> 24

<211> 241

<212> DNA

<213> Homo sapiens

<400> 24

ctgttcagca tgagaagctg gagtgacatg cgacaggagg tgatgtttct gaccaatgtg 60
5 aacagctcca gctcctccac ccaaattctac caggctgtgt ctctattgt ctgcgggcat 120
cccgaggag gggggctgaa gatcaagtct ctcaactggt atgaggacaa caactacaaa 180
gccctctttg gaggcaatgg cactgaggaa gatgctgaaa ccttctatga caactctaca 240
a 241

10

<210> 25

<211> 140

<212> DNA

<213> Homo sapiens

15

<400> 25

ctccttactg caatgatttg atgaagaatt tggagtctag tcctctttcc cgcattatct 60
ggaaagctct gaagccgctg ctctgttgga agatcctgta tacacctgac actccagcca 120
caaggcaggt catggctgag 140

20

<210> 26

<211> 117

<212> DNA

25 <213> Homo sapiens

<400> 26

gtgaacaaga ccttccagga actggctgtg ttccatgac tggaaggcat gtgggaggaa 60
ctcagcccca agatctggac cttcatggag aacagccaag aaatggacct tgtccgg 117

30

<210> 27

<211> 178

<212> DNA

35 <213> Homo sapiens

<400> 27

atgctgttgg acagcagga caatgaccac ttttggaac agcagttgga tggcttagat 60

tggacagccc aagacatcgt ggcgtttttg gccaaagcacc cagaggatgt ccagtccagt 120
aatgggttctg tgtacacctg gagagaagct ttcaacgaga ctaaccaggc aatccggacc 180
atatctcgct tcatggag 198

5

<210> 28
<211> 114
<212> DNA
<213> Homo sapiens

10

<400> 28
gccagtacgg aattcccagg ccctggtatt ttccttgca caagtcctac tggtttggcg 60
aggaaagtga tgagaagagc caccctggtt ccaaccagaa gagaatatca gaaa 114

15

<210> 29
<211> 172
<212> DNA
<213> Homo sapiens

20

<400> 29
tctgcatgga ggaggaaccc acccacttga agctgggctg gtccattcag aacctggtaa 60
aagtctaccg agatgggatg aaggtggctg tcgatggcct ggcactgaat ttttatgagg 120
gccagatcac ctcttctctg ggccacaatg ggcgggggaa gacgaccacc at 172

25

<210> 30
<211> 124
<212> DNA

30 <213> Homo sapiens

<400> 30
aagctgaata atatcaatga tctcctgaag tccgtgttct tgatcttccc acatttttgc 60
ctgggacgag ggctcatcga catggtgaaa aaccaggcaa tggctgatgc cctggaaagg 120
tttg 124

<210> 31

<211> 107

<212> DNA

<213> Homo sapiens

5 <400> 31

tgctttgggc tcctgggagt taatggggct ggaaaatcat caactttcaa gatgttaaca 60
ggagatacca ctgttaccag aggagatgct ttccttaaca gaaatag 107

10 <210> 32

<211> 142

<212> DNA

<213> Homo sapiens

15 <400> 32

tatcttatca aacatccatg aagtacatca gaacatgggc tactgccctc agtttgatgc 60
catcacagag ctgttgactg ggagagaaca cgtggagtcc ttgcccttt tgagaggagt 120
cccagagaaa gaagttggca ag 142

20

<210> 33

<211> 135

<212> DNA

<213> Homo sapiens

25

<400> 33

gttgggtgagt gggcgattcg gaaactgggc ctctgaagt atggagaaaa atatgctggt 60
aactatagtg gaggcaacaa acgcaagctc tctacagcca tggctttgat cggcgggcct 120
cctgtggtgt ttctg 135

30

<210> 34

<211> 104

<212> DNA

35 <213> Homo sapiens

<400> 34

gatgaaccca ccacaggcat ggatocccaaa gcccggcggt tcttgtggaa ttgtgcccta 60

agtgttgtca aggaggggag atcagtagtg cttacatctc atag 104

<210> 35

5 <211> 93

<212> DNA

<213> Homo sapiens

<400> 35

10 tatggaagaa tgtgaagctc tttgcactag gatggcaatc atgggtcaatg gaaggttcag 60
gtgccttggc agtgtccagc atctaaaaaa tag 93

<210> 36

15 <211> 2894

<212> DNA

<213> Homo sapiens

<400> 36

20 gtattttgtga actttgccaa ggaccaaagt gatgatgacc acttaaaaga cctctcatta 60
cacaaaaacc agacagtagt ggacgttgca gttctcacat cttttctaca ggatgagaaa 120
gtgaaagaaa gctatgtatg aagaatcctg ttcatacggg gtggctgaaa gtaaagaggn 180
actagacttt cctttgcacc atgtgaagtg ttgtggagaa aagagccaga agttgatgtg 240
ggaagaagta aactggatac tgtactgata ctattcaatg caatgcaatt caatgcaatg 300

25 aaaacaaaat tccattacag gggcagtgcc tttgtagcct atgtcttgta tggctctcaa 360
gtgaaagact tgaatttagt tttttaccta tacctatgtg aaactctatt atggaaccca 420
atggacatat gggtttgaac tcacactttt tttttttttt tgttcctgtg tattctcatt 480
ggggttgcaa caataattca tcaagtaatc atggccagcg attattgatc aaaatcaaaa 540
ggtaatgcac atcctcattc actaagccat gccatgccca ggagactggt ttcccgggtga 600

30 cacatccatt gctggcaatg agtgtgccag agttattagt gccaagtttt tcagaaagtt 660
tgaagcacca tgggtgtgtca tgctcacttt tgtgaaagct gctctgctca gagtctatca 720
acattgaata tcagttgaca gaatgggtgcc atgcgtggct aacatcctgc tttgattccc 780
tctgataagc tgttctgggtg gcagtaacat gcaacaaaaa tgtgggtgtc tctaggcacg 840
ggaaacttgg ttccattggt atattgtcct atgcttcgag ccatgggtct acaggggtcat 900

35 ccttatgaga ctcttaaata tacttagatc ctggtaagag gcaaagaatc aacagccaaa 960
ctgctggggc tgcaagctgc tgaagccagg gcatgggatt aaagagattg tgcgttcaaa 1020
cctaggggaa cctgtgccca tttgtcctga ctgtctgcta acatggtaca ctgcatctca 1080
agatgtttat ctgacacaag tgtattattt ctggcttttt gaattaatct agaaaaatgaa 1140

aagatggagt tgtatattga caaaaatggt tgtacttttt aatgttattt ggaattttta 1200
 gttctatcag tgacttctga atccttagaa tggcctcttt gtagaaccct gtggtataga 1260
 ggagtatggc cactgcccc aattttttat tttcttatgt aagtttgcat atcagtcattg 1320
 actagtgcct agaaagcaat gtgatgggtc ggatctcatg acattatatt tgagtctctt 1380
 5 tcagatcatt taggatactc ttaatctcac ttcacatc aaatattttt tgagtgtatg 1440
 ctgtagctga aagagtattg acgtacgtat aagactagag agatattaag tctcagtaca 1500
 cttctgtgct catgttatct agctcactgg ttacaaaata taggttgtct tgtggttgta 1560
 ggagccact gtaacaatac tgggcagcct tttttttttt ttttaattgc aacaatgcaa 1620
 aagccaagaa agtataaggg tcacaagtct aaacaatgaa ttcttcaaca gggaaaacag 1680
 10 ctagcttgaa aacttgctga aaaacacaac ttgtgtttat ggcatttagt accttcaaat 1740
 aattggcttt gcagatattg gatccccat taaatctgac agtctcaa at tttcatctc 1800
 ttcaatcact agtcaagaaa aatataaaaa caacaatac ttccatattg agcatttttc 1860
 agagtcttct aacccagtct ttttttctta gtcagtaa ac atttgtaaaa atactgttct 1920
 actaatactt actgttaact gtcttgagag aaaagaaaaa tatgagagaa ctattgtttg 1980
 15 gggaagtcca agtgatcttt caatatcatt actaacttct tccacttttt ccaaaatttg 2040
 aatattaacg ctaaagggtg aagacttcag atttcaaatt aatctttctt ttttttttaa 2100
 atttacagaa tattatataa cccactgctg aaaaagaaaa aaatgattgt tttagaagtt 2160
 aaagtcaata ttgattttta atataagtaa tgaaggcata tttccaataa ctagtgatat 2220
 ggcatcggtg cattttacag tatcttcaaa aatacagaat ttatagaata atttctctc 2280
 20 atttaatat tttcaaaatc aaagtattgg ttctctcatt ttactaaaat cgtattctaa 2340
 ttcttcatta tagtaaatct atgagcaact ccttacttcg gttctcttga tttcaaggcc 2400
 atatttttaa aaatcaaaag gcactgtgaa ctattttgaa gaaaacacaa cattttaata 2460
 cagattgaaa ggacctcttc tgaagctaga aacaatctat agttatacat cttcattaat 2520
 actgtgttac cttttaaaat agtaattttt tacattttcc tgtgtaaacc taattgtggt 2580
 25 agaaattttt accaactcta tactcaatca agcaaaattt ctgtatatc cctgtggaat 2640
 gtacctatgt gagtttcaga aattctcaaa atacgtgttc aaaaatttct gcttttgcat 2700
 ctttgggaca cctcagaaaa cttattaaca actgtgaata tgagaaatac agaagaaaat 2760
 aataagccct ctatacataa atgccagca caattcattg ttaaaaaaca accaaacctc 2820
 acactactgt atttcattat ctgtactgaa agcaaatgct ttgtgactat taaatgttgc 2880
 30 acatcattca ttca 2894

<210> 17

<211> 4646

35 <212> DNA

<213> Homo sapiens

<400> 37

ccattccacc tagtggggcc atttccctacc tgagtcaccc gtggtgtcaa atagaatgtc 60
atgtggcctc ctgagttggg tagaattggc tgctcatctc aaccccgcta ctgactatct 120
ctgtgattta cccctctccc agccttaggc ttgtacata taaaatcaag acaataatgt 180
ttctatctc acagggttgt cctgaggatt aaattaagta attaatataa aatgtgcctt 240
5 gtacatattg ggcctaaat aaacagtagc tactatttat ccttaaagta caaatggtag 300
tttcagagct tcaaggctga ttgtttctt ttctttttt ttctttttt ttctttttt 360
ttttccct aatttcact ctgttccca gttctctgc caatggagcg atcttggctc 420
tttggaggtg aagtctact gtccaaca gttctctgc ctacgctcc cagatagctg 480
acccaacct ctgtctctg gttccaac gttctctgc ctacgctcc cagatagctg 540
10 ggattacagg ctcccgccac catgcccagc tttttttt tattttcagt agatagctg 600
tttcacct ttgaccaggc ttgtcttgaa ctctgacct catgatcaac ccacctcagc 660
ctcccaagt gtgggatta caggtgtgag ccaccagcc cggcctcata agtattttct 720
aaatttatt ttgaccaggc ttgtcttgaa ctctgacct catgatcaac ccacctcagc 780
tataagtgt ttatctcagc caattataat ttgtttct tattttcagt agtattttct 840
15 ttacttaatt ttatctcagc caattataat ttgtttct tattttcagt agtattttct 900
catgatata ttgtgagtc taatgatttc ttgtttct tattttcagt agtattttct 960
aagtgtttc caatatttg caattataat ttgtttct tattttcagt agtattttct 1020
aaatgggata aacatgctc ttgaatacgt attgttaac ttgtttct tattttcagt 1080
20 actgatttat atttccgtg ttgaatacgt attgttaac ttgtttct tattttcagt 1140
tatataaaa taggttctt ttgaatacgt attgttaac ttgtttct tattttcagt 1200
aattgagatg agggagctt ttgaatacgt attgttaac ttgtttct tattttcagt 1260
tttgggata ttatctcagc ttgaatacgt attgttaac ttgtttct tattttcagt 1320
25 tttaagcca ttatctcagc ttgaatacgt attgttaac ttgtttct tattttcagt 1380
tatataaaa taggttctt ttgaatacgt attgttaac ttgtttct tattttcagt 1440
aattgagatg agggagctt ttgaatacgt attgttaac ttgtttct tattttcagt 1500
aggtataatt gacataaaa aattgttat ttgaatacgt attgttaac ttgtttct 1560
tatctcaact taaaaataa gctacagaat aaaaaggtgt ttgtattga tatatatga 1620
aaggctgaat gctatccca agcttggaaa ttgtattga ttgtattga tatatatga 1680
acagaaatat tagcaagacc agcttggaaa ttgtattga ttgtattga tatatatga 1740
30 actattcttg gaaaatttg gtaacagtg tttttttt ttgtattga ttgtattga 1800
gtctatttg tttttttt gcaacctccg ctccaggt ttgtattga ttgtattga 1860
tttttttt ttgtattga gcaacctccg ctccaggt ttgtattga ttgtattga 1920
tggtgtgac ttgtattga gcaacctccg ctccaggt ttgtattga ttgtattga 1980
agctcccaa gtgtgtggg ccatgttggc caggtattga ttgtattga ttgtattga 2040
35 ttagtagaga ttgtgtggc ccatgttggc caggtattga ttgtattga ttgtattga 2100
gatccgctg ttgtattga ccatgttggc caggtattga ttgtattga ttgtattga 2160
cacacctag ttgtattga ccatgttggc caggtattga ttgtattga ttgtattga 2220
tgccagctc cactctgac atgcagtggt gtgatctcg gtcactgca 2280

acctaggcct tctgggttcg agtgattctc ctgccttagc ctctcgggtt caagtgttc 2340
tcttgccctg gcctcccaag tagctgggat tacaggcata cacccecatg cccatcta 2400
ttttgtattt ttagtagaca cagcgtttca ctaaaatttt gtatttttag tagagatggg 2460
gtttcaccat gttggccagg ctggtctcca actcctgacc tcaggtgatc cgctgcctt 2520
5 ggctcaca agtgattaca ggcagagcc ctttggaat tcgccaataa gatttttaa 2580
aatgagttta tgtagaacca tatcaagggt ctttggaat aaaaaacagt ttttaaaaa 2640
tatcagaat aaaacaaca ataatataat aaataaaaaa cccaaacaa tctgaagcac 2700
gagcactag cagaaagggt caattatgat ctattcata gtcagagaa agtggaatat caagtagaca 2760
ttacaggaca tgttttaaga caaaagtata tatgctgat aatgctctcc cagtatgat 2820
10 ttaaatgaaa aaacagaata ataaataat ttatcttata tgctctgat agtctcaata tcttagaga 2880
aaaatattat ttatgtatgc atgaaaaaag acaaaagatg ttaacagaga tccattgta 2940
cttcagttta ctagggtatg tctctgggag gtaggattaa ggtgattat atttacctt 3000
tcaagaaaaa atttctgctt ttatcttcaa atttccata aaaatataag gactgaaga 3060
15 tgggagcct cgtaccgctt ggagatgga gcaagacct gtctcaaaa aaaaatctt 3120
atctcggat cgtaccgctt tttagagag gactctctt ctgttgcctt cccagcagt 3180
tgctttttt tttgtttgt ttttagagc gactctctt ctgttgcctt cccagcagt 3240
cagtggcaca atctcagctt accgcaacct ctgctctctt ggttcaagc agctggagt 3300
ctcagcctcc caagtacctt ttccacctt ttgcccagc ttgctctga tctctgact 3360
20 tatcttctt agagacagg ttccacctt ttgcccagc ttgctctga tctctgact 3420
cagctgatcc accgctctt ttttcaaaa aagaagaca aaaggatct tataccagt 3480
cccagcccaa tcttttctt gcttcccaa gttgtggtt ttacacgtt tgaacaca 3540
ttatcttctt gttgtgact ctcttttctt gttgtggtt ttacacgtt tgaacaca 3600
ggcctctga ctcttttctt gttgtggtt ttacacgtt tgaacaca 3660
25 aatgaaagaa atgggagagg ctcttttctt gttgtggtt ttacacgtt tgaacaca 3720
ggtactcac tgaagcagg ttctcttctt aactcagct ctgctctga tttatcgtt 3780
atgcttctt agaagttcaa tgactctctt ctttccctt gagaacctt attgtttta 3840
ggacagatgg ggaagcact ttgctctctt tgagagcctt ctgctctga tttatcgtt 3900
30 atggaactat gttgaattt tgactctctt aactcagct ctgctctga tttatcgtt 4020
cagcttctt tctcaacata gtcaccat acctggcact atgctaagg caggaatga 4200
ggtctctctt tgctgtctt cagagctctt aatgtctga ggaagcagc aacagaaca 4260
gatgattca ggaagcctt gtcagagc aatgtctga ggaagcagc aacagaaca 4320
35 gcacagagg ggaagcctt gtcagagc aatgtctga ggaagcagc aacagaaca 4380
gaatcctgaa gaatgaatg aatgaacca gataagcac aatgtctga ggaagcagc 4440
acctaaagg agacacag gatatgaa tggatgta aaaggttgg actccaaaca 4500
gttctgtta agcttagaga gttgtggag agctggaga agttgatta ttagtaaatg 4560

aagttgtctg tggatttccc agatcccagt ggcattggat atccgtatca ttttaaatta 4620
cagtgttcta tcttatttcc actcag 4646

5 <210> 38

<211> 4533

<212> DNA

<213> Homo sapiens

10 <400> 38

gtaagtaact gtggatgttg cctgagactc accaatggca gggaaaatcc aggcaattaa 60
cgtgggctaa attggacttt tccaaagatg ctgtcttttg gaaacatcac acatgctttg 120
gatcagaaaa cctaggcttc taatttggtg ataaggcatg aactcaggag actgttttca 180
gtcctagtga atgggtgataa ttgtaattat aacagtagac aacatctctt ttacacattt 240
15 taaatcatga aatagaata accttactga taattttaga aagtgggtgat taaaagcaca 300
tttaagataa tgccttaaca cctagtcttt tccatatgca tgatgtctta atcacacatt 360
gcaaatcatg gaacacagaa ttttaagcag cttttgtgta gaacttctca gttttactaa 420
tattatttta ttttattctc ataacaacct tgaatagaac tcagatcatc tgtcaatcat 480
gtattttgat aacagccttt acagtgaaca tagaaaatac agtagtggtt aacaacacag 540
20 gctccagatg tcaggttatc tgggtatgaa ttctggtgtc agcattcact aagcatatga 600
ccttggacaa gtgatttaag tttcttttaa acagagaata gtaataccta cctcatatta 660
ttattgtcag tgtatcatct tacaatcaca gtctttctct tagggctggg ctcaagtggg 720
ggattgacac tgcagaaatg gccagatcta aaggatcaac atttacgtag ctgggaaatg 780
tagctgggac ttcagtttca ctgcgctagt gatttttctt accactaagc agctcagtc 840
25 ataccctac gagaccacac agcttatgag atactgttct tccaggaaag cagtggggcc 900
agggccacct ttaattgtg tttcttggcc tgggtccatc tttctcaca tatatagcaa 960
cagttattta cttgctgatt ttctaataca catcacacat agtcatatta aacacacaca 1020
cacacacaca cacacacaca caccctcaa gaaacatttt ctgagacgtg atttcctgat 1080
ttcatcaaaa aagaaaagag cgggccaggc acagtgggaa gtcaagggtg gtggatcact 1140
30 tgaggtcagg agtttgaaac cagcctggcc aacacggtgg aacctcgtct ctactaaaaa 1200
tacaaaaatt agccaggcgt ggtggcgcac acctgtaatc ccagctactg gggaggctga 1260
ggcaggagaa ttgcttcaac ctgcgaggct gaggttgag tgagccgaga ttgcgccatt 1320
gcactccagc ctgggcaaca gagtgaact ctgtctcaaa aaaaaaaaaa aaaaaaaag 1380
cataaactga aatttatatg caatttatat gcctgtgaga taattctgtt ttctcttttg 1440
35 gaaccccaaa gagatttttt tgattgatga gcaatacat ttagattttt atttaagcat 1500
tatgccaagc accactgaag tataagtttc aagggcaaac tcagtttttt catctactag 1560
acgaatgatt ttctggaatg attacaagca ggcaagatgg ttagtggaat atagcaaatg 1620
tcttcggcat cagacaagtt ggggtttgtt tgtatcctgc ctctgccctt caccgaggtt 1680

gtgatcttgg gcagattggt gagttttaac ctgattccct ctgactccag atcataaatt 1740
ttcagaaaaa ttctgaaatt ctgtatatata ctgatggtaa atgagacttt tccttacatc 1800
tatgcacttc ttgtttgtt tggtttgaga tggtcttctg ctgttgcaca gactggagtg 1860
cagtagtgca atctccgctc actacaatgt ctgcttccca cagtcacag agctctctgc 1920
5 ctcagctccc caaataagct ttgcatgt tgaccacact ggtctcgaac tcctggcttc 1980
atcttttagta gagacaggt cctcccaag tgcctcttt tctcatcace ctcaggagac 2040
aggtagttcg ccgcctcag ctgcaacct tacctcttt gagaggtgtc ttgtctctgt 2100
ccggccatat ccatgcactt aaagtttaag gtgaaacttg agttcaaac agagttatca 2160
ctagttggaa gagcagagtt attctctgta aatcttcccc ttatttactt gcttctctgt 2220
10 gaacaaagga ctggtttgaa attctctgta gcttctgaga gccattata taggatgggg cacaactgac 2280
aggctctaaa aacttccctg ggtctctgta aatcttcccc ttatttactt gcttctctgt 2340
acaccactg cctagctctg atcttacttt tggttgcaca taggatgggg cacaactgac 2400
aaggaagggc cctagctctg atcttacttt tggttgcaca taggatgggg cacaactgac 2460
cctgtctctg ttttccacta tgcagctctg tctacagtg aataacttca cctgactgac 2520
15 aggggagaa ccttctctg atcttacttt tggttgcaca taggatgggg cacaactgac 2580
agagcagctg acttaggcaa atgttcaata ggcagagtg cctgagagtg gtaggagtg 2640
tagggagatt aactgtgtaa atgttcaata ggcagagtg cctgagagtg gtaggagtg 2700
tgatcagatc ttatcacatc attgaaatgc aaagtgcagc aagtcctgac tttggattaa 2760
aaaagaaaga aagaccctat attgaaatgc aaagtgcagc aagtcctgac tttggattaa 2820
20 cttctcagcc ctttctgag atgttcaata ggcagagtg cctgagagtg gtaggagtg 2880
ggaggtggtg cactccaca gtgcttgtaa aatctctata ggtctcagc agtaggagtg 2940
gtcctacacc aggcactctg caaaaaacgt ttctctctg ggtctcagc agtaggagtg 3000
acagctctgt gaagttaatt gtacttctat caccatttta ggcagagtg gtaggagtg 3060
atgggggcaa tgacttggt aaagtctgaa gctacttctt cctcaccacc tagagagtg 3120
25 tccaattggt ttgactccaa agctctgtaa gctacttctt cctcaccacc tagagagtg 3180
gttcttgata actgtgaact ctttctctg ctcataagca gcatccatgt ataaaggccg caaaccac 3240
aggagctctg gcttctctg ctcataagca gcatccatgt ataaaggccg caaaccac 3300
agggcctatt aatcttgatc ctcataagca gcatccatgt ataaaggccg caaaccac 3360
30 tggtccagac cgaatccctg gaccaagccc aaatatgtcc catcatcctt ttggttaaga 3420
gtctattgta agaaagaaag aggaagagca gaggatgacc cctgagagtg gtaggagtg 3480
tttaattag tgacaaaca acaataataa tgcccttgag gagctttgta gctggcagag 3540
atcagacccc aagctgtgt gtttttcag gaggagagta ccagaggggt ttgagagtg 3600
gaggtgaaac tgacaaatgt ttggcagatg aagagggctg gattgggacc atggagagtg 3660
35 ctaaatcca atctaaccgc aggtgtgag ttgagagtg aagagggctg gattgggacc atggagagtg 3720
gggtctact cccagtcacg ccagctgact ttgagagtg aagagggctg gattgggacc atggagagtg 3780
ttattttatt tatttttatt tttttgaaat ggagttctgc tcttctgcag tcactttatc 3840
tgaaatggcg cgtctctggc tcaactgcaac ctccccctcc tgagttcaag cgattctctc 3900

gcctcagcct ccagagtacc tgggattaca ggcgcctgcc accaagccca tcgaattttt 4020
 gtatgcttag tagagacagg gtttcgccat gttggccagg gtggtcttga actcctgacc 4080
 tcaggtgatc cgcccacctt ggccctcccaa agtgctggga ttacaggcgc gagccactgt 4140
 gccagccca cttcatctta ccgtagttac ctcttagag tatgaaaaa taggcttagg 4200
 5 gcatcccaa gtccctcta tgtctgagag ctgaggctgg ctgtcaaaga ggaactaagg 4260
 atgccaggga ctttctgctt aggaccctc tcatcacttc tccaacgctg gtatcatgaa 4320
 cccattcta cagatgatgt ccactagatt aagaatggca tgtgaggcca agtttccacc 4380
 tgagagtcag ttttattcag aagagacagg tctctgggat gtggggaatg ggacggacag 4440
 acttggcattg aagcattgta taaatggagc ctcaaatcg cttcaggga ttaatgtttc 4500
 10 tccctgtgtt tttctactcc tcgatttgaa cag 4533

<210> 39

<211> 1269

15 <212> DNA

<213> Homo sapiens

<400> 39

gtaagtatca gatcagggtt tctttccaaa cttgtcagtt aatccttttc cttcctttct 60
 20 tgtcctctgg agaattttga atggctggat ttaagtgaag ttgtttttgt aaatgcttgt 120
 gtgatagagt ctgcagaatg aggggaaggga gaattttgga gaatttgagg tatttgagg 180
 atccatcacc tcgagtattt atcatttctg tatgtttgtga acatttcaag tcctgtctgc 240
 tagctatttt ggaatatact atatgttgtt aatgatata tgcagcagac gtgcatctga 300
 atgggctggc tctaggagct agagggtagg ggctggcaca aagatgcatg ctggaagggt 360
 25 ccttgcccat aagaagctga cagccaaggc taggggagtt ctgtcttctc tgcacaggt 420
 cacctctctc acctctgtca ctgcccac acactacaat gtctgcaggt ctttctcccc 480
 tgagtgtgag ctccctgagc aaagcaggat gctgcccctt ccctttgtat tcctggctcc 540
 tggcttcagt gcctggacat aagtatggc ataataagt tccccaaat gagacattga 600
 ggattcttca aatgcacagg accgtgatgt gagttaggac ggagtaagga cgatgggatg 660
 30 tggctcagga caatcctgag gaagctgcag ctgcggcacg cagggccaca ctgtcatgtt 720
 catggaccct agactggctt tgtagcctcc atgggcccct tccatacaca aatattaaaa 780
 attatatttc atgactgcat tggatataa atgaatataa tccagaccag attcatgatt 840
 attcatacat ttttagtgta ttaactttta attctgcttt taaaataaat taaaacattc 900
 taatatgccc ttaagagtat ccagggccca ggccactgag cctactgttg ttcattggata 960
 35 agttggccct gggggcatgt gtgtgcatgc atgtgtgtgc acatgcatga tgagccgggc 1020
 cttgaagggt ggtaagattt ggggtgttag accaatggag aaaggcattt ggggcagtga 1080
 tgatgggttg gggagggaac atggtgatga atggagctgg gtgtggggag ccatgggagt 1140
 ggggttagggc cagcctgttg aggacctggg agccaggctg agttctatgc acttggcagt 1200

cactttctgta aagcagcaga ggcagttggc ctacgctaaag cctttcgcct tttcttgac 1260
cctttacag 1269

5 <210> 40
<211> 951
<212> DNA
<213> Homo sapiens

10 <400> 40
gtaagtaaaa accttctctg catccgttta taattggaaa ttgacctgca ccagggaaa 60
agagtagccc aggtgtcttg ggcttggtcc cattagatct tccccaaggg gtttttctcc 120
ttggtggctg gcctgtgggg cccctctcca ggaggcattg gtgaagaaac taggggagct 180
ggttgccaca gacagtgatg tactaatctt ctctgggaag acagaagaaa agtccccagg 240
15 gaagaatact acagacttg ccttagggac agctaggggt gcagattgct gccaactgca 300
tttttctga agttggccat atggttgacg tgaatggatt tatagacaga gtatttctgt 360
gcatataaga gcaattacag ttgtaagttg atatggataa gtgaaagtta agcacttctt 420
tctaaaaaga gaatgcaatt cattttcccc taatcatttc aattagtctg atgggcattt 480
gaacttggtg tctttaaaaa gtgaaatctt tacctctgat ctggtaagta tccaggcaat 540
20 ttcttctgtg ccaccaggga ggtatctggg gagtgggcat tttctgactg aggcattggc 600
tgccatagca tcagagcagc cttccaggca gtggcctggc aaggggacag aggcgtgtgg 660
gagcagctgg ctgagtgcag ccagtaatgg catgtgcatg gtctgtagag aatgtagaag 720
caataatgaa gccgataaaa gctggtctgc attttattat tatcatgcgc cgggtgttct 780
aaacaatgtc agtgataaat tactcctccc catcatggac caatggctgc cactgctcca 840
25 gggaagtgtc ttttattccg tttggtgttt agggagggat ggagttggct ggcctttgct 900
gaaaggccta ccagtttgtt ttctatttgg caaagaaga aatgataaag t 951

<210> 41
30 <211> 253
<212> DNA
<213> Homo sapiens

<400> 41
35 ttcttgggtc cgtttttttc ttcctttcag gtgtcgtgaa aagcttgaat tcggcgcgcc 60
agatatcaca cgtgccaaag ggctggctca ctgatatggc gatgctcccc tatctcattc 120
ctgtgtgtgt ttagccaggc aactgttgat catcaatatt atgataacgt ttctccactg 180
tcccattgtg ccactttttt tttttttttt gaggttactt actaaataaa aataaaacac 240

tattttctcaa tag

253

<210> 42

5 <211> 196

<212> DNA

<213> Homo sapiens

<400> 42

10 gtaagctgat gcctccagct tcctcagtag ggctgatggc aattacgttg tgcagctact 60
ggaaagaaat gaataaaccc ttgtccttgt aatggtggtg aaggggaggg aggtagtttg 120
aatacaactt cacttaattt tacttcctta ttcaggcagg aattgccaaa ccatccagga 180
ctccaatatg caacct 196

15

<210> 43

<211> 160

<212> DNA

<213> Homo sapiens

20

<400> 43

gtcagtaaag agacctgatg cattggactg ttgcaatgga acctgtttta agatcttcaa 60
agctgtattg atatgaagtt ctccaaaaga cttcaaggac ccagcttcca atcttcataa 120
tcctcttggtg cttgtctctc ttgcatgaa atgcttccag 160

25

<210> 44

<211> 91

<212> DNA

30 <213> Homo sapiens

<400> 44

gtgagtagac ttgctcactg gagaaacttc aagcactaat gctttcggaa tgtgaggctt 60
ttccttggac agcatgactt tgtttttag c 91

35

<210> 45

<211> 106

<212> DNA

<213> Homo sapiens

<400> 48

5	gtgagtgtcc atgcagaccc cagccctgtc cccaacccca tccctccctt agttctggcc	60
	ttggcctgtg tcatctcttc cctctgtagc agcgttagat gtctacatgc ccatttgccc	120
	accagactga gctcttccta gaggagagag gcttctcttg aatagctacc tgtccccagt	180
	tctctgaatg cagcctggca catctcaggt gcacagtagt gtttatcaat ggaatgaatg	240
	attgacagcc aaccttctgg ttttctgggg gatgtggaag ggtggcttcc aggggatca	300
10	agaatgagat aatggcagaa ggacaaatcc tgcaagatct cacttatata tggaatatat	360
	gtaaggtaga aagtgtcagt ttcacatgat gaataagttc ctgggatctt gatgtacatc	420
	gtgatgacta tagttagtaa cactgtatag tatacttgaa atttgctaag agagtagatc	480
	cgaagtgttc aacttacaca aaaaaggcaa ctatgagggtg atggatttat taacaagctt	540
	ggattgnggt gatccttt	558
15		

<210> 49

<211> 614

<212> DNA

20 <213> Homo sapiens

<400> 49

	cctanttttg	tattttttaga	aaagacaggg	tttttccatg	ttggtcaggc	tggtctcgaa	60
	ctcccacct	cagggtgggtc	gcccgccttg	gcctcccaaa	gtgctgggat	tgcaggcatg	120
25	agccactgcg	cccagcccca	aattttgggt	tttgcttgaa	aactgaggtc	tgaattcagc	180
	cttctgggtg	cccctcaaga	gtcagtttaa	atgttggtca	tgttagttgt	cagtgaaaac	240
	aatggtgagg	ctggcatgag	agtgtgaacc	tggatgggag	ggcttgtgtc	tcacgaaaac	300
	atttttccag	atcagctcag	tcgtgagtta	tccgtcattg	acgttataat	aagctctgat	360
	tatttatcaa	gcatcattct	ttatagatat	ctcagtttaa	tctgagataa	tcttctccac	420
30	atctctocac	atagatgtta	tgaattttac	ttttacagag	gagccaactg	aggctcagat	480
	aagttaactta	ttatatgact	agtagtggn	gagctggggt	ttcaaactaa	gaactntctg	540
	gctccaaagc	ccttgtaagt	ttctatcagt	atatgaccat	gcatatgagc	atttgtctct	600
	cctcttcttc	atag					614

35

<210> 50

<211> 329

<212> DNA

<213> Homo sapiens

<400> 50

gtaagctgcc cccagcccaa gactccctcc ccagaatctc cccagaactg ggggcaaaaa 60
5 actcaaggta gcttcagagg tgtgcgctaa gtatactcac ggctcttctg gaattcccag 120
agtgaaaacc tcaagtctga tgcagaccag agctgggcca gctccccagt cgtgggtata 180
gaatcatagt tacaagcagg catttcttgg ggatggggag gactggcaca gggctgctgt 240
gatgggggat cttttcaggg aggagccaaa gcgctcattg tctgtgcttc tcctttttct 300
gcggccctg gctcccacc tgactccag 329

10

<210> 51

<211> 608

<212> DNA

15 <213> Homo sapiens

<400> 51

gtgagtgtcc ctcccattat taccatgtgc ctgcttgata ctggagaggt gagtttctgg 60
tcactttccc aggtgtgagt gaggtgagaa ttctttcagt tcatctagct gggggaaatt 120
20 gtagtgagca tagctaaaag tcacatgggg caccaacctc tccatgaagt acaggccatg 180
gtgcaagaga taacgcntgt gcatatnagc catcccatgc ccacntcanc ggtccaaata 240
agcagttttc tgcaaaactt agtgagggct ggtgtttgga agtgaggattg agtaattgca 300
gtaccctatt ttcttttttg gctgcagcct ctccagccagc cacagcatct ccctgtgtct 360
tggtaggttt tggaaagaag tgtgggagca aaagcatgat gttacatgta gactggcctg 420
25 agatactcat tctcagggca ctgtgtgaat gatgagctgc tgttactgtg tggaggggaa 480
atgcacttag tgcttcagag ccacttgaaa gggataagtg ctctagagac aattggattc 540
aaatgtggag caggctgagc aagaacagaa tgtctccttt gcctgagcct gagtgtctgg 600
aatcacat 608

30

<210> 52

<211> 15

<212> DNA

<213> Homo sapiens

35

<400> 52

gtaatctggt gctgg

15

<210> 53

<211> 639

<212> DNA

5 <213> Homo sapiens

<400> 53

tttggtcctt ggcaaagttc acaaatactg gatttgataa caaaaggnac ttaataaatg 60
ttagttgagt ggttgaatga gtaaataaac ctctagcttt agtaaattaa ctctagcctt 120
10 attctatata ggctcaagag aatatttcta cccattttct tctaggtttt cctatctcag 180
tgactaatgg tagcaaagca ttcccttaaa aaggcattat ttgtgaaact tatctaaaaat 240
cgaattcggg tccaattaaa tttttgaaat tttatattaa aaattatatt agtagggatg 300
ggtaagaggt gttttggtct ggttggttgg ttagttgcta tgactcagaa ttgctaagaa 360
aacagaaaag taagataaga tcattgtttt aacctctttt cctccacaaa atcaataaat 420
15 aacatatccc taaattactc ttagaatttc tcttaaattg cagtgaaaaa ccaaaatcct 480
tcattcttgg ttgaaggttg gaaaactacg ttagagagga ttagagagag aggatgagca 540
atcgtgtagt cagcccttgc ctctagtgt aggatttgtc tcagccactg cttgttgtcc 600
tggtgccaa cgttctcatg aaggctgttc ttctatcag 639

20

<210> 54

<211> 387

<212> DNA

<213> Homo sapiens

25

<400> 54

ttagatctat ccaagttgtg tgtgtcaaca gttcattcct ctntcactgc tgagtgtgt 60
tccctgggag ggggtgatca cagttccatg gcanttttta gatgtatttt ttaaacagct 120
ttcagcatcc tctattttta ttgtntcatc aagtcctttt tcccaataga ctctgaatgc 180
30 tcctttatca tcgtanttcc catcaccaac atcagtacc aaataggccc taaataaaca 240
tttatangcc tcctgcctgc ctgagaaacc aggggtggaca tggagagaag gcacttcntg 300
aaagttcaag cgcagtgcc tgtgtcctta cactccactc ctcaagtgcnt ttctgtgggt 360
tcatttctgt cttctctcct gtcacag 387

35

<210> 55

<211> 19

<212> DNA

<213> Homo sapiens

<400> 55

gtcaatgagg gcgggtagc

19

5

<210> 56

<211> 3

<212> DNA

10 <213> Homo sapiens

<400> 56

tag

3

15

<210> 57

<211> 257

<212> DNA

<213> Homo sapiens

20

<400> 57

gtgagtgaag cagtggctgt aggatgcttt aatggagatg gcactctgca taggccttgg 60

taccctgaac tttgttttgg aaagaagcag gtgactaagc acaggatggt cccccacccc 120

catgcccaagt aacagggctc atgccaacac agctgggtgt ggcattgggt ttgtgacaca 180

25 accatttgtc tgtgtctctg atagcattag aaaagtaaag ggcagtttta aggtaaggaa 240

aaagggtttg ctggaca 257

<210> 58

30 <211> 265

<212> DNA

<213> Homo sapiens

<400> 58

35 tggctagctg gctttcatta ctgtttttca cacattaact ttggcctcaa cttgacaact 60

caaataatat ttataaatac agccacactt aaaatgggtcc cattatgaaa tacatattta 120

aatatctata cgatgtgtta aaaccaagaa aatatttgat tcttctctga tatttaagaa 180

ttgaagggtt gaggtagtta cgtgttaggg gcatttatat tcatgttttt agagtntgct 240

tancaactta atctttcctt ttcag 265

<210> 59
5 <211> 14
<212> DNA
<213> Homo sapiens

<400> 59
10 gtgagaaaag aagt 14

<210> 60
<211> 15
15 <212> DNA
<213> Homo sapiens

<400> 60
tcttgtcctt tgcag 15
20

<210> 61
<211> 188
<212> DNA
25 <213> Homo sapiens

<400> 61
gtactagtgn ggcacctgaa agccagccta gtctcctttg gcctcctaga caatatatac 60
cttatgagct ttccacacg ccattagact tcagagctag tttttccttc atgatannca 120
30 gcagcacaaa atgcctgagt tctttgtatc tgctttcaga ngtnngaaac cntggtaacg 180
agtgagtg 188

<210> 62
35 <211> 176
<212> DNA
<213> Homo sapiens

<400> 62
gtgcctgctc ccaccacacg agtcccttct cccctgctttg gctcctcacc agttgtcagg 60
ttatgattat agaattctagt cctactcagt gaaagaactt tcatacatgt atgtgtagga 120
cagcatgata aaattcccaa gccagaccaa agtcaagggtg ctttttatca ctgtag 176
5

<210> 63
<211> 307
<212> DNA
10 <213> Homo sapiens

<400> 63
gtataactgt ggatggaaaa ctgttggttct ggcctgagtg gaaaacatga ctgttcaaaa 60
gtcctatatg tccagggctg ttgtatgatt ggcttgtctt cccccaggga cagcagagca 120
15 accttgaaaa agcagaggga agcttctccc ttggcacaca ctgggggtggc tgtaccatgc 180
ctgcagatgc tcccaaatag aggcactcca agcacntttg tttcttagcg tgattgaggc 240
tggatatgtg atttgatctt tctctggaac attctttcta atcatctttg tgttcattcc 300
ctgaaaa 307

20

<210> 64
<211> 376
<212> DNA
<213> Homo sapiens

25

<400> 64
aaaggaattt caccccaatc ttatactgac ttcaatagag ctttcagaca aaaagttggt 60
ttgtatatac tnatcagtca tgaaaagata attacaacta aatggccttt ttccttcctt 120
atztattttg agaaatttaa ttacataaga aagtactcag aatatgtgag tttcctgcat 180
30 caataagaca tttataataa tgacctgtt taaaaatgaa tttgaaagtn actctaattc 240
tttgattcat caagaaataa ctagaatggc aagttaaaat ttaagctgtt tcaaagatgc 300
ttcngcantt agaaactcnn ttatctttga tnttctgtcc cncnagcaaa taanacttan 360
tntattntna' tancag 376

35

<210> 65
<211> 482
<212> DNA

<213> Homo sapiens

<400> 65

gtccgtagta aagtcttggg ttctcactg tgggatgttt taactttcca agtagaatat 60
5 gcgatcattt tgtaaaaatt agaaaataca gaaaagcaaa gagtaaaaca attattacct 120
gaaattatat atgcatattc ttacaaaaat gcaagcccag tataaatact gctctttttc 180
acttaatata ttgtaaacad tattccaagt cagtgcattt aggtgtcatt tcttatagct 240
ggatagtatt ccattaggat atactcttat ttaactattc ccccttttgt agacatttgg 300
attattttcca acttgttcac aattgtanac nccaccacac tgaacagcat catccctata 360
10 tccacatgna cttgtaacag aatacaattc cctaggaagc tggaatgctg gaagtcatgg 420
tgatgttctc atggtnacag agaattctctc taganctaan acctctctct gttttaccgc 480
ag 482

15 <210> 66

<211> 47

<212> DNA

<213> Artificial Sequence

20 <220>

<223> Description of Artificial Sequence: Multiple
Cloning Site

<400> 66

25 cggccgcggc ggcgccggac cgcctaggat ttaaatcgcg gcccgcg 47

<210> 67

<211> 69

30 <212> DNA

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence: Multiple
Cloning Site

<400> 67

gctctagaat tcggcctccg tggccgttta aacgctagcg cccgggctta attaagtcga 60

ctctagagc

69

<210> 68

5 <211> 194

<212> DNA

<213> Homo sapiens

<400> 68

10 aagtctatatt ttaagttggt attgcttttt tcaagtattc ttccctcctt cacacacagt 60
tttctagtta atccatttat gtaattctgt atgctcctac ttgacctaat ttcaacatct 120
ggaaaaatag aactagaata aagaatgagc aagttgagtg gtatttataa aggtccatct 180
taatctttta acag 194

15

<210> 69

<211> 9741

<212> DNA

<213> Homo sapiens

20

<400> 69

cttgtttttt ccccggttct gttttctccc cttctccgga aggcttggtca aggggtagga 60
gaaagagacg caaacacaaa agtggaanaac agttaatgac cagccacggc gtccctgctg 120
tgagctctgg ccgctgcctt ccagggtctc cgagccacac gctgggggtg ctggctgagg 180
25 gaacatggct tggtggcctc agctgaggtt gctgctgttg aagaacctca ctttcagaag 240
aagacaaaca tgctagctgc tgctggaagt ggctggcct ctatttatct tctgatcct 300
gatctctgtt cggctgagct acccacccta tgaacaacat gaatgccatt ttccaaataa 360
agccatgccc tctgcaggaa cacttccttg ggttcagggg attatctgta atgccaacaa 420
cccctgtttc cgttaccoga ctctgggga ggctcccgga gttgttgga actttaacaa 480
30 atccattgtg gctcgcctgt tctcagatgc tcggaggctt cttttataca gccagaaaga 540
caccagcatg aaggacatgc gcaaagttct gagaacatta cagcagatca agaatccag 600
ctcaaaacttg aagcttcaag atttcttgtt ggacaatgaa accttctctg ggttcctgta 660
tcacaacctc tctctcccaa agtctactgt ggacaagatg ctgaggjctg atgtcattct 720
ccacaaggta tttttgcaag gctaccagtt acatttgaca agtctgtgca atggatcaaa 780
35 atcagaagag atgattcaac ttggtgacca agaagtttct gagctttgtg gcctaccaag 840
ggagaaactg gctgcagcag agcgagtact tcgttccaac atggacatcc tgaagccaat 900
cctgagaaca ctaaactcta catctccctt cccgagcaag gagctggccg aagccacaaa 960
aacattgctg catagtcttg ggactctggc ccaggagctg ttcagcatga gaagctggag 1020

tgacatgcga caggaggtga tgtttctgac caatgtgaac agctccagct cctccacca 1080
 aatctaccag gctgtgtctc gtattgtctg cgggcatccc gagggagggg ggctgaagat 1140
 caagtctctc aactggtatg aggacaacaa ctacaaagcc ctctttggag gcaatggcac 1200
 tgaggaagat gctgaaacct tctatgacaa ctctacaact ccttactgca atgatttgat 1260
 5 gaagaatttg gagtctagtc ctctttcccg cattatctgg aaagctctga agccgctgct 1320
 cgttggggaag atcctgtata cacctgacac tccagccaca aggcaggtca tggctgaggt 1380
 gaacaagacc ttccaggaac tggctgtgtt ccatgatctg gaaggcatgt gggaggaact 1440
 cagccccaag atctggacct tcatggagaa cagccaagaa atggaccttg tccggatgct 1500
 gttggacagc agggacaatg accacttttg ggaacagcag ttggatggct tagattggac 1560
 10 agcccaagac atcgtggcgt ttttggccaa gcaccagag gatgtccagt ccagtaatgg 1620
 ttctgtgtac acctggagag aagctttcaa cgagactaac caggcaatcc ggaccatata 1680
 tcgcttcatg gagtgtgtca acctgaacaa gctagaacct atagcaacag aagtctggct 1740
 catcaacaag tccatggagc tgctggatga gaggaagttc tgggctggta ttgtgttcac 1800
 tgggaattact ccaggcagca ttgagctgcc ccatcatgtc aagtacaaga tccgaatgga 1860
 15 cattgacaat gtggagagga caaataaaat caaggatggg tactgggacc ctggtcctcg 1920
 agctgacccc tttagggaca tgcggtacgt ctgggggggc ttcgcctact tgcaggatgt 1980
 ggtggagcag gcaatcatca ggtgtctgac gggcaccgag aagaaaactg gtgtctatat 2040
 gcaacagatg ccctatccct gttacgttga tgacatcttt ctgcgggtga tgagccggtc 2100
 aatgcccctc ttcatgacgc tggcctggat ttactcagtg gctgtgatca tcaagggcat 2160
 20 cgtgtatgag aaggaggcac ggctgaaaga gaccatgcgg atcatgggcc tggacaacag 2220
 catcctcttg tttagctggg tcattagtag cctcattcct cttcttgtga gcgctggcct 2280
 gctagtggtc atcctgaagt taggaaacct gctgccctac agtgatccca gcgtggtgtt 2340
 tgtcttcttg tccgtgtttg ctgtggtgac aatcctgcag tgcttctga ttagcacact 2400
 cttctccaga gccaacctgg cagcagcctg tgggggcatc atctacttca cgctgtacct 2460
 25 gccctacgtc ctgtgtgttg catggcagga ctacgtgggc ttcacactca agatcttcgc 2520
 tagcctgctg tctcctgttg cttttgggtt tggctgtgag tactttgccc tttttgagga 2580
 gcagggcatt ggagtgcagt gggacaacct gtttgagagt cctgtggagg aagatggctt 2640
 caatctcacc acttcgggtc ccatgatgct gtttgacacc ttcctctatg gggatgatgac 2700
 ctggtacatt gaggtgtctt ttccaggcca gtacggaatt cccaggccct ggtattttcc 2760
 30 ttgcaccaag tcctactggg ttggcgagga aagtgatgag aagagccacc ctggttccaa 2820
 ccagaagaga atatcagaaa tctgcatgga ggaggaacct acccacttga agctgggcgt 2880
 gtccattcag aacctggtaa aagtctaccg agatgggatg aaggtggctg tcgatggcct 2940
 ggcactgaat ttttatgagg gccagatcac ctcttctctg ggccacaatg gagcgggaa 3000
 gacgaccacc atgtcaatcc tgaccgggtt gttccccccg acctcgggca ccgcctacat 3060
 35 cctgggaaaa gacattcgct ctgagatgag caccatccgg cagaacctgg gggctctgtc 3120
 ccagcataac gtgctgtttg acatgctgac tgtcgaagaa cacatctggt tctatgccc 3180
 cttgaaaggg ctctctgaga agcacgtgaa ggcggagatg gagcagatgg ccctggatgt 3240
 tggtttgcca tcaagcaagc tgaaaagcaa aacaagccag ctgtcaggtg gaatgcagag 3300

aaagctatct gtggccttgg cctttgtcgg gggatctaag gttgtcattc tggatgaacc 3360
cacagctggg gtggaccctt actcccgcag gggaaatatgg gagctgctgc tgaataaccg 3420
acaaggccgc accattattc tctctacaca ccacatggat gaagcggacg tcctggggga 3480
caggattgcc atcatctccc atgggaagct gtgctgtgtg ggctcctccc tgtttctgaa 3540
5 gaaccagctg ggaacaggct actacctgac cttgggtcaag aaagatgtgg aatcctccct 3600
cagttcctgc agaaacagta gtagcactgt gtcatacctg aaaaaggagg acagtgtttc 3660
tcagagcagt tctgatgctg gcctgggcag cgaccatgag agtgacacgc tgaccatcga 3720
tgtctctgct atctccaacc tcatacaggaa gcatgtgtct gaagcccggc tgggtggaaga 3780
catagggcag gagctgacct atgtgctgcc atatgaagct gctaaggagg gagcctttgt 3840
10 ggaactcttt catgagattg atgaccggct ctcagacctg ggcatttcta gttatggcat 3900
ctcagagacg accctggaag aaatattcct caaggtggcc gaagagagtg ggggtggatgc 3960
tgagacctca gatggtacct tgccagcaag acgaaacagg cgggccttcg gggacaagca 4020
gagctgtctt cgcccgttca ctgaagatga tgctgctgat ccaaagtatt ctgacataga 4080
cccagaatcc agagagacag acttgctcag tgggatggat ggcaaagggt cctaccaggt 4140
15 gaaaggctgg aaacttacac agcaacagtt tgtggccctt ttgtggaaga gactgctaata 4200
tgccagacgg agtcggaaag gatTTTTTgc tcagattgtc ttgccagctg tgtttgtctg 4260
cattgccctt gtgttcagcc tgatcgtgcc accctttggc aagtaccca gcctggaact 4320
tcagccctgg atgtacaacg aacagtacac atttgtcagc aatgatgctc ctgaggacac 4380
gggaaccctg gaactcttaa acgcccctac caaagaccct ggcttcggga cccgctgtat 4440
20 ggaaggaaac ccaatcccag acacgccttg ccaggcaggg gaggaagagt ggaccactgc 4500
cccagttccc cagaccatca tggacctctt ccagaatggg aactggacaa tgcagaacct 4560
ttcacctgca tgccagtgtg gcagcgacaa aatcaagaag atgctgcctg tgtgtcccc 4620
aggggcaggg gggctgcctc ctccacaaaag aaaacaaaac actgcagata tccttcagga 4680
cctgacagga agaaacattt cggtattatc ggtgaagacg tatgtgcaga tcatagccaa 4740
25 aagcttaaag aacaagatct gggatgaatga gtttaggtat ggcggtttt ccctgggtgt 4800
cagtaatact caagcattc ctccgagtca agaagttaat gatgccacca aacaaatgaa 4860
gaaacacctg aagctggcca aggacagttc tgcagatcga tttctcaaca gcttgggaag 4920
atztatgaca ggactggaca ccagaaataa tgtcaagggt tggttcaata acaagggtg 4980
gcatgcaatc agctctttcc tgaatgtcat caacaatgcc attctccggg ccaacctgca 5040
30 aaagggagag aacctagcc attatggaat tactgctttc aatcatcccc tgaatctcac 5100
caagcagcag ctctcagagg tggctccgat gaccacatca gtggatgtcc ttgtgtccat 5160
ctgtgtcatc tttgcaatgt ccttcgtccc agccagcttt gtcgtattcc tgatccagga 5220
gcgggtcagc aaagcaaac acctgcagtt catcagtggg gtgaagcctg tcatctactg 5280
gctctctaata tttgtctggg atatgtgcaa ttacgttgtc cctgccacac tggtcattat 5340
35 catcttcata tgcttcagc agaagtccta tgtgtcctcc accaatctgc ctgtgctagc 5400
ccttctactt ttgtgtatg ggtgggtcaat cacacctctc atgtaccag cctcctttgt 5460
gttcaagatc ccagcacag cctatgtggg gctcaccagc gtgaacctct cattggcat 5520
taatggcagc gtggccacct ttgtgctgga gctgttcacc gacaataagc tgaataatat 5580

caatgatatc ctgaagtcgc tgttcttgat cttccacat ttttgctgg gacgagggct 5640
catcgacatg gtgaaaaacc aggcaatggc tgatgccctg gaaaggtttg gggagaatcg 5700
ctttgtgtca ccattatctt gggacttggg gggacgaaac ctcttcgcca tggccgtgga 5760
aggggtggtg ttcttcctca ttactgttct gatccagtac agattcttca tcaggccccag 5820
5 acctgtaaat gcaaagctat ctctctgaa tgatgaagat gaagatgtga ggcgggaaag 5880
acagagaatt cttgatggtg gaggccagaa tgacatctta gaaatcaagg agttgacgaa 5940
gatatataga aggaagcgga agcctgctgt tgacaggatt tgcgtgggca ttcctcctgg 6000
tgagtgtttt gggctcctgg gagttaatgg ggctggaaaa tcatcaactt tcaagatgtt 6060
aacaggagat accactgtta ccagaggaga tgctttcctt aacagaaata gtatcttctc 6120
10 aaacatccat gaagtacatc agaacatggg ctactgccct cagtttgatg ccatcacaga 6180
gctgttgact gggagagAAC acgtggagtt ctttgccctt ttgagaggag tcccagagaa 6240
agaagtggc aaggttggtg agtggcgat tcggaactg ggctcgtga agtatggaga 6300
aaaatatgct ggtaactata gtggaggcaa caacgcaag ctctctacag ccatggcttt 6360
gatcggcggg cctcctgtgg tgtttctgga tgaaccacc acaggcatgg atcccaaagc 6420
15 ccggcggttc ttgtggaatt gtgccctaag tgtgtcaag gaggggagat cagtagtgct 6480
tacatctcat agtatggaag aatgtgaagc tctttgact aggatggcaa tcatggtcaa 6540
tggaaggttc aggtgccttg gcagtgtcca gcatctaaaa aataggtttg gagatggtta 6600
tacaatagtt gtacgaatag cagggtccaa cccggacctg aagcctgtcc aggatctctt 6660
tggaactgca tttcctggaa gtgttccaaa agagaaacac cggaacatgc tacaatacca 6720
20 gcttccatct tcattatctt ctctggccag gatattcagc atcctctccc agagcaaaaa 6780
gcgactccac atagaagact actctgtttc tcagacaaca cttgaccaag tatttgtgaa 6840
ctttgccaag gaccaaagtg atgatgacca cttaaagac ctctcattac acaaaaacca 6900
gacagtagtg gacgttgca tttctcacatc ttttctacag gatgagaaaag tgaaagaaaag 6960
ctatgtatga agaactctgt tcatacgggg tggtgaaaag taaagaggna ctgactttc 7020
25 ctttgacca tgtgaagtgt tgtggagaaa agagccagaa gttgatgtgg gaagaagtaa 7080
actggatact gtactgatac tattcaatgc aatgcaattc aatgcaatga aaacaaaatt 7140
ccattacagg ggcagtgcct ttgtagccta tgtcttgat ggctctcaag tgaaagactt 7200
gaatttagtt ttttacctat acctatgtga aactctatta tggaaccaa tggacatatg 7260
ggtttgaaact cacacttttt tttttttttt gttcctgtgt attctcattg gggttgcaac 7320
30 aataattcat caagtaatca tggccagcga ttattgatca aaatcaaaag gtaatgcaca 7380
tcctcattca ctaagccatg ccatgccag gagactggtt tcccggtgac acatccattg 7440
ctggcaatga gtgtgccaga gttatttagt ccaagttttt cagaaagttt gaagcaccat 7500
gggtgtgcat gtcactttt gtgaaagctg ctctgctcag agtctatcaa cattgaatat 7560
cagttgacag aatggtgcca tgcgtggcta acatcctgct ttgattccct ctgataagct 7620
35 gttctggtg cagtaacatg caacaaaaat gtgggtgtct ctaggcacgg gaaacttgg 7680
tccattgtta tattgtccta tgcttcgagc catgggtcta cagggtcatc cttatgagac 7740
tcttaaatat acttagatcc tggtaaagag caaagaatca acagccaaac tgctggggct 7800
gcaagctgct gaagccagg catgggatta aagagattgt gcgttcaaac ctagggaagc 7860

ctgtgccccat ttgtcctgac tgtctgctaa catggtacac tgcattctcaa gatgtttatc 7920
tgacacaagt gtattatttc tggctttttg aattaatcta gaaaatgaaa agatggagtt 7980
gtattttgac aaaaatgttt gtacttttta atgttatttg gaattttaag ttctatcagt 8040
gacttctgaa tccttagaat ggccctcttg tagaaccctg tggatatagag gagtatggcc 8100
5 actgccccac tatttttatt ttcttatgta agtttgcata tcagtcatga ctagtgccta 8160
gaaagcaatg tgatggtcag gatctcatga cattatattt gagtttcttt cagatcattt 8220
aggatactct taatctcact tcatcaatca aatatttttt gagtgtatgc tgtagctgaa 8280
agagtatgta cgtacgtata agactagaga gatattaagt ctcatgtacac ttctgtgccc 8340
atgttattca gctcactggg ttacaaatat aggttgtctt gtgggtgtag gagccctg 8400
10 taacaatact gggcagcctt tttttttttt tttaattgca acaatgcaaa agccaagaaa 8460
gtataagggt cacaagtcta aacaatgaat tcttcaacag ggaaaacagc tagcttgaaa 8520
acttgcctgaa aaacacaact tgtgtttatg gcatttagta ccttcaaata attggctttg 8580
cagatatttg atacccattt aaatctgaca gtctcaaatt tttcatctct tcaatcacta 8640
gtcaagaaaa atataaaaa acaaaatact tccatatgga gcatttttca gagttttcta 8700
15 acccagtctt atttttctag tcagtaaaca ttgtaaaaa tactgtttca ctaatactta 8760
ctgttaactg tcttgagaga aaagaaaaat atgagagaac tattgtttgg ggaagttcaa 8820
gtgatctttc aatatcatta ctaactctt ccactttttc caaaatttga atattaacgc 8880
taaagggtgta agacttcaga ttctcaaatta atctttctat attttttaaa ttacagaat 8940
attatataac ccactgctga aaaagaaaaa aatgattgtt ttagaagtta aagtcaatat 9000
20 tgatttttaa tataagtaat gaaggcatat ttccaataac tagtgatatg gcacgtgtgc 9060
attttacagt atcttcaaaa atacagaatt tatagaataa tttctctca tttaatattt 9120
ttcaaaatca aagttatggg ttctcattt tactaaaatc gtatttctaat tcttcattat 9180
agtaaactta tgagcaactc cttacttcgg ttctctctgat ttcaaggcca tatttttaaa 9240
aatcaaaagg cactgtgaac tattttgaag aaaacacaac attttaatac agattgaaag 9300
25 gacctcttct gaagctagaa acaatctata gttatacatc ttcattaata ctgtgttacc 9360
tttttaaaata gtaatttttt acattttctt gtgtaaaacct aattgtggta gaaattttta 9420
ccaactctat actcaatcaa gcaaaatttc tgtatatctc ctgtggaatg tacctatgtg 9480
agtttcagaa attctcaaaa tacgtgttca aaaatttctg cttttgcac tttgggacac 9540
ctcagaaaaac ttattaacaa ctgtgaatat gagaaatata gaagaaaata ataagccctc 9600
30 tatacataaa tgcccagcac aattcattgt taaaaaaca ccaaacctca cactactgta 9660
tttcattatc tgtactgaaa gcaaatgctt tgtgactatt aaatgttgca catcattcat 9720
tcaaaaaaaaa aaaaaaaaaa a 9741

- 35 <210> 70
<211> 9854
<212> DNA
<213> Homo sapiens

<400> 70

gtgagtgggg ccgggacccg cagagccgag ccgacccttc tctcccgggc tgcggcaggg 60
cagggcgggg agctccgagc accaacagag ccggttctca gggcgctttg ctccctgttt 120
5 tttccccggg tctgttttct ccccttctcc ggaaggcttg tcaaggggta ggagaaagag 180
acgcaaacac aaaagtggaa aacagttaat gaccagccac ggcgtccctg ctgtgagctc 240
tggccgctgc ctccagggc tcccagacca cacgctgggg gtgctggctg agggaacatg 300
gcttgttggc ctgagctgag gttgctgctg tggaagaacc tcaactttcag aagaagacaa 360
acatgtcagc tgctgctgga agtggcctgg cctctattta tcttctgat cctgatctct 420
10 gttcggtga gctaccacc ctatgaacaa catgaatgcc attttccaaa taaagccatg 480
ccctctgcag gaacacttcc ttgggttcag gggattatct gtaatgcaa caacccctgt 540
ttccgttacc cgactcctgg ggaggctccc ggagttgttg gaaactttaa caaatccatt 600
gtggctcgcc tgttctcaga tgctcgagg cttcttttat acagccagaa agacaccagc 660
atgaaggaca tgcgcaaagt tctgagaaca ttacagcaga tcaagaaatc cagctcaaac 720
15 ttgaagcttc aagatttctt ggtggacaat gaaaccttct ctgggttctt gtatcacaa 780
ctctctctcc caaagtctac tgtggacaag atgctgagg ctgatgtcat tctccacaag 840
gtatttttgc aaggtacca gttacatttg acaagtctgt gcaatggatc aaaatcagaa 900
gagatgattc aacttgggtga ccaagaagtt tctgagcttt gtggcctacc aaggagagaa 960
ctggctgcag cagagcgagt acttcgttcc aacatggaca tcctgaagcc aatcctgaga 1020
20 aactaaact ctacatctcc ctcccgagc aaggagctgg ccgaagccac aaaaacattg 1080
ctgcatagtc ttgggactct ggcccaggag ctgttcagca tgagaagctg gagtacatg 1140
cgacaggagg tgatgtttct gaccaatgtg aacagctcca gctcctccac ccaaactctac 1200
caggctgtgt ctggtattgt ctggggcat cccgaggag gggggctgaa gatcaagtct 1260
ctcaactggt atgaggacaa caactacaaa gccctctttg gaggcaatgg cactgaggaa 1320
25 gatgctgaaa ccttctatga caactctaca actccttact gcaatgattt gatgaagaat 1380
ttggagtcta gtcctcttcc ccgcattatc tggaaagctc tgaagccgct gctcgttggg 1440
aagatcctgt atacacctga cactccagcc acaaggcagg tcatggctga ggtgaacaag 1500
accttccagg aactggctgt gttccatgat ctggaaggca tgtgggagga actcagcccc 1560
aagatctgga ccttcatgga gaacagcaa gaaatggacc ttgtccgat gctgttggac 1620
30 agcagggaca atgaccactt ttgggaacag cagttggatg gcttagattg gacagcccaa 1680
gacatcgtgg cgttttttggc caagcaccca gaggatgtcc agtccagtaa tggttctgtg 1740
tacacctgga gagaagcttt caacgagact aaccaggcaa tccggacat atctcgcttc 1800
atggagtgtg tcaacctgaa caagctagaa cccatagcaa cagaagtctg gctcatcaac 1860
aagtccatgg agctgctgga tgagaggaag ttctgggctg gtattgtgtt cactggaatt 1920
35 actccaggca gcattgagct gccccatcat gtcaagtaca agatccgaat ggacattgac 1980
aatgtggaga ggacaaataa aatcaaggat ggggtactgg accctggtcc tcgagctgac 2040
ccctttgagg acatgcggtg cgtctggggg ggcttcgctt acttgcagga tgtgggtggag 2100
caggcaatca tcagggtgct gacgggcacc gagaagaaaa ctggtgtcta tatgcaacag 2160

atgccctatc cctgttacgt tgatgacatc tttctgcggg tgatgagccg gtcaatgccc 2220
 ctcttcatga cgctggcctg gatttactca gtggctgtga tcatcaaggg catcgtgtat 2280
 gagaaggagg cacggctgaa agagaccatg cggatcatgg gcctggacaa cagcatcctc 2340
 tggtttagct ggttcattag tagcctcatt cctcttcttg tgagcgctgg cctgctagt 2400
 5 gtcacctga agttaggaaa cctgctgccc tacagtgatc ccagcggtgt gtttgtcttc 2460
 ctgtccgtgt ttgctgtggt gacaatcctg cagtgtcttc tgattagcac actcttctcc 2520
 agagccaacc tggcagcagc ctgtgggggc atcatctact tcacgctgta cctgccctac 2580
 gtccctgtgt tggcatggca ggactacgtg ggcttcacac tcaagatctt cgctagcctg 2640
 ctgtctcctg tggcttttg gtttggtgt gagtactttg ccctttttga ggagcagggc 2700
 10 attggagtgc agtgggacaa cctgtttgag agtcctgtgg aggaagatgg cttcaatctc 2760
 accacttcgg tctccatgat gctgtttgac accttctct atggggtgat gacctggtac 2820
 attgaggtg tctttccagg ccagtacgga attcccaggc cctggatttt tcttgacc 2880
 aagtcctact ggtttggcga ggaaagtgat gagaagagcc accctgggtc caaccagaag 2940
 agaatatcag aaatctgcat ggagaggaa cccaccact tgaagctggg cgtgtccatt 3000
 15 cagaacctgg taaaagtcta ccgagatggg atgaaggtg ctgtcgatgg cctggcactg 3060
 aatttttatg agggccagat cacctccttc ctgggccaca atggagcggg gaagacgacc 3120
 accatgtcaa tctgaccgg gttgttcccc ccgacctcg gcaccgccta catcctggga 3180
 aaagacattc gctctgagat gagcaccatc cggcagaacc tgggggtctg tccccagcat 3240
 aacgtgctgt ttgacatgct gactgtcgaa gaacacatct ggttctatgc ccgcttga 3300
 20 gggctctctg agaagcacgt gaaggcggag atggagcaga tggccctgga tgttggtttg 3360
 ccatcaagca agctgaaaag caaaacaagc cagctgtcag gtggaatgca gagaaagcta 3420
 tctgtggcct tggcctttgt cgggggatct aaggttgtca ttctggatga acccacagct 3480
 ggtgtggacc ctactcccg caggggaata tgggagctgc tgctgaaata ccgacaaggc 3540
 cgcaccatta ttctctctac acaccacatg gatgaagcgg acgtcctggg ggacaggatt 3600
 25 gccatcatct cccatgggaa gctgtgctgt gtgggctcct ccctgtttct gaagaaccag 3660
 ctgggaacag gctactacct gaccttggtc aagaaagatg tggaaatcct cctcagttcc 3720
 tgcagaaaca gtagtagcac tgtgtcatac ctgaaaaagg aggacagtgt ttctcagagc 3780
 agttctgatg ctggcctggg cagcgaccat gagagtga cgtgacctat cgatgtctct 3840
 gctatctcca acctcatcag gaagcatgtg tctgaagccc ggctggtgga agacataggg 3900
 30 catgagctga cctatgtgct gccatatgaa gctgctaagg agggagcctt tgtggaactc 3960
 tttcatgaga ttgatgaccg gctctcagac ctgggcattt ctagtattgg catctcagag 4020
 acgaccctgg aagaaatatt cctcaagggt gccgaagaga gtgggggtgga tgctgagacc 4080
 tcagatggta ccttgccagc aagacgaaac aggcgggcct tcggggacaa gcagagctgt 4140
 cttcgcccg tcaactgaaga tgatgctgct gatccaaatg attctgacat agaccagaa 4200
 35 tccagagaga cagacttgct cagtgggatg gatggcaaag ggtcctacca ggtgaaaggc 4260
 tggaaactta cacagcaaca gtttgtggcc cttttgtgga agagactgct aattgccaga 4320
 cggagtcgga aaggattttt tgctcagatt gtcttgccag ctgtgtttgt ctgcattgcc 4380
 cttgtgttca gcctgatcgt gccacccttt ggcaagtacc ccagcctgga acttcagccc 4440

tggatgtaca acgaacagta cacatttgtc agcaatgatg ctcttgagga cacgggaacc 4500
ctggaactct taaacgcctt caccaaagac cctggcttcg ggacccgctg tatggaagga 4560
aaccgaatcc cagacacgcc ctgccaggca ggggaggaag agtggaccac tgccccagtt 4620
ccccagacca tcatggacct cttccagaat gggaactgga caatgcagaa cccttcacct 4680
5 gcatgccagt gtagcagcga caaaatcaag aagatgctgc ctgtgtgtcc ccaggggca 4740
ggggggctgc ctctccaca aagaaaacaa aacactgcag atatccttca ggacctgaca 4800
ggaagaaaca tttcggatta tctggtgaag acgtatgtgc agatcatagc caaaagctta 4860
aagaacaaga tctgggtgaa tgagtttagg tatggcggct tttccctggg tgtcagtaat 4920
actcaagcac ttcctccgag tcaagaagtt aatgatgcca ccaaacaat gaagaaacac 4980
10 ctaaagctgg ccaaggacag ttctgcagat cgatttctca acagcttggg aagatttatg 5040
acaggactgg acaccagaaa taatgtcaag gtgtggttca ataacaaggg ctggcatgca 5100
atcagctctt tcctgaatgt catcaacaat gccattctcc gggccaacct gcaaaaggga 5160
gagaacccta gccattatgg aattactgct ttcaatcatc cctgaatct caccaagcag 5220
cagctctcag aggtggctcc gatgaccaca tcagtggatg tccttgtgtc catctgtgtc 5280
15 atctttgcaa tgccttcgt cccagccagc tttgtcgtat tcctgatcca ggagcgggtc 5340
agcaaagcaa aacacctgca gtcatcagt ggagtgaagc ctgtcatcta ctggctctct 5400
aattttgtct gggatatgtg caattacgtt gtccctgcca cactggatcat tatcatcttc 5460
atctgcttcc agcagaagtc ctatgtgtcc tccaccaatc tgctgtgtc agccttcta 5520
cttttgtgt atgggtggtc aatcacacct ctcatgtacc cagcctcctt tgtgttcaag 5580
20 atccccagca cagcctatgt ggtgctcacc agcgtgaacc tcttcattgg cattaatggc 5640
agcgtggcca cctttgtgtc ggagctgttc accgacaata agctgaataa tatcaatgat 5700
atcctgaagt ccgtgttctt gatcttcca catTTTTGCC tgggacgagg gctcatcgac 5760
atggtgaaaa accaggcaat ggctgatgcc ctggaaggt ttggggagaa tcgctttgtg 5820
tcaccattat cttgggactt ggtgggacga aacctcttcg ccatggccgt ggaaggggtg 5880
25 gtgttcttcc tcattactgt tctgatccag tacagattct tcatcaggcc cagacctgta 5940
aatgcaaagc tatctcctct gaatgatgaa gatgaagatg tgaggcgga aagacagaga 6000
attcttgatg gtggaggcca gaatgacatc ttagaaatca aggagttgac gaagatatat 6060
agaaggaagc ggaagcctgc tgttgacagg atttgctgg gcattcctcc tggtagtg 6120
tttgggctcc tgggagttaa tggggctgga aaatcatcaa ctttcaagat gttaacagga 6180
30 gataccactg ttaccagagg agatgcttct cttaacagaa atagtatctt atcaaacatc 6240
catgaagtac atcagaacat gggctactgc cctcagtttg atgccatcac agagctgttg 6300
actgggagag aacacgtgga gttctttgcc cttttgagag gagtcccaga gaaagaagtt 6360
ggcaagggtg gtgagtggc gattcgaaa ctgggcctcg tgaagtatgg agaaaaatat 6420
gctggttaact atagtggagg caacaaacgc aagctctcta cagccatggc tttgatcggc 6480
35 gggcctcctg tgggtgttct ggatgaacc accacaggca tggatcccaa agcccgcg 6540
ttcttggga attgtgccct aagtgtgtc aaggagggga gatcagtagt gcttacatct 6600
catagtatgg aagaatgtga agctctttgc actaggatgg caatcatggt caatggaagg 6660
ttcaggtgcc ttggcagtg ccagcatcta aaaaataggt ttggagatgg ttatacaata 6720

gttgtacgaa tagcagggtc caaccgggac ctgaagcctg tccaggattt ctttggactt 6780
 gcatttcctg gaagtgttcc aaaagagaaa caccggaaca tgctacaata ccagcttcca 6840
 tcttcattat cttctctggc caggatattc agcatcctct cccagagcaa aaagcgactc 6900
 cacatagaag actactctgt ttctcagaca acacttgacc aagtatttgt gaactttgcc 6960
 5 aaggaccaa gtgatgatga ccacttaaaa gacctctcat tacacaaaaa ccagacagta 7020
 gtggacgttg cagttctcac atcttttcta caggatgaga aagtgaaga aagctatgta 7080
 tgaagaatcc tgttcatacg ggggtgctga aagtaaagag gnactagact ttcctttgca 7140
 ccatgtgaag tgttgtggag aaaagagcca gaagttgatg tgggaagaag taaactggat 7200
 actgtactga tactattcaa tgcaatgcaa ttcaatgcaa tgaaaacaaa attccattac 7260
 10 aggggcagtg cttttgtagc ctatgtcttg tatggctctc aagtgaaga cttgaattta 7320
 gttttttacc tatacctatg tgaaactcta ttatggaacc caatggacat atggggttga 7380
 actcacactt tttttttttt ttgttctctg tgtattctca ttgggggttg aacaataatt 7440
 catcaagtaa tcatggccag cgattattga tcaaatcaa aaggtaatgc acatcctcat 7500
 tctaagacc atgccatgcc caggagactg gtttcccggt gacacatcca ttgctggcaa 7560
 15 tgagtgtgcc agagtatta gtgccaagtt tttcagaaaag tttgaagcac catggtgtgt 7620
 catgctcact tttgtgaaag ctgctctgct cagagtctat caacattgaa tatcagttga 7680
 cagaatggtg ccatgcgtgg ctaacatcct gctttgattc cctctgataa gctgttctgg 7740
 tggcagtaac atgcaacaaa aatgtgggtg tctctaggca cgggaaactt ggttccattg 7800
 ttatattgtc ctatgcttcg agccatgggt ctacagggtc atccttatga gactcttaaa 7860
 20 tatacttaga tcctggtaag aggcaaagaa tcaacagcca aactgctggg gctgcaagct 7920
 gctgaagcca gggcatggga ttaaagagat tgtgcgttca aacctaggga agcctgtgcc 7980
 catttgtcct gactgtctgc taacatggta cactgcatct caagatgttt atctgacaca 8040
 agtgtattat ttctggcttt ttgaattaat ctagaaaatg aaaagatgga gttgtatttt 8100
 gacaaaaatg tttgtacttt ttaatgttat ttggaatttt aagttctatc agtgacttct 8160
 25 gaatccttag aatggcctct ttgtagaacc ctgtgggtata gaggagtatg gccactgccc 8220
 cactattttt attttcttat gtaagtttgc atatcagtca tgactagtgc ctagaaagca 8280
 atgtgatggt caggatctca tgacattata tttgagtttc tttcagatca tttaggatac 8340
 tcttaatctc acttcatcaa tcaaatattt tttgagtgtg tgctgtagct gaaagagtat 8400
 gtacgtacgt ataagactag agagatatta agtctcagta cacttcctgt gccatgttat 8460
 30 tcagctcact ggtttacaaa tataggttgt cttgtgggtg taggagccca ctgtaacaat 8520
 actgggcagc cttttttttt ttttttaatt gcaacaatgc aaaagccaag aaagtataag 8580
 ggtcacaagt ctaaacaatg aattcttcaa cagggaaaac agctagcttg aaaacttgct 8640
 gaaaaaaca acttgtgttt atggcattta gtaccttcaa ataattggct ttgcagatat 8700
 tggatacccc attaaatctg acagtctcaa atttttcatc tcttcaatca ctagtcaaga 8760
 35 aaaaataaaa aacaacaaat acttccatat ggagcatttt tcagagtttt ctaaccaggt 8820
 cttatttttc tagtcagtaa acatttgtta aaatactgtt tctaataac ttactgttaa 8880
 ctgtcttgag agaaaagaaa aatatgagag aactattgtt tggggaagtt caagtgatct 8940
 ttcaatatca ttactaactt cttccacttt ttccaaaatt tgaatattaa cgctaaaggt 9000

gtaagacttc agatttcaaa ttaatctttc tatatttttt aaatttacag aatattatat 9060
 aaccactgc tgaaaaagaa aaaaatgatt gttttagaag ttaaagtcaa tattgatttt 9120
 aaatataagt aatgaaggca tttttccaat aactagtgat atggcatcgt tgcattttac 9180
 agtatcttca aaaatacaga atttatagaa taatttctcc tcatttaata tttttcaaaa 9240
 5 tcaaagttat ggtttcctca ttttactaaa atcgtattct aattcttcat tatagtaaat 9300
 ctatgagcaa ctcttactt cggttcctct gatttcaagg ccatatttta aaaaatcaaa 9360
 aggactgtg aactattttg aagaaaacac aacattttta tacagattga aaggacctct 9420
 tctgaagcta gaaacaatct atagttatac atcttcatta atactgtgtt accttttaaa 9480
 atagtaattt tttacatttt cctgtgtaaa cctaattgtg gtagaaattt ttaccaactc 9540
 10 tatactcaat caagcaaat ttctgtatat tccctgtgga atgtacctat gtgagtttca 9600
 gaaattctca aaatacgtgt tcaaaaattt ctgcttttgc atctttggga cacctcagaa 9660
 aacttattaa caactgtgaa tatgagaaat acagaagaaa ataataagcc ctctatacat 9720
 aaatgccag cacaattcat tgtaaaaaa caaccaaacc tcacactact gtatttcatt 9780
 atctgtactg aaagcaaatg ctttgtgact attaaatggt gcacatcatt cattcaaaaa 9840
 15 aaaaaaaaaa aaaa 9854

<210> 71

<211> 2261

20 <212> PRT

<213> Homo sapiens

<400> 71

Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr
 25 1 5 10 15
 Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro
 20 25 30
 30 Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro
 35 40 45
 Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala
 50 55 60
 35 Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro
 65 70 75 80

	Cys	Phe	Arg	Tyr	Pro	Thr	Pro	Gly	Glu	Ala	Pro	Gly	Val	Val	Gly	Asn	
					85						90					95	
5	Phe	Asn	Lys	Ser	Ile	Val	Ala	Arg	Leu	Phe	Ser	Asp	Ala	Arg	Arg	Leu	
			100						105					110			
	Leu	Leu	Tyr	Ser	Gln	Lys	Asp	Thr	Ser	Met	Lys	Asp	Met	Arg	Lys	Val	
			115					120					125				
10	Leu	Arg	Thr	Leu	Gln	Gln	Ile	Lys	Lys	Ser	Ser	Ser	Asn	Leu	Lys	Leu	
		130					135					140					
	Gln	Asp	Phe	Leu	Val	Asp	Asn	Glu	Thr	Phe	Ser	Gly	Phe	Leu	Tyr	His	
15		145				150					155					160	
	Asn	Leu	Ser	Leu	Pro	Lys	Ser	Thr	Val	Asp	Lys	Met	Leu	Arg	Ala	Asp	
				165					170					175			
	Val	Ile	Leu	His	Lys	Val	Phe	Leu	Gln	Gly	Tyr	Gln	Leu	His	Leu	Thr	
20			180						185					190			
	Ser	Leu	Cys	Asn	Gly	Ser	Lys	Ser	Glu	Glu	Met	Ile	Gln	Leu	Gly	Asp	
		195					200						205				
25	Gln	Glu	Val	Ser	Glu	Leu	Cys	Gly	Leu	Pro	Arg	Glu	Lys	Leu	Ala	Ala	
		210					215					220					
	Ala	Glu	Arg	Val	Leu	Arg	Ser	Asn	Met	Asp	Ile	Leu	Lys	Pro	Ile	Leu	
	225				230					235						240	
30	Arg	Thr	Leu	Asn	Ser	Thr	Ser	Pro	Phe	Pro	Ser	Lys	Glu	Leu	Ala	Glu	
				245					250						255		
	Ala	Thr	Lys	Thr	Leu	Leu	His	Ser	Leu	Gly	Thr	Leu	Ala	Gln	Glu	Leu	
35			260						265					270			
	Phe	Ser	Met	Arg	Ser	Trp	Ser	Asp	Met	Arg	Gln	Glu	Val	Met	Phe	Leu	
			275						280					285			

Thr Asn Val Asn Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val
 290 295 300

5 Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys
 305 310 315 320

Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly
 325 330 335

10 Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr
 340 345 350

Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser
 15 355 360 365

Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu
 370 375 380

20 Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn
 385 390 395 400

Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu Glu Gly Met Trp
 405 410 415

25 Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu Asn Ser Gln Glu
 420 425 430

Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp Asn Asp His Phe
 30 435 440 445

Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala Gln Asp Ile Val
 450 455 460

35 Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser Ser Asn Gly Ser
 465 470 475 480

Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn Gln Ala Ile Arg

	485	490	495
	Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn Lys Leu Glu Pro		
	500	505	510
5	Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met Glu Leu Leu Asp		
	515	520	525
	Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly Ile Thr Pro Gly		
10	530	535	540
	Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile		
	545	550	555 560
15	Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro		
	565	570	575
	Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr Val Trp Gly Gly		
	580	585	590
20	Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile Ile Arg Val Leu		
	595	600	605
	Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln Gln Met Pro Tyr		
25	610	615	620
	Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met Ser Arg Ser Met		
	625	630	635 640
30	Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val Ala Val Ile Ile		
	645	650	655
	Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys Glu Thr Met Arg		
	660	665	670
35	Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser Trp Phe Ile Ser		
	675	680	685

Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val Ile Leu
 690 695 700

5 Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser Val Val Phe Val
 705 710 715 720

Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln Cys Phe Leu Ile
 725 730 735

10 Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala Cys Gly Gly Ile
 740 745 750

Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys Val Ala Trp Gln
 755 760 765

15 Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser Leu Leu Ser Pro
 770 775 780

Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Gln
 20 785 790 795 800

Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu
 805 810 815

25 Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr
 820 825 830

Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly
 835 840 845

30 Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr
 850 855 860

Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln
 35 865 870 875 880

Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys
 885 890 895

Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met
 900 905 910

5 Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile
 915 920 925

Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Met Ser
 930 935 940

10 Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu
 945 950 955 960

Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Leu Gly
 15 965 970 975

Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu
 980 985 990

20 His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val
 995 1000 1005

Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser
 1010 1015 1020

25 Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys
 1025 1030 1035 1040

Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu
 30 1045 1050 1055

Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp
 1060 1065 1070

35 Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr
 1075 1080 1085

His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile

	1090	1095	1100	
	Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu Phe Leu Lys Asn			
	1105	1110	1115	1120
5	Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys Lys Asp Val Glu			
	1125	1130	1135	
	Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Ser Thr Val Ser Tyr Leu			
10	1140	1145	1150	
	Lys Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly			
	1155	1160	1165	
15	Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser			
	1170	1175	1180	
	Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile			
	1185	1190	1195	1200
20	Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly			
	1205	1210	1215	
	Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu			
25	1220	1225	1230	
	Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe			
	1235	1240	1245	
30	Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp Gly			
	1250	1255	1260	
	Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys Gln Ser			
	1265	1270	1275	1280
35	Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro Asn Asp Ser			
	1285	1290	1295	

	Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu Ser Gly Met Asp
	1300 1305 1310
5	Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu Thr Gln Gln Gln
	1315 1320 1325
	Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala Arg Arg Ser Arg
	1330 1335 1340
10	Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val Phe Val Cys Ile
	1345 1350 1355 1360
	Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly Lys Tyr Pro Ser
	1365 1370 1375
15	Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr Thr Phe Val Ser
	1380 1385 1390
	Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu
20	1395 1400 1405
	Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile
	1410 1415 1420
25	Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro
	1425 1430 1435 1440
	Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met
	1445 1450 1455
30	Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys
	1460 1465 1470
	Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Pro Gln
35	1475 1480 1485
	Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg Asn
	1490 1495 1500

Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala Lys Ser
 1505 1510 1515 1520

5 Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr Gly Gly Phe Ser
 1525 1530 1535

Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Pro Ser Gln Glu Val Asn
 1540 1545 1550

10 Asp Ala Thr Lys Gln Met Lys Lys His Leu Lys Leu Ala Lys Asp Ser
 1555 1560 1565

Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly Arg Phe Met Thr Gly Leu
 15 1570 1575 1580

Asp Thr Arg Asn Asn Val Lys Val Trp Phe Asn Asn Lys Gly Trp His
 1585 1590 1595 1600

20 Ala Ile Ser Ser Phe Leu Asn Val Ile Asn Asn Ala Ile Leu Arg Ala
 1605 1610 1615

Asn Leu Gln Lys Gly Glu Asn Pro Ser His Tyr Gly Ile Thr Ala Phe
 1620 1625 1630

25 Asn His Pro Leu Asn Leu Thr Lys Gln Gln Leu Ser Glu Val Ala Pro
 1635 1640 1645

Met Thr Thr Ser Val Asp Val Leu Val Ser Ile Cys Val Ile Phe Ala
 30 1650 1655 1660

Met Ser Phe Val Pro Ala Ser Phe Val Val Phe Leu Ile Gln Glu Arg
 1665 1670 1675 1680

35 Val Ser Lys Ala Lys His Leu Gln Phe Ile Ser Gly Val Lys Pro Val
 1685 1690 1695

Ile Tyr Trp Leu Ser Asn Phe Val Trp Asp Met Cys Asn Tyr Val Val

	1700	1705	1710
	Pro Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe Gln Gln Lys Ser		
	1715	1720	1725
5			
	Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu Leu Leu Leu Leu		
	1730	1735	1740
	Tyr Gly Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala Ser Phe Val Phe		
10	1745	1750	1755 1760
	Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser Val Asn Leu Phe		
	1765	1770	1775
15	Ile Gly Ile Asn Gly Ser Val Ala Thr Phe Val Leu Glu Leu Phe Thr		
	1780	1785	1790
	Asp Asn Lys Leu Asn Asn Ile Asn Asp Ile Leu Lys Ser Val Phe Leu		
	1795	1800	1805
20	Ile Phe Pro His Phe Cys Leu Gly Arg Gly Leu Ile Asp Met Val Lys		
	1810	1815	1820
	Asn Gln Ala Met Ala Asp Ala Leu Glu Arg Phe Gly Glu Asn Arg Phe		
25	1825	1830	1835 1840
	Val Ser Pro Leu Ser Trp Asp Leu Val Gly Arg Asn Leu Phe Ala Met		
	1845	1850	1855
30	Ala Val Glu Gly Val Val Phe Phe Leu Ile Thr Val Leu Ile Gln Tyr		
	1860	1865	1870
	Arg Phe Phe Ile Arg Pro Arg Pro Val Asn Ala Lys Leu Ser Pro Leu		
	1875	1880	1885
35	Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln Arg Ile Leu Asp		
	1890	1895	1900

	Gly Gly Gly Gln Asn Asp Ile Leu Glu Ile Lys Glu Leu Thr Lys Ile	
	1905	1910 1915 1920
5	Tyr Arg Arg Lys Arg Lys Pro Ala Val Asp Arg Ile Cys Val Gly Ile	
	1925	1930 1935
	Pro Pro Gly Glu Cys Phe Gly Leu Leu Gly Val Asn Gly Ala Gly Lys	
	1940	1945 1950
10	Ser Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr Val Thr Arg Gly	
	1955	1960 1965
	Asp Ala Phe Leu Asn Arg Asn Ser Ile Leu Ser Asn Ile His Glu Val	
	1970	1975 1980
15	His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Thr Glu Leu	
	1985	1990 1995 2000
	Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu Leu Arg Gly Val	
20	2005	2010 2015
	Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala Ile Arg Lys Leu	
	2020	2025 2030
25	Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly Asn Tyr Ser Gly Gly	
	2035	2040 2045
	Asn Lys Arg Lys Leu Ser Thr Ala Met Ala Leu Ile Gly Gly Pro Pro	
	2050	2055 2060
30	Val Val Phe Leu Asp Glu Pro Thr Thr Gly Met Asp Pro Lys Ala Arg	
	2065	2070 2075 2080
	Arg Phe Leu Trp Asn Cys Ala Leu Ser Val Val Lys Glu Gly Arg Ser	
35	2085	2090 2095
	Val Val Leu Thr Ser His Ser Met Glu Glu Cys Glu Ala Leu Cys Thr	
	2100	2105 2110

Arg Met Ala Ile Met Val Asn Gly Arg Phe Arg Cys Leu Gly Ser Val
2115 2120 2125

5 Gln His Leu Lys Asn Arg Phe Gly Asp Gly Tyr Thr Ile Val Val Arg
2130 2135 2140

Ile Ala Gly Ser Asn Pro Asp Leu Lys Pro Val Gln Asp Phe Phe Gly
2145 2150 2155 2160

10 Leu Ala Phe Pro Gly Ser Val Pro Lys Glu Lys His Arg Asn Met Leu
2165 2170 2175

Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile Phe Ser
15 2180 2185 2190

Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr Ser Val
2195 2200 2205

20 Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Asp Gln
2210 2215 2220

Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn Gln Thr
2225 2230 2235 2240

25 Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp Glu Lys Val
2245 2250 2255

Lys Glu Ser Tyr Val
30 2260

<210> 72
<211> 122
35 <212> DNA
<213> Homo sapiens

<400> 72

acttgaagct tcaagatttc ctggtggaca atgaaacctt ctctgggttc ctatatcaca 60
acctctctct cccaaagtct actgtggaca agatgctgag ggctgatgtc attctccaca 120
ag 122

5

<210> 73
<211> 177
<212> DNA
<213> Homo sapiens

10

<400> 73
gtatttttgc aaggctacca gttacatttg acaagtctgt gcaatggatc aaaatcagaa 60
gagatgattc aacttgggtga ccaagaagtt tctgagcttt gtggcctacc aaaggagaaa 120
ctggctgcag cagagcgagt acttcgttcc aacatggaca tcctgaagcc aatcctg 177

15

<210> 74
<211> 177
<212> DNA
20 <213> Homo sapiens

<400> 74
gtatttttgc aaggctacca gttacatttg acaagtctgt gcaatggatc aaaatcagaa 60
gagatgattc aacttgggtga ccaagaagtt tctgagcttt gtggcctacc aaggagagaaa 120
25 ctggctgcag cagagtgagt acttcgttcc aacatggaca tcctgaagcc aatcctg 177

<210> 75
<211> 241
30 <212> DNA
<213> Homo sapiens

<400> 75
ctgttcagca tgagaagctg gactgacatg tgacaggagg tgatgtttct gaccaatgtg 60
35 aacagctcca gtcctccac ccaaatctac caggctgtgt ctctgattgt ctgcgggcat 120
cccaggggag gggggctgaa gatcaagtct ctcaactggt atgaggacaa caactacaaa 180
gccctctttg gaggcaatgg cactgaggaa gatgctgaaa ccttctatga caactctaca 240
a 241

<210> 76

<211> 241

5 <212> DNA

<213> Homo sapiens

<400> 76

ctgttcagca tgagaagctg gagtgacatg cgacaggagg tgatgtttct gaccaatgtg 60
10 aacagctcca gtcctccac ccaaattctac caggctgtgt ctcgtattgt ctgcgggcat 120
cctgagggag gggggctgaa gatcaagtct ctcaactggt atgaggacaa caactacaaa 180
gccctctttg gaggcaatgg cactgaggaa gatgctgaaa ccttctatga caactctaca 240
a 241

15

<210> 77

<211> 241

<212> DNA

<213> Homo sapiens

20

<400> 77

ctgttcagca tgagaagctg gagtgacatg cgacaggagg tgatgtttct gaccaatgtg 60
aacagctcca gtcctccac ccaaattctac caggctgtgt ctcgtattgt ctgcgggcat 120
cccgagggag ggggactgaa gatcaagtct ctcaactggt atgaggacaa caactacaaa 180
25 gccctctttg gaggcaatgg cactgaggaa gatgctgaaa ccttctatga caactctaca 240
a 241

<210> 78

30 <211> 176

<212> DNA

<213> Homo sapiens

<400> 78

gtactgggac cctggtcctc gagctgaccc ctttgaggac atgcggtacg tctggggggg 60
cttcgcctac ttgcaggatg tggtaggagca ggcaatcctc aggttgctac gggcaccgag 120
aagaaaactg gtgtctatat gcaacagatg ccctatccct gttacgttga tgacat 176

<210> 79

<211> 222

<212> DNA

5 <213> Homo sapiens

<400> 79

ttaggaaacc tgctgcccta cagtgatccc agcgtggtgt ttgtcttcct gtccgtgttt 60
gctgtggtga caatcctgca gtgcttcctg attagcacac tcttctccag agccaacctg 120
10 gcagcagcct gtgggggcat catctacttc acgctgtacc tgccctacgt cctgtgtgtg 180
gcatggcagg actacgtggg cttcccactc aagatcttcg ct 222

<210> 80

15 <211> 114

<212> DNA

<213> Homo sapiens

<400> 80

gccagtacag aattcccagg ccctggtatt ttccttgac caagtcctac tggtttggcg 60
aggaaagtga tgagaagagc caccctggtt ccaaccagaa gagaatatca gaaa 114

<210> 81

25 <211> 114

<212> DNA

<213> Homo sapiens

<400> 81

gccagtacgg aattcccagg ccctggtatt ttccttgac caagtcctac tggtttggcg 60
aggaaagtga tgagaagagc caccctggtt ccaaccagaa gagaatgtca gaaa 114

<210> 82

35 <211> 219

<212> DNA

<213> Homo sapiens

<400> 82
gccgcacccat tattctctct acacaccaca tggatgaagc ggacgtcctg ggggacagga 60
ttgccatcat ctcccatggg aagctgtgct gtgtgggctc ccctgtttct gaagaaccag 120
ctgggaacag gctactacct gaccttggtc aagaaagatg tggaatcctc cctcagttcc 180
5 tgcagaaaca gtagtagcac tgtgtcatat ctgaaaaag 219

<210> 83
<211> 219
10 <212> DNA
<213> Homo sapiens

<400> 83
gccgcacccat tattctctct acacaccaca tggatgaagc ggacgtcctg ggggacagga 60
15 ttgccatcat ctcccatggg aagctgtgct gtgtgggctc ccctgtttct gaagaaccag 120
ctgggaacag gctactacct gaccttggtc aagaaagatg tggaatcctc cctcagttcc 180
tgcagaaaca gtagtagcac tgtgtcatat ctgaaaaag 219

20 <210> 84
<211> 149
<212> DNA
<213> Homo sapiens

25 <400> 84
aatccagaga gacagacttg ctacgtggga tggatggcaa agggtcctac caggtgaaag 60
gctggaaact tacacagcaa cagtttgtgg cccttttgtg gaagagactg ctaattgcc 120
gatggagtcg gaaaggattt tttgctcag 149

30 <210> 85
<211> 33
<212> DNA
<213> Homo sapiens

35 <400> 85
cttaaagaac aagatctgag tgaatgagtt tag 33

<210> 86
<211> 75
<212> DNA
5 <213> Homo sapiens

<400> 86
gacagttctg cagatcgatt tctcaacagc ttgggaagat ttatgacagg actggacacc 60
aaaaataatg tcaag 75

10

<210> 87
<211> 93
<212> DNA
15 <213> Homo sapiens

<400> 87
tgtggaagaa tgtgaagctc tttgcactag gatggcaatc atggccaatg gaaggttcag 60
gtgccttggc agtgtccagc atctaaaaaa tag 93

20

<210> 88
<211> 92
<212> DNA
25 <213> Homo sapiens

<400> 88
tatggaagaa tgtgaagctc tttgcatagg atggcaatca tggccaatgg aaggttcagg 60
tgccttggca gtgtccagca tctaaaaaat ag 92

30

<210> 89
<211> 2261
<212> PRT
35 <213> Homo sapiens

<400> 89
Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr

	1		5		10		15									
	Phe	Arg	Arg	Arg	Gln	Thr	Cys	Gln	Leu	Leu	Leu	Glu	Val	Ala	Trp	Pro
				20					25						30	
5																
	Leu	Phe	Ile	Phe	Leu	Ile	Leu	Ile	Ser	Val	Arg	Leu	Ser	Tyr	Pro	Pro
				35				40						45		
	Tyr	Glu	Gln	His	Glu	Cys	His	Phe	Pro	Asn	Lys	Ala	Met	Pro	Ser	Ala
10		50						55						60		
	Gly	Thr	Leu	Pro	Trp	Val	Gln	Gly	Ile	Ile	Cys	Asn	Ala	Asn	Asn	Pro
	65					70					75				80	
15	Cys	Phe	Arg	Tyr	Pro	Thr	Pro	Gly	Glu	Ala	Pro	Gly	Val	Val	Gly	Asn
						85				90					95	
	Phe	Asn	Lys	Ser	Ile	Val	Ala	Arg	Leu	Phe	Ser	Asp	Ala	Arg	Arg	Leu
						100				105					110	
20																
	Leu	Leu	Tyr	Ser	Gln	Lys	Asp	Thr	Ser	Met	Lys	Asp	Met	Arg	Lys	Val
						115				120					125	
	Leu	Arg	Thr	Leu	Gln	Gln	Ile	Lys	Lys	Ser	Ser	Ser	Asn	Leu	Lys	Leu
25		130						135							140	
	Gln	Asp	Phe	Leu	Val	Asp	Asn	Glu	Thr	Phe	Ser	Gly	Phe	Leu	Tyr	His
	145						150					155			160	
30	Asn	Leu	Ser	Leu	Pro	Lys	Ser	Thr	Val	Asp	Lys	Met	Leu	Arg	Ala	Asp
						165					170				175	
	Val	Ile	Leu	His	Lys	Val	Phe	Leu	Gln	Gly	Tyr	Gln	Leu	His	Leu	Thr
					180					185					190	
35																
	Ser	Leu	Cys	Asn	Gly	Ser	Lys	Ser	Glu	Glu	Met	Ile	Gln	Leu	Gly	Asp
					195					200					205	

	Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala	
	210	215 220
	Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu	
5	225	230 235 240
	Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu	
	245	250 255
10	Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu	
	260	265 270
	Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu Val Met Phe Leu	
	275	280 285
15	Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val	
	290	295 300
	Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys	
20	305	310 315 320
	Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly	
	325	330 335
25	Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr	
	340	345 350
	Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser	
	355	360 365
30	Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu	
	370	375 380
	Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn	
35	385	390 395 400
	Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu Glu Gly Met Trp	
	405	410 415

Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu Asn Ser Gln Glu
 420 425 430

5 Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp Asn Asp His Phe
 435 440 445

Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala Gln Asp Ile Val
 450 455 460

10 Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser Ser Asn Gly Ser
 465 470 475 480

Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn Gln Ala Ile Arg
 15 485 490 495

Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn Lys Leu Glu Pro
 500 505 510

20 Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met Glu Leu Leu Asp
 515 520 525

Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly Ile Thr Pro Gly
 530 535 540

25 Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile
 545 550 555 560

Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro
 30 565 570 575

Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr Val Trp Gly Gly
 580 585 590

35 Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile Ile Arg Val Leu
 595 600 605

Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln Gln Met Pro Tyr

	610	615	620	
	Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met Ser Arg Ser Met			
	625	630	635	640
5	Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val Ala Val Ile Ile			
	645	650	655	
	Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys Glu Thr Met Arg			
10	660	665	670	
	Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser Trp Phe Ile Ser			
	675	680	685	
15	Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val Ile Leu			
	690	695	700	
	Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser Val Val Phe Val			
	705	710	715	720
20	Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln Cys Phe Leu Ile			
	725	730	735	
	Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala Cys Gly Gly Ile			
25	740	745	750	
	Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys Val Ala Trp Gln			
	755	760	765	
30	Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser Leu Leu Ser Pro			
	770	775	780	
	Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Gln			
	785	790	795	800
35	Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu			
	805	810	815	

Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr

020

025

030

Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys
 1025 1030 1035 1040

5 Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu
 1045 1050 1055

Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp
 1060 1065 1070

10 Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr
 1075 1080 1085

His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile
 15 1090 1095 1100

Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu Phe Leu Lys Asn
 1105 1110 1115 1120

20 Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys Lys Asp Val Glu
 1125 1130 1135

Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Ser Thr Val Ser Tyr Leu
 1140 1145 1150

25 Lys Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly
 1155 1160 1165

Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser
 30 1170 1175 1180

Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile
 1185 1190 1195 1200

35 Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly
 1205 1210 1215

Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu

	1220	1225	1230
	Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe		
	1235	1240	1245
5	Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp Gly		
	1250	1255	1260
	Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys Gln Ser		
10	1265	1270	1275 1280
	Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro Asn Asp Ser		
	1285	1290	1295
15	Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu Ser Gly Met Asp		
	1300	1305	1310
	Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu Thr Gln Gln Gln		
	1315	1320	1325
20	Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala Arg Arg Ser Arg		
	1330	1335	1340
	Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val Phe Val Cys Ile		
25	1345	1350	1355 1360
	Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly Lys Tyr Pro Ser		
	1365	1370	1375
30	Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr Thr Phe Val Ser		
	1380	1385	1390
	Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu		
	1395	1400	1405
35	Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile		
	1410	1415	1420

Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro
 1425 1430 1435 1440

Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met
 5 1445 1450 1455

Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys
 1460 1465 1470

10 Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Pro Gln
 1475 1480 1485

Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg Asn
 1490 1495 1500

15 Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala Lys Ser
 1505 1510 1515 1520

Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr Gly Gly Phe Ser
 20 1525 1530 1535

Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Pro Ser Gln Glu Val Asn
 1540 1545 1550

25 Asp Ala Thr Lys Gln Met Lys Lys His Leu Lys Leu Ala Lys Asp Ser
 1555 1560 1565

Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly Arg Phe Met Thr Gly Leu
 1570 1575 1580

30 Asp Thr Arg Asn Asn Val Lys Val Trp Phe Asn Asn Lys Gly Trp His
 1585 1590 1595 1600

Ala Ile Ser Ser Phe Leu Asn Val Ile Asn Asn Ala Ile Leu Arg Ala
 35 1605 1610 1615

Asn Leu Gln Lys Gly Glu Asn Pro Ser His Tyr Gly Ile Thr Ala Phe
 1620 1625 1630

Asn His Pro Leu Asn Leu Thr Lys Gln Gln Leu Ser Glu Val Ala Pro
 1635 1640 1645

5 Met Thr Thr Ser Val Asp Val Leu Val Ser Ile Cys Val Ile Phe Ala
 1650 1655 1660

Met Ser Phe Val Pro Ala Ser Phe Val Val Phe Leu Ile Gln Glu Arg
 1665 1670 1675 1680

10 Val Ser Lys Ala Lys His Leu Gln Phe Ile Ser Gly Val Lys Pro Val
 1685 1690 1695

Ile Tyr Trp Leu Ser Asn Phe Val Trp Asp Met Cys Asn Tyr Val Val
 15 1700 1705 1710

Pro Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe Gln Gln Lys Ser
 1715 1720 1725

20 Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu Leu Leu Leu
 1730 1735 1740

Tyr Gly Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala Ser Phe Val Phe
 1745 1750 1755 1760

25 Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser Val Asn Leu Phe
 1765 1770 1775

Ile Gly Ile Asn Gly Ser Val Ala Thr Phe Val Leu Glu Leu Phe Thr
 30 1780 1785 1790

Asp Asn Lys Leu Asn Asn Ile Asn Asp Ile Leu Lys Ser Val Phe Leu
 1795 1800 1805

35 Ile Phe Pro His Phe Cys Leu Gly Arg Gly Leu Ile Asp Met Val Lys
 1810 1815 1820

Asn Gln Ala Met Ala Asp Ala Leu Glu Arg Phe Gly Glu Asn Arg Phe

	1825	1830	1835	1840
	Val Ser Pro Leu Ser Trp Asp Leu Val Gly Arg Asn Leu Phe Ala Met			
	1845	1850	1855	
5	Ala Val Glu Gly Val Val Phe Phe Leu Ile Thr Val Leu Ile Gln Tyr			
	1860	1865	1870	
	Arg Phe Phe Ile Arg Pro Arg Pro Val Asn Ala Lys Leu Ser Pro Leu			
10	1875	1880	1885	
	Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln Arg Ile Leu Asp			
	1890	1895	1900	
15	Gly Gly Gly Gln Asn Asp Ile Leu Glu Ile Lys Glu Leu Thr Lys Ile			
	1905	1910	1915	1920
	Tyr Arg Arg Lys Arg Lys Pro Ala Val Asp Arg Ile Cys Val Gly Ile			
	1925	1930	1935	
20	Pro Pro Gly Glu Cys Phe Gly Leu Leu Gly Val Asn Gly Ala Gly Lys			
	1940	1945	1950	
	Ser Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr Val Thr Arg Gly			
25	1955	1960	1965	
	Asp Ala Phe Leu Asn Arg Asn Ser Ile Leu Ser Asn Ile His Glu Val			
	1970	1975	1980	
30	His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Thr Glu Leu			
	1985	1990	1995	2000
	Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu Leu Arg Gly Val			
	2005	2010	2015	
35	Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala Ile Arg Lys Leu			
	2020	2025	2030	

Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly Asn Tyr Ser Gly Gly
 2035 2040 2045

Asn Lys Arg Lys Leu Ser Thr Ala Met Ala Leu Ile Gly Gly Pro Pro
 5 2050 2055 2060

Val Val Phe Leu Asp Glu Pro Thr Thr Gly Met Asp Pro Lys Ala Arg
 2065 2070 2075 2080

10 Arg Phe Leu Trp Asn Cys Ala Leu Ser Val Val Lys Glu Gly Arg Ser
 2085 2090 2095

Val Val Leu Thr Ser His Ser Met Glu Glu Cys Glu Ala Leu Cys Thr
 2100 2105 2110

15 Arg Met Ala Ile Met Val Asn Gly Arg Phe Arg Cys Leu Gly Ser Val
 2115 2120 2125

Gln His Leu Lys Asn Arg Phe Gly Asp Gly Tyr Thr Ile Val Val Arg
 20 2130 2135 2140

Ile Ala Gly Ser Asn Pro Asp Leu Lys Pro Val Gln Asp Phe Phe Gly
 2145 2150 2155 2160

25 Leu Ala Phe Pro Gly Ser Val Pro Lys Glu Lys His Arg Asn Met Leu
 2165 2170 2175

Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile Phe Ser
 2180 2185 2190

30 Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr Ser Val
 2195 2200 2205

Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Asp Gln
 35 2210 2215 2220

Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn Gln Thr
 2225 2230 2235 2240

Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp Glu Lys Val
 2245 2250 2255

5 Lys Glu Ser Tyr Val
 2260

<210> 90
 10 <211> 226
 <212> PRT
 <213> Homo sapiens

<400> 90
 15 Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr
 1 5 10 15

Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro
 20 25 30

20 Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro
 35 40 45

Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala
 25 50 55 60

Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro
 65 70 75 80

30 Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn
 85 90 95

Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Arg Leu
 100 105 110

35 Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val
 115 120 125

Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu
 130 135 140

Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly Phe Leu Tyr His
 5 145 150 155 160

Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met Leu Arg Ala Asp
 165 170 175

10 Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr
 180 185 190

Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp
 195 200 205

15 Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala
 210 215 220

Ala Glu
 20 225

<210> 91
 <211> 281
 25 <212> PRT
 <213> Homo sapiens

<400> 91
 Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr
 30 1 5 10 15

Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro
 20 25 30

35 Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro
 35 40 45

Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala

	50		55		60
	Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro				
	65		70		75 80
5					
	Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn				
		85		90	95
	Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Arg Leu				
10		100		105	110
	Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val				
		115		120	125
15	Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu				
		130		135	140
	Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly Phe Leu Tyr His				
	145		150		155 160
20					
	Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met Leu Arg Ala Asp				
		165		170	175
	Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr				
25		180		185	190
	Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp				
		195		200	205
30	Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala				
		210		215	220
	Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu				
	225		230		235 240
35					
	Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu				
		245		250	255

Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu
260 265 270

Phe Ser Met Arg Ser Trp Ser Asp Met
5 275 280

<210> 92
<211> 634
10 <212> PRT
<213> Homo sapiens

<400> 92
Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr
15 1 5 10 15

Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro
20 25 30

Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro
20 35 40 45

Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala
25 50 55 60

Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro
65 70 75 80

Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn
30 85 90 95

Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Arg Leu
100 105 110

Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val
35 115 120 125

Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu

	130	135	140
	Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly Phe Leu Tyr His		
	145	150	155 160
5	Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met Leu Arg Ala Asp		
	165	170	175
	Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr		
10	180	185	190
	Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp		
	195	200	205
15	Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala		
	210	215	220
	Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu		
	225	230	235 240
20	Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu		
	245	250	255
	Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu		
25	260	265	270
	Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu Val Met Phe Leu		
	275	280	285
30	Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val		
	290	295	300
	Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys		
	305	310	315 320
35	Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly		
	325	330	335

	Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr		
	340	345	350
5	Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser		
	355	360	365
	Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu		
	370	375	380
10	Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn		
	385	390	395 400
	Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu Glu Gly Met Trp		
	405	410	415
15	Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu Asn Ser Gln Glu		
	420	425	430
	Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp Asn Asp His Phe		
20	435	440	445
	Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala Gln Asp Ile Val		
	450	455	460
25	Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser Ser Asn Gly Ser		
	465	470	475 480
	Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn Gln Ala Ile Arg		
	485	490	495
30	Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn Lys Leu Glu Pro		
	500	505	510
	Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met Glu Leu Leu Asp		
35	515	520	525
	Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly Ile Thr Pro Gly		
	530	535	540

Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile
 545 550 555 560

5 Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro
 565 570 575

Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr Val Trp Gly Gly
 580 585 590

10 Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile Ile Arg Val Leu
 595 600 605

Arg Ala Pro Arg Arg Lys Leu Val Ser Ile Cys Asn Arg Cys Pro Ile
 15 610 615 620

Pro Val Thr Leu Met Thr Ser Phe Cys Gly
 625 630

20

<210> 93
 <211> 2261
 <212> PRT
 <213> Homo sapiens

25

<400> 93
 Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr
 1 5 10 15

30 Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro
 20 25 30

Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro
 35 40 45

35 Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala
 50 55 60

	Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro	
	65	70 75 80
5	Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn	
	85	90 95
	Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Arg Leu	
	100	105 110
10	Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val	
	115	120 125
	Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu	
	130	135 140
15	Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly Phe Leu Tyr His	
	145	150 155 160
	Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met Leu Arg Ala Asp	
20	165	170 175
	Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr	
	180	185 190
25	Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp	
	195	200 205
	Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala	
	210	215 220
30	Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu	
	225	230 235 240
	Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu	
35	245	250 255
	Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu	
	260	265 270

Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu Val Met Phe Leu
 275 280 285

5 Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val
 290 295 300

Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys
 305 310 315 320

10 Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly
 325 330 335

Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr
 15 340 345 350

Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser
 355 360 365

20 Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu
 370 375 380

Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn
 385 390 395 400

25 Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu Glu Gly Met Trp
 405 410 415

Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu Asn Ser Gln Glu
 30 420 425 430

Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp Asn Asp His Phe
 435 440 445

35 Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala Gln Asp Ile Val
 450 455 460

Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser Ser Asn Gly Ser

	465		470			475		480
	Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn Gln Ala Ile Arg							
			485			490		495
5	Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn Lys Leu Glu Pro							
			500			505		510
	Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met Glu Leu Leu Asp							
10			515			520		525
	Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly Ile Thr Pro Gly							
			530			535		540
15	Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile							
			545			550		555
								560
	Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro							
			565			570		575
20	Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr Val Trp Gly Gly							
			580			585		590
	Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile Ile Arg Val Leu							
25			595			600		605
	Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln Gln Met Pro Tyr							
			610			615		620
30	Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met Ser Arg Ser Met							
			625			630		635
								640
	Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val Ala Val Ile Ile							
			645			650		655
35	Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys Glu Thr Met Arg							
			660			665		670

Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser Trp Phe Ile Ser
 675 680 685

Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val Ile Leu
 5 690 695 700

Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser Val Val Phe Val
 705 710 715 720

10 Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln Cys Phe Leu Ile
 725 730 735

Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala Cys Gly Gly Ile
 740 745 750

15 Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys Val Ala Trp Gln
 755 760 765

Asp Tyr Val Gly Phe Pro Leu Lys Ile Phe Ala Ser Leu Leu Ser Pro
 20 770 775 780

Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Gln
 785 790 795 800

25 Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu
 805 810 815

Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr
 820 825 830

30 Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly
 835 840 845

Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr
 35 850 855 860

Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln
 865 870 875 880

Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys
 885 890 895

5 Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met
 900 905 910

Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile
 915 920 925

10 Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Met Ser
 930 935 940

Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu
 15 945 950 955 960

Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Leu Gly
 965 970 975

20 Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu
 980 985 990

His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val
 995 1000 1005

25 Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser
 1010 1015 1020

Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys
 30 1025 1030 1035 1040

Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu
 1045 1050 1055

35 Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp
 1060 1065 1070

Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr

	1075	1080	1085
	His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile		
	1090	1095	1100
5	Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu Phe Leu Lys Asn		
	1105	1110	1115 1120
	Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys Lys Asp Val Glu		
10	1125	1130	1135
	Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Ser Thr Val Ser Tyr Leu		
	1140	1145	1150
15	Lys Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly		
	1155	1160	1165
	Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser		
	1170	1175	1180
20	Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile		
	1185	1190	1195 1200
	Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly		
25	1205	1210	1215
	Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu		
	1220	1225	1230
30	Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe		
	1235	1240	1245
	Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp Gly		
	1250	1255	1260
35	Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys Gln Ser		
	1265	1270	1275 1280

	Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro Asn Asp Ser		
	1285	1290	1295
5	Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu Ser Gly Met Asp		
	1300	1305	1310
	Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu Thr Gln Gln Gln		
	1315	1320	1325
10	Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala Arg Arg Ser Arg		
	1330	1335	1340
	Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val Phe Val Cys Ile		
	1345	1350	1355 1360
15	Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly Lys Tyr Pro Ser		
	1365	1370	1375
	Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr Thr Phe Val Ser		
20	1380	1385	1390
	Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu		
	1395	1400	1405
25	Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile		
	1410	1415	1420
	Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro		
	1425	1430	1435 1440
30	Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met		
	1445	1450	1455
	Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys		
35	1460	1465	1470
	Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Pro Gln		
	1475	1480	1485

	Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg Asn
	1490 1495 1500
5	Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala Lys Ser
	1505 1510 1515 1520
	Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr Gly Gly Phe Ser
	1525 1530 1535
10	Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Pro Ser Gln Glu Val Asn
	1540 1545 1550
	Asp Ala Thr Lys Gln Met Lys Lys His Leu Lys Leu Ala Lys Asp Ser
15	1555 1560 1565
	Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly Arg Phe Met Thr Gly Leu
	1570 1575 1580
20	Asp Thr Arg Asn Asn Val Lys Val Trp Phe Asn Asn Lys Gly Trp His
	1585 1590 1595 1600
	Ala Ile Ser Ser Phe Leu Asn Val Ile Asn Asn Ala Ile Leu Arg Ala
	1605 1610 1615
25	Asn Leu Gln Lys Gly Glu Asn Pro Ser His Tyr Gly Ile Thr Ala Phe
	1620 1625 1630
	Asn His Pro Leu Asn Leu Thr Lys Gln Gln Leu Ser Glu Val Ala Pro
30	1635 1640 1645
	Met Thr Thr Ser Val Asp Val Leu Val Ser Ile Cys Val Ile Phe Ala
	1650 1655 1660
35	Met Ser Phe Val Pro Ala Ser Phe Val Val Phe Leu Ile Gln Glu Arg
	1665 1670 1675 1680
	Val Ser Lys Ala Lys His Leu Gln Phe Ile Ser Gly Val Lys Pro Val

	1685	1690	1695
	Ile Tyr Trp Leu Ser Asn Phe Val Trp Asp Met Cys Asn Tyr Val Val		
	1700	1705	1710
5	Pro Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe Gln Gln Lys Ser		
	1715	1720	1725
	Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu Leu Leu Leu Leu		
10	1730	1735	1740
	Tyr Gly Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala Ser Phe Val Phe		
	1745	1750	1755 1760
15	Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser Val Asn Leu Phe		
	1765	1770	1775
	Ile Gly Ile Asn Gly Ser Val Ala Thr Phe Val Leu Glu Leu Phe Thr		
	1780	1785	1790
20	Asp Asn Lys Leu Asn Asn Ile Asn Asp Ile Leu Lys Ser Val Phe Leu		
	1795	1800	1805
	Ile Phe Pro His Phe Cys Leu Gly Arg Gly Leu Ile Asp Met Val Lys		
25	1810	1815	1820
	Asn Gln Ala Met Ala Asp Ala Leu Glu Arg Phe Gly Glu Asn Arg Phe		
	1825	1830	1835 1840
30	Val Ser Pro Leu Ser Trp Asp Leu Val Gly Arg Asn Leu Phe Ala Met		
	1845	1850	1855
	Ala Val Glu Gly Val Val Phe Phe Leu Ile Thr Val Leu Ile Gln Tyr		
	1860	1865	1870
35	Arg Phe Phe Ile Arg Pro Arg Pro Val Asn Ala Lys Leu Ser Pro Leu		
	1875	1880	1885

Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln Arg Ile Leu Asp
 1890 1895 1900

Gly Gly Gly Gln Asn Asp Ile Leu Glu Ile Lys Glu Leu Thr Lys Ile
 5 1905 1910 1915 1920

Tyr Arg Arg Lys Arg Lys Pro Ala Val Asp Arg Ile Cys Val Gly Ile
 1925 1930 1935

10 Pro Pro Gly Glu Cys Phe Gly Leu Leu Gly Val Asn Gly Ala Gly Lys
 1940 1945 1950

Ser Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr Val Thr Arg Gly
 1955 1960 1965

15 Asp Ala Phe Leu Asn Arg Asn Ser Ile Leu Ser Asn Ile His Glu Val
 1970 1975 1980

His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Thr Glu Leu
 20 1985 1990 1995 2000

Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu Leu Arg Gly Val
 2005 2010 2015

25 Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala Ile Arg Lys Leu
 2020 2025 2030

Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly Asn Tyr Ser Gly Gly
 2035 2040 2045

30 Asn Lys Arg Lys Leu Ser Thr Ala Met Ala Leu Ile Gly Gly Pro Pro
 2050 2055 2060

Val Val Phe Leu Asp Glu Pro Thr Thr Gly Met Asp Pro Lys Ala Arg
 35 2065 2070 2075 2080

Arg Phe Leu Trp Asn Cys Ala Leu Ser Val Val Lys Glu Gly Arg Ser
 2085 2090 2095

Val Val Leu Thr Ser His Ser Met Glu Glu Cys Glu Ala Leu Cys Thr
2100 2105 2110

5 Arg Met Ala Ile Met Val Asn Gly Arg Phe Arg Cys Leu Gly Ser Val
2115 2120 2125

Gln His Leu Lys Asn Arg Phe Gly Asp Gly Tyr Thr Ile Val Val Arg
2130 2135 2140

10 Ile Ala Gly Ser Asn Pro Asp Leu Lys Pro Val Gln Asp Phe Phe Gly
2145 2150 2155 2160

Leu Ala Phe Pro Gly Ser Val Pro Lys Glu Lys His Arg Asn Met Leu
15 2165 2170 2175

Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile Phe Ser
2180 2185 2190

20 Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr Ser Val
2195 2200 2205

Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Asp Gln
2210 2215 2220

25 Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn Gln Thr
2225 2230 2235 2240

Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp Glu Lys Val
30 2245 2250 2255

Lys Glu Ser Tyr Val
2260

35
<210> 94
<211> 2261
<212> PRT

100

<213> Homo sapiens

<400> 94

Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr
 5 1 5 10 15

Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro
 20 25 30

10 Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro
 35 40 45

Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala
 50 55 60

15 Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro
 65 70 75 80

Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn
 20 85 90 95

Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Arg Leu
 100 105 110

25 Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val
 115 120 125

Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu
 130 135 140

30 Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly Phe Leu Tyr His
 145 150 155 160

Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met Leu Arg Ala Asp
 35 165 170 175

Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr
 180 185 190

Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp
 195 200 205

5 Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala
 210 215 220

Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu
 225 230 235 240

10 Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu
 245 250 255

Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu
 15 260 265 270

Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu Val Met Phe Leu
 275 280 285

20 Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val
 290 295 300

Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys
 305 310 315 320

25 Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly
 325 330 335

Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr
 30 340 345 350

Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser
 355 360 365

35 Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu
 370 375 380

Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn

102

	385		390			395			400							
	Lys	Thr	Phe	Gln	Glu	Leu	Ala	Val	Phe	His	Asp	Leu	Glu	Gly	Met	Trp
				405					410						415	
5	Glu	Glu	Leu	Ser	Pro	Lys	Ile	Trp	Thr	Phe	Met	Glu	Asn	Ser	Gln	Glu
				420					425						430	
	Met	Asp	Leu	Val	Arg	Met	Leu	Leu	Asp	Ser	Arg	Asp	Asn	Asp	His	Phe
10		435						440					445			
	Trp	Glu	Gln	Gln	Leu	Asp	Gly	Leu	Asp	Trp	Thr	Ala	Gln	Asp	Ile	Val
		450					455					460				
15	Ala	Phe	Leu	Ala	Lys	His	Pro	Glu	Asp	Val	Gln	Ser	Ser	Asn	Gly	Ser
	465				470					475					480	
	Val	Tyr	Thr	Trp	Arg	Glu	Ala	Phe	Asn	Glu	Thr	Asn	Gln	Ala	Ile	Arg
				485					490						495	
20	Thr	Ile	Ser	Arg	Phe	Met	Glu	Cys	Val	Asn	Leu	Asn	Lys	Leu	Glu	Pro
				500					505					510		
	Ile	Ala	Thr	Glu	Val	Trp	Leu	Ile	Asn	Lys	Ser	Met	Glu	Leu	Leu	Asp
25		515					520					525				
	Glu	Arg	Lys	Phe	Trp	Ala	Gly	Ile	Val	Phe	Thr	Gly	Ile	Thr	Pro	Gly
		530					535					540				
30	Ser	Ile	Glu	Leu	Pro	His	His	Val	Lys	Tyr	Lys	Ile	Arg	Met	Asp	Ile
	545				550					555					560	
	Asp	Asn	Val	Glu	Arg	Thr	Asn	Lys	Ile	Lys	Asp	Gly	Tyr	Trp	Asp	Pro
				565					570					575		
35	Gly	Pro	Arg	Ala	Asp	Pro	Phe	Glu	Asp	Met	Arg	Tyr	Val	Trp	Gly	Gly
				580					585					590		

	Phe	Ala	Tyr	Leu	Gln	Asp	Val	Val	Glu	Gln	Ala	Ile	Ile	Arg	Val	Leu	
				595					600					605			
	Thr	Gly	Thr	Glu	Lys	Lys	Thr	Gly	Val	Tyr	Met	Gln	Gln	Met	Pro	Tyr	
5		610						615					620				
	Pro	Cys	Tyr	Val	Asp	Asp	Ile	Phe	Leu	Arg	Val	Met	Ser	Arg	Ser	Met	
	625					630					635				640		
10	Pro	Leu	Phe	Met	Thr	Leu	Ala	Trp	Ile	Tyr	Ser	Val	Ala	Val	Ile	Ile	
						645					650				655		
	Lys	Gly	Ile	Val	Tyr	Glu	Lys	Glu	Ala	Arg	Leu	Lys	Glu	Thr	Met	Arg	
				660					665					670			
15	Ile	Met	Gly	Leu	Asp	Asn	Ser	Ile	Leu	Trp	Phe	Ser	Trp	Phe	Ile	Ser	
			675						680					685			
	Ser	Leu	Ile	Pro	Leu	Leu	Val	Ser	Ala	Gly	Leu	Leu	Val	Val	Ile	Leu	
20		690						695					700				
	Lys	Leu	Gly	Asn	Leu	Leu	Pro	Tyr	Ser	Asp	Pro	Ser	Val	Val	Phe	Val	
	705					710					715				720		
25	Phe	Leu	Ser	Val	Phe	Ala	Val	Val	Thr	Ile	Leu	Gln	Cys	Phe	Leu	Ile	
						725					730				735		
	Ser	Thr	Leu	Phe	Ser	Arg	Ala	Asn	Leu	Ala	Ala	Ala	Cys	Gly	Gly	Ile	
				740						745				750			
30	Ile	Tyr	Phe	Thr	Leu	Tyr	Leu	Pro	Tyr	Val	Leu	Cys	Val	Ala	Trp	Gln	
			755							760				765			
	Asp	Tyr	Val	Gly	Phe	Thr	Leu	Lys	Ile	Phe	Ala	Ser	Leu	Leu	Ser	Pro	
35		770						775					780				
	Val	Ala	Phe	Gly	Phe	Gly	Cys	Glu	Tyr	Phe	Ala	Leu	Phe	Glu	Glu	Gln	
	785					790					795				800		

Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu
 805 810 815

5 Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr
 820 825 830

Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly
 835 840 845

10 Gln Tyr Arg Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr
 850 855 860

Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln
 15 865 870 875 880

Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys
 885 890 895

20 Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met
 900 905 910

Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile
 915 920 925

25 Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Met Ser
 930 935 940

Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu
 30 945 950 955 960

Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Leu Gly
 965 970 975

35 Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu
 980 985 990

His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val

	995	1000	1005
	Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser		
	1010	1015	1020
5	Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys		
	1025	1030	1035 1040
	Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu		
10	1045	1050	1055
	Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp		
	1060	1065	1070
15	Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr		
	1075	1080	1085
	His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile		
	1090	1095	1100
20	Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu Phe Leu Lys Asn		
	1105	1110	1115 1120
	Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys Lys Asp Val Glu		
25	1125	1130	1135
	Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Ser Thr Val Ser Tyr Leu		
	1140	1145	1150
30	Lys Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly		
	1155	1160	1165
	Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser		
	1170	1175	1180
35	Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile		
	1185	1190	1195 1200

106

	Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly		
	1205	1210	1215
5	Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu		
	1220	1225	1230
	Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe		
	1235	1240	1245
10	Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp Gly		
	1250	1255	1260
	Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys Gln Ser		
	1265	1270	1275 1280
15	Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro Asn Asp Ser		
	1285	1290	1295
	Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu Ser Gly Met Asp		
20	1300	1305	1310
	Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu Thr Gln Gln Gln		
	1315	1320	1325
25	Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala Arg Arg Ser Arg		
	1330	1335	1340
	Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val Phe Val Cys Ile		
	1345	1350	1355 1360
30	Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly Lys Tyr Pro Ser		
	1365	1370	1375
	Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr Thr Phe Val Ser		
35	1380	1385	1390
	Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu		
	1395	1400	1405

Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile
 1410 1415 1420

5 Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro
 1425 1430 1435 1440

Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met
 1445 1450 1455

10 Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys
 1460 1465 1470

Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Pro Gln
 15 1475 1480 1485

Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg Asn
 1490 1495 1500

20 Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala Lys Ser
 1505 1510 1515 1520

Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr Gly Gly Phe Ser
 1525 1530 1535

25 Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Pro Ser Gln Glu Val Asn
 1540 1545 1550

Asp Ala Thr Lys Gln Met Lys Lys His Leu Lys Leu Ala Lys Asp Ser
 30 1555 1560 1565

Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly Arg Phe Met Thr Gly Leu
 1570 1575 1580

35 Asp Thr Arg Asn Asn Val Lys Val Trp Phe Asn Asn Lys Gly Trp His
 1585 1590 1595 1600

Ala Ile Ser Ser Phe Leu Asn Val Ile Asn Asn Ala Ile Leu Arg Ala

108

	1605	1610	1615
	Asn Leu Gln Lys Gly Glu Asn Pro Ser His Tyr Gly Ile Thr Ala Phe		
	1620	1625	1630
5	Asn His Pro Leu Asn Leu Thr Lys Gln Gln Leu Ser Glu Val Ala Pro		
	1635	1640	1645
	Met Thr Thr Ser Val Asp Val Leu Val Ser Ile Cys Val Ile Phe Ala		
10	1650	1655	1660
	Met Ser Phe Val Pro Ala Ser Phe Val Val Phe Leu Ile Gln Glu Arg		
	1665	1670	1675
	1680		
15	Val Ser Lys Ala Lys His Leu Gln Phe Ile Ser Gly Val Lys Pro Val		
	1685	1690	1695
	Ile Tyr Trp Leu Ser Asn Phe Val Trp Asp Met Cys Asn Tyr Val Val		
	1700	1705	1710
20	Pro Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe Gln Gln Lys Ser		
	1715	1720	1725
	Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu Leu Leu Leu Leu		
25	1730	1735	1740
	Tyr Gly Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala Ser Phe Val Phe		
	1745	1750	1755
	1760		
30	Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser Val Asn Leu Phe		
	1765	1770	1775
	Ile Gly Ile Asn Gly Ser Val Ala Thr Phe Val Leu Glu Leu Phe Thr		
	1780	1785	1790
35	Asp Asn Lys Leu Asn Asn Ile Asn Asp Ile Leu Lys Ser Val Phe Leu		
	1795	1800	1805

Ile Phe Pro His Phe Cys Leu Gly Arg Gly Leu Ile Asp Met Val Lys
 1810 1815 1820

Asn Gln Ala Met Ala Asp Ala Leu Glu Arg Phe Gly Glu Asn Arg Phe
 5 1825 1830 1835 1840

Val Ser Pro Leu Ser Trp Asp Leu Val Gly Arg Asn Leu Phe Ala Met
 1845 1850 1855

10 Ala Val Glu Gly Val Val Phe Phe Leu Ile Thr Val Leu Ile Gln Tyr
 1860 1865 1870

Arg Phe Phe Ile Arg Pro Arg Pro Val Asn Ala Lys Leu Ser Pro Leu
 1875 1880 1885

15 Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln Arg Ile Leu Asp
 1890 1895 1900

Gly Gly Gly Gln Asn Asp Ile Leu Glu Ile Lys Glu Leu Thr Lys Ile
 20 1905 1910 1915 1920

Tyr Arg Arg Lys Arg Lys Pro Ala Val Asp Arg Ile Cys Val Gly Ile
 1925 1930 1935

25 Pro Pro Gly Glu Cys Phe Gly Leu Leu Gly Val Asn Gly Ala Gly Lys
 1940 1945 1950

Ser Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr Val Thr Arg Gly
 1955 1960 1965

30 Asp Ala Phe Leu Asn Arg Asn Ser Ile Leu Ser Asn Ile His Glu Val
 1970 1975 1980

His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Thr Glu Leu
 35 1985 1990 1995 2000

Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu Leu Arg Gly Val
 2005 2010 2015

Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala Ile Arg Lys Leu
2020 2025 2030

5 Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly Asn Tyr Ser Gly Gly
2035 2040 2045

Asn Lys Arg Lys Leu Ser Thr Ala Met Ala Leu Ile Gly Gly Pro Pro
2050 2055 2060

10 Val Val Phe Leu Asp Glu Pro Thr Thr Gly Met Asp Pro Lys Ala Arg
2065 2070 2075 2080

Arg Phe Leu Trp Asn Cys Ala Leu Ser Val Val Lys Glu Gly Arg Ser
15 2085 2090 2095

Val Val Leu Thr Ser His Ser Met Glu Glu Cys Glu Ala Leu Cys Thr
2100 2105 2110

20 Arg Met Ala Ile Met Val Asn Gly Arg Phe Arg Cys Leu Gly Ser Val
2115 2120 2125

Gln His Leu Lys Asn Arg Phe Gly Asp Gly Tyr Thr Ile Val Val Arg
2130 2135 2140

25 Ile Ala Gly Ser Asn Pro Asp Leu Lys Pro Val Gln Asp Phe Phe Gly
2145 2150 2155 2160

Leu Ala Phe Pro Gly Ser Val Pro Lys Glu Lys His Arg Asn Met Leu
30 2165 2170 2175

Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile Phe Ser
2180 2185 2190

35 Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr Ser Val
2195 2200 2205

Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Asp Gln

	2210	2215	2220
	Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn Gln Thr		
	2225	2230	2235 2240
5	Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp Glu Lys Val		
	2245	2250	2255
	Lys Glu Ser Tyr Val		
10	2260		
	<210> 95		
	<211> 2261		
15	<212> PRT		
	<213> Homo sapiens		
	<400> 95		
	Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr		
20	1 5 10 15		
	Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro		
	20 25 30		
25	Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro		
	35 40 45		
	Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala		
	50 55 60		
30	Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro		
	65 70 75 80		
	Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn		
35	85 90 95		
	Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Arg Leu		
	100 105 110		

Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val
 115 120 125

5 Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu
 130 135 140

Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly Phe Leu Tyr His
 145 150 155 160

10 Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met Leu Arg Ala Asp
 165 170 175

Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr
 15 180 185 190

Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp
 195 200 205

20 Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala
 210 215 220

Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu
 225 230 235 240

25 Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu
 245 250 255

Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu
 30 260 265 270

Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu Val Met Phe Leu
 275 280 285

35 Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val
 290 295 300

Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys

305		310		315		320										
Ser	Leu	Asn	Trp	Tyr	Glu	Asp	Asn	Asn	Tyr	Lys	Ala	Leu	Phe	Gly	Gly	
		325						330					335			
5																
Asn	Gly	Thr	Glu	Glu	Asp	Ala	Glu	Thr	Phe	Tyr	Asp	Asn	Ser	Thr	Thr	
		340						345					350			
Pro	Tyr	Cys	Asn	Asp	Leu	Met	Lys	Asn	Leu	Glu	Ser	Ser	Pro	Leu	Ser	
10		355					360						365			
Arg	Ile	Ile	Trp	Lys	Ala	Leu	Lys	Pro	Leu	Leu	Val	Gly	Lys	Ile	Leu	
	370					375					380					
15	Tyr	Thr	Pro	Asp	Thr	Pro	Ala	Thr	Arg	Gln	Val	Met	Ala	Glu	Val	Asn
	385					390					395				400	
Lys	Thr	Phe	Gln	Glu	Leu	Ala	Val	Phe	His	Asp	Leu	Glu	Gly	Met	Trp	
			405						410					415		
20																
Glu	Glu	Leu	Ser	Pro	Lys	Ile	Trp	Thr	Phe	Met	Glu	Asn	Ser	Gln	Glu	
			420						425					430		
Met	Asp	Leu	Val	Arg	Met	Leu	Leu	Asp	Ser	Arg	Asp	Asn	Asp	His	Phe	
25		435					440						445			
Trp	Glu	Gln	Gln	Leu	Asp	Gly	Leu	Asp	Trp	Thr	Ala	Gln	Asp	Ile	Val	
	450						455						460			
30	Ala	Phe	Leu	Ala	Lys	His	Pro	Glu	Asp	Val	Gln	Ser	Ser	Asn	Gly	Ser
	465					470						475			480	
Val	Tyr	Thr	Trp	Arg	Glu	Ala	Phe	Asn	Glu	Thr	Asn	Gln	Ala	Ile	Arg	
				485					490					495		
35																
Thr	Ile	Ser	Arg	Phe	Met	Glu	Cys	Val	Asn	Leu	Asn	Lys	Leu	Glu	Pro	
				500					505					510		

	Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met Glu Leu Leu Asp
	515 520 525
5	Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly Ile Thr Pro Gly
	530 535 540
	Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile
	545 550 555 560
10	Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro
	565 570 575
	Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr Val Trp Gly Gly
	580 585 590
15	Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile Ile Arg Val Leu
	595 600 605
	Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln Gln Met Pro Tyr
20	610 615 620
	Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met Ser Arg Ser Met
	625 630 635 640
25	Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val Ala Val Ile Ile
	645 650 655
	Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys Glu Thr Met Arg
	660 665 670
30	Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser Trp Phe Ile Ser
	675 680 685
	Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val Ile Leu
35	690 695 700
	Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser Val Val Phe Val
	705 710 715 720

Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln Cys Phe Leu Ile
 725 730 735

5 Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala Cys Gly Gly Ile
 740 745 750

Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys Val Ala Trp Gln
 755 760 765

10 Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser Leu Leu Ser Pro
 770 775 780

Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Gln
 15 785 790 795 800

Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu
 805 810 815

20 Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr
 820 825 830

Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly
 835 840 845

25 Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr
 850 855 860

Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln
 30 865 870 875 880

Lys Arg Met Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys
 885 890 895

35 Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met
 900 905 910

Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile

	915	920	925
	Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Met Ser		
	930	935	940
5	Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu		
	945	950	955 960
	Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Leu Gly		
10	965	970	975
	Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu		
	980	985	990
15	His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val		
	995	1000	1005
	Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser		
	1010	1015	1020
20	Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys		
	1025	1030	1035 1040
	Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu		
25	1045	1050	1055
	Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp		
	1060	1065	1070
30	Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr		
	1075	1080	1085
	His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile		
	1090	1095	1100
35	Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu Phe Leu Lys Asn		
	1105	1110	1115 1120

117

Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys Lys Asp Val Glu
 1125 1130 1135

5 Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Ser Thr Val Ser Tyr Leu
 1140 1145 1150

Lys Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly
 1155 1160 1165

10 Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser
 1170 1175 1180

Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile
 1185 1190 1195 1200

15 Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly
 1205 1210 1215

20 Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu
 1220 1225 1230

Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe
 1235 1240 1245

25 Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp Gly
 1250 1255 1260

Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys Gln Ser
 1265 1270 1275 1280

30 Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro Asn Asp Ser
 1285 1290 1295

35 Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu Ser Gly Met Asp
 1300 1305 1310

Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu Thr Gln Gln Gln
 1315 1320 1325

Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala Arg Arg Ser Arg
 1330 1335 1340

5 Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val Phe Val Cys Ile
 1345 1350 1355 1360

Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly Lys Tyr Pro Ser
 1365 1370 1375

10 Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr Thr Phe Val Ser
 1380 1385 1390

Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu
 15 1395 1400 1405

Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile
 1410 1415 1420

20 Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro
 1425 1430 1435 1440

Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met
 1445 1450 1455

25 Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys
 1460 1465 1470

Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Pro Gln
 30 1475 1480 1485

Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg Asn
 1490 1495 1500

35 Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala Lys Ser
 1505 1510 1515 1520

Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr Gly Gly Phe Ser

1525 1530 1535

Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Pro Ser Gln Glu Val Asn
1540 1545 1550

5 Asp Ala Thr Lys Gln Met Lys Lys His Leu Lys Leu Ala Lys Asp Ser
1555 1560 1565

Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly Arg Phe Met Thr Gly Leu
10 1570 1575 1580

Asp Thr Arg Asn Asn Val Lys Val Trp Phe Asn Asn Lys Gly Trp His
1585 1590 1595 1600

15 Ala Ile Ser Ser Phe Leu Asn Val Ile Asn Asn Ala Ile Leu Arg Ala
1605 1610 1615

Asn Leu Gln Lys Gly Glu Asn Pro Ser His Tyr Gly Ile Thr Ala Phe
1620 1625 1630

20 Asn His Pro Leu Asn Leu Thr Lys Gln Gln Leu Ser Glu Val Ala Pro
1635 1640 1645

Met Thr Thr Ser Val Asp Val Leu Val Ser Ile Cys Val Ile Phe Ala
25 1650 1655 1660

Met Ser Phe Val Pro Ala Ser Phe Val Val Phe Leu Ile Gln Glu Arg
1665 1670 1675 1680

30 Val Ser Lys Ala Lys His Leu Gln Phe Ile Ser Gly Val Lys Pro Val
1685 1690 1695

Ile Tyr Trp Leu Ser Asn Phe Val Trp Asp Met Cys Asn Tyr Val Val
1700 1705 1710

35 Pro Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe Gln Gln Lys Ser
1715 1720 1725

120

Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu Leu Leu Leu
 1730 1735 1740

Tyr Gly Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala Ser Phe Val Phe
 5 1745 1750 1755 1760

Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser Val Asn Leu Phe
 1765 1770 1775

10 Ile Gly Ile Asn Gly Ser Val Ala Thr Phe Val Leu Glu Leu Phe Thr
 1780 1785 1790

Asp Asn Lys Leu Asn Asn Ile Asn Asp Ile Leu Lys Ser Val Phe Leu
 1795 1800 1805

15 Ile Phe Pro His Phe Cys Leu Gly Arg Gly Leu Ile Asp Met Val Lys
 1810 1815 1820

Asn Gln Ala Met Ala Asp Ala Leu Glu Arg Phe Gly Glu Asn Arg Phe
 20 1825 1830 1835 1840

Val Ser Pro Leu Ser Trp Asp Leu Val Gly Arg Asn Leu Phe Ala Met
 1845 1850 1855

25 Ala Val Glu Gly Val Val Phe Phe Leu Ile Thr Val Leu Ile Gln Tyr
 1860 1865 1870

Arg Phe Phe Ile Arg Pro Arg Pro Val Asn Ala Lys Leu Ser Pro Leu
 1875 1880 1885

30 Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln Arg Ile Leu Asp
 1890 1895 1900

Gly Gly Gly Gln Asn Asp Ile Leu Glu Ile Lys Glu Leu Thr Lys Ile
 35 1905 1910 1915 1920

Tyr Arg Arg Lys Arg Lys Pro Ala Val Asp Arg Ile Cys Val Gly Ile
 1925 1930 1935

Pro Pro Gly Glu Cys Phe Gly Leu Leu Gly Val Asn Gly Ala Gly Lys
 1940 1945 1950

5 Ser Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr Val Thr Arg Gly
 1955 1960 1965

Asp Ala Phe Leu Asn Arg Asn Ser Ile Leu Ser Asn Ile His Glu Val
 1970 1975 1980

10 His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Thr Glu Leu
 1985 1990 1995 2000

Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu Leu Arg Gly Val
 15 2005 2010 2015

Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala Ile Arg Lys Leu
 2020 2025 2030

20 Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly Asn Tyr Ser Gly Gly
 2035 2040 2045

Asn Lys Arg Lys Leu Ser Thr Ala Met Ala Leu Ile Gly Gly Pro Pro
 2050 2055 2060

25 Val Val Phe Leu Asp Glu Pro Thr Thr Gly Met Asp Pro Lys Ala Arg
 2065 2070 2075 2080

Arg Phe Leu Trp Asn Cys Ala Leu Ser Val Val Lys Glu Gly Arg Ser
 30 2085 2090 2095

Val Val Leu Thr Ser His Ser Met Glu Glu Cys Glu Ala Leu Cys Thr
 2100 2105 2110

35 Arg Met Ala Ile Met Val Asn Gly Arg Phe Arg Cys Leu Gly Ser Val
 2115 2120 2125

Gln His Leu Lys Asn Arg Phe Gly Asp Gly Tyr Thr Ile Val Val Arg

122

	2130	2135	2140
	Ile Ala Gly Ser Asn Pro Asp Leu Lys Pro Val Gln Asp Phe Phe Gly		
	2145	2150	2155 2160
5	Leu Ala Phe Pro Gly Ser Val Pro Lys Glu Lys His Arg Asn Met Leu		
	2165	2170	2175
	Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile Phe Ser		
10	2180	2185	2190
	Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr Ser Val		
	2195	2200	2205
15	Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Asp Gln		
	2210	2215	2220
	Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn Gln Thr		
	2225	2230	2235 2240
20	Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp Glu Lys Val		
	2245	2250	2255
	Lys Glu Ser Tyr Val		
25	2260		
	<210> 96		
	<211> 1144		
30	<212> PRT		
	<213> Homo sapiens		
	<400> 96		
	Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr		
35	1	5	10 15
	Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro		
	20	25	30

Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro
 35 40 45

5 Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala
 50 55 60

Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro
 65 70 75 80

10 Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn
 85 90 95

Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Arg Leu
 15 100 105 110

Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val
 115 120 125

20 Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu
 130 135 140

Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly Phe Leu Tyr His
 145 150 155 160

25 Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met Leu Arg Ala Asp
 165 170 175

Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr
 30 180 185 190

Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp
 195 200 205

35 Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala
 210 215 220

Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu

124

	225	230	235	240
	Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu			
	245	250	255	
5	Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu			
	260	265	270	
	Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu Val Met Phe Leu			
10	275	280	285	
	Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val			
	290	295	300	
15	Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys			
	305	310	315	320
	Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly			
	325	330	335	
20	Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr			
	340	345	350	
	Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser			
25	355	360	365	
	Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu			
	370	375	380	
30	Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn			
	385	390	395	400
	Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu Glu Gly Met Trp			
	405	410	415	
35	Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu Asn Ser Gln Glu			
	420	425	430	

	Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp Asn Asp His Phe		
	435	440	445
	Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala Gln Asp Ile Val		
5	450	455	460
	Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser Ser Asn Gly Ser		
	465	470	475 480
10	Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn Gln Ala Ile Arg		
	485	490	495
	Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn Lys Leu Glu Pro		
	500	505	510
15	Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met Glu Leu Leu Asp		
	515	520	525
	Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly Ile Thr Pro Gly		
20	530	535	540
	Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile		
	545	550	555 560
25	Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro		
	565	570	575
	Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr Val Trp Gly Gly		
	580	585	590
30	Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile Ile Arg Val Leu		
	595	600	605
	Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln Gln Met Pro Tyr		
35	610	615	620
	Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met Ser Arg Ser Met		
	625	630	635 640

Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val Ala Val Ile Ile
645 650 655

5 Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys Glu Thr Met Arg
660 665 670

Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser Trp Phe Ile Ser
675 680 685

10 Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val Ile Leu
690 695 700

Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser Val Val Phe Val
15 705 710 715 720

Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln Cys Phe Leu Ile
725 730 735

20 Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala Cys Gly Gly Ile
740 745 750

Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys Val Ala Trp Gln
755 760 765

25 Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser Leu Leu Ser Pro
770 775 780

Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Gln
30 785 790 795 800

Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu
805 810 815

35 Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr
820 825 830

Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly

	835	840	845
	Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr		
	850	855	860
5	Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln		
	865	870	875 880
	Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys		
10	885	890	895
	Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met		
	900	905	910
15	Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile		
	915	920	925
	Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Met Ser		
	930	935	940
20	Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu		
	945	950	955 960
	Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Leu Gly		
25	965	970	975
	Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu		
	980	985	990
30	His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val		
	995	1000	1005
	Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser		
	1010	1015	1020
35	Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys		
	1025	1030	1035 1040

128

Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu
 1045 1050 1055

5 Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp
 1060 1065 1070

Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr
 1075 1080 1085

10 His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile
 1090 1095 1100

Ser His Gly Lys Leu Cys Cys Val Gly Ser Pro Val Ser Glu Glu Pro
 1105 1110 1115 1120

15 Ala Gly Asn Arg Leu Leu Pro Asp Leu Gly Gln Glu Arg Cys Gly Ile
 1125 1130 1135

Leu Pro Gln Phe Leu Gln Lys Gln
 20 1140

<210> 97
 <211> 1144
 25 <212> PRT
 <213> Homo sapiens

<400> 97
 Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr
 30 1 5 10 15

Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro
 20 25 30

35 Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro
 35 40 45

Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala

	50	55	60
	Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro		
	65	70	75 80
5	Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn		
	85	90	95
	Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Arg Leu		
10	100	105	110
	Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val		
	115	120	125
15	Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu		
	130	135	140
	Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly Phe Leu Tyr His		
	145	150	155 160
20	Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met Leu Arg Ala Asp		
	165	170	175
	Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr		
25	180	185	190
	Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp		
	195	200	205
30	Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala		
	210	215	220
	Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu		
	225	230	235 240
35	Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu		
	245	250	255

	Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu		
	260	265	270
5	Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu Val Met Phe Leu		
	275	280	285
	Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val		
	290	295	300
10	Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys		
	305	310	315 320
	Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly		
	325	330	335
15	Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr		
	340	345	350
	Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser		
20	355	360	365
	Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu		
	370	375	380
25	Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn		
	385	390	395 400
	Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu Glu Gly Met Trp		
	405	410	415
30	Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu Asn Ser Gln Glu		
	420	425	430
	Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp Asn Asp His Phe		
35	435	440	445
	Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala Gln Asp Ile Val		
	450	455	460

Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser Ser Asn Gly Ser
465 470 475 480

5 Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn Gln Ala Ile Arg
485 490 495

Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn Lys Leu Glu Pro
500 505 510

	660	665	670
	Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser Trp Phe Ile Ser		
	675	680	685
5	Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val Ile Leu		
	690	695	700
	Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser Val Val Phe Val		
10	705	710	715 720
	Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln Cys Phe Leu Ile		
	725	730	735
15	Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala Cys Gly Gly Ile		
	740	745	750
	Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys Val Ala Trp Gln		
	755	760	765
20	Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser Leu Leu Ser Pro		
	770	775	780
	Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Gln		
25	785	790	795 800
	Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu		
	805	810	815
30	Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr		
	820	825	830
	Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly		
	835	840	845
35	Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr		
	850	855	860

133

Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln
 865 870 875 880
 Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys
 5 885 890 895
 Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met
 900 905 910
 10 Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile
 915 920 925
 Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Met Ser
 930 935 940
 15 Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu
 945 950 955 960
 Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Leu Gly
 20 965 970 975
 Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu
 980 985 990
 25 His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val
 995 1000 1005
 Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser
 1010 1015 1020
 30 Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys
 1025 1030 1035 1040
 Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu
 35 1045 1050 1055
 Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp
 1060 1065 1070

Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr
 1075 1080 1085

5 His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile
 1090 1095 1100

Ser His Gly Lys Leu Cys Cys Val Gly Ser Pro Val Ser Glu Glu Pro
 1105 1110 1115 1120

10 Ala Gly Asn Arg Leu Leu Pro Asp Leu Gly Gln Glu Arg Cys Gly Ile
 1125 1130 1135

Leu Pro Gln Phe Leu Gln Lys Gln
 15 1140

<210> 98
 <211> 2261
 20 <212> PRT
 <213> Homo sapiens

<400> 98
 Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr
 25 1 5 10 15

Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro
 20 25 30

30 Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro
 35 40 45

Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala
 50 55 60

35 Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro
 65 70 75 80

135

[illegible]

Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val
 290 295 300

5 Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys
 305 310 315 320

Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly
 325 330 335

10 Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr
 340 345 350

Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser
 15 355 360 365

Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu
 370 375 380

20 Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn
 385 390 395 400

Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu Glu Gly Met Trp
 405 410 415

25 Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu Asn Ser Gln Glu
 420 425 430

Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp Asn Asp His Phe
 30 435 440 445

Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala Gln Asp Ile Val
 450 455 460

35 Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser Ser Asn Gly Ser
 465 470 475 480

Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn Gln Ala Ile Arg

137

	485	490	495
	Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn Lys Leu Glu Pro		
	500	505	510
5	Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met Glu Leu Leu Asp		
	515	520	525
	Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly Ile Thr Pro Gly		
10	530	535	540
	Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile		
	545	550	555 560
15	Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro		
	565	570	575
	Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr Val Trp Gly Gly		
	580	585	590
20	Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile Ile Arg Val Leu		
	595	600	605
	Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln Gln Met Pro Tyr		
25	610	615	620
	Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met Ser Arg Ser Met		
	625	630	635 640
30	Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val Ala Val Ile Ile		
	645	650	655
	Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys Glu Thr Met Arg		
	660	665	670
35	Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser Trp Phe Ile Ser		
	675	680	685

Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val Ile Leu
 690 695 700

Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser Val Val Phe Val
 5 705 710 715 720

Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln Cys Phe Leu Ile
 725 730 735

10 Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala Cys Gly Gly Ile
 740 745 750

Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys Val Ala Trp Gln
 755 760 765

15 Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser Leu Leu Ser Pro
 770 775 780

Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Gln
 20 785 790 795 800

Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu
 805 810 815

25 Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr
 820 825 830

Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly
 835 840 845

30 Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr
 850 855 860

Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln
 35 865 870 875 880

Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys
 885 890 895

Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met
 900 905 910

5 Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile
 915 920 925

Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Met Ser
 930 935 940

10 Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu
 945 950 955 960

Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Leu Gly
 15 965 970 975

Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu
 980 985 990

20 His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val
 995 1000 1005

Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser
 1010 1015 1020

25 Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys
 1025 1030 1035 1040

Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu
 30 1045 1050 1055

Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp
 1060 1065 1070

35 Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr
 1075 1080 1085

His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile

140

	1090	1095	1100
	Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu Phe Leu Lys Asn		
	1105	1110	1115 1120
5	Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys Lys Asp Val Glu		
	1125	1130	1135
	Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Ser Thr Val Ser Tyr Leu		
10	1140	1145	1150
	Lys Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly		
	1155	1160	1165
15	Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser		
	1170	1175	1180
	Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile		
	1185	1190	1195 1200
20	Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly		
	1205	1210	1215
	Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu		
25	1220	1225	1230
	Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe		
	1235	1240	1245
30	Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp Gly		
	1250	1255	1260
	Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys Gln Ser		
	1265	1270	1275 1280
35	Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro Asn Asp Ser		
	1285	1290	1295

141

	Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu Ser Gly Met Asp
	1300 1305 1310
5	Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu Thr Gln Gln Gln
	1315 1320 1325
	Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala Arg Trp Ser Arg
	1330 1335 1340
10	Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val Phe Val Cys Ile
	1345 1350 1355 1360
	Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly Lys Tyr Pro Ser
	1365 1370 1375
15	Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr Thr Phe Val Ser
	1380 1385 1390
	Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu
20	1395 1400 1405
	Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile
	1410 1415 1420
25	Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro
	1425 1430 1435 1440
	Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met
	1445 1450 1455
30	Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys
	1460 1465 1470
	Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Pro Gln
35	1475 1480 1485
	Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg Asn
	1490 1495 1500

Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala Lys Ser
 1505 1510 1515 1520

5 Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr Gly Gly Phe Ser
 1525 1530 1535

Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Pro Ser Gln Glu Val Asn
 1540 1545 1550

10 Asp Ala Thr Lys Gln Met Lys Lys His Leu Lys Leu Ala Lys Asp Ser
 1555 1560 1565

Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly Arg Phe Met Thr Gly Leu
 15 1570 1575 1580

Asp Thr Arg Asn Asn Val Lys Val Trp Phe Asn Asn Lys Gly Trp His
 1585 1590 1595 1600

20 Ala Ile Ser Ser Phe Leu Asn Val Ile Asn Asn Ala Ile Leu Arg Ala
 1605 1610 1615

Asn Leu Gln Lys Gly Glu Asn Pro Ser His Tyr Gly Ile Thr Ala Phe
 1620 1625 1630

25 Asn His Pro Leu Asn Leu Thr Lys Gln Gln Leu Ser Glu Val Ala Pro
 1635 1640 1645

Met Thr Thr Ser Val Asp Val Leu Val Ser Ile Cys Val Ile Phe Ala
 30 1650 1655 1660

Met Ser Phe Val Pro Ala Ser Phe Val Val Phe Leu Ile Gln Glu Arg
 1665 1670 1675 1680

35 Val Ser Lys Ala Lys His Leu Gln Phe Ile Ser Gly Val Lys Pro Val
 1685 1690 1695

Ile Tyr Trp Leu Ser Asn Phe Val Trp Asp Met Cys Asn Tyr Val Val

	1700	1705	1710
	Pro Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe Gln Gln Lys Ser		
	1715	1720	1725
5	Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu Leu Leu Leu		
	1730	1735	1740
	Tyr Gly Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala Ser Phe Val Phe		
10	1745	1750	1755 1760
	Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser Val Asn Leu Phe		
	1765	1770	1775
15	Ile Gly Ile Asn Gly Ser Val Ala Thr Phe Val Leu Glu Leu Phe Thr		
	1780	1785	1790
	Asp Asn Lys Leu Asn Asn Ile Asn Asp Ile Leu Lys Ser Val Phe Leu		
	1795	1800	1805
20	Ile Phe Pro His Phe Cys Leu Gly Arg Gly Leu Ile Asp Met Val Lys		
	1810	1815	1820
	Asn Gln Ala Met Ala Asp Ala Leu Glu Arg Phe Gly Glu Asn Arg Phe		
25	1825	1830	1835 1840
	Val Ser Pro Leu Ser Trp Asp Leu Val Gly Arg Asn Leu Phe Ala Met		
	1845	1850	1855
30	Ala Val Glu Gly Val Val Phe Phe Leu Ile Thr Val Leu Ile Gln Tyr		
	1860	1865	1870
	Arg Phe Phe Ile Arg Pro Arg Pro Val Asn Ala Lys Leu Ser Pro Leu		
	1875	1880	1885
35	Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln Arg Ile Leu Asp		
	1890	1895	1900

Gly Gly Gly Gln Asn Asp Ile Leu Glu Ile Lys Glu Leu Thr Lys Ile
 1905 1910 1915 1920

Tyr Arg Arg Lys Arg Lys Pro Ala Val Asp Arg Ile Cys Val Gly Ile
 5 1925 1930 1935

Pro Pro Gly Glu Cys Phe Gly Leu Leu Gly Val Asn Gly Ala Gly Lys
 1940 1945 1950

10 Ser Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr Val Thr Arg Gly
 1955 1960 1965

Asp Ala Phe Leu Asn Arg Asn Ser Ile Leu Ser Asn Ile His Glu Val
 1970 1975 1980

15 His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Thr Glu Leu
 1985 1990 1995 2000

Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu Leu Arg Gly Val
 20 2005 2010 2015

Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala Ile Arg Lys Leu
 2020 2025 2030

25 Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly Asn Tyr Ser Gly Gly
 2035 2040 2045

Asn Lys Arg Lys Leu Ser Thr Ala Met Ala Leu Ile Gly Gly Pro Pro
 2050 2055 2060

30 Val Val Phe Leu Asp Glu Pro Thr Thr Gly Met Asp Pro Lys Ala Arg
 2065 2070 2075 2080

Arg Phe Leu Trp Asn Cys Ala Leu Ser Val Val Lys Glu Gly Arg Ser
 35 2085 2090 2095

Val Val Leu Thr Ser His Ser Met Glu Glu Cys Glu Ala Leu Cys Thr
 2100 2105 2110

Arg Met Ala Ile Met Val Asn Gly Arg Phe Arg Cys Leu Gly Ser Val
 2115 2120 2125

5 Gln His Leu Lys Asn Arg Phe Gly Asp Gly Tyr Thr Ile Val Val Arg
 2130 2135 2140

Ile Ala Gly Ser Asn Pro Asp Leu Lys Pro Val Gln Asp Phe Phe Gly
 2145 2150 2155 2160

10 Leu Ala Phe Pro Gly Ser Val Pro Lys Glu Lys His Arg Asn Met Leu
 2165 2170 2175

Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile Phe Ser
 15 2180 2185 2190

Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr Ser Val
 2195 2200 2205

20 Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Asp Gln
 2210 2215 2220

Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn Gln Thr
 2225 2230 2235 2240

25 Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp Glu Lys Val
 2245 2250 2255

Lys Glu Ser Tyr Val
 30 2260

<210> 99
 <211> 1525
 35 <212> PRT
 <213> Homo sapiens
 <400> 99

146

Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Trp Lys Asn Leu Thr
 1 5 10 15

Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Glu Val Ala Trp Pro
 5 20 25 30

Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro
 35 40 45

10 Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala
 50 55 60

Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro
 65 70 75 80

15 Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn
 85 90 95

Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Arg Leu
 20 100 105 110

Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val
 115 120 125

25 Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu
 130 135 140

Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly Phe Leu Tyr His
 145 150 155 160

30 Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met Leu Arg Ala Asp
 165 170 175

Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr
 35 180 185 190

Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp
 195 200 205

Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala
 210 215 220

5 Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu
 225 230 235 240

Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu
 245 250 255

10 Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu
 260 265 270

Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu Val Met Phe Leu
 15 275 280 285

Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val
 290 295 300

20 Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys
 305 310 315 320

Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly
 325 330 335

25 Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr
 340 345 350

Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser
 30 355 360 365

Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu
 370 375 380

35 Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn
 385 390 395 400

Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu Glu Gly Met Trp

148

	405	410	415
	Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu Asn Ser Gln Glu		
	420	425	430
5	Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp Asn Asp His Phe		
	435	440	445
	Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala Gln Asp Ile Val		
10	450	455	460
	Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser Ser Asn Gly Ser		
	465	470	475 480
15	Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn Gln Ala Ile Arg		
	485	490	495
	Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn Lys Leu Glu Pro		
	500	505	510
20	Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met Glu Leu Leu Asp		
	515	520	525
	Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly Ile Thr Pro Gly		
25	530	535	540
	Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile		
	545	550	555 560
30	Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro		
	565	570	575
	Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr Val Trp Gly Gly		
	580	585	590
35	Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile Ile Arg Val Leu		
	595	600	605

Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln Gln Met Pro Tyr
 610 615 620

Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met Ser Arg Ser Met
 5 625 630 635 640

Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val Ala Val Ile Ile
 645 650 655

10 Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys Glu Thr Met Arg
 660 665 670

Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser Trp Phe Ile Ser
 675 680 685

15 Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val Ile Leu
 690 695 700

Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser Val Val Phe Val
 20 705 710 715 720

Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln Cys Phe Leu Ile
 725 730 735

25 Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala Cys Gly Gly Ile
 740 745 750

Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys Val Ala Trp Gln
 755 760 765

30 Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser Leu Leu Ser Pro
 770 775 780

Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Gln
 35 785 790 795 800

Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu
 805 810 815

Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr
 820 825 830

5 Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly
 835 840 845

Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr
 850 855 860

10 Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln
 865 870 875 880

Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys
 15 885 890 895

Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met
 900 905 910

20 Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile
 915 920 925

Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Met Ser
 930 935 940

25 Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu
 945 950 955 960

Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Leu Gly
 30 965 970 975

Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu
 980 985 990

35 His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val
 995 1000 1005

Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser

	1010	1015	1020
	Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys		
	1025	1030	1035 1040
5	Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu		
	1045	1050	1055
	Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp		
10	1060	1065	1070
	Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr		
	1075	1080	1085
15	His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile		
	1090	1095	1100
	Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu Phe Leu Lys Asn		
	1105	1110	1115 1120
20	Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys Lys Asp Val Glu		
	1125	1130	1135
	Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Ser Thr Val Ser Tyr Leu		
25	1140	1145	1150
	Lys Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly		
	1155	1160	1165
30	Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser		
	1170	1175	1180
	Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile		
	1185	1190	1195 1200
35	Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly		
	1205	1210	1215

152

	Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu
	1220 1225 1230
5	Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe
	1235 1240 1245
	Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp Gly
	1250 1255 1260
10	Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys Gln Ser
	1265 1270 1275 1280
	Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro Asn Asp Ser
	1285 1290 1295
15	Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu Ser Gly Met Asp
	1300 1305 1310
	Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu Thr Gln Gln Gln
20	1315 1320 1325
	Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala Arg Arg Ser Arg
	1330 1335 1340
25	Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val Phe Val Cys Ile
	1345 1350 1355 1360
	Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly Lys Tyr Pro Ser
	1365 1370 1375
30	Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr Thr Phe Val Ser
	1380 1385 1390
	Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu
35	1395 1400 1405
	Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile
	1410 1415 1420

Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro
 1425 1430 1435 1440

5 Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met
 1445 1450 1455

Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys
 1460 1465 1470

10 Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Pro Gln
 1475 1480 1485

Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg Asn
 15 1490 1495 1500

Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala Lys Ser
 1505 1510 1515 1520

20 Leu Lys Asn Lys Ile
 1525

<210> 100

25 <211> 2261
 <212> PRT
 <213> Homo sapiens

<400> 100

30 Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr
 1 5 10 15

Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro
 20 25 30

35 Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro
 35 40 45

154

Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala
 50 55 60

Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro
 5 65 70 75 80

Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn
 85 90 95

10 Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Arg Leu
 100 105 110

Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val
 115 120 125

15 Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu
 130 135 140

Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly Phe Leu Tyr His
 20 145 150 155 160

Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met Leu Arg Ala Asp
 165 170 175

25 Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr
 180 185 190

Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp
 195 200 205

30 Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala
 210 215 220

Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu
 35 225 230 235 240

Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu
 245 250 255

	Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu		
	260	265	270
5	Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu Val Met Phe Leu		
	275	280	285
	Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val		
	290	295	300
10	Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys		
	305	310	315 320
	Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly		
15	325	330	335
	Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr		
	340	345	350
20	Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser		
	355	360	365
	Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu		
	370	375	380
25	Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn		
	385	390	395 400
	Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu Glu Gly Met Trp		
30	405	410	415
	Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu Asn Ser Gln Glu		
	420	425	430
35	Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp Asn Asp His Phe		
	435	440	445
	Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala Gln Asp Ile Val		

	450	455	460
	Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser Ser Asn Gly Ser		
	465	470	475 480
5	Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn Gln Ala Ile Arg		
	485	490	495
	Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn Lys Leu Glu Pro		
10	500	505	510
	Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met Glu Leu Leu Asp		
	515	520	525
15	Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly Ile Thr Pro Gly		
	530	535	540
	Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile		
	545	550	555 560
20	Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro		
	565	570	575
	Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr Val Trp Gly Gly		
25	580	585	590
	Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile Ile Arg Val Leu		
	595	600	605
30	Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln Gln Met Pro Tyr		
	610	615	620
	Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met Ser Arg Ser Met		
	625	630	635 640
35	Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val Ala Val Ile Ile		
	645	650	655

157

	Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys Glu Thr Met Arg	
	660	665 670
5	Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser Trp Phe Ile Ser	
	675	680 685
	Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val Ile Leu	
	690	695 700
10	Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser Val Val Phe Val	
	705	710 715 720
	Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln Cys Phe Leu Ile	
	725	730 735
15	Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala Cys Gly Gly Ile	
	740	745 750
	Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys Val Ala Trp Gln	
20	755	760 765
	Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser Leu Leu Ser Pro	
	770	775 780
25	Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Gln	
	785	790 795 800
	Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu	
	805	810 815
30	Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr	
	820	825 830
	Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly	
35	835	840 845
	Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr	
	850	855 860

Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln
 865 870 875 880

5 Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys
 885 890 895

Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met
 900 905 910

10 Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile
 915 920 925

Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Met Ser
 15 930 935 940

Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu
 945 950 955 960

20 Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Leu Gly
 965 970 975

Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu
 980 985 990

25 His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val
 995 1000 1005

Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser
 30 1010 1015 1020

Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys
 1025 1030 1035 1040

35 Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu
 1045 1050 1055

Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp

	1060	1065	1070
	Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr		
	1075	1080	1085
5	His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile		
	1090	1095	1100
	Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu Phe Leu Lys Asn		
10	1105	1110	1115 1120
	Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys Lys Asp Val Glu		
	1125	1130	1135
15	Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Ser Thr Val Ser Tyr Leu		
	1140	1145	1150
	Lys Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly		
	1155	1160	1165
20	Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser		
	1170	1175	1180
	Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile		
25	1185	1190	1195 1200
	Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly		
	1205	1210	1215
30	Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu		
	1220	1225	1230
	Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe		
	1235	1240	1245
35	Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp Gly		
	1250	1255	1260

160

Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys Gln Ser
1265 1270 1275 1280

Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro Asn Asp Ser
5 1285 1290 1295

Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu Ser Gly Met Asp
1300 1305 1310

10 Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu Thr Gln Gln Gln
1315 1320 1325

Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala Arg Arg Ser Arg
1330 1335 1340

15 Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val Phe Val Cys Ile
1345 1350 1355 1360

Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly Lys Tyr Pro Ser
20 1365 1370 1375

Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr Thr Phe Val Ser
1380 1385 1390

25 Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu
1395 1400 1405

Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile
1410 1415 1420

30 Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro
1425 1430 1435 1440

Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met
35 1445 1450 1455

Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys
1460 1465 1470

Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Pro Gln
 1475 1480 1485

5 Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg Asn
 1490 1495 1500

Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala Lys Ser
 1505 1510 1515 1520

10 Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr Gly Gly Phe Ser
 1525 1530 1535

Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Pro Ser Gln Glu Val Asn
 15 1540 1545 1550

Asp Ala Thr Lys Gln Met Lys Lys His Leu Lys Leu Ala Lys Asp Ser
 1555 1560 1565

20 Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly Arg Phe Met Thr Gly Leu
 1570 1575 1580

Asp Thr Lys Asn Asn Val Lys Val Trp Phe Asn Asn Lys Gly Trp His
 1585 1590 1595 1600

25 Ala Ile Ser Ser Phe Leu Asn Val Ile Asn Asn Ala Ile Leu Arg Ala
 1605 1610 1615

Asn Leu Gln Lys Gly Glu Asn Pro Ser His Tyr Gly Ile Thr Ala Phe
 30 1620 1625 1630

Asn His Pro Leu Asn Leu Thr Lys Gln Gln Leu Ser Glu Val Ala Pro
 1635 1640 1645

35 Met Thr Thr Ser Val Asp Val Leu Val Ser Ile Cys Val Ile Phe Ala
 1650 1655 1660

Met Ser Phe Val Pro Ala Ser Phe Val Val Phe Leu Ile Gln Glu Arg

162

	1665	1670	1675	1680
	Val Ser Lys Ala Lys His Leu Gln Phe Ile Ser Gly Val Lys Pro Val			
	1685	1690	1695	
5	Ile Tyr Trp Leu Ser Asn Phe Val Trp Asp Met Cys Asn Tyr Val Val			
	1700	1705	1710	
	Pro Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe Gln Gln Lys Ser			
10	1715	1720	1725	
	Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu Leu Leu Leu			
	1730	1735	1740	
15	Tyr Gly Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala Ser Phe Val Phe			
	1745	1750	1755	1760
	Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser Val Asn Leu Phe			
	1765	1770	1775	
20	Ile Gly Ile Asn Gly Ser Val Ala Thr Phe Val Leu Glu Leu Phe Thr			
	1780	1785	1790	
	Asp Asn Lys Leu Asn Asn Ile Asn Asp Ile Leu Lys Ser Val Phe Leu			
25	1795	1800	1805	
	Ile Phe Pro His Phe Cys Leu Gly Arg Gly Leu Ile Asp Met Val Lys			
	1810	1815	1820	
30	Asn Gln Ala Met Ala Asp Ala Leu Glu Arg Phe Gly Glu Asn Arg Phe			
	1825	1830	1835	1840
	Val Ser Pro Leu Ser Trp Asp Leu Val Gly Arg Asn Leu Phe Ala Met			
	1845	1850	1855	
35	Ala Val Glu Gly Val Val Phe Phe Leu Ile Thr Val Leu Ile Gln Tyr			
	1860	1865	1870	

	Arg Phe Phe Ile Arg Pro Arg Pro Val Asn Ala Lys Leu Ser Pro Leu	
	1875	1880 1885
5	Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln Arg Ile Leu Asp	
	1890	1895 1900
	Gly Gly Gly Gln Asn Asp Ile Leu Glu Ile Lys Glu Leu Thr Lys Ile	
	1905	1910 1915 1920
10	Tyr Arg Arg Lys Arg Lys Pro Ala Val Asp Arg Ile Cys Val Gly Ile	
	1925	1930 1935
	Pro Pro Gly Glu Cys Phe Gly Leu Leu Gly Val Asn Gly Ala Gly Lys	
	1940	1945 1950
15	Ser Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr Val Thr Arg Gly	
	1955	1960 1965
	Asp Ala Phe Leu Asn Arg Asn Ser Ile Leu Ser Asn Ile His Glu Val	
20	1970	1975 1980
	His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Thr Glu Leu	
	1985	1990 1995 2000
25	Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu Leu Arg Gly Val	
	2005	2010 2015
	Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala Ile Arg Lys Leu	
	2020	2025 2030
30	Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly Asn Tyr Ser Gly Gly	
	2035	2040 2045
	Asn Lys Arg Lys Leu Ser Thr Ala Met Ala Leu Ile Gly Gly Pro Pro	
35	2050	2055 2060
	Val Val Phe Leu Asp Glu Pro Thr Thr Gly Met Asp Pro Lys Ala Arg	
	2065	2070 2075 2080

Arg Phe Leu Trp Asn Cys Ala Leu Ser Val Val Lys Glu Gly Arg Ser
2085 2090 2095

5 Val Val Leu Thr Ser His Ser Met Glu Glu Cys Glu Ala Leu Cys Thr
2100 2105 2110

Arg Met Ala Ile Met Val Asn Gly Arg Phe Arg Cys Leu Gly Ser Val
2115 2120 2125

10 Gln His Leu Lys Asn Arg Phe Gly Asp Gly Tyr Thr Ile Val Val Arg
2130 2135 2140

Ile Ala Gly Ser Asn Pro Asp Leu Lys Pro Val Gln Asp Phe Phe Gly
15 2145 2150 2155 2160

Leu Ala Phe Pro Gly Ser Val Pro Lys Glu Lys His Arg Asn Met Leu
2165 2170 2175

20 Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile Phe Ser
2180 2185 2190

Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr Ser Val
2195 2200 2205

25 Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Asp Gln
2210 2215 2220

Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn Gln Thr
30 2225 2230 2235 2240

Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp Glu Lys Val
2245 2250 2255

35 Lys Glu Ser Tyr Val
2260

165

<210> 101

<211> 2261

<212> PRT

<213> Homo sapiens

5

<400> 101

Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr

1 5 10 15

10 Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro

20 25 30

Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro

35 40 45

15

Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala

50 55 60

Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro

20 65 70 75 80

Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn

85 90 95

25 Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Arg Leu

100 105 110

Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val

115 120 125

30

Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu

130 135 140

Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly Phe Leu Tyr His

35 145 150 155 160

Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met Leu Arg Ala Asp

165 170 175

Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr
180 185 190

5 Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp
195 200 205

Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala
210 215 220

10 Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu
225 230 235 240

Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu
15 245 250 255

Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu
260 265 270

20 Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu Val Met Phe Leu
275 280 285

Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val
290 295 300

25 Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys
305 310 315 320

Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly
30 325 330 335

Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr
340 345 350

35 Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser
355 360 365

Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu

	370		375		380	
	Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn					
	385		390		395	400
5	Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu Glu Gly Met Trp					
		405		410		415
	Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu Asn Ser Gln Glu					
10		420		425		430
	Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp Asn Asp His Phe					
	435		440		445	
15	Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala Gln Asp Ile Val					
	450		455		460	
	Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser Ser Asn Gly Ser					
	465		470		475	480
20	Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn Gln Ala Ile Arg					
		485		490		495
	Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn Lys Leu Glu Pro					
25		500		505		510
	Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met Glu Leu Leu Asp					
	515		520		525	
30	Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly Ile Thr Pro Gly					
	530		535		540	
	Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile					
	545		550		555	560
35	Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro					
		565		570		575

168

	Gly	Pro	Arg	Ala	Asp	Pro	Phe	Glu	Asp	Met	Arg	Tyr	Val	Trp	Gly	Gly	
																	580 585 590
5	Phe	Ala	Tyr	Leu	Gln	Asp	Val	Val	Glu	Gln	Ala	Ile	Ile	Arg	Val	Leu	595 600 605
	Thr	Gly	Thr	Glu	Lys	Lys	Thr	Gly	Val	Tyr	Met	Gln	Gln	Met	Pro	Tyr	610 615 620
10	Pro	Cys	Tyr	Val	Asp	Asp	Ile	Phe	Leu	Arg	Val	Met	Ser	Arg	Ser	Met	625 630 635 640
	Pro	Leu	Phe	Met	Thr	Leu	Ala	Trp	Ile	Tyr	Ser	Val	Ala	Val	Ile	Ile	645 650 655
15	Lys	Gly	Ile	Val	Tyr	Glu	Lys	Glu	Ala	Arg	Leu	Lys	Glu	Thr	Met	Arg	660 665 670
	Ile	Met	Gly	Leu	Asp	Asn	Ser	Ile	Leu	Trp	Phe	Ser	Trp	Phe	Ile	Ser	675 680 685
20	Ser	Leu	Ile	Pro	Leu	Leu	Val	Ser	Ala	Gly	Leu	Leu	Val	Val	Ile	Leu	690 695 700
	Lys	Leu	Gly	Asn	Leu	Leu	Pro	Tyr	Ser	Asp	Pro	Ser	Val	Val	Phe	Val	705 710 715 720
	Phe	Leu	Ser	Val	Phe	Ala	Val	Val	Thr	Ile	Leu	Gln	Cys	Phe	Leu	Ile	725 730 735
30	Ser	Thr	Leu	Phe	Ser	Arg	Ala	Asn	Leu	Ala	Ala	Ala	Cys	Gly	Gly	Ile	740 745 750
	Ile	Tyr	Phe	Thr	Leu	Tyr	Leu	Pro	Tyr	Val	Leu	Cys	Val	Ala	Trp	Gln	755 760 765
35	Asp	Tyr	Val	Gly	Phe	Thr	Leu	Lys	Ile	Phe	Ala	Ser	Leu	Leu	Ser	Pro	770 775 780

Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Gln
 785 790 795 800

5 Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu
 805 810 815

Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr
 820 825 830

10 Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly
 835 840 845

Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr
 15 850 855 860

Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln
 865 870 875 880

20 Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys
 885 890 895

Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met
 900 905 910

25 Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile
 915 920 925

Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Met Ser
 30 930 935 940

Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu
 945 950 955 960

35 Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Leu Gly
 965 970 975

Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu

170

	980	985	990
	His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val		
	995	1000	1005
5	Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser		
	1010	1015	1020
	Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys		
10	1025	1030	1035 1040
	Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu		
	1045	1050	1055
15	Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp		
	1060	1065	1070
	Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr		
	1075	1080	1085
20	His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile		
	1090	1095	1100
	Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu Phe Leu Lys Asn		
25	1105	1110	1115 1120
	Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys Lys Asp Val Glu		
	1125	1130	1135
30	Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Ser Thr Val Ser Tyr Leu		
	1140	1145	1150
	Lys Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly		
	1155	1160	1165
35	Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser		
	1170	1175	1180

171

	Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile
	1185 1190 1195 1200
5	Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly
	1205 1210 1215
	Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu
	1220 1225 1230
10	Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe
	1235 1240 1245
	Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp Gly
	1250 1255 1260
15	Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys Gln Ser
	1265 1270 1275 1280
	Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro Asn Asp Ser
20	1285 1290 1295
	Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu Ser Gly Met Asp
	1300 1305 1310
25	Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu Thr Gln Gln Gln
	1315 1320 1325
	Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala Arg Arg Ser Arg
	1330 1335 1340
30	Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val Phe Val Cys Ile
	1345 1350 1355 1360
	Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly Lys Tyr Pro Ser
35	1365 1370 1375
	Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr Thr Phe Val Ser
	1380 1385 1390

Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu
 1395 1400 1405

5 Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile
 1410 1415 1420

Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro
 1425 1430 1435 1440

10 Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met
 1445 1450 1455

Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys
 15 1460 1465 1470

Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Pro Gln
 1475 1480 1485

20 Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg Asn
 1490 1495 1500

Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala Lys Ser
 1505 1510 1515 1520

25 Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr Gly Gly Phe Ser
 1525 1530 1535

Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Pro Ser Gln Glu Val Asn
 30 1540 1545 1550

Asp Ala Thr Lys Gln Met Lys Lys His Leu Lys Leu Ala Lys Asp Ser
 1555 1560 1565

35 Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly Arg Phe Met Thr Gly Leu
 1570 1575 1580

Asp Thr Arg Asn Asn Val Lys Val Trp Phe Asn Asn Lys Gly Trp His

173

	1585	1590	1595	1600
	Ala Ile Ser Ser Phe Leu Asn Val Ile Asn Asn Ala Ile Leu Arg Ala			
	1605	1610	1615	
5	Asn Leu Gln Lys Gly Glu Asn Pro Ser His Tyr Gly Ile Thr Ala Phe			
	1620	1625	1630	
	Asn His Pro Leu Asn Leu Thr Lys Gln Gln Leu Ser Glu Val Ala Pro			
10	1635	1640	1645	
	Met Thr Thr Ser Val Asp Val Leu Val Ser Ile Cys Val Ile Phe Ala			
	1650	1655	1660	
15	Met Ser Phe Val Pro Ala Ser Phe Val Val Phe Leu Ile Gln Glu Arg			
	1665	1670	1675	1680
	Val Ser Lys Ala Lys His Leu Gln Phe Ile Ser Gly Val Lys Pro Val			
	1685	1690	1695	
20	Ile Tyr Trp Leu Ser Asn Phe Val Trp Asp Met Cys Asn Tyr Val Val			
	1700	1705	1710	
	Pro Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe Gln Gln Lys Ser			
25	1715	1720	1725	
	Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu Leu Leu Leu Leu			
	1730	1735	1740	
30	Tyr Gly Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala Ser Phe Val Phe			
	1745	1750	1755	1760
	Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser Val Asn Leu Phe			
	1765	1770	1775	
35	Ile Gly Ile Asn Gly Ser Val Ala Thr Phe Val Leu Glu Leu Phe Thr			
	1780	1785	1790	

	Asp Asn Lys Leu Asn Asn Ile Asn Asp Ile Leu Lys Ser Val Phe Leu		
	1795	1800	1805
5	Ile Phe Pro His Phe Cys Leu Gly Arg Gly Leu Ile Asp Met Val Lys		
	1810	1815	1820
	Asn Gln Ala Met Ala Asp Ala Leu Glu Arg Phe Gly Glu Asn Arg Phe		
	1825	1830	1835 1840
10	Val Ser Pro Leu Ser Trp Asp Leu Val Gly Arg Asn Leu Phe Ala Met		
	1845	1850	1855
	Ala Val Glu Gly Val Val Phe Phe Leu Ile Thr Val Leu Ile Gln Tyr		
	1860	1865	1870
15	Arg Phe Phe Ile Arg Pro Arg Pro Val Asn Ala Lys Leu Ser Pro Leu		
	1875	1880	1885
	Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln Arg Ile Leu Asp		
20	1890	1895	1900
	Gly Gly Gly Gln Asn Asp Ile Leu Glu Ile Lys Glu Leu Thr Lys Ile		
	1905	1910	1915 1920
25	Tyr Arg Arg Lys Arg Lys Pro Ala Val Asp Arg Ile Cys Val Gly Ile		
	1925	1930	1935
	Pro Pro Gly Glu Cys Phe Gly Leu Leu Gly Val Asn Gly Ala Gly Lys		
	1940	1945	1950
30	Ser Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr Val Thr Arg Gly		
	1955	1960	1965
	Asp Ala Phe Leu Asn Arg Asn Ser Ile Leu Ser Asn Ile His Glu Val		
35	1970	1975	1980
	His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Thr Glu Leu		
	1985	1990	1995 2000

Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu Leu Arg Gly Val
 2005 2010 2015

5 Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala Ile Arg Lys Leu
 2020 2025 2030

Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly Asn Tyr Ser Gly Gly
 2035 2040 2045

10 Asn Lys Arg Lys Leu Ser Thr Ala Met Ala Leu Ile Gly Gly Pro Pro
 2050 2055 2060

Val Val Phe Leu Asp Glu Pro Thr Thr Gly Met Asp Pro Lys Ala Arg
 15 2065 2070 2075 2080

Arg Phe Leu Trp Asn Cys Ala Leu Ser Val Val Lys Glu Gly Arg Ser
 2085 2090 2095

20 Val Val Leu Thr Ser His Ser Val Glu Glu Cys Glu Ala Leu Cys Thr
 2100 2105 2110

Arg Met Ala Ile Met Val Asn Gly Arg Phe Arg Cys Leu Gly Ser Val
 2115 2120 2125

25 Gln His Leu Lys Asn Arg Phe Gly Asp Gly Tyr Thr Ile Val Val Arg
 2130 2135 2140

Ile Ala Gly Ser Asn Pro Asp Leu Lys Pro Val Gln Asp Phe Phe Gly
 30 2145 2150 2155 2160

Leu Ala Phe Pro Gly Ser Val Pro Lys Glu Lys His Arg Asn Met Leu
 2165 2170 2175

35 Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile Phe Ser
 2180 2185 2190

Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr Ser Val

	2195	2200	2205
	Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Asp Gln		
	2210	2215	2220
5	Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn Gln Thr		
	2225	2230	2235 2240
	Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp Glu Lys Val		
10	2245	2250	2255
	Lys Glu Ser Tyr Val		
	2260		
15	<210> 102		
	<211> 2130		
	<212> PRT		
	<213> Homo sapiens		
20	<400> 102		
	Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Leu Trp Lys Asn Leu Thr		
	1 5 10 15		
25	Phe Arg Arg Arg Gln Thr Cys Gln Leu Leu Leu Glu Val Ala Trp Pro		
	20 25 30		
	Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro		
	35 40 45		
30	Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala		
	50 55 60		
	Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro		
35	65 70 75 80		
	Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn		
	85 90 95		

Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Arg Leu
 100 105 110

5 Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val
 115 120 125

Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu
 130 135 140

10 Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly Phe Leu Tyr His
 145 150 155 160

Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met Leu Arg Ala Asp
 15 165 170 175

Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr
 180 185 190

20 Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp
 195 200 205

Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala
 210 215 220

25 Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu
 225 230 235 240

Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu
 30 245 250 255

Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu
 260 265 270

35 Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu Val Met Phe Leu
 275 280 285

Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val

	290	295	300
	Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly Leu Lys Ile Lys		
	305	310	315 320
5	Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly		
	325	330	335
	Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr		
10	340	345	350
	Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser		
	355	360	365
15	Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu		
	370	375	380
	Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn		
	385	390	395 400
20	Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu Glu Gly Met Trp		
	405	410	415
	Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu Asn Ser Gln Glu		
25	420	425	430
	Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp Asn Asp His Phe		
	435	440	445
30	Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala Gln Asp Ile Val		
	450	455	460
	Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser Ser Asn Gly Ser		
	465	470	475 480
35	Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn Gln Ala Ile Arg		
	485	490	495

	Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn Lys Leu Glu Pro	
	500	505 510
5	Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met Glu Leu Leu Asp	
	515	520 525
	Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly Ile Thr Pro Gly	
	530	535 540
10	Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile	
	545	550 555 560
	Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro	
	565	570 575
15	Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr Val Trp Gly Gly	
	580	585 590
	Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile Ile Arg Val Leu	
20	595	600 605
	Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln Gln Met Pro Tyr	
	610	615 620
25	Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met Ser Arg Ser Met	
	625	630 635 640
	Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val Ala Val Ile Ile	
	645	650 655
30	Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys Glu Thr Met Arg	
	660	665 670
	Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser Trp Phe Ile Ser	
35	675	680 685
	Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val Ile Leu	
	690	695 700

Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser Val Val Phe Val
 705 710 715 720

5 Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln Cys Phe Leu Ile
 725 730 735

Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala Cys Gly Gly Ile
 740 745 750

10 Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys Val Ala Trp Gln
 755 760 765

Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser Leu Leu Ser Pro
 15 770 775 780

Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Gln
 785 790 795 800

20 Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu
 805 810 815

Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr
 820 825 830

25 Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly
 835 840 845

Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr
 30 850 855 860

Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln
 865 870 875 880

35 Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys
 885 890 895

Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met

	900	905	910
	Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile		
	915	920	925
5	Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Met Ser		
	930	935	940
	Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu		
10	945	950	955 960
	Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Leu Gly		
	965	970	975
15	Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu		
	980	985	990
	His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val		
	995	1000	1005
20	Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser		
	1010	1015	1020
	Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys		
25	1025	1030	1035 1040
	Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu		
	1045	1050	1055
30	Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp		
	1060	1065	1070
	Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr		
	1075	1080	1085
35	His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile		
	1090	1095	1100

Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu Phe Leu Lys Asn
 1105 1110 1115 1120

5 Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys Lys Asp Val Glu
 1125 1130 1135

Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Ser Thr Val Ser Tyr Leu
 1140 1145 1150

10 Lys Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly
 1155 1160 1165

Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser
 1170 1175 1180

15 Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile
 1185 1190 1195 1200

Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly
 20 1205 1210 1215

Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu
 1220 1225 1230

25 Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe
 1235 1240 1245

Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp Gly
 1250 1255 1260

30 Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys Gln Ser
 1265 1270 1275 1280

Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro Asn Asp Ser
 35 1285 1290 1295

Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu Ser Gly Met Asp
 1300 1305 1310

Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu Thr Gln Gln Gln
 1315 1320 1325

5 Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala Arg Arg Ser Arg
 1330 1335 1340

Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val Phe Val Cys Ile
 1345 1350 1355 1360

10 Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly Lys Tyr Pro Ser
 1365 1370 1375

Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr Thr Phe Val Ser
 15 1380 1385 1390

Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu
 1395 1400 1405

20 Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile
 1410 1415 1420

Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro
 1425 1430 1435 1440

25 Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met
 1445 1450 1455

Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys
 30 1460 1465 1470

Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Pro Gln
 1475 1480 1485

35 Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg Asn
 1490 1495 1500

Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala Lys Ser

	1505	1510	1515	1520
	Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr Gly Gly Phe Ser			
	1525	1530	1535	
5	Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Pro Ser Gln Glu Val Asn			
	1540	1545	1550	
	Asp Ala Thr Lys Gln Met Lys Lys His Leu Lys Leu Ala Lys Asp Ser			
10	1555	1560	1565	
	Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly Arg Phe Met Thr Gly Leu			
	1570	1575	1580	
15	Asp Thr Arg Asn Asn Val Lys Val Trp Phe Asn Asn Lys Gly Trp His			
	1585	1590	1595	1600
	Ala Ile Ser Ser Phe Leu Asn Val Ile Asn Asn Ala Ile Leu Arg Ala			
	1605	1610	1615	
20	Asn Leu Gln Lys Gly Glu Asn Pro Ser His Tyr Gly Ile Thr Ala Phe			
	1620	1625	1630	
	Asn His Pro Leu Asn Leu Thr Lys Gln Gln Leu Ser Glu Val Ala Pro			
25	1635	1640	1645	
	Met Thr Thr Ser Val Asp Val Leu Val Ser Ile Cys Val Ile Phe Ala			
	1650	1655	1660	
30	Met Ser Phe Val Pro Ala Ser Phe Val Val Phe Leu Ile Gln Glu Arg			
	1665	1670	1675	1680
	Val Ser Lys Ala Lys His Leu Gln Phe Ile Ser Gly Val Lys Pro Val			
	1685	1690	1695	
35	Ile Tyr Trp Leu Ser Asn Phe Val Trp Asp Met Cys Asn Tyr Val Val			
	1700	1705	1710	

Pro Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe Gln Gln Lys Ser
 1715 1720 1725

Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu Leu Leu Leu Leu
 5 1730 1735 1740

Tyr Gly Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala Ser Phe Val Phe
 1745 1750 1755 1760

10 Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser Val Asn Leu Phe
 1765 1770 1775

Ile Gly Ile Asn Gly Ser Val Ala Thr Phe Val Leu Glu Leu Phe Thr
 1780 1785 1790

15 Asp Asn Lys Leu Asn Asn Ile Asn Asp Ile Leu Lys Ser Val Phe Leu
 1795 1800 1805

Ile Phe Pro His Phe Cys Leu Gly Arg Gly Leu Ile Asp Met Val Lys
 20 1810 1815 1820

Asn Gln Ala Met Ala Asp Ala Leu Glu Arg Phe Gly Glu Asn Arg Phe
 1825 1830 1835 1840

25 Val Ser Pro Leu Ser Trp Asp Leu Val Gly Arg Asn Leu Phe Ala Met
 1845 1850 1855

Ala Val Glu Gly Val Val Phe Phe Leu Ile Thr Val Leu Ile Gln Tyr
 1860 1865 1870

30 Arg Phe Phe Ile Arg Pro Arg Pro Val Asn Ala Lys Leu Ser Pro Leu
 1875 1880 1885

Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln Arg Ile Leu Asp
 35 1890 1895 1900

Gly Gly Gly Gln Asn Asp Ile Leu Glu Ile Lys Glu Leu Thr Lys Ile
 1905 1910 1915 1920

Tyr Arg Arg Lys Arg Lys Pro Ala Val Asp Arg Ile Cys Val Gly Ile
 1925 1930 1935

5 Pro Pro Gly Glu Cys Phe Gly Leu Leu Gly Val Asn Gly Ala Gly Lys
 1940 1945 1950

Ser Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr Val Thr Arg Gly
 1955 1960 1965

10 Asp Ala Phe Leu Asn Arg Asn Ser Ile Leu Ser Asn Ile His Glu Val
 1970 1975 1980

His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Thr Glu Leu
 15 1985 1990 1995 2000

Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu Leu Arg Gly Val
 2005 2010 2015

20 Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala Ile Arg Lys Leu
 2020 2025 2030

Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly Asn Tyr Ser Gly Gly
 2035 2040 2045

25 Asn Lys Arg Lys Leu Ser Thr Ala Met Ala Leu Ile Gly Gly Pro Pro
 2050 2055 2060

Val Val Phe Leu Asp Glu Pro Thr Thr Gly Met Asp Pro Lys Ala Arg
 30 2065 2070 2075 2080

Arg Phe Leu Trp Asn Cys Ala Leu Ser Val Val Lys Glu Gly Arg Ser
 2085 2090 2095

35 Val Val Leu Thr Ser His Ser Met Glu Glu Cys Glu Ala Leu Cys Ile
 2100 2105 2110

Gly Trp Gln Ser Trp Ser Met Glu Gly Ser Gly Ala Leu Ala Val Ser

2115

2120

2125

Ser Ile

2130

5

<210> 103

<211> 603

<212> DNA

10 <213> Homo sapiens

<400> 103

ttcattgcnt gacactttac tgagaccaag ataggggaact tcacatacca gaccttttct 60
cccaaggcgg aagagggtg ttcaatttct aactagagt tcggggagtt ttagaaatga 120
15 gccagttgtc gaggatgaga gcagttcctg ataggctcaa ccacaatgag atgtagctgt 180
tcagagaaag cattcttata tataaactgg aagataatcc cggtgaaaca aagcccagcc 240
ccaggggctt cactaactcc aggtgtgtct tctcaaactt tagtgagcat aggaatcacc 300
tgggcatctt gtgaagctgt agatttgaat tctgcaggtc ggcagagggg tctcagaatc 360
cgcatttcca acaatgtctc cagtaatgct gatgtgtctc gtccctggac cacagattgg 420
20 gtagccaggt tctggcaagc tcatcccaag gctttgagat gacatcagac aaaatatgtt 480
ctgggacatg gcttttgaga ggtcaagaaa ataagatgtt tctttctctt ctcatcccca 540
acccttgac tgcccttttc tcccttcccc taccctcctt tctgtcccca tccctgacgc 600
cag 603

25

<210> 104

<211> 1667

<212> DNA

<213> Homo sapiens

30

<400> 104

gtaagttaag tggctgactg tcggaatata tagcaaggcc aaatgtccta aggccagacc 60
agtagcctgc attgggagca ggattatcat ggagttagtc attgagtttt taggtcatcg 120
acatctgatt aatgttggcc ccagtgaagc atttaagatg gtagtgggag atagcaggaa 180
35 agaagtgttt tcctctgtac cacagtacat gcctgagatt tgtgtgttga aaccagtggc 240
acctaacaca ttacatccc aaccttaaac tcctatgcac ttatttacc ttaatatgagc 300
ctctttactt aagtacagt tgaggaacag cggcatcagg atcacttggg aacttgtag 360
aaatacagca acttgggccc agctcagacc tactgaatca gaatcaggag caattctctg 420

gtgtgactgt gtcacagcca ggtatcaact ggattctcat acataggaaa tgacaaacgt 480
 ttatggatgg atagtctact tgtgccaggt gctgagattt gttttttgtt ttttgatttt 540
 tttttaataca ctgtgacctc atttaattct caaaaaaaga tgaaaaaatg aacactcagg 600
 aatgctgaca tgagattcag aatcaggggt ttggggcttc aaagtccatc ctctctttat 660
 5 ccatgtaatg cctcccccta gagatacaac atcacagacc ttgaaggctg aaggggatat 720
 aaaagctgtc tggccaagtg gtcctcaagc ttgacagtgc agcagaatca cctggggata 780
 ttattaaaaa taaacatact aaggtttggc ttcagggcct gtgaatcaga atttctggag 840
 gtgaggcctt gaagtctgta tttctattgc atactttgga cacagtggtc tatagactag 900
 agtttggaat tgattgcgtc cattcagatt ctcttctgat gtttgaattg ctgccatcat 960
 10 atttctagtg ctctatttcc tctgtctcat tctgtcttgg ataacttate atagtactag 1020
 cctactcaaa gatttagagc cacagtcctg aaagaagcca cttgactcat tccctgtagg 1080
 ttcagaataa atttcttctg cgcagtgtct gtcatagctt tttttaaatt tttttttatt 1140
 tttgatgaga ctggagtttt gctcttattg cccaagctgg agtgcagtgg tgcgattttg 1200
 gctcactgca acctccacct cccaggttca agcgattctc ctgcctcagc ctcccaagta 1260
 15 gctgagatta caagcatgtg ctaccacgcc cagctaattt tgtattttta gtagagatgg 1320
 gttttatcca tgttggtcag gctgggtctg agctccagac ctcaggatgat ctgcccgcct 1380
 cggcctccca aagtgtctgg attataggcc tgagccacag cgctcagcca taactttaat 1440
 ttgaaaatga ttgtctagct tgatagctct caccactgag gaaatgttct ctggcaaaaa 1500
 cggcttctct cccaggtaac tctgagaaag tgttattaag aaatgtggct tctactttct 1560
 20 ctgtcttacg gggctaacat gccactcagt aatataataa tcgtggcagt ggtgactact 1620
 ctgtaaatgt tgggtgcttat aatgttctca tctctctcat tttccag 1667

<210> 105

25 <211> 1309

<212> DNA

<213> Homo sapiens

<400> 105

30 gtgacttttt actaaacttg gcccctgccg tattattact aattagagga attaaagacc 60
 taaaaataac agactgaaac agtgggggaa atgccagatt atggcctgat tctgtctatt 120
 ggaagttag gatattatcc caaactagaa aagatgacga gagggactgt gaacattcag 180
 ttgtcagctt caaggctgag gcagcctggt ctagaatgaa atagaaatg gattcaacgt 240
 caaattttgc cacttagtag caacttgacc aggtaactgg ttatcctttt aaagccttag 300
 35 tttatctaaa ttgtgatatt aatgttgctc ttataagttt gtcattgagga cttaaattaaa 360
 tgggtgtacat agagtgcctt ggggtactctc tgatggggga ctccatgata atttgtgggc 420
 tcatggaggg agctctggga aggttagga gcctgccttg gctctgcagc cttgggagag 480
 ccttctagct tcccaggaca tggcagccta gtgttgaatg cttggctcag caaatgtttg 540

ttctcgtttc cttcccatca acttgggtcag ttgggggtctt tcagtttagga gtatctcagt 600
 gacttttaaat ggcatgggca tgctggagtg atagtgacca tgagtttcta agaaagaagc 660
 ataattttctc catatgtcat ccacaattga aatattattg ttaattgaaa aagcttctag 720
 gccaggcacg gtgggtcatg cctgtaatcc cagcacttta ggaggccaag gcgggtggat 780
 5 cacttgaggt caggagtttg agaccagcct ggccaacatg gggaaaccct gtctctacta 840
 aaaatacaaa ataagctggg cgtgggtggg cgtgcctgta atcccagcta cttgggaggc 900
 tgaggcagga gaattgcttg aatctgggag gcggaggttg cagtgagctg agttcatgcc 960
 attgcattcc agcctgggca acaagagcga aaccatctcc caaaagaaaa aaaaaagaaa 1020
 gaaaaagctt ctagtttggt tacatcttgg tctataaggt ggtttgtaaa ttggtttaac 1080
 10 ccaaggcctg gttctcatat aagtaatagg gtatttatga tggagagaag gctggaagag 1140
 gcctgaacac aggccttctt tctctagcac aaccctacaa ggccagctga ttctagggtt 1200
 atttctgtcc gttccttata tctcaggtg gatatttact ctttttgcatt cattaggaat 1260
 aggcctcagtg ctttcttga actgattttt tgtttctttg tctctgcag 1309

15
 <210> 106
 <211> 1124
 <212> DNA
 <213> Homo sapiens

20
 <400> 106
 gtaagttgct gtctttcttg cacgttttagc tcagggggag gatggtgttg taggtgtctt 60
 ggattgaaga aagccttggg gattgtttgt cactcacaca cttgtgggtg ccatctcact 120
 gtgaggagga cagaagccct gtgaacatgt ggagcacaca ggggcacaga cagatttaga 180
 25 ttaggcctgc tttatagagt ttctgcctag agcatcatgg ctcagtgcc agcagcccct 240
 ccagaggcct ctgaaatatt tgatatactg atttcttga ggagaatcag aaatctcctg 300
 cagggtgtcta gggatttcaa gtaagtagtg ttgtgagggg aatacctact tgtactttcc 360
 ccccaaacca gattcccgag gcttcttaag gactcaagga caatttctag gcatttagca 420
 cgggactaaa aaggtcttag aggaataag aagcgccaaa accatctctt tgcactgtat 480
 30 ttcaacccat ttgtccttct gggttttgaa ggaacaggtg ggactgggga cagaagagtt 540
 cttgaagcca gtttgtccat catggaaaat gagataggtg atgtggctac gtcagggggc 600
 ccgaaggctc cttgttactg atttccgtct tttctctctg ctttttcccc aagggccagg 660
 acccctggat ctctgggcag agcagacgca ggccctata atagccctca tgctagaaag 720
 gagccggagc ctgtgtataa ggccagcgca gcctactctg gacagtgcag ggttcccact 780
 35 ctcccaactc cccatctgct tgcctccaga cccacattca cacacgagcc actgggttgg 840
 aggagcatct gtgagatgaa acaccattct ttcctcaatg tctcagctat ctaactgtgt 900
 gtgtaatcag gccaggctc cctgctggg cagaaacat gggagttaag agattgccaa 960
 catttattag aggaagctga cgtgtaactt ctctgaggca aaatttagcc ctctttttaa 1020

caggaatttg actcagtga ccttgtagac actcgactg agtctgctgc tgatgatact 1080
gtgcacccca ctgtctgggt tttaatgtca ggctgttctt ttag 1124

5 <210> 107
<211> 1124
<212> DNA
<213> Homo sapiens

10 <400> 107
gtaagtgtct gtctttcttg cacgttttagc tcagggggag gatggtgttg taggtgtctt 60
ggattgaaga aagccttggg gattgtttgt cactcacaca cttgtgggtg ccatctcact 120
gtgaggagga cagaagccct gtgaacatgt ggagcacaca ggggcacaga cagatttaga 180
ttaggcctgc ttatagagt ttctgcctag agcatcatgg ctcaagtccc agcagccct 240
15 ccagaggcct ctgaaatatt tgatatactg atttccttga ggagaatcag aaatctctctg 300
caggtgtcta gggatttcaa gtaagtagtg ttgtgagggg aatacctact tgtactttcc 360
ccccaaacca gattcccag gcttcttaag gactcaagga caatttctag gcatttagca 420
cgggactaaa aaggtcttag aggaaataag aagcgccaaa accatctctt tgcactgtat 480
ttcaaccat ttgtccttct gggttttgaa ggaacaggtg ggactgggga cagaagagtt 540
20 cttgaagcca gtttgtccat catggaaaat gagataggtg atgtggctac gtcagggggc 600
ccgaaggctc cttgttactg atttccgtct tttctctctg ctttttcccc aagggccagg 660
acccctggat ctctgggcag agcagacgca ggcccctata atagccctca tgctagaaag 720
gagccggagc ctgtgtataa ggccagcgca gcctactctg gacagtgcag ggttccact 780
ctcccaactc ccatctgtct tgcctccaga cccacattca cacacgagcc actgggttg 840
25 aggagcatct gtgagatgaa acaccattct ttcctcaatg tctcagctat ctaactgtgt 900
gtgtaatcag gccaggctct ccctgctggg cagaaccat gggagttaag agattgccaa 960
catttattag aggaagctga cgtgtaactt ctctgaggca aaatttagcc ctcccttgaa 1020
caggaatttg actcagtga ccttgtagac actcgactg agtctgctgc tgatgatact 1080
gtgcacccca ctgtctgggt tttaatgtca ggctgttctt ttag 1124

30

<210> 108
<211> 264
<212> DNA
35 <213> Homo sapiens

<400> 108
gtgagctttt tcttagaacc cgtggagcac ctggttgagg gtcacagagg aggcgcacag 60

ggaaacactc accaatgggg gttgcattga actgaactca aaatatgtga taaaactgat 120
tttctctgatg tgggcatccc gcagccccct cctgcccac cctggagact gtggcaagta 180
ggttttataa tactacgtta gagactgaat ctttgcctg aaaaatagtt tgaaagggtc 240
atttttcttg ttttttcccc caag 264

5

<210> 109

<211> 274

<212> DNA

10 <213> Homo sapiens

<400> 109

gtaataaaga taatttcttt gggatangtg cctagtgaga aggcttgata tttattcttt 60
tgtngagtat ataaatgggtg cctctaaaat aaagggaaat aaaactgagc aaaacagtgt 120
15 agtggaaaga atgagggcctt tgaagtccga actgcattca aattctgtct ttaccattta 180
ctggttctgt gactcttggg caagttactt aactactgta agagttagtt tccctggaag 240
atctacctcc tagctttgtg ctatagatga aatg 274

20 <210> 110

<211> 274

<212> DNA

<213> Homo sapiens

25 <400> 110

gtaataaaga taatttcttt gggatangtg cctagtgaga aggcttgata tttattcttt 60
tgtngagtat ataaatgggtg cctctaaaat aaagggaaat aaaactgagc aaaacagtgt 120
agtggaaaga atgagggcctt tgaagtccga actgcattca aattctgtct ttaccattta 180
ctggttctgt gactcttggg caagttactt aactactgta agagttagtt tccctggaag 240
30 atctacctcc tagctttgtg ctatagatga aatg 274

<210> 111

<211> 604

35 <212> DNA

<213> Homo sapiens

<400> 111

ttcattgcnt gacactttac tgagaccaag ataggggaact tcacatacca gaccttttct 60
 cccaaggcgg aagagggctg ttcaatttct acactagagt tcggggagtt ttagaaatga 120
 gccagttgtc gaggatgaga gcagttcctg ataggctcaa ccacaatgag atgtagctgt 180
 tcagagaaag cattcttata tataaactgg aagataatcc cggtgaaaca aagcccagcc 240
 5 ccaggggctt cactaactcc aggctgtgct tctcaaactt tagtgagcat aggaatcacc 300
 tgggcacatt gtgaagctgt agatttgaat tctgcaggtc ggcagagggg tctcagaatc 360
 cgcatttcca acaatgtctc cagtaatgct gatgctgctc gtccctggac cacagattgg 420
 gtagccaggt tctggcaagc tcatcccaag gctttgagat gacatcagac aaaatatgtt 480
 ctgggacatg gcttttgaga ggtcaagaaa ataagatgtt tctttctctt ctcattccca 540
 10 acccttgcaac tgcccttttc tcccttcccc taccctcctt tctgtcccca atccctgacg 600
 ccag 604

<210> 112

15 <211> 1667

<212> DNA

<213> Homo sapiens

<400> 112

20 gtaagttaag tggctgactg tcagaatata tagcaaggcc aaatgtccta aggccagacc 60
 agtagcctgc attgggagca ggattatcat ggagttagtc attgagtttt taggtcatcg 120
 acatctgatt aatgttgccc ccagtgaacc atttaagatg gtagtgggag atagcaggaa 180
 agaagtgttt tcctctgtac cacagtacat gcctgagatt tgtgtgttga aaccagtggg 240
 acctaacaca ttacatccc aaccttaaac tcctatgcac ttatttacct ttaaatgagc 300
 25 ctctttactt aagtacagtg tgaggaacag cggcatcagg atcacttggg aacttgtag 360
 aaatacagca acttgggccc agctcagacc tactgaatca gaatcaggag caattctctg 420
 gtgtgactgt gtcacagcca ggtatcaact ggattctcat acataggaaa tgacaaacgt 480
 ttatggatgg atagtctact tgtgccaggt gctgagattt gttttttgtt ttttgatttt 540
 tttttaatca ctgtgacctc atttaattct caaaaaaaga tgaaaaaatg aacactcagg 600
 30 aatgctgaca tgagattcag aatcaggggt ttggggcttc aaagtccatc ctctctttat 660
 ccatgtaatg cctcccctta gagatacaac atcacagacc ttgaaggctg aaggggatat 720
 aaaagctgtc tggccaagtg gtctccaagc ttgacagtgc agcagaatca cctggggata 780
 ttattaaaaa taaacatact aaggtttggc ttcagggcct gtgaatcaga atttctggag 840
 gtgaggcctt gaagtctgta tttctattgc atactttgga cacagtggtc tatagactag 900
 35 agtttggaat tgattgcgct cattcagatt ctctctctgat gtttgaattg ctgccatcat 960
 atttctagtg ctctatttcc tcctgtcat tctgtcttg ataaacttat atagtactag 1020
 cctactcaaa gatttagagc cacagtctct aaagaagcca cttgactcat tccctgtagg 1080
 ttcagaataa atttctctg cgcagtgtct gtcatagctt tttttaaat tttttttatt 1140

tttgatgaga ctggagtttt gctcttattg cccaagctgg agtgcagtg tgcgattttg 1200
gctcactgca acctccacct cccaggttca agcgattctc ctgcctcagc ctcccaagta 1260
gctgagatta caagcatgtg ctaccacgcc cagctaattt tgtattttta gtagagatgg 1320
gttttatcca tgttggtcag gctggctctg agctccagac ctcaggatgat ctgcccgcct 1380
5 cggcctccca aagtgcctgg attataggcc tgagccacag cgctcagcca taactttaat 1440
ttgaaaatga ttgtctagct tgatagctct caccactgag gaaatgttct ctggcaaaaa 1500
cggcttctct cccaggtaac tctgagaaa gtttattaag aaatgtggct tctactttct 1560
ctgtcttacg gggctaacat gccactcagt aatataataa tcgtggcagt ggtgactact 1620
ctcgtaatgt tgggtgcttat aatgttctca tctctctcat tttccag 1667

10

<210> 113

<211> 1309

<212> DNA

15 <213> Homo sapiens

<400> 113

gtgacttttt actaaacttg gcccctgcct tattattact aattagagga attaaagacc 60
tacaaataac agactgaaac agtgggggaa atgccagatt atggcctgat tctgtctatt 120
20 ggaagtttag gatattatcc caaactagaa aagatgacga gagggactgt gaacattcag 180
ttgtcagctt caaggctgag gcagcctggc ctagaatgaa aatagaaatg gattcaacgt 240
caaattttgc cacttagtag caacttgacc aggtaactgg ttatcctttt aaagccttag 300
tttatctaaa ttgtgatatt aatgttgctc ttataagttt gtcattgagga ctaaattaaa 360
tgggtgtacat agagtgcctt ggggtactctc tgatggggga ctccatgata atttgtggctc 420
25 tcatggaggg agctctggga aggttttagga gcctgccttg gctctgcagc cttgggagag 480
ccttctagct tcccaggaca tggcagccta gtgttgaatg cttggctcag caaatgtttg 540
ttctcgtttc cttcccatca acttggtcag ttgggggtctt tcagtttagga gtatctcagt 600
gactttaaat ggcatgggca tgctggagtg atagtacca tgagtctcta agaaagaagc 660
ataatttctc catatgtcat ccacaattga aatattattg ttaattgaaa aagcttctag 720
30 gccaggcacg gtggctcatg cctgtaatcc cagcacttta ggaggccaag gcgggtggat 780
cacttgaggt caggagtgtt agaccagcct ggccaacatg gggaaaccct gtctctacta 840
aaaatacaaa ataagctggg cgtgggtgtg cgtgcctgta atcccagcta cttgggaggc 900
tgaggcagga gaattgcttg aatctgggag gcggagggtg cagttagctg agttcatgcc 960
attgcattcc agcctgggca acaagagcga aaccatctcc caaaagaaaa aaaaaagaaa 1020
35 gaaaaagctt ctagtttggg tacatcttgg tctataaggt ggtttgtaaa ttggtttaac 1080
ccaaggcctg gttctcatat aagtaatagg gtatttatga tggagagaag gctggaagag 1140
gcctgaacac aggttctttt tctctagcac aaccctacaa ggccagctga ttctagggtt 1200
atctctgtcc gttccttata tctcaggtg gatatttact ctttttgcatt cattaggaat 1260

aggctcagtg ctttctttga actgattttt tgtttctttg tctctgcag

1309

<210> 114

5 <211> 1124

<212> DNA

<213> Homo sapiens

<400> 114

10 gtaagttgct gtctttctgg cacgttttagc tcagggggag gatggtgttg taggtgtctt 60
ggattgaaga aagccttggg gattgtttgt cactcacaca cttgtgggtg ccattctact 120
gtgaggagga cagaagccct gtgaacatgt ggagcacaca ggggcacaga cagatttaga 180
ttaggcctgc tttatagagt ttctgcctag agcatcatgg ctacgtgccc agcagccct 240
ccagaggcct ctgaaatatt tgatatactg atttccttga ggagaatcag aaatctcctg 300
15 caggtgtcta gggatttcaa gtaagtagtg ttgtgagggg aatacctact tgtactttcc 360
cccaaacca gattcccag gcttcttaag gactcaagga caatttctag gcatttagca 420
cgggactaaa aaggtcttag aggaataag aagcgccaaa accatctctt tgcactgtat 480
ttcaaccat ttgtccttct gggttttgaa ggaacaggtg ggactgggga cagaagagtt 540
cttgaagcca gtttgtccat catggaaaat gagataggtg atgtggctac gtcagggggc 600
20 ccgaaggtc cttgttactg atttccgtct tttctctctg ctttttcccc aagggccagg 660
accctggat ctctgggcag agcagacgca ggccctata atagccctca tgctagaaag 720
gagccggagc ctgtgtataa ggccagcgca gcctactctg gacagtgcag ggttcccact 780
ctcccaactc cccatctgct tgcctccaga cccacattca cacacgagcc actgggttgg 840
aggagcatct gtgagatgaa acaccattct ttcctcaatg tctcagctat ctaactgtgt 900
25 gtgtaatcag gccaggtcct ccctgctggg cagaaacat gggagttaag agattgccaa 960
catttattag aggaagctga catgtaactt ctctgaggca aaatttagcc ctcccttgaa 1020
caggaatttg actcagtga cctgttacac actcgactg agtctgctgc tgatgatact 1080
gtgcacccca ctgtctggct tttaatgtca ggctgttctt ttag 1124

30

<210> 115

<211> 1124

<212> DNA

<213> Homo sapiens

35

<400> 115

gtaagttgct gtctttctgg cacgttttagc tcagggggag gatggtgttg taggtgtctt 60
ggattgaaga aagccttggg gattgtttgt cactcacaca cttgtgggtg ccattctact 120

gtgaggagga cagaagccct gtgaacatgt ggagcacaca ggggcacaga cagatttaga 180
 ttaggcctgc tttatagagt ttctgcctag agcatcatgg ctgagtccc agcagcccct 240
 ccagaggcct ctgaaatatt tgatatactg atttccttga ggagaatcag aaatctcctg 300
 cagggtgtcta gggatttcaa gtaagtagtg ttgtgagggg aatacctact tgtactttcc 360
 5 ccccaaacca gattcccag gcttcttaag gactcaagga caatttctag gcatttagca 420
 cgggactaaa aagggtcttag aggaaataag aagcgccaaa accatctctt tgcactgtat 480
 ttcaacccat ttgtccttct gggttttgaa ggaacaggtg ggactgggga cagaagagtt 540
 cttgaagcca gtttgtccat catggaaaat gagataggtg atgtggctac gtcagggggc 600
 ccgaaggctc cttgttactg atttccgtct tttctctctg ctttttcccc aagggccagg 660
 10 acccctggat ctctgggcag agcagacgca ggccctata atagccctca tgctagaaag 720
 gagccggagc ctgtgtataa ggccagcgca gcctactctg gacagtgcag ggttccccact 780
 ctcccaactc cccatctgct tgcctccaga cccacattca cacacgagcc actgggttgg 840
 aggagcatct gtgagatgaa acaccattct ttctcaatg tctcagctat ctaactgtgt 900
 gtgtaatcag gccaggtcct cctgctggg cagaaccat gggagttaag agattgccaa 960
 15 catttattag aggaagctga cgtgtaactt ctctgaggca aaatttagcc ctcttttgaa 1020
 caggaatttg actcagtga cctgtacac actcgactg agtctgctgc tgatgatact 1080
 gtgcacccca ctgtctggct ttaaatgtca ggctgttctt ttag 1124

20 <210> 116

<211> 264

<212> DNA

<213> Homo sapiens

25 <400> 116

gtgagctttt tcttagaacc cgtggagcac ctgggtgagg gtcacagagg aggcgcacag 60
 ggaaacactc accaatgggg gttgcattga actgaactca aaatatgtga taaaactgat 120
 tttcctgatg tgggcatccc gcagctccct ccctgcccac cctggagact gtggcaagta 180
 ggttttataa tactacgtta gagactgaat ctttgccttg aaaaatagtt tgaaagggtc 240

30 atttttcttg ttttttcccc caag

264

<210> 117

<211> 274

35 <212> DNA

<213> Homo sapiens

<400> 117

gtaataaaga tagtttcttt gggatangtg cctagtgaga aggcttgata ttatttcttt 60
tgtngagtat ataaatgggtg cctctaaaat aaagggaaat aaaactgagc aaaacagtgt 120
agtggaaaga atgagggctt tgaagtccga actgcattca aattctgtct ttaccattta 180
ctggttctgt gactcttggg caagttactt aactactgta agagttagtt tccctggaag 240
5 atctacctcc tagctttgtg ctatagatga aatg 274

<210> 118

<211> 274

10 <212> DNA

<213> Homo sapiens

<400> 118

gtaataaaga taatttcttt gggatangtg cctagtgaga aggcttgata ttatttcttt 60
15 tgtngagtat ataaatgggtg cctctaact aaagggaaat aaaactgagc aaaacagtgt 120
agtggaaaga atgagggctt tgaagtccga actgcattca aattctgtct ttaccattta 180
ctggttctgt gactcttggg caagttactt aactactgta agagttagtt tccctggaag 240
atctacctcc tagctttgtg ctatagatga aatg 274

20

<210> 119

<211> 22

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

30

<400> 119

cagtgttcta tcttatttcc ac

22

<210> 120

35 <211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

5 <400> 120

aatttagccc acgttaattg c

21

<210> 121

10 <211> 20

<212> DNA

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

<400> 121

gagcctcaaa atcgcttcag

20

20

<210> 122

<211> 21

<212> DNA

25 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

30

<400> 122

tgatggatac cccaaatacc c

21

35 <210> 123

<211> 21

<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide
5
<400> 123
tgggtgtgta gaccaatgga g 21

10 <210> 124
<211> 18
<212> DNA
<213> Artificial Sequence

15 <220>
<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide
<400> 124
20 aatgggaaca agccccag 18

<210> 125
<211> 21
25 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer
30 Oligonucleotide
<400> 125
gatgctcccc tatctcattc c 21

35
<210> 126
<211> 20
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

5 Oligonucleotide

<400> 126

actacctccc tccccttcac

20

10

<210> 127

<211> 20

<212> DNA

<213> Artificial Sequence

15

<220>

<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

20 <400> 127

ccaaaagact tcaaggaccc

20

<210> 128

25 <211> 18

<212> DNA

<213> Artificial Sequence

<220>

30 <223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

<400> 128

gcctcacatt ccgaaagc

18

35

<210> 129

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

5 <223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

<400> 129

taaactcaag attgtgaacg ag

22

10

<210> 130

<211> 20

<212> DNA

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

20

<400> 130

agacacaact tacctcctgg

20

25 <210> 131

<211> 22

<212> DNA

<213> Artificial Sequence

30 <220>

<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

<400> 131

35 aggccttgag atgacatcag ac

22

<210> 132

<211> 19

<212> DNA

<213> Artificial Sequence

5 <220>

<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

<400> 132

10 gaactaaggg agggatggg

19

<210> 133

<211> 22

15 <212> DNA

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

<400> 133

ttttacagag gagccaactg ag

22

25

<210> 134

<211> 19

<212> DNA

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

35 <400> 134

tatacccacg actggggag

19

<210> 135
<211> 22
<212> DNA
<213> Artificial Sequence
5
<220>
<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide
10 <400> 135
cccagagtga aaacctcaag tc 22

<210> 136
15 <211> 20
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

<400> 136
tgctcactac aatttcccc 20
25

<210> 137
<211> 274
<212> DNA
30 <213> Homo sapiens

<400> 137
gtaataaaga taatttcttt gggatangtg cctagtgaga aggcttgata ttatttcttt 60
tgtngagtat ataatgggtg cctctaaaat aaagggaat aaaactgagc aaaacagtgt 120
35 agtggaaga atgagggctt tgaagtccga actgcattca aattctgtct ttaccattta 180
ctggttctgt gactcttggg caagttactt aactactgta agagttagtt tccctggaag 240
atctacctcc tagctttgtg ctatagatga aatg 274

<210> 138
<211> 22
<212> DNA
5 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide
10

<400> 138
gcaacagatt acctccatga ag 22

15 <210> 139
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence:
Oligonucleotide Primer

<400> 139
25 ccaacaactc cgggagcctc c 21

<210> 140
<211> 23
30 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
35 Oligonucleotide Primer

<400> 140
agcggataac aatttcacac agg 23

<210> 141
<211> 19
5 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer
10 Oligonucleotide

<400> 141
tcctgcctgc ctgagaaac 19

15
<210> 142
<211> 20
<212> DNA
<213> Artificial Sequence

20
<220>
<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

25 <400> 142
ccctcattga catggtggtc 20

<210> 143
30 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
35 <223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

<400> 143

- ttgaggtagt tacgtgttag g 21
- <210> 144
- 5 <211> 22
- <212> DNA
- <213> Artificial Sequence
- <220>
- 10 <223> Description of Artificial Sequence: PCR Primer
Oligonucleotide
- <400> 144
- cttcttttct cacctatttc tg 22
- 15
- <210> 145
- <211> 21
- <212> DNA
- 20 <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence: PCR Primer
Oligonucleotide
- 25
- <400> 145
- gcagtatctt atcaaacatc c 21
- 30 <210> 146
- <211> 19
- <212> DNA
- <213> Artificial Sequence
- 35 <220>
- <223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

<400> 146

gatgccaaag gagactagg

19

5 <210> 147

<211> 18

<212> DNA

<213> Artificial Sequence

10 <220>

<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

<400> 147

15 tcccttctcc ctgctttg

18

<210> 148

<211> 19

20 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

25

<400> 148

agcttccctc tgcttttcc

19

30

<210> 149

<211> 21

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

<400> 149
cagaatatgt gagtttcctg c 21

5
<210> 150
<211> 22
<212> DNA
<213> Artificial Sequence

10
<220>
<223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

15 <400> 150
aatgatcgca tattctactt gg 22

<210> 151
20 <211> 20
<212> DNA
<213> Artificial Sequence

<220>
25 <223> Description of Artificial Sequence: PCR Primer
Oligonucleotide

<400> 151
aactgaaca gcatcatccc 20

30
<210> 152
<211> 22
<212> DNA
35 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<223> Description of Artificial Sequence:

Oligonucleotide Primer

<400> 155

5 gctcagaaac ttcttggtca cc

22

<210> 156

<211> 25

10 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

15 Oligonucleotide Primer

<400> 156

cttgtggaga atgacatcag ccctc

25

20